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ABSTRACT 
 
 
SCREENING PROSTATE SPECIFIC ANTIGEN EFFECTS ON RACIAL DISPARATE 
MORTALITY: A PROPENSITY SCORE ANALYSIS 
 
By R. David McNally, Ph.D., M.S.H.A. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2011 
 
Dissertation Chair: Jeffrey S. Legg, Ph.D., Associate Professor and Chair,  
Doctoral Program in Health Related Sciences 
Department of Radiation Sciences 
 
 Prostate cancer is the most commonly diagnosed cancer among men in the United 
States. It is frequently cited that racial disparities in mortality between Caucasian and 
African American men with localized prostate cancer exist. In addition, the question of 
whether prostate cancer screening with the prostate specific antigen blood test (PSA) 
leads to reduced mortality remains unanswered. Outcomes theory and survival analysis 
have shown controversial inconsistencies in support of early detection methods for 
prostate cancer to the extent that experts in the medical community do not agree on best-
practice guidelines suggestive of eliminating such disparities and reducing mortality. 
 The purpose of this study was to explore the relationship between screening PSA 
tests and racial differences in mortality among Caucasian and African American men 
 
 
 
with application of a propensity scoring analysis on a large population-based data set. 
Prostate cancer patients diagnosed from January 1, 1986 through December 31, 2006  
(n = 515,802 cases) from the SEER-17 data set linked to Medicare claims files were 
included. A separate analysis using a 5% randomized group of over 263,000 men without 
prostate cancer was also examined.  
 The results demonstrated that no statistically significant differences in mortality 
between Caucasians and African Americans in the prostate cancer group existed 
(p=0.993). Further, the same result was found among men from the 5% randomized 
group without prostate cancer (p= 0.832), that no statistically significant difference exists 
for this study population when using a propensity scoring analysis and a conditional Cox 
regression model. From both analyses, no survival benefit was found for screened men 
versus non-screened men when using the PSA test for early detection. In addition, 
because age is a well-known predictor of death, a separate analysis was performed on 
age-matched men. The results for the age analysis also demonstrated no statistically 
significant differences in racial mortality or whether screening PSA reduced mortality 
after applying a propensity scoring analysis to a conditional Cox regression model. 
 In conclusion, it is believed that using a propensity scoring method and Cox 
regression analysis improved the evaluation of this large population data set where 
censoring for survival time was important and where matched pairs were utilized. Further 
work in health services research using large population-based data sets should be pursued 
and incorporating Cox regression with a propensity analysis can be helpful. 
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CHAPTER 1:  INTRODUCTION 
 
Overview of Prostate Cancer 
The American Cancer Society (ACS) estimates that 217,730 new cases of prostate 
cancer in men of all races would be diagnosed in 2010 making prostate cancer the most 
commonly diagnosed cancer among men in the United States. The ACS reported in 2010 
that almost 63% of all prostate cases are diagnosed in men over 65 (ACS, 2010). 
However, the 2010 estimate is 13% higher than 2009 (217,730/192,280) yet still remains 
approximately 1% lower for new cases that were expected in 2007 (218,890).  A reason 
for the decrease from 2010 and 2007 may reflect changes in prostate screening habits and 
improved treatment strategies in surgery and radiation therapy over the past few years. 
For example, cancer screening educational initiatives aimed at increasing men’s 
knowledge about possible benefits from early detection and aggressive treatment have 
increased throughout communities. Improved imaging techniques and new technologies 
in surgery such as robotic prostatectomy for improved nerve sparing and brachytherapy 
and intensity modulated radiation therapy treatments in radiation therapy are being 
implemented to provide greater access to new and aggressive treatment (ACS, 2010; 
ACS, 2009). The estimated number of deaths from prostate cancer in men of all races for 
2010 (32,050) represents 11% of all cancer deaths, second to lung and bronchus cancers 
which account for 29% of cancer deaths (ACS, 2010). Although previous estimates
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illustrated decreases in both the numbers of new cases and deaths, the number of 
estimated new prostate cases in 2010 increased by 13% over 2009 with the estimated 
percentage of deaths from prostate cancer for the same period also rising by 17% for all 
races (32,050/27,360) (ACS, 2010). The estimated cases found in the ACS Facts and 
Figures report for 2010 are based on 1995-2005 incidence rates from 41 states and the 
District of Columbia as reported by the North American Association of Central Cancer 
Registries (NAACCR) for men of all races and does not include a separate statistical 
result for Caucasians. The estimated numbers of deaths are based on data from the U.S. 
Mortality Public Use Data from 1969-2006 reported by the National Center for Health 
Statistics, Centers for Disease Control and Prevention, 2009 and also does not include 
separate statistics for the Caucasian race. The report does include separate statistics for 
other races, such as African American: Table 1 shows a similar trend expected for 
African American men with estimated deaths from prostate cancer for 2009/2010 
projected at 3,690 or 13% fewer than the estimated death rate for the 2007/2008 period at 
4,240. However like new cases and deaths for all races, estimates indicate that African 
Americans will experience a significant increase in the number of new cases and cancer 
deaths for the 2011-2012 period (see Table 1) (American Cancer Society-African 
Americans [ACS-AA], 2007-2008, 2009-2010, 2011-2012).  
 Although death rates have fallen more quickly for African American men than for 
Caucasian men since early 1990, the death rate for African American men remains more 
than twice that of Caucasian men. These varying rates may be due in part to differences  
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Table 1. Estimated Total of New Prostate Cancer Cases and Deaths 2008-2010 (all races) 
and African American Cases 2008-2012. 
 
Year Total 
new 
cases 
% 
new 
cases 
(yearly) 
Total 
deaths 
% 
deaths 
(yearly) 
African 
American 
new cases 
% new 
cases 
(yearly) 
African 
American 
deaths 
%  
deaths 
(yearly) 
2008 186,320 
3.2% 
28,660 
-4.5% 
30,780 
-12% 
4,240 
-13% 2009-
2010 
192,280 27,360 27,130 3,690 
2011-
2012 
217,730 13.2% 32,050 17% 35,110 29% 5,300 44% 
 
Source: American Cancer Society, 2010; American Cancer Society – African American 
Men, 2009-2010, 2011/2012. 
 
in treatment choices, screening habits, and education about prostate cancer among the 
races (ACS-AA, 2011/2012; National Centers for Health Statistics, 2006).  The disparity 
also translates into poorer survival rates in African American men who tend to present 
with advanced stage disease and have less access to appropriate and timely treatment. For 
example, Figure 1 shows death rates for both African Americans (dark line) and 
Caucasians (light line) increasing from 1975 through 1988 where for African Americans 
the rate increased more sharply to nearly 70 per 100,000 and only slowly rising to 33 per 
100,000 for Caucasians. After 1988, the rates began to rise again for both races; however, 
the increase was much greater for African Americans. For instance, Figure 1 shows the  
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Figure 1. Trends in death rates for African American (dark line) and Caucasian men 
(light line) with prostate cancer, 1975-2005. source: National Center for Health statistics, 
Centers for Disease Control and Prevention, 2008. 
 
rates peaked near 81 per 100,000 African Americans and 38 per 100,000 Caucasians 
around 1993 at which time they began to fall. 
The rates for African Americans decreased much faster than for Caucasians 
through 2003; however, they still remained more than 2.4 times greater as demonstrated 
in Figure 1. Finally, by 2005 the death rates for African Americans and Caucasians fell to 
near 55 and 22 per 100,000 men, respectively. Similar rates were reported by the 
National Cancer Institute’s Surveillance, Epidemiology, and End Results data (SEER). 
These rate changes may reflect increased prostate specific antigen (PSA) test utilization 
during the same period, as the dissemination of the test grew quickly throughout the U.S. 
after its first introduction in 1986 as a screening tool. 
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The National Cancer Institute’s (SEER) Cancer Statistics Review provides 
information on incidence, mortality, and prevalence of disease in the United States. In a 
review of prostate cancer trends using the SEER-Medicare data from 1973-1995 it was 
reported that the burden of prostate cancer is carried mostly among elderly men and 
African American men. The median age in men diagnosed with prostate cancer was 71 
and the median age at death was 78. In addition, more than 75% of all cases of prostate 
cancer were diagnosed in men over 65 with greater than 90% of deaths occurring in this 
age group (Harris & Lohr, 2002). In a more recent review from 2000-2004, the SEER-
Medicare data suggests that the median age at diagnosis for prostate cancer during that 
period was 68 with the median age of death reported to be 80 (National Cancer Institute 
[NCI], 2008).  Differences in age at diagnosis between the two datasets are explained by 
the increased use of screening to detect earlier stage disease in younger men (ACS, 2008; 
ACS, 2009; Harris & Lohr, 2002).  
The SEER report also compared cancer incidence rates and death rates between 
African American and Caucasian men. The report noted an incidence rate of 258.3 to 
163.4 (1.6 rate ratio) and a death rate of 64 to 26.2 (2.4 rate ratio) for African American 
to Caucasian men per 100,000, respectively. Therefore, African American men are 1.6 
times more likely to develop prostate cancer and 2.4 times more likely to die from 
prostate cancer than Caucasian men.  
A review sponsored by the U.S. Environmental Protection Agency (EPA) in 2004 
also expressed concerns over increased incidence rates of prostate cancer by noting 
significant differences among African American men and Caucasian men. In addition, the 
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ACS-AA noted similar significant incidence rate differences from 1975 through 2005 for 
African American and Caucasian men, suggesting that a racial disparity may reflect 
higher incidence rates for African American men than for Caucasian men. Both reports 
claimed that increased incidence could be related to early detection by screening thus 
resulting in increased numbers of cases including those of more aggressive disease as 
well as more indolent prostate cancers. 
Definitions and Terminology 
Prostate Gland 
 
The prostate gland is part of the male reproductive system and surrounds the 
urethra, a tube that empties urine from the bladder and carries semen during ejaculation. 
The prostate’s main purpose is to produce fluid for semen in order to transport sperm. 
Normally, it is the shape of a walnut or crab apple and weighs only a few grams. It is 
located in front of the rectum, behind the pubic symphysis, beneath the bladder and is 
divided into three parts or zones (see Figure 2). The tissue immediately surrounding the 
urethra and down the center is the transition zone. The transition zone is the area of 
prostate tissue that grows during a non-cancerous condition known as benign prostatic 
hyperplasia (BPH).  
Benign prostatic hyperplasia is the most common non-cancerous growth process 
in men (Carter, 2007). It is more commonly found in western countries (i.e., United 
States, United Kingdom, and Canada) rather than eastern countries (i.e., Japan and 
China). Within the U.S., BPH is more commonly seen in African American men 
 
7 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Illustration of prostate zones. CZ central, TZ transitional, and PZ peripheral 
zone. 
 
than in Caucasian men (Carter, 2007). The central zone lies outside the transition zone 
and the largest and outermost zone is called the peripheral zone. It is the peripheral zone 
in which most cancers are found. The prostate gland is encapsulated within a fibrous 
tissue (Carter, 2007; ACS, 2008; ACS, 2009; ACS-AA, 2007/2008) (see Figure 2). 
Screening Tests 
 
Population or mass screening programs are meant to detect early stage cancers 
with the goal of curing disease (reducing mortality) and improving outcomes (quality of 
life issues). These programs are designed to examine asymptomatic men at risk. In 
contrast, early detection or opportunistic screening is guided toward the patient and his 
physician usually initiated by one or the other at the time of consultation and from 
resulting symptoms experienced by the patient. Opportunistic screening is a setting where 
Front 
view CZ = central zone 
TZ = transitional zone 
PZ = peripheral zone 
Side 
view 
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patients have not been invited to participate in a study protocol or are not part of an 
organized population-based screening program (Schmidt, Riesen, & Prikler, 2004; 
Legler, Feuer, Potosky, Merrill & Kramer, 1998).   
Generally, men with localized prostate cancer have no symptoms; however, 
slowing of urinary flow, having to void during the night (nocturia), and increased urinary 
frequency can be common low grade symptoms. These are some of the same symptoms 
experienced by aging men without prostate cancer. It is for these reasons that early 
detection tests were developed in order to identify prostate cancer while it remains 
confined to the gland itself. However, to date, there remains controversy with the idea of 
early detection by screening.  The three most commonly used tests are a blood serum 
prostate specific antigen (PSA), a digital rectal exam (DRE), and transrectal ultrasound 
imaging (TRUS) (ACS, 2008; ACS, 2009; ACS-AA, 2007/2008; Challen, 1998). It is 
suggested that use of any of these tests on their own may result in low sensitivity, 
specificity, and decreased positive predictive value for prostate cancer detection and that 
more favorable results could be obtained by using a combination of the three (ACS, 
2009; ACS-AA, 2007/2008, American Urological Association [AUA], 2009, Carter, 
2008).      
Prostate Specific Antigen 
Prostate specific antigen is a protein produced within the prostate gland that is 
easily measured when found in the bloodstream. Every man has some concentration of 
PSA in the bloodstream that varies with many factors, including age. Other factors 
associated with increased serum PSA values could include a recent DRE where palpation 
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of the gland itself may cause a rise in PSA. More factors include biopsy, transurethral 
resection, urinary retention, prostatitis, and ejaculation. Physical exercise has not been 
associated with increased PSA levels (Schmid et. al, 2004; Challen, 1998).  Increased 
PSA levels can indicate prostate problems and even cancer; however, elevated levels are 
not always indicative of prostate cancer.  
The PSA test was first approved by the Food and Drug Administration (FDA) in 
1986 as a method to determine the success of treatment in men who have cancer and to 
monitor the gland for cancer recurrence and not initially as a screening tool. Currently, 
the PSA test is used in the United States as a means of early detection and has been 
credited by advocates of screening as the reason why prostate cancer incidence and 
mortality rates are declining (ACS, 2008; AUA, 2009; American Medical Association 
[AMA], 2007).  However, it remains unclear whether the test reduces prostate cancer-
specific death rates. In fact, some have criticized use of the test because most men with 
an elevated PSA do not have cancer. These ideas are continually debated and remain 
controversial (Carter, 2007; ACS, 2009, ACS-AA, 2007/2008). The major disadvantage 
of the PSA test is its lack of specificity and sensitivity, where sensitivity for screening 
tests is defined as the ability of a test to detect cancer that would have been diagnosed in 
the future in the absence of the screening test. It is has been noted that 25% of prostate 
cancer patients show no elevated PSA level and that in order to define the true value for 
both the sensitivity and specificity of the test, that all prostate glands would have to be 
removed and evaluated pathologically (Schmid, 2004; Hakama, Auviven, Day & Miller, 
2007). In a separate report using SEER-Medicare data, the authors noted that 18-39% of 
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white men and 20-44% of African American men were over diagnosed by use of the PSA 
test (Schmid, 2004), and one study of veterans concluded that PSA screening rates among 
elderly men were higher than men of other age groups (Walter, Bertenthal, Lindquist & 
Konety, 2006). The term over diagnosed suggests that screening may detect cancers that 
would have never been diagnosed in the absence of screening and which could 
potentially lead to unnecessary treatment (Draisma, Boer, Otto, Van der Cruijsen, 
Damhuis & Schroder, 2003). A more formal definition of the term over diagnosis 
includes detecting indolent non-aggressive cancers that would have never become 
clinically evident without screening (Ciatto, Gervasi, Bonardi, Frullini, Zendron, 
Lombardi et. al, 2003).  
Digital Rectal Exam 
 
A digital rectal examination (DRE) is an examination by a physician who places 
their index finger inside the rectum to feel the surface of the prostate gland. The gland 
sits anterior to (in front of) the rectum thus making palpation easy with only minor 
discomfort. The physician notes any hard nodules (surfaces) or irregularities in shape that 
may indicate prostate cancer based on volume and gland size.  
Volume measurements can be verified manually during the DRE. Specifically, 
measurements are determined once physicians have first, noted landmarks and have 
identified abnormalities by palpating the gland, they would then move the index finger 
across the furrow to the right and left lateral sulcus adding the numbers of finger widths it 
took to cross the full width of the gland. This dimension provides the width in 
centimeters (cm) as most fingers tend to be close to one centimeter across. The physician 
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would then move the finger over the surface of the gland in the length direction from the 
apex to the base while estimating the numbers of fingernails. This method is used to 
estimate the length because most fingernails also tend to be approximately one centimeter 
across (Zackrisson, Aus et al., 2003; Pinsky et al., 2006). If the DRE is used alone, it can 
miss 30-40% of prostate cancers (Carter, 2007; ACS, 2009, ACS-AA, 2007/2008). If 
abnormalities are noted, further testing is indicated usually through an ultrasound study to 
define the prostate volume and biopsy for pathological confirmation.  
Transrectal Ultrasound and Prostate Biopsy 
 
Typically, should a patient have an elevated PSA and/or abnormal DRE, the 
physician would order further pathological work up in the form of a transrectal 
ultrasound and then a tissue biopsy in order to confirm presence of disease. During 
transrectal ultrasound imaging the prostate volume can be measured and any irregularities 
visualized. For biopsies, the method of obtaining the tissue is typically through the use of 
a biopsy needle under the guidance of ultrasound imaging. The physician positions the 
biopsy needle affixed to the probe using ultrasound imaging, guides the probe to 
specifically identified regions within the gland, and punctures the gland by triggering the 
needle. This method removes a small tissue core that is placed into a container for later 
evaluation and observation of tumor characteristics by a pathologist to determine if 
cancer is present (Carter, 2007; ACS, 2009, ACS-AA, 2007/2008).      
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Tumor Characteristics 
Grade 
Tumor aggressiveness is determined by examining the microscopic pattern of 
cells obtained from biopsy tissue samples. The most common type of tissue biopsy is 
called a sextant biopsy where a physician obtains tissue samples from six different 
regions within the prostate gland: three samples from the right lobe and three from the 
left lobe. When cancer is confirmed by biopsy, a pathologist grades the disease based on 
specific cell characteristics. The most common grading system is known as the Gleason 
scoring method. The Gleason score method assigns a numerical value to each of the six 
tissue core samples and can range from 1 (least aggressive) to 5 (most aggressive) based 
on extent of tumor cell differentiation within a core sample (Gleason, 1977). Typically, 
the Gleason score is displayed as the sum of two numbers from the two most common 
patterns of tumor visualized by pathology. For example, 3 + 4 = 7 would indicate a 
Gleason score 7, from summing the most common tumor pattern seen in a single core 
sample and the second most common tumor pattern within a separate core sample. Given 
that the Gleason score can range from 1 to 5, the added values can range from 1+1 to 5+5 
or from 2 to 10. The majority of detected tumors range from 5 to 10. The Gleason score is 
believed to be the most important predictor of disease extent and overall prognostic 
outcome (ACS, 2009; AUA, 2009; Carter, 2007). 
Stage  
 
Tumor stage is the extent to which the tumor has involved the prostate gland or 
spread outside the gland. The American Joint Committee on Cancer (AJCC) has 
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established a system of tumor staging. For instance in localized/regional disease, stage 1 
indicates tumors of T1, T1a, T1b, and T1c grade and with no known nodal involvement 
(N0) and no known metastasis or spread of disease (M0). According to AJCC 
nomenclature, this study will focus only on clinical Stage 1 and Stage 2 tumors of T1 or 
T2, N0, and M0 since 88% and 92% of prostate cancers diagnosed in African American 
and Caucasian men respectively are staged with localized/regional disease (ACS-AA, 
2007/2008).  
Risk Factors 
 
Consensus for risk factors associated with prostate cancer varies; however, the 
ACS identifies age, ethnicity, family history, and socioeconomic status as the greatest 
factors to which aggressive disease can be attributed. African American and Jamaican 
men of African descent have the highest incidence rates worldwide (ACS, 2010). Family 
history has consistently shown to be a significant risk factor with positive association of 
two to three times more likely for men to develop prostate cancer when they have first 
degree relatives with prostate cancer, such as a father, brother, or son. However, some 
studies suggest that this association may be contaminated by selection bias claiming that 
clinical and pathological features of familial cancers are similar to nonfamilial cancers 
(Bostwick et al., 2004; U.S. Preventive Services Task Force, [USPSTF], 2002; 
Whittemore, 1995).   
Socioeconomic factors may also influence prevention and early detection 
methods, treatment choices, quality of life, and survival. Approximately 24% of African 
Americans live below the poverty level compared to only 10% of Caucasians. 
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Additionally, 20% of African Americans are uninsured while only 11% of Caucasians are 
without health insurance. Other modifiable personal factors affecting cancer control and 
detection include weight and diet, obesity, physical activity and exposure to some known 
environmental carcinogens (ACS-AA, 2007/2008). 
There are increasing public health initiatives aimed at informing men about the 
risk of prostate cancer through community screenings. The ACS has sponsored programs 
to create change in public policy to help reduce health disparities among races. In 
addition, agencies such as the Centers for Disease Control and Prevention (CDC) have 
early detection programs that provide education and screenings. Many of these agencies 
work to reduce both modifiable and non-modifiable risk factors by educating men among 
races about the differences (ACS, 2009; ACS-AA, 2007/2008).  
PSA-based Screening  
Despite the considerable societal impact of prostate cancer, screening with the 
PSA serum test has raised considerable debate. There exists no standardized consensus 
within the medical community when weighing the benefits and harms associated with 
prostate cancer screening. Currently there are insufficient data linking screening with 
improved survival and therefore, no evidence suggesting that prostate screening should or 
should not be considered for low or average risk men and elderly men over age 75. 
Among men with low grade disease, opinions among clinicians vary out of concern over 
unnecessary biopsies, increased detection of possibly indolent cancers, dilemmas over 
treatment options, and uncertain complications of morbidity. In contrast, among men with 
aggressive disease, prostate cancer creates extensive societal anxiety to find a cure or 
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preventive measures while concerns loom over substantial resource consumptions that 
lead to high health care costs (Crawford & Abrahamsson, 2008).  
The ACS recommends men of average risk receive both a PSA test and a DRE 
annually beginning at age 50. For men of higher risk (African Americans and men with 
strong family history) screening is recommended starting at age 45 years. The ACS-AA 
report noted that while having breast, cervical, and colon and rectum screening tests were 
not significantly different among African Americans compared to Caucasians in both 
males and females, use of screening tests among men for prostate cancer was clearly 
different for the 2004 year. For example, the Behavioral Risk Factor Surveillance System 
(BRFSS) of 2004 reported the proportion of women receiving a mammogram for breast 
screening was 59.4% and 58.6% among African Americans and Caucasians, respectively 
(see Table 2). The same survey noted the proportion of women receiving pap smears test 
for cervical cancer among African Americans and Caucasians to be 86.7% and 85.6% 
with screening for colon and rectum cancer at 19.2% and 19.4%. However, prostate 
screening using a PSA test was 50% and 55.4% and a DRE was 47.4% and 52.2% for 
African Americans and Caucasians, a relative percent difference of greater than 10% for 
both tests (50%/55.4% and 47.4%/52.2%). The survey noted no known reasons for the 
discrepancy in prostate screening use among races other than, perhaps, African American 
men’s distrust in the medical community, lack of education about screening, and less 
likelihood of participating in community screening programs (Behavioral Risk 
Surveillance System, Public Use Data File, 2004). 
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Table 2. Percent Use of Cancer Screening Examinations, 2004. 
 
 
Cancer Site African 
American 
Caucasian Relative percent 
difference * 
Breast 
Mammogram 
Clinical breast exam (CBE) 
Mammogram and CBE 
 
59.4 
64.3 
51.2 
 
58.6 
65.6 
52.2 
 
1.3 
-2.0 
-1.9 
Cervical 
Pap smear test 
 
86.7 
 
85.6 
 
1.30 
Colon and Rectum 
Fecal occult blood test (FOBT) 
Flexible Sigmoidoscopy 
 
19.2 
44.3 
 
19.4 
47.0 
 
-1.0 
-6.0 
Prostate 
Prostate Specific Antigen 
(PSA)  
Digital rectal exam (DRE) 
 
50 
47.4 
 
55.4 
52.2 
 
-10.8 
-10.1 
*negative value indicates percent fewer African Americans having tests. Source: 
Behavioral Risk Surveillance System, Public Use Data File, 2004. 
 
Problem Statement 
With final results from the European Randomized Screening for Prostate Cancer 
(ERSPC) and the Prostate, Lung, Colorectal, and Ovary Cancer Screening trial (PLCO) 
in the United States not yet available, researchers must rely on retrospective studies using 
observational datasets. The ERSPC and the PLCO trials are two randomized clinical 
trials that have closed however, continue to follow enrollees to evaluate the efficacy of 
prostate cancer screening with hopes of explaining differences in incidence and mortality 
rates, treatment strategies, and outcomes while addressing whether early prostate 
screening leads directly to saving lives. A randomized clinical trial has been described as 
the gold standard in most research areas. It involves the careful design of an experiment 
that ensures assignment of participants to treatment groups in a pure random fashion in 
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that assignment to groups is independent of the characteristics of the subjects and that the 
groups are similar in all other characteristics. The experiment is performed without 
biases.  Because RCTs are carried out under these strict conditions, they are generally 
recognized as being internally valid. In contrast, because RCTs often exhibit results that 
are less than generalizable to the population, they can experience weak external validity. 
However, as valuable as RCTs may be, they are not without inherent limitations such as 
usually being conducted on highly selected patients in centers of excellence, under 
optimal strict protocol conditions, and sometimes costly and time consuming (Earle et al., 
2001).  
The decline in observed mortality rates for prostate cancer during the past decade 
suggests that early detection from increased screening and aggressive treatments may 
play a role. However, there remains no proven association. No national consensus 
regarding best practice patterns and screening patterns exist thus leaving the management 
of prostate cancer controversial (Harris & Lohr, 2002; Carter, 2007; AUA, 2009; ACS, 
2009, 2010). Differences exist between African American men and Caucasian men 
regarding treatment strategies offered or chosen and in how they view screening 
programs that can result in different outcomes between these groups of men. These 
differences may result from African American men having less access to aggressive 
curative treatment, participating in fewer early detection screening programs, and 
possibly different risk and behavioral factors contributing to higher stage disease at 
diagnosis and worse overall prognosis. Available treatment options include surgery to 
remove the gland, radiation therapy including brachytherapy implants, hormone therapy 
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deprivation (ADT), and watchful waiting or active surveillance as it is sometimes called 
(ACS-AA, 2007/2008; Richert-Boe et al., 2003; Freedland & Isaacs, 2005; Jones, Shipp, 
Thompson & Davis, 2005; Marion & Schover, 2006).    
Extensive studies exist using a multitude of secondary datasets evaluating 
screening habits and treatment management for prostate cancer. Even with community 
screenings and advanced technological treatments, differences have been reported among 
races.  Most studies have shown conflicting and contrasting results or mixed outcomes at 
best. Often these studies consist of small sample sizes, fail to control for multiple factors 
that may confound treatment comparisons, and most do not show results from community 
practice.   
In addition, the NCI has spent over $2 billion dollars on prostate cancer research. 
By the end of 2005 there were over 28,000 scientific papers published in peer-reviewed 
journals on prostate cancer. Advances have been made in regards to treatment, imaging, 
biopsy technology, screening tests, along with attempts to understand risk factors and 
disease, and in understanding behavioral issues (Roemeling & Schroder, 2006; Schmid, 
2004; Carroll et al., 2001). Despite these recent advances, the frequency and variation of 
complications reported have differed. No emerging consensus exists regarding the 
optimal treatment for the most common cancer in men (AUA, 2009; Schmid et al., 2004; 
Draisma et al., 2004; Frankel, Smith, Donovan & Neal, 2003; Otto & deKoning, 2004).  
No uniform consensus exists regarding the efficacy of prostate screening and whether any 
beneficial effect that can be linked to reduced mortality. In fact, there are agencies that 
recommend screening and those who do not for various reasons. Some groups, such as 
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the American Urology Association (AUA) and the U.S. Preventive Services Task Force 
(USPSTF) suggest that prostate screening can be harmful with studies showing that PSA 
false positives may lead to unnecessary treatment and anxiety (AUA, 2009; USPSTF, 
2008; Carter, 2007). Likewise, studies exist that show health disparities between African 
American and Caucasian men while others have not.  A majority of these use population 
sizes from specific geographical regions making generalization improbable and robust 
power unlikely. Most studies use conventional statistical methods that are often filled 
with bias and multiple limitations (ACS, 2008, 2009; ACS-AA, 2007/2008; Harris & 
Lohr, 2002; Black, 2006). 
In the absence of randomized clinical trial data and with the known limitations to 
resolve questions of whether early detection and aggressive treatment leads to decreased 
mortality rates in men with prostate cancer, use of the PSA test remains a subject of 
controversy. Therefore, researchers can only conduct studies using current observational 
data with analysis evaluated through traditional statistical methods to seek comparable 
outcomes to questions like why African American men have higher mortality rates than 
Caucasian men. And, if mortality rates are declining in both races, why then does a health 
disparity gap remain?  Moreover, if conventional statistical methods continue resulting in 
mixed and variable resolutions to these unanswered questions, then additional statistical 
methods should be considered. Various limitations exist when performing retrospective 
observational studies. Confounders are difficult to account for due to lack of 
randomization and inherent selection bias that often lead to mixed results.  
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This study seeks to expand on previous research providing new information by 
exploring use of the PSA test as a screening tool to gain knowledge and better 
understanding of its relationship to disparate mortality rates among elderly African 
American and Caucasian men. Men become Medicare eligible beginning at age 65; 
however, men aged 66 and over are included in this study because the median age of men 
diagnosed with prostate cancer is 68 with almost 64% of prostate cancer diagnosed in 
men over 66. Including men aged 66 instead of 65 also provides a full year of Medicare 
claims data to assess comorbidities.  A secondary aim will be to explore PSA utilization 
rates among race for the group of men diagnosed with localized/regional prostate cancer 
and from the group of men without prostate cancer. A 5% randomized sample of non-
cancer cases are provided in the SEER-Medicare dataset and will be used to develop 
population-based estimates of use of the PSA test throughout the study period. Figure 3 
represents an illustrative model for the groups, the treatment (binary intervention), and 
the outcome for the study. The solid lines indicate the direction of the primary goal of 
examining screening PSA tests (treatment intervention) and its effectiveness on disparate 
mortality rates among race from the group of men with prostate cancer. Additionally, the 
study will be repeated comparing men receiving screening PSA tests (treatment 
intervention) and its effectiveness on overall mortality among race in men who do not 
have prostate cancer. Finally, the dashed lines show the path of the secondary aim which 
is to analyze PSA utilization rates among race from the group of men with prostate 
cancer as well as utilization rates for race from the group of men with no cancer.  
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Figure 3. Illustrative model of groups, treatment intervention (screening PSA), and 
outcome. 
 
Evaluation of this research study will be a multi-stage process. Baseline, 
summary, and descriptive statistics will be provided for the categorical independent 
variables and tests for differences in means will be assessed for the continuous 
independent variables. Initial logistic regression models will be created to assess variance 
among independent variables for screening versus non screening and among race. These 
initial logistic models will be compared to other logistic and Cox regression models once 
a propensity analysis has been applied and men matched and paired.   
The distributional variance of covariates will be examined for differences and 
balance among race within each of the five quintiles within the treatment group 
(screening PSA) and the control group (no screening PSA). Balance of covariates will be 
assessed by quality assessment tools presented in chapter three using various graphical 
SEER-Medicare
Analysis file
(n =515,802)
Prostate Cancer Cases 
       n = 72,777 
Non-Cancer Cases
(5% randomized sample)
      sPSA 
   n = 32,210
Treatment 
 
      sPSA       dPSA 
   n = 37,854 
       dPSA 
Overall mortality Prostate Cancer Mortality 
 
Outcome
Group 
PSA utilization 
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plots. After generating initial logistic regression models, a propensity analysis using 
logistic regression with the intervention (sPSA) as the dependent variable will be 
performed. The propensity analysis provides the estimated propensity scores (p-score) for 
all independent variables. The p-score is defined as the probability of a man having a 
screening PSA test based on the baseline characteristics. The regression model will yield 
estimates of this probability and will range from 0-1. Following this analysis, all men will 
be matched, paired, and placed into strata of five quintiles based on their p-scores. 
Assessment of whether the p-score helped to balance the covariates can then be 
performed by again, examining differences in racial groups within quintiles and notation 
of the adjusted p-value provided in the propensity logistic model (in this case, a p-value > 
0.05 would show no significant differences between covariates and therefore indicate 
balance has been achieved). Further assessment of covariate distributions within each 
quintile may show the inability to detect differences after p-score adjustment. For 
example, the initial regression model should indicate sufficient overlap of covariates by 
showing no extensive or consistent patterns of interactions between screening PSA and 
each quintile. This would allow for including the p-score as a covariate in all subsequent 
regression models to explicitly account for most of the selection bias. Should assessment 
of overlap prove sufficient, a final propensity score adjusted logistic regression and 
conditional Cox regression model will be developed for group comparisons. A final 
statistical analysis will be performed using both regression models for examining main 
treatment effects that independent variables, including p-scores, have on the 
dichotomized outcome response variable mortality.  
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Propensity scoring analysis is helpful for removing selection bias by balancing 
groups on all observed variables thus allowing placement of men into quintiles of which 
conventional statistical methods can then be applied. This method provides a means of 
achieving randomization in descriptive observational studies. Propensity scoring analysis 
also increases statistical power and aids in further improving overall generalization 
similar to that of randomized clinical trials (Rosenbaum & Rubin, 1983; Love, 2003; 
D’Agostino, 1998). Multivariate matching and stratifying are also helpful when trying to 
control confounders that cause bias. An advantage to these methods is the effect of 
multiple other factors can be controlled for at the same time (Grimes & Schulz, 2002).  
A large database compiled from SEER-Medicare linked files will help to ensure 
external validity by providing greater generalization to the national population. The 
SEER Medicare linked files are population-based where incidence data for individuals 
are linked to their mortality data therefore making it possible to examine mortality by 
using variables determined at the time of diagnosis, such as PSA screening. The NCI 
defines this as incidence-based mortality (IBM). 
Purpose  
The purpose of this study is to extend previous research and provide new 
information for effectively identifying PSA screening’s influence on disparate mortality 
between African American and Caucasian men who have and who do not have localized 
prostate cancer. The secondary dataset used are merged SEER-Medicare files from 1986 
through 2006. The primary aim of the research is to conduct an analysis of prostate 
screening with PSA and its effect on racial disparate mortality among a group of men 
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with prostate cancer and repeated for a group of men without cancer using the latest 
SEER-Medicare dataset and a relatively new statistical method in the propensity scoring 
method. Once propensity scores are determined and shown to have sufficient overlap, 
that is, selection bias has been removed; groups can be matched and placed into quintiles. 
Subsequent multivariate logistic regression analysis will be performed. Finally, a main 
effects logistic and conditional Cox regression model will be developed demonstrating 
the greatest association between independent variables and the outcome response variable 
of mortality.  
The same analysis will occur for the non-cancer cases to examine if differences 
exist in overall mortality between races in men without prostate cancer. Knowing 
whether mortality rates among race differ in men without prostate cancer could produce 
clues for the presence of any unobserved variables and help explain bias effects in 
mortality differences in men with prostate cancer. For example, if differences are 
established in one group and not the other, then other factors (unobserved variables) 
could be involved calling into question the reliability of using mortality as an endpoint to 
assess screening efficacy in nonrandomized studies. This is reasoned by the notion that 
any realized health benefit from screening PSA (early detection) would be evident only 
through differences in prostate cancer-specific mortality but should differences appear in 
overall mortality (men without prostate cancer) then selection bias would be playing a 
greater role and should lead the way for further exploration.  
Given the controversy surrounding unproven survival benefits, harms, and 
screening guidelines of prostate screening, a secondary aim will be to evaluate PSA 
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utilization rates over a two period era, the PSA era and the post-PSA era. The study 
period of 1986-1995 will serve as the PSA era and the period of 1996-2006 as the post-
PSA era. Among groups, those men diagnosed with prostate cancer and those without 
cancer but who received regular screening will be evaluated by test of proportions for the 
two periods. Should factors be identified showing differences between African American 
men and Caucasian men regarding screening habits and mortality then new race-based 
public policy prevention mechanisms could be examined. Hope lies with randomized 
clinical trials for proving that PSA screening for early detection and prevention can lead 
to reduced mortality rates and narrowing the disparity gap among races. Until then, 
observational studies using secondary data sets are warranted. The strengths of this study 
are use of the most recent SEER-Medicare data and a propensity scoring methodology, 
which is generally regarded as robust and accurate, subject to fewer restrictions, and 
enables improved confounder accountability (Rosenbaum & Rubin, 1983; Love, 2003; 
Grimes & Schulz, 2002).   
Research Questions 
1. Are men with prostate cancer equally likely to have similar prostate cancer-
specific mortality rates among race for screening PSA tests compared with 
diagnostic PSA tests? 
 
2. Are men without prostate cancer equally likely to have similar overall mortality 
rates among race for screening PSA tests compared with diagnostic PSA tests? 
 
3. Did baseline (initial) PSA screening rates differ among men with prostate cancer 
during two eras, the PSA era 1986-1995 and the post-PSA era 1996-2006? 
 
4. Did baseline (initial) PSA screening rates differ among men without prostate 
cancer during two eras, the PSA era 1986-1995 and the post-PSA era 1996-2006? 
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Based on the overview presented, the following hypotheses are provided 
regarding the extent that screening has on disparate mortality rates among African 
American and Caucasian men with prostate cancer.  
 Hypotheses 
H1: No statistically significant differences exist in prostate cancer-specific 
mortality rates among race for men with PSA screen detected cancer and 
men with clinically diagnosed cancer, 
 
H2: No statistically significant differences exist in overall mortality rates among 
race for men without prostate cancer receiving screening PSA tests and men 
receiving diagnostic PSA tests, 
   
H3: The baseline (initial) PSA screening rates among race in men with prostate 
cancer in the two PSA eras from 1986-2006 will show no statistically 
significant differences, 
 
H4: The baseline (initial) PSA screening rates among race in men without 
prostate cancer in the two PSA eras from 1986-2006 will show no statistically 
significant differences. 
 
Significance of the Study 
 
The outcome of this study is to understand the disparate relationship in mortality 
among African American and Caucasian men with localized prostate cancer. This 
observational retrospective study may guide future research in developing treatment 
regimens formulated from race-based PSA guidelines and unique to the individual patient 
based on improved knowledge and understanding of the complex factors associated with 
racial disparate mortality rates. Furthermore, the current study may become a surrogate or 
complement to time consuming and costly prospective randomized clinical trials. The 
study will also provide more objective clinical data in order that shared decision making 
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among physicians and patients concerning screening practices will be clearer. The study 
will generate debate of whether the PSA test should ever be used as a screening tool for a 
cohort of elderly men with and without localized/regional prostate cancer thus having a 
major impact on the validity of the PSA test itself. Using a robust statistical analysis such 
as the propensity scoring method along with one of the most recent population based 
secondary datasets could help shape public policy toward establishing race-based 
screening guidelines for improved prostate screening programs.  
Data and Analysis 
 
The study is a retrospective observational design analyzing data from the 1986-
2006 SEER-Medicare linked datasets (National Cancer Institute). Prostate cancer patients 
diagnosed from January 1, 1986 through December 31, 2006 (n = 515,802 cases) whose 
data were entered into the linked databases are included. Surveillance, Epidemiology, and 
end Results (SEER) cancer registry data merged with Medicare health care claims 
provide linked patient demographic information, initial PSA testing and diagnostic 
information, initial treatment, and long-term follow-up status of national cancer incidence 
and mortality rates making the data suitable for health services research (Warren, 
Klabunde, Schrag, Bach, & Riley, 2002). The latest release of SEER-Medicare linked 
data includes cases diagnosed through 2006 from all regions except Alaska and the 
Arizona Indians and Medicare claims data through 2005.  
The SEER Medicare linked database is sponsored by the National Cancer Institute 
and combines clinical information from population-based cancer registries with claims 
information from the Medicare program. Since initial data collection began in 1973, the 
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number of registries has expanded and now includes approximately 26% of the U.S. 
population. The SEER data are considered highly valid with quality and completeness 
studies performed yearly to ensure accuracy by holding the highest level of certification 
of quality as provided by the National American Association of Central Cancer 
Registries. The program’s standard for completeness of data ascertainment is 98% 
(Warren et al., 2002).  
Summary 
Prostate cancer is the second leading cause of cancer death among men in the U.S. 
with over 2.6 million men diagnosed and almost 375,000 deaths occurring since 1995 
(AUA, 2007). However, because of improved treatment technologies and possibly from 
early detection, mortality rates for the disease have been declining since that time with 
34,475 men dying in 1995 compared with more than 27,300 deaths estimated for  2009 
(AUA, 2007; ACS, 2009).  
Many studies have shown improved outcomes due to advances in treatment 
regimens, prostate imaging, biopsy methodology, in understanding risks, education, and 
public awareness. However, there still remains no consensus for optimal screening 
patterns, screening intervals, and screening tests that might lead to best practice 
guidelines for early stage disease. Furthermore, there have been few studies that 
evaluated race-based policy concerning screening with PSA to help in understanding the 
mortality differences in African American and Caucasian men. This study examines 
several variables to determine the extent to which they might contribute to the racial 
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disparate mortality rates observed among African American and Caucasian men when 
considering PSA utilization.  
The study will incorporate a robust, statistical method in the propensity analysis 
that has not yet been applied to evaluations of race-based mortality differences and 
screening PSA tests alone. The propensity method will allow for matched groups on 
observed variables in order to simulate randomization. This method together with the 
most update and complete dataset of the National Cancer Institute’s SEER-Medicare 
merged file system will advance not only perceptions of screening efficacy for prostate 
cancer, but also it will increase clinical knowledge of the disease by identifying, 
quantifying, and analyzing variables and correlating them to the value of the PSA test to 
determine if their presence, absence, or variance might explain disparate mortality rates 
among African American and Caucasian men. Results may help guide public policy 
toward more individualized race-based screening guidelines and provide physicians with 
new information about ways to communicate screening tests that may be best for 
individuals. 
Organization of Dissertation  
The literature review in the following chapter includes an overview of prostate 
cancer in the U.S. and describes relationships between screening and mortality rates 
among African American and Caucasian elderly men. It includes discussion of various 
screening studies along with current guidelines, available screening tests, and observed 
mortality among races. Chapter 3, entitled Methods begins with a brief examination of 
the theory of the propensity scoring method and its applications to health services 
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research along with sample graphical assessment tools. A description of the analytical 
strategies employed in the study, including data source, sample population, methods, 
study variables, and hypothesis testing are provided along with discussions of the study 
limitations. Chapter 4, Results will present and briefly discuss findings. Chapter 5, 
Discussion, will address results, limitations of the study, and implications for public 
health policy and future health services research. 
 
 
31 
 
CHAPTER 2:  LITERATURE REVIEW 
 
The purpose of this review is to summarize literature concerning PSA use in men 
with prostate cancer and subsequent outcomes associated with African American and 
Caucasian men. The chapter begins with a discussion of prostate cancer followed by a 
brief discussion of prostate screening utilization in the United States including the PSA 
test and screening guidelines. This is then followed by a more extensive discussion of 
prostate screening studies including initial evaluations from two large population-based 
randomized clinical trials (RCTs) of the European Randomized Screening Prostate 
Cancer in Europe and the Prostate, Lung, Colorectal, and Ovarian trial in the U.S. Also 
discussed are factors associated with cancer specific mortality and risks of prostate 
cancer. Lastly a summary of the literature reviewed for this study is provided. 
Much of the research focusing on prostate cancer emphasizes screening 
controversies, treatment strategies, and outcomes issues within the U.S. and 
internationally. Other research focuses on barriers associated with access, social- 
behavioral relationships, and racial disparities observed in screening programs, treatment 
choices, and outcomes across ethnic groups. Most studies are retrospective in design and 
use secondary datasets mainly because complete results from randomized clinical trials 
are small in number or not yet available due to numerous years of follow-up required 
before statistical inferences can be made.
32 
 
 
 
Prostate Cancer 
 
Prostate cancer is a malignant disease that begins growing within the prostate 
gland. It is the most common cancer diagnosed in American men with 192,280 new cases 
and 27,360 deaths estimated for 2009 (ACS, 2009; ACS-AA, 2007/2008). Since 1995, 
2,600,000 men in the U.S. have been diagnosed with prostate cancer and almost 375,000 
have died from the disease (AUA, 2007). Autopsies have shown that about 15-30% of 
men over age 50 have microscopic cancerous cells present. By age 80 the percent rises to 
60-70% of men. In addition, a newborn boy has a 16% chance of developing prostate 
cancer in his life time but only a 3% chance of dying from the disease (Carter, 2007).   
Cancer is a disease characterized by the uncontrolled growth of cells having the 
potential to spread or metastasize to other parts of the body. Normally, cells divide with 
regularity in order to sustain life. However, when cells grow abnormally and at 
uncontrolled rates they become masses known as tumors. Some tumors are malignant 
(cancerous) and others are benign (non-malignant). Sometimes the growth of benign 
prostate tumors can interfere with normal bodily functions such as urinating; however, 
they are seldom life threatening. Any time the prostate gland enlarges, men experience 
urinary symptoms such as nocturia (nighttime urination) and increased urgency and 
frequency (the need to urinate more often). These symptoms can be mistaken for a 
common condition known as benign prostatic hyperplasia (BPH). BPH occurs when the 
tissue of the transition zone grows or swells causing stricture of the urethra that can lead 
to urinary problems (Carter, 2007). However, these same symptoms may also be 
experienced in men with early stage localized disease as well. 
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In early stage prostate cancer, men typically experience minimal or no symptoms 
when the tumor remains localized within the gland and has not yet invaded or extended 
through the capsule surrounding the gland. On the other hand, if cells of malignant 
tumors spread beyond the prostate capsule and enter the bloodstream or lymphatic system 
they may eventually invade and destroy normal tissues and organs at distant sites. When 
this occurs, new tumors are formed in those areas which eventually lead to symptoms and 
problems.  Many men often experience erectile dysfunction or loss of penile firmness 
when prostate cancer has spread to the nerves that control erections. Unfortunately, 
usually once prostate cancer has spread to lymph nodes, bones, or other organs, many 
men experience pain in the pelvic region, hips, back, ribs, and other bones (Carter, 2007; 
TAP Pharmaceuticals, 2003).  
The natural history of prostate cancer is not well understood, and as mentioned 
earlier, most men die with rather than from prostate cancer. A recent Lancet report noted 
that of patients who had their prostate cancers found through screening and ones that may 
not evolve into life threatening disease or reduced quality of life, only 16% would benefit 
from aggressive treatment. This implies that the remaining 84% receiving aggressive 
treatment would not benefit (Frankel et al., 2003).  
Prostate Screening  
PSA Evolution and Screening 
In 1986 the Food and Drug Administration (FDA) first approved use of serum 
PSA in the U.S. for testing recurrence of prostate cancer. PSA was not initially intended 
as an early detection tool for screening. However, as a result of its ease of measurement 
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and minimal invasiveness, rapid dissemination of the PSA test as an early screening test 
increased in the U.S. from the late 1980s through 1990. Since that date, use of the PSA 
test to detect cancer has been debated, scrutinized, contradicted, and contrasted by 
multiple case-finding studies throughout the world. Normal levels of PSA found in the 
blood varies with each individual, ideally ranging from zero to less than 4.0 ng/ml; 
however, today in the U.S. a threshold value of 4.0 ng/ml is the accepted minimum value 
that would trigger further diagnostic work up.   
Although the question of whether to use the PSA test for prostate screening 
remains unanswered and is one of the most controversial and debated topics in medicine 
today, one important clinical finding of the PSA test, or any screening test for that matter, 
must be its ability to differentiate cancer from benign disease (Roemeling & Schroder, 
2006; Schmid, 2004; Carroll et al., 2001). Opponents argue against screening with the 
PSA test for several reasons, including its unproven effectiveness to reduce prostate 
cancer-specific mortality, the unknown risks and benefits regarding the psychological 
effects of additional unnecessary testing such as biopsies, and the increased risk of 
overdetection and unnecessary side effects of aggressive treatment (Schmid, 2004; 
Draisma et al., 2004; Frankel et al., 2003; Otto & DeKoning, 2004).   
Although it is widely believed that early detection and aggressive treatment may 
reduce incidence and mortality rates for some cancers, it remains unclear whether 
prostate screening is useful for early detection and whether it is linked to increased cure 
rates and prevention without confirmation by randomized clinical trials. These were some 
of the concerns surrounding the creation of an international cooperative led by multiple 
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European countries to form the European Randomized Screening for Prostate Cancer 
Trial (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial in the U.S.  
An Austrian study using data collected by the ERSPC trial examined the effect of 
PSA screening on mortality in the city of Tyrol, Austria. The city of Tyrol had no 
particular screening guideline other than the PSA which was offered free of charge. PSA 
was received by 100% of the eligible male population. The authors compared mortality 
rates from Tyrol with other cities within Austria that either did not offer prostate 
screening or did for a minimum cost. The study noted that PSA screening utilization was 
used in 5.1% of all newly diagnosed cases in 1984 with the utilization rate rising to 
60.6% by 1994 (Bartsch et al., 2001). Bartsch and colleagues (2001) reported that using 
PSA screening for early detection showed a significant down-staging of disease leading 
to more successful aggressive treatments in Tyrol. Of the 307,249 men living in the 
Alpine region of western Austria during 1993, 65,123 (21%) of them between the age of 
45 and 75 were advised and encouraged to undergo a PSA test. No significant differences 
were noted between the trends in Tyrol and the rest of Austria before 1993. However, a 
decrease in mortality was reported in Tyrol after 1993 (χ2 = 12.74, df = 1, p = 0.0004) 
where the log mortality rate decreased at a rate of 0.092 (SE 0.024) per year from 1993 
onward.  
The results of this study showed that when PSA screening was offered to a 
population-based environment free of charge and where utilization rates increased by 
almost 12 fold over ten years, mortality was reduced. The authors believed the results 
were as expected because the screening was performed in a uniformly available and free 
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testing program where a large proportion of men were screened. Race or ethnicity was 
not considered as a factor for PSA screening differences for this study (Bartsch et al., 
2001). The authors concluded that while it is likely that programs offering PSA testing in 
support of early detection may contribute to a decline in mortality, they acknowledged 
that their study did not support such a statement. They believed that further research into 
the PSA and DRE test would be necessary.   
A PSA test and a DRE are the common tests performed at community screenings 
mainly because of their ease of measurement and non-invasiveness. However, not enough 
evidence has been produced regarding the efficacy of both, whether used together or 
separately, the PSA and DRE still remain controversial and as a result guidelines on 
screening have varied (Coldman, Phillips & Pickles, 2003; Weinmann, Richert-Boe, 
Glass & Weiss, 2004). Despite the controversy and uncertainty surrounding the use of 
prostate screening and screening guidelines, the American Cancer Society for African 
Americans reported that during 2004, 50% of African American men aged 50 or older 
had a PSA test and 47.4% had a DRE exam within the past year compared to 55.4% and 
52.2% for Caucasian men (ACS-AA, 2007/2008). The report did not mention why the 
year 2004 was the single year analyzed. It may have been because of known costs and 
length of time required for following cohorts longitudinally (Altman, 1999). 
When being screened for prostate cancer, men can be divided into various groups; 
1) screen detected men with prostate cancer but who would have never become 
symptomatic and whose outcome would not be affected by aggressive treatment in their 
lifetime (overdetection); 2) screen detected men with curable early stage prostate cancer 
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that would not have been clinically diagnosed until distant metastasis occurred thus 
screening would have improved their outcome; and 3) screen detected men with prostate 
cancer and diagnosed at the same stage as if diagnosed by clinical methods and who 
would benefit from treatment (see Table 3). 
Table 3. List of Men Benefiting from Prostate Screening. 
 
 Screen 
detected 
prostate 
cancer 
Symptomatic Outcome 
affected 
by 
treatment 
Distant 
metastasis 
Would 
benefit 
from 
screening 
Men of 
group 1 
Yes No No No No 
Men of 
group 2 
Yes No Yes Yes Yes 
Men of 
group 3 
Yes Likely Yes No No 
 
 
The first group would die with indolent prostate cancer and should have never 
been screened. The second group would benefit the most from screening and would most 
likely contribute to real reductions in mortality rates. The third group should not have 
been screened because they were likely symptomatic at the time of screening and thus 
should have been categorized as clinically diagnosed instead (Frankel et al., 2003; 
Roemeling & Schroder, 2006).  
However, if men are screened and disease is detected at early stages, they will 
most likely benefit from aggressive treatment as 5-year survival rates during the late 
1980s and early 1990s (initial PSA utilization periods) were between 75-85% among all 
races (ACS, 2008; ACS-AA, 2007/2008; Carter, 2007). Transitioning through the 1996 -
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2004 period (later PSA utilization periods), the race-based 5-year survival rates for 
African Americans and Caucasians were reported as 96% and 99%, respectively. Finally, 
further improvements were made as current 5-year survival rates are 98.9% for all stages 
and 100% for localized disease for men of all races (ACS, 2009). Although survival rates 
have improved for various reasons, including the possible contribution from early 
detection by screening, there is little evidence that PSA screening has led to reduced 
cancer specific mortality in these men (ACS, 2008; ACS, 2009; Challen, 1998; Gottlieb, 
2003; Roemeling & Schroder, 2006; Harris & Lohr, 2002). In fact, it has been suggested 
that if threshold values for the PSA test (currently accepted as 4.0 ng/ml in the U.S.) were 
lowered in order to detect even earlier stage disease in younger men, overdetection rates 
(false positives) would increase and subject some men to increased anxiety, more positive 
biopsies, and aggressive treatments that may lead to the unnecessary harmful effects of 
incontinence, impotence, and bowel problems. In contrast, it has been suggested that the 
PSA threshold value be raised for the elderly where PSA levels rise naturally in men of 
that group anyway (Gottlieb, 2003; Frankel, 2003; Roemeling & Schroder, 2006; Carroll 
et al., 2001).  
Furthermore, it has been suggested that the PSA test is ineffective and inaccurate 
since results frequently vary between multiple tests for the same patient. Yet, most of the 
medical community continues to offer that men with varying results undergo additional 
invasive testing and expensive treatments which can cause complications and lead to 
unnecessary distress, anxiety, and poor health related quality of life issues. For example, 
urinary and sexual dysfunctions are associated with surgical procedures such as 
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prostatectomy whereas bowel complications are associated with radiation therapy 
treatments. Of these complications, sexual dysfunction has the greatest association with a 
man’s perception of how well his cancer was managed, perceptions of masculinity, and 
self-confidence (Douglas, 2007; Dale, Bilir, Han & Meltzer, 2005; Otto & DeKoning, 
2004). 
Moreover, only 15% of men with PSA results less than the normally accepted 
value in the U.S. of 4.0 ng/ml will have prostate cancer, and only 2% of those will have 
advanced high grade disease. These conflicting results have likely helped to generate a 
nearly universally accepted consensus that thresholds may be impossible to achieve 
(National Comprehensive Cancer Network [NCCN], 2008; Carroll, 2001). Therefore, the 
current U.S. threshold limit of 4.0 ng/ml itself is unsubstantiated as it has been shown that 
up to two thirds of cancers can be missed at this level. Further, early results from the 
ERSPC trial found that among the men with PSA levels less than 4.0 ng/ml cancer 
detection rates of 36.5% were identified (Frankel et al., 2003). Moreover, because the 
ERSPC had not substantiated a threshold level prior to 1997 and because fear existed 
among researchers that too many cancers would go undiagnosed, the ERSPC decided to 
lower its threshold level to 3 ng/ml in early 1997 (Otto & DeKoning, 2004). So there may 
be an indication for re-evaluating current PSA threshold values, even the possibility of 
setting values based on age or race instead.    
Screening Guidelines  
Screening for disease has become part of contemporary medicine and already 
normal practice for cancers like breast, cervical, colorectal, lung, and ovarian. The 
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rationale for population or community screenings is straight forward: use of sensitive and 
specific screening tests with the ability to detect asymptomatic cancers in their earliest 
stage in order to provide treatments that can cure the disease. Often it is difficult to 
determine whether men participate in community screening programs because they 
believe it to be a preventive measure and beneficial to their health or because they are 
symptomatic and wish to confirm the presence of disease by further diagnostic work up.  
Guidelines for prostate screening have been controversial and debated for years. 
Bostwick and colleagues (2004) reported that in the United States, the lifetime risk of a 
man dying from prostate cancer is only 3%, whereas the risk of dying with prostate 
cancer is approximately 72% (Bostwick et al. 2004; Giri et al., 2007). However, most 
authorities agree that men at increased risk for prostate cancer may have more aggressive 
disease and would therefore benefit from screening and treatment. Most organizations 
recommend screening beginning at age 40 to 45 for men at increased risk. High risk men 
are generally defined as African Americans and those men with a family history of 
prostate cancer (Grubb, Roehl, Antenor & Catalona, 2005; Giri et al., 2007; ACS, 2009; 
AUA, 2009; NCCN, 2008). 
Screening guidelines vary among the majority of leading health care agencies 
with the most common variations occurring in the initial age recommended for screening, 
the definition of risk factors, and the potential harms and benefits from screening and are 
listed later in the chapter. In general, the American Cancer Society and the American 
Cancer Society for African Americans recommend baseline screening using both the PSA 
test and a DRE in men 50 years of age and who have a life expectancy of at least 10 
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years. The American Urological Association recently released its latest New PSA Best 
Practice Statement: 2009 Update (AUA, 2009) revising its original position that 
followed the American Cancer Society and instead now recommends that all men have a 
baseline PSA and DRE at age 40. The AUA further recommends that only well-informed 
men who wish to pursue early diagnosis be offered a PSA test. A well-informed man is 
one who has communicated and fully understands the information provided by his 
physician on topics of risks and benefits of screening, of all treatment options (including 
active surveillance), has been provided with a pre-treatment individualized risk 
assessment, and post-treatment monitoring. Lastly, the AUA now does not recommend a 
single PSA threshold value be used to prompt a biopsy. In addition, the National 
Comprehensive Cancer Network (NCCN) along with both the ACS and the AUA 
recommends considering biopsy beginning at age 45 in men who had PSA test results 
greater than 2.5 ng/ml and in all men of high risk. The MD Anderson Cancer Center in 
Houston, Texas recommends all men, including those of high risk and African Americans 
begin at age 45 with a baseline PSA and annual tests thereafter. In men of ages 50-74, 
MD Anderson recommends using both the PSA and DRE but suggests consideration be 
given on issues of ethnicity, family history, comorbid conditions, life expectancy, and 
results from previous testing. Memorial Sloan-Kettering Cancer Center of New York 
recommends men have both a PSA and DRE at age 50 and African Americans and high 
risk men begin screening at age 40. 
In contrast, the U.S. Preventive Services Task Force, the American College of 
Physicians, and the Canadian Task Force on the Periodic Health Examination have 
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concluded that evidence is lacking on whether benefits of prostate screening outweigh the 
harm. Therefore, they make no recommendations for routine screening in asymptomatic 
men younger than 75 and caution that risks and costs of potential harm may outweigh 
benefits of screening (Weinmann et al., 2005). For men age 75 and older with a life 
expectancy of 10 years or less, they have suggested that the incremental benefit from 
treatment of prostate cancer detected by screening is minimal: “the harms outweigh the 
benefits and that screening should not take place” (Weinmann, et al., 2005, pg. 367).  
Some groups, such as the U.S. Preventive Services Task Force suggest that 
physicians should describe and discuss potential benefits and harms associated with 
prostate screening, explain diagnosis and treatment options, and inform patients of the 
lack of evidence of the benefits of screening. As a result, these groups propose that an 
individual’s personal preference should take precedence in guiding the shared-decision 
making of patients and their physicians on screening (Bunting, 2002; Calonge et al., 
2008). Unfortunately, controversial guidelines could make physicians reluctant to follow 
any guidelines and thus recommend their own specialty as the appropriate treatment 
choice. For example, urologists may suggest surgery or watchful waiting and radiation 
oncologists may suggest radiation therapy with neither offering the patient counsel by the 
other professional provider which therefore, could preclude the patient from having 
complete information to make informed decisions. 
The poor specificity of PSA testing increases the likelihood of false positive 
results that can lead to unnecessary prostate biopsies and emotional distress. Researchers 
have attempted to improve specificity by using age-adjusted PSA values or free-to-total 
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serum PSA ratios (percent free PSA) as indicators of cancer (Carroll, 2001; AUA, 2009; 
Carter, 2007). The free/total PSA ratio or percent free PSA is defined as the ratio of the 
amount of unbound PSA (free) in the blood to the total amount of PSA in the blood as 
serum PSA exists in two forms; one bound to plasma proteins and one in a free state 
(Carroll, 2001). Age-adjusted PSA values, as recommended by physicians for young men 
and men of high risk, may need to range from 0-2.0 ng/ml for ages up to 49 years, 0-
4.0ng/ml for men 50-59 years, 0-4.5 ng/ml for men of 60-69 years, and 0-5.5 ng/ml for 
men over 70 years (Carroll, 2001).  
Ambiguous results and controversial experiences noted above point to the need 
for randomized clinical trials to address the effectiveness of prostate screening to reduce 
mortality. However, some researchers believe that beneficial results from a RCT may be 
difficult to obtain or even unlikely if contamination occurs within control arms (Otto & 
Roobol, 2006). Contamination bias occurs when men within control groups (no 
screening) of randomized clinical trials have had previous PSA tests performed (before 
inclusion into RCT) and who elect to participate simply to confirm presence of disease. 
Therefore, there continues to be controversy surrounding the effectiveness of current 
prostate screening tools. The various agents that lead to the controversial debate on 
screening guidelines are listed later in the section. 
Screening Studies 
A summary of screening studies are listed later in this section. A recent 
comprehensive review of the literature conducted by the Prostate Cancer Prevention Trial 
(PCPT) examined the performance of screening for multiple cancers, including prostate. 
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The study acquired reviews based on sensitivity and specificity of screening tests, the 
positive predictive value of screening tests, the number of men needed to screen (NNS) in 
order to detect one case, and the cost per quality-adjusted life-year (QALY) used for 
various screening programs. For the PSA test, the Prostate Cancer Prevention Trial 
(Crawford & Abrahamsson, 2008) reported a direct linear relation for the risk of positive 
biopsy and risk of high-grade disease with an increasing PSA test. The PCPT also noted 
that there was no justification in using a PSA value of 4.0 ng/ml as a threshold for 
detecting prostate cancer all of which contribute to the debate on screening guideline 
discrepancies (see Table 4). In particular, the report noted that a PSA value of 2.6 ng/ml 
had a sensitivity of 40.5% and a specificity of 81.1% for detecting cancer, whereas a PSA 
value of 4.1 ng/ml had a sensitivity and specificity of 20.5% and 93.8%. In other words, 
sensitivity to detect prostate cancer decreases and specificity increases with rising PSA. 
Overall, the PSA test proved a better tumor marker for advanced stage disease rather than 
for early stage disease. 
Although the sensitivity of the PSA test to detect prostate cancer is low compared 
with other cancer detection tools, specificity for the test remains high. So then, high 
specificity of the PSA test begs whether correctly identified cancer cases through 
detection will ever be clinically significant to the patient. Basically, is prostate screening 
associated with reduced mortality (Crawford & Abrahamsson, 2008)?  The PCPT report 
acknowledged that although the sensitivity/specificity profile was not perfect, it could 
still be useful when measured more than once and over time. It is important to note that 
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Table 4. Summary of Screening Guidelines from Various Health Care Organizations. 
 
Medical organizations Initial evaluation 
American Cancer Society 
American Cancer Society for  
African Americans 
Offer PSA and DRE beginning at age 50 in men with life expectancy greater than 
10 years. 
For African Americans and those with family history beginning at age 45. 
Provide information about potential benefits/harms associated with screening 
AUA New PSA best practice 
statement: 2009 update 
Recommend for well-informed men wishing to pursue early diagnosis 
Age lowered to 40 for all men 
Discussions of risk vs. benefits, treatment options, pre-treatment individualized 
risk assessment, post-treatment monitoring 
No longer recommends a single threshold value that would prompt biopsy 
American Academy of Family 
Physicians 
American College of Physicians 
American College of Preventive 
Medicine 
American Medical Association 
Offer PSA and DRE beginning at age 50 in men with life expectancy greater than 
10 years. 
Discuss potential benefits/harms, consider patient preferences, and share in 
decision making. 
U.S. Preventive Services Task 
Force 
Canadian Task Force 
International Cancer Union (UICC) 
World Health Organization (WHO) 
 
Men younger than 75 years and < 10 yr. expected life - No recommendation due to 
insufficient evidence 
Men ≥ 75 years – do not screen because there is moderate to high certainty of no 
screening benefit or harms outweigh benefits.  
Discuss potential benefits/harms, consider patient preferences, and share in 
decision making. 
MD Anderson Cancer Center, 
Houston Texas 
Consider baseline PSA in men at age 45. 
Annual PSA and DRE in men 50-74 years & age 45 for African Americans and 
men with family history. 
Memorial Sloan-Kettering Cancer 
Center, New York 
Annual PSA and DRE men beginning at age 50. 
African Americans and men with family history beginning at age 40. 
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cancers not detected by an initial PSA test could most likely be detected by a second test 
at a later time, conceding that delays in measurement would most likely not cause the 
disease to progress to non-curable stages (Crawford & Abrahamsson, 2008).  
A recent update on the evidence of PSA use conducted for the U.S. Preventive 
Services Task Force (USPSTF) with assistance from the Research Triangle Institute-
University of North Carolina Evidence-Based Practice Center examined key research 
publications (Harris & Lohr, 2002). The USPSTF reviewed literature looking for indirect 
evidence relating improved mortality and PSA screening based on 8 key themes. These 
included questions on the efficacy of 1) screening, 2) yield of screening, 3) surgery, 4) 
radiation therapy, 5) androgen hormone deprivation, 6) watchful waiting, 7) harms of 
treatment, and 8) cost and cost effectiveness of treatment (Harris & Lohr, 2002). The 
study examined relevant search terms from the MEDLINE database and the Cochrane 
Library for publications from January 1994 through September 2002. All articles were 
abstracted by the first author, and one trained assistant.  
Within the first theme, efficacy of screening, Harris and Lohr (2002) found one 
randomized clinical trial dealing with efficacy of prostate screening conducted in 1988 in 
Quebec City. A sample of 46,000 men was randomized into two groups: one group 
invited to receive a PSA and DRE test and a control group not invited to receive the tests. 
Twenty three percent of the invited group and 6.5% of the non-invited group received a 
PSA and DRE test. After 8 years of follow up, study results indicated no differences in 
prostate cancer death rates between the groups (4.6 vs. 4.8 deaths per 100,000 men) 
(Harris & Lohr, 2002).  
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An extension of this 1988 Quebec study was conducted from the Laval University 
Prostate Cancer Screening Program (LUPCSP) extending the 8 year follow up out to 11 
years (Labrie et.al, 2004). This study reported findings after 11 years of total follow up 
and again only noted a 23.6% response rate. The results indicated that 74 men died of 
prostate cancer out of a sample of 14, 321 unscreened controls and 10 deaths occurred in 
the screened group of 7, 348 men (Labrie et al., 2004). The study involved men aged 45-
80 years that were randomized into screening and non-screening groups and included 
both a PSA and a DRE, with a threshold value of 3.0 ng/ml as the upper limit for a 
normal PSA. Labrie and colleagues (2004) reported an annual prostate cancer-specific 
death rate during the 11 year period from November 15, 1988 through December 31, 
1999 as 19.8 and 52.3 per 100,000 man-years in the screened and non-screened groups 
respectively. This is equivalent to a 62% reduction in mortality in the screened versus 
non-screened group (two-sided p value < 0.002, Fisher’s exact test). Results were 
expressed as events per 100,000 man-years in order to account for the specific years of 
exposure for each man in each group. The report noted that age and whether a man was 
screened or unscreened were the only significant explanatory variables in the study. 
Dummy variables created for the residential locations of men within the areas of Quebec 
City had no effect on the results, however age and screened versus unscreened had a 
highly significant effect (p = 0.0054 and p = 0.0025 respectively). The study did not 
mention whether ethnic groups were evaluated. In addition, contamination rates within 
the control group were not assessed with reasons not listed (Labrie et al., 2004). 
Furthermore, because of the low response rate for men randomized to receive a PSA test 
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(23.6%), the Quebec study’s susceptibility bias was high. Susceptibility bias is created 
when small numbers of participants are reported (Concato, Peduzzi, Kamina, & Horwitz, 
2001). Labrie and colleague’s study was rated as “poor” by the Annals of Internal 
Medicine because of the lack of sociodemographic comparisons between groups and 
because death rates from other causes were not examined (Lin, Lipsitz, Miller & 
Janakiraman, 2008). 
A separate study performed on men from Quebec sought to determine the efficacy 
of PSA screening by hypothesizing that changes in prostate cancer incidence from 1989 – 
1993 would be attributable to the PSA test and that an inverse relationship would be 
observed between changes in incidence and mortality. For example, if PSA testing leads 
to reduced mortality, then the greater the increase in incidence due to PSA screening a 
greater decrease in mortality would be observed. Their variables were the magnitude of 
change in incidence and the magnitude of change in mortality (Perron, Moore, Bairati, 
Bernard & Meyer, 2002).  
Perron and colleagues (2002) observed men aged 50 to 80 years by forming 15 
age cohorts to adjust for age differences. They also divided the men into 15 geographical 
regions. Their aim was to assess the extent to which increases in incidence rates were 
associated with decreases in mortality rates and found no negative association between 
the study populations for either the age cohorts or the geographic regions noting that 
incidence rates increased sharply but age adjusted mortality rates only decreased slightly 
within the age cohorts. In other words, they did not observe that large increases in 
incidence were associated with large decreases in mortality with follow-up at 6 years 
49 
 
 
 
(Perron et al., 2002). They concluded that the magnitude in change rates between 
incidence and mortality was not inversely related (Pearson’s r = 0.33, 1-sided p = 0.89). 
Similarly, by regional population, they found that a greater increase in incidence did not 
indicate a greater decrease in prostate cancer mortality (Pearson’s r = 0.13, 1-sided p = 
0.68). The authors noted limitations to their study as they only evaluated changes of 
incidence and mortality over one year whereas researchers suggest that magnitudes of 
changes should be evaluated over several years. They further reported that the Quebec 
cancer registry relies only on patients discharged from hospitals and increasingly, 
prostate cancer patients are treated as outpatient status. Finally, the authors noted that 
because age is a strong predictor of incidence and mortality, variations in results may 
have been skewed slightly because they used birth cohorts instead (Perron et al., 2002).  
Well designed case-control studies can provide quality results in less time, at less 
cost, and do not require large numbers of subjects compared with a RCT (Otto & Roobol, 
2006; Weinmann, Richert-Boe, Glass & Weiss, 2004; Concato et al., 2001).  An 
important factor in a successful case-control study is that the control subjects must be 
alive at the death of their matched case subjects and without cancer at the time of 
diagnosis of their matched case subjects (Otto & Roobol, 2006; Weinmann et al., 2004). 
Case-control studies may also vary in design. However, in all studies, screening histories 
are determined for both the case subjects (those who have died from the disease) and the 
control subjects (those who have not died from the disease or those who may or may not 
have the disease) (Weinmann et al., 2004). It may be difficult to obtain complete and 
accurate screening histories especially when the screening tests can be used for 
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diagnosing the disease thus rendering the sample population non-representative; such 
may be the case in prostate screening with the PSA test. To further complicate case-
control studies, African American men are considered high risk for prostate cancer, yet 
screening for these men is less frequent than that of Caucasian men. This can be a major 
drawback causing contamination bias in most research designs (Otto & Roobol, 2006; 
Weinmann et al., 2004).  
Important disadvantages associated with case-control studies commonly include 
selection bias and misclassification bias (coding error). Misclassification bias occurs if a 
screening PSA test for a case subject is classified as a diagnostic PSA test resulting in a 
bias against screening. In contrast, if a diagnostic PSA test for a control is classified as a 
screening test, then a bias that favors screening occurs. Self-selection bias may occur 
when a subject presents to his physician because of “opportunistic” screening, meaning 
that he has a preconceived idea that he may have prostate cancer (as a result of prior 
testing elsewhere or symptoms) and would like to confirm the notion one way or the 
other and is not part of a study or population-based screening program. In addition, men 
at high risk (e.g., African Americans) often do not participate in community screenings 
due to less access to program sites or differences in their socioeconomic status (Otto & 
Roobol, 2006; Weinmann et al., 2004; Concato et al., 2001). In any case-control study, 
there should be a lower proportion or deficit of screening among cases in order to see a 
protective effect for the screening test. In all case-control studies the cases are matched 
with controls on specific independent variables and confounders (Concato et al., 2001; 
Concato et al., 2006).  
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The case-control studies evaluated by the USPSTF examined the association 
between the DRE and prostate cancer death, and therefore, could not make inferences 
regarding the PSA test. None of the three studies evaluated by the USPSTF included PSA 
because not enough follow-up time had elapsed from the initial dissemination of the PSA 
test (FDA approved in 1986) and 2002 (Harris & Lohr, 2002). However, when looking at 
just DRE, two of the case-control studies resulted in no association between DRE and 
mortality however, a third found that men who died of prostate cancer had fewer DRE 
exams prior to diagnosis with an odds ratio indicating only a slight protective effect for 
the DRE (O.R. 0.51 [95% CI, 0.31 to 0.84]). It was noted that these studies differed in 
methodology and design, definition of cases, reliance on individual medical records, and 
use of different approaches to distinguish screening DRE with clinical diagnostic DRE 
(Harris & Lohr, 2002).  
More case-control studies emerged in the U.S. once the PSA test disseminated as 
a screening tool and became complimentary to the DRE. Some studies evaluated the 
associations of the PSA test used together with the DRE and without the DRE when 
examining prostate cancer deaths (Concato et al., 2000; Benson et al., 2000; Concato et 
al., 2001). One study used a nested case-control design to evaluate the effectiveness of 
either a PSA or DRE. The main hypothesis being that screening with the PSA test would 
be associated with improved survival and a secondary hypothesis being that using both 
the PSA and DRE together would be associated with further improved survival (Concato 
et al., 2001; Concato et al., 2006). The cohort of men came from 10 Veteran Affairs 
Medical Centers (VAMC) in New England during 1989 and 1990. Case subjects were 
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chosen from 1991 through 1995. The authors believed that a nested study design would 
be stronger than traditional cohort designs because only some and not all control subjects 
were enrolled. Case-control subjects were matched on age and on which VAMC facility 
they received treatment. Additionally, the authors reported a strength of the study to be 
that subjects were chosen from the same sample population to help reduce possibilities of 
unreported screening tests (Concato et al., 2001; Concato et al., 2006). For example, they 
had hoped to reduce bias by these two matching criteria as age is known to be associated 
with prior screenings and is related to mortality. And a sample of men from the same 
nearby 10 VA facilities would help reduce the chances of men having previous 
screenings outside these regions (Concato et al., 2001; Concato et al., 2006).  
It was noted that because race was not specified in the VA databases it was not 
possible to identify subject race until the time of medical record review. The authors 
could not match race beforehand. Therefore, they statistically adjusted for race in the 
analysis portion. The authors also noted that although less than 1% of men had medical 
records indicating whether PSA tests were performed outside the VA system, the data 
was not available for non-VA screenings (Concato et al., 2006). This is a weakness of the 
study with possible loss of acuity for race-based disparate mortality. Further, it is 
believed that matching from similar facilities may weaken the study’s external validity of 
generalizing to the population level because of the restriction to men receiving care only 
from within the VA system in New England.  
The authors of the study cited their calculated sample size of 498 case subjects to 
be sufficient for a power of 80% for identifying a clinical reduction of 33% in deaths 
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among subjects screened with PSA (odds ratio of 0.67, alpha = 0.05, two-tailed, and beta 
= 0.20) (Concato et al, 2001; Concato et al., 2006). Their final cohort included 501 cases 
meeting inclusion criteria and thus exceeded their power calculation of 498 cases. They 
randomly matched 501 control subjects to each case subject on age and VA facility. Their 
findings of an unadjusted, matched odds ratio (OR) of 1.10 (95% CI, 0.75-1.62, p = 0.62) 
for PSA screening and overall mortality suggests no evidence of a screening benefit in 
this matched case-control sampling. After adjusting for race and comorbidity, the odds 
ratio for screening still remained statistically insignificant at 1.08 (95% CI, 0.71-1.64, p = 
0.72) for overall mortality.  
In a secondary analysis examining associations of PSA screening and cause-
specific mortality, statistical insignificance was again found in an adjusted odds ratio of 
1.13 (95% CI, 0.63-2.06, P = 0.68). However, when adjusting for race and comorbidity, 
black race presented with an adjusted OR of 4.46 (95% CI, 1.39-14.3, p = 0.01) and for 
comorbidity, an adjusted OR of 1.26 (95% CI; 1.01-1.57, P = 0.04) indicating a 
statistically significant association of PSA screening to cause-specific mortality for 
African Americans. The authors concluded overall that there was no evidence suggestive 
of a survival benefit associated with the PSA or DRE test and failed to elaborate further 
on the significance found for race and comorbidity. 
Another case-control study was performed on members at Kaiser Permanente 
Northwest (KPNW) Health Plan from 1991-1999 in Portland, Oregon. Case subjects 
included men who were 45-84 years of age at time of death due to prostate cancer. Two 
control subjects were matched for each case subject on age, date of enrollment into the 
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plan, number of months in the health plan, and pattern of health plan membership. 
Controls were randomly matched to cases and had to be alive two years prior to their 
matched case and without prostate cancer at the time of diagnosis of their corresponding 
case subject. Medical chart review and death certificates were the source of data. The 
authors also reviewed charts and gathered data on possible covariates of height, weight, 
family and personal history of cancer, prior prostate related conditions and treatment 
(BPH, prostatitis, transurethral resection [TURP], vasectomy), tobacco use, and diabetes 
(Weinmann et al., 2004). 
A pilot study was performed prior to the Kaiser study’s initiation to determine if 
medical records could correctly identify PSA tests that were used for screening purposes 
only. PSA tests were defined as true screening tests when there were no signs or 
symptoms of prostate cancer noted in the medical record. As a secondary follow up to 
further verify medical record accuracy, telephone interviews were obtained on 97 of the 
randomly matched control subjects. Ninety-nine percent of the men concurred that they 
were without symptoms when they received their initial PSA screening tests. The final 
number of cases was 171 with 342 controls. The study’s total population consisted of 
94.7% and 95% case-controls respectively for Caucasians and only 4.7% and 1.8% case-
controls for African Americans.  
The results of the study indicated an inverse relation between receiving any 
screening test (DRE and/or PSA) and cancer-specific mortality with a reduction in 
mortality of 30% (OR 0.70 (95% CI: 0.46-1.1). These values show that a history of 
prostate screening was less common among cases than among controls thus providing a 
55 
 
 
 
protective effect for the controls (Weinmann et al., 2004). A major limitation to the study 
was that they were not able to separate the influence of a DRE on a PSA test result 
because the study time period included pre-PSA era (when PSA testing was not used as 
often) through a time in which the PSA test disseminated quickly throughout the U.S. 
(when PSA testing rates grew). Therefore, study subjects had more exposures to DRE 
than PSA screenings in the beginning of the study. They concluded that the initial rise in 
PSA screening during the study period may have inflated the odds ratio (Weinmann et al., 
2004).  
A different study, performed by many of the same authors of the previously 
described case-control study, sought to determine the same question of whether screening 
with PSA or DRE was associated with reduced prostate cancer mortality in a case-control 
design. However, the study used a population-based cohort of men from four health 
maintenance organizations (HMO). The four HMOs included the Kaiser Permanente 
Northern California Region, Kaiser Permanente Southern California Region, Henry Ford 
Health System, and Kaiser Permanente Northwest Region. Case subjects were from one 
of these HMOs and were either Caucasians or African Americans who died from prostate 
cancer between 1997 through 1999. Age groups for the men ranged from 45-84 years at 
time of death and men had to be members of one of the HMO plans for at least three 
years prior to diagnosis (Weinmann et al., 2005). Final inclusion criteria resulted in 769 
confirmed cases.  
Medical chart review and death certificates helped to identify case subjects who 
were selected if diagnosed with and dying from prostate cancer. The authors also 
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reviewed medical records and death certificates identifying men who were diagnosed 
with prostate cancer yet died of unknown other causes, who died of complications 
associated with prostate surgery, or who died as a result of suicide caused by 
complications from treatment for prostate cancer (Weinmann et al., 2005). In addition, 
information on other possible confounders was obtained from the subject’s medical 
record and included height, weight, family and personal history of cancer, prior prostate 
or genitourinary complications or treatments (BPH, prostatitis, TURP, and vasectomy). 
Comorbid conditions included hypertension, diabetes and life-style habits including 
smoking (Weinmann et al., 2005). 
Controls were randomly selected from the HMOs and were matched to case 
subjects on health plan, age, race, and plan membership history. One control for each of 
the 608 Caucasian case subjects and two controls for each of the 160 African American 
cases were matched. Like other case-control studies, controls had to be alive and a plan 
member at the time of his corresponding case diagnosis and alive at the time of his 
matched case’s death. In addition, any control that died during the study period as a result 
of prostate cancer was subsequently added to the case group (Weinmann et al., 2005). 
Screening with PSA was defined as having at least one test during the 10 year prior to 
primary analysis of the patient. The authors used logistic regression, calculated odds 
ratios, and 95% confidence intervals for estimating the risk of mortality due to prostate 
cancer.  
The authors categorized PSA tests or DRE according to likelihood of being 
performed for screening or diagnostic purposes. Categories for the study included one of 
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three definitions namely “definitely screening”, “probably screening”, and “no screening” 
(Weinmann et al., 2005). The most restricted category being “definitely screening” 
required that subjects have no history of prior PSA or DRE tests and that tests be 
performed on subjects without symptoms, no history of BPH, and no firm or enlarged 
prostate gland. The second category, “probably screening”, included subjects with no 
previous PSA or DRE test but with unchanged or improved symptoms unrelated to 
prostate cancer and with history of BPH or firm or enlarged glands but with no symptoms 
at time of tests. The third category “no screening” was defined as men who had never 
been screened by either the PSA or DRE (Weinmann et al., 2005). 
The authors further noted that only one covariate, history of smoking, differed 
significantly between cases and controls (Weinmann et al., 2005). As with their first 
study, the ability to account for the effects of the DRE on the PSA test was impossible 
because most of the men received DREs. The authors noted that due to the rapid 
dissemination of the PSA tests during their time frame, most of the PSA tests ordered 
were probably meant for diagnostic purposes rather than for true screening purposes 
because of the number of abnormal DREs found (Weinmann et al., 2005). In addition, the 
authors noted that even with the rapid use of the PSA test, only 7% of the control subjects 
met the “definitely screening” category for PSA. Most of the tests were DRE with 74% of 
Caucasian cases and 83% of Caucasian controls having DREs. For African Americans, 
67% of cases and 83% of the controls had DREs. The final conclusions were that having 
a DRE and or PSA was associated with reduced prostate mortality in Caucasians but not 
in African Americans. The odds ratios indicated a 30% reduction in death due to prostate 
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mortality for Caucasians (OR = 0.71; 95% CI = 0.53-0.94) whereas in African 
Americans, the odds ratio indicated no significant protective effect with screening (OR = 
0.95; 95% CI = 0.61-1.5). One possible reason for the difference in odds ratio between 
Caucasians and African Americans included the low number of African Americans 
participating and thus differences could have been contributed by chance alone. Other 
possible reasons could have been that differences exist in patient-physician 
communications and that medical record notations may be different between African 
Americans and Caucasians. For example, if symptoms for African Americans were not 
recorded accurately in the medical record, then misclassification bias of diagnostic tests 
versus screening tests could have occurred thus falsely increasing odds ratios (Weinmann 
et al., 2005).   
Randomized Clinical Trials 
Advancements in imaging technology combined with simple non-invasive blood 
tests have provided physicians with diagnostic tools that have dramatically improved 
early detection of some cancers and proving invaluable when used for cancer screening in 
others (Black, 2006). However, even when using state-of-the-art technologies, there can 
be harms associated with screening tests. For example, false-positive results that lead to 
unnecessary anxiety and over diagnosis which often results in unnecessary treatment. 
To help guard against the negative effects associated with inaccurate and 
ineffective screening tests, well designed randomized clinical trials (RCTs) may help 
meet this requirement. Randomized clinical trials are considered the gold standard in 
research design for much of medical research as well as one of the most valid study 
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designs for cancer screening. During the mid-1960s, the Health Insurance Plan (HIP) 
study proved the validity of RCTs when study results showed that screening with 
mammography and physical examination reduced breast cancer mortality (Black, 2006). 
Randomized clinical trials have also proven useful in determining the effectiveness of 
treatments or interventions because known (observed) and unknown (unobserved) 
variables are equally balanced throughout groups by randomization. The overall goal of 
an RCT is to simply balance the groups such that all bias is eliminated thereby ensuring 
that all differences in outcomes can only be attributed to differences in the treatment or 
intervention (Black, 2006). 
There are two large randomized clinical trials that have ended, the European 
Randomized Screening for Prostate Cancer (ERSPC) and in the United State, the 
Prostate, Lung, Colorectal, and Ovary (PLCO) cancer trial. Both trials are aimed at 
assessing the efficacy of early screening and aggressive treatment to reduce incidence and 
mortality. Both trials have closed enrollment and began initial evaluation of data with 
hopes of determining the impact of annual prostate screening on cancer-specific 
mortality. A cooperative initiative between both trials was formed in 1995 so that 
information and datasets could be shared annually in order to combine analysis with 
hopes of strengthening overall results. Agreements regarding baseline measurements, 
procedures, collection mechanisms, and follow-up were made (Schroder, Denis & 
Roobol, 2003).    
Key characteristics similar to both the ERSPC and the PLCO trials are age, 
subject exclusion criteria, and outcome. The age of men eligible for the trials is between 
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55-74 years. Exclusion criteria for all countries are men with preexisting prostate cancer 
and prior PSA tests. The outcome of interest for all countries is death from prostate 
cancer. Key differences in the two trials are the screening procedure and PSA threshold 
values indicative for biopsy. The European trial uses a cut off level of 3.0ng/ml along 
with a 4 year screening interval in the Spain and Sweden arm and the U.S. trial uses a 
4.0ng/ml as its cut off level and an annual screening interval (Otto & DeKoning, 2004). 
Additional important characteristics that differ among the two trials include, type of trial, 
time of randomization, period of initial recruitment, identification of patient population, 
and source of follow-up information (DeKoning, Auvinen et al., 2002; Auviven & 
Hugosson, 2003).     
Initial results from the ERSPC released in 2002 tested the power necessary to 
provide a time-frame to confirm an expected mortality reduction in prostate cancer due to 
screening. It was determined that a target power level of 80%-90% was sufficient but was 
not reached until the end of 2008 when it rose to a level of 86%. Even with sufficient 
power levels reached in 2008,  fears of intervention effects from screened men and 
effects from contamination were realized in the range of 25% and 20% respectively 
(DeKoning, Auviven et al., 2002; DeKoning, Liem et al., 2002). The ERSPC and PLCO 
trials are reviewed individually with a summary listed later in the chapter.  
In a randomized clinical trial performed in Sweden as a pilot study for the 
ERSPC, Sandblom and colleagues (2004) studied the 15 year follow-up on (n = 9,026) 
men aged 50-69 years with prostate cancer to test the feasibility of a large population-
based screening program (Sandblom, Varenhorst, Lofman, Rosell & Carlsson, 2004). 
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They designed a pilot study using randomization and created a control group and a 
screened group of men during a three year screening interval. Data were collected on 
tumor stage, grade, treatment and survival for both groups with the risks of selection bias 
removed due to randomization. The study began in 1987 before PSA was used as a 
screening tool and using a 3 year screening interval to track changes over the three tests. 
At the first two screenings (initially in 1987 and again in 1990), the DRE was the only 
test used however at the third screening of 1993 the PSA was added. The study showed 
that 5.7% of men had prostate cancer detected in the screened group and only 3.9% in the 
control group. Of particular interest within the screened group, 56.5% of cancers detected 
were localized as T1 or T2 whereas within the control group, only 26.7% of men had the 
same disease stage (p<0.001). In addition, the screened group was significantly more 
likely to have organ-confined prostate cancer than the control group (p<0.005). A lower 
proportion of men with distant metastasis were found in the screened group and those 
cancers were less significantly graded than in the control group (Sandblom et al., 2004).   
The authors noted that a three year screening schedule for men aged 50-69 years 
was sufficient for detecting early stage prostate cancer and was the first randomized 
clinical trial offering 15 year follow-up. They further suggested that the study would be 
cost-effective when considering the risk of detecting cancer early and having the disease 
change from a curable disease to an incurable late stage disease. Sandblom and 
colleagues (2004) reported that a prostate screening program was feasible when screening 
with both the DRE and PSA test and that these tests were effective at detecting early 
stage disease of prostate cancer. Disparate mortality rates among race or ethnic groups 
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were not investigated in the study with the population restricted to one city of 9,026 men 
aged 50-69 years. One limitation of the study was the small population and single 
geographical region of interest thus leaving power insufficient to show screening effects 
on mortality (Sandblom et al., 2004).   
The European Randomized Screening for Prostate Cancer Trial 
The ERSPC evolved out of the many discrepancies noted with use of the PSA test 
which, therefore, led to a need to determine whether the test may lead to reduced prostate 
cancer mortality when used as an early detection tool (Schroder, Denis & Roobol, 2003; 
Auvinen & Hugosson, 2003). Strict protocol definitions were formulated by all eight 
participating countries with two such definitions being the primary outcome of “prostate 
cancer-specific mortality” and “not all cause mortality”. This was decided mainly 
because subjects within RCTs are free of the disease and only cancer-specific mortality is 
influenced by screening for the disease (DeKoning, Hakulinen et al., 2003). Therefore, 
the definition agreed upon for subjects to meet the endpoint of cancer-specific mortality 
include those men having died, known to have prostate cancer, and where prostate cancer 
was listed on the death certificates.      
The ERSPC has recruited approximately 193,000 men since 1992 from eight 
European countries. There are differences within study parameters for the European trial 
due to multiple centers being involved. Some differences include age variations (from 50-
74 years old), PSA threshold values, and screening intervals (DeKoning, Auvinen et al., 
2002). For example, PSA thresholds were set to ≥ 4.0ng/ml in all countries except Spain 
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and Sweden, where thresholds of ≥ 3.0ng/ml and ≥ 4.1ng/ml were used respectively. The 
ERSPC has maintained a 4 year interval for screening.   
Noted limitations of the European trial include selection bias and contamination 
by opportunistic screening of the control arm. For instance, it is possible for subjects who 
choose to participate do so because they are symptomatic or know they may be at 
increased risk for prostate cancer and simply wish to rule it out. It is also possible that 
men who participate are healthier and care more about their health. These forms of 
selection biases were not controlled for in the ERSPC because the authors noted that it 
was impossible to measure their extent and effect on power (DeKoning, Liem et al., 
2002; Schroder et al., 2003). 
Contamination bias by opportunistic screening could also affect power. In an ideal 
study, men in the control group would not have been screened prior or during the study; 
however, that proportion of men in a control group who have received screening prior to 
trial dates is called the contamination rate. Opportunistic screening occurs when men 
within a control group received PSA testing at any time prior to trial enrollment either by 
their own submission or by a physician’s suggestion in a prior clinical visit (Ciatto, 
Zappa et al., 2003).  
A study to determine contamination rates and its effect on power evolved from 
the Rotterdam section of the ERSPC data in 2003. The study noted that PSA 
contamination (testing of asymptomatic men in the control group) could adversely affect 
the power of the ERSPC trial (Otto, Van Der Cruijsen et al., 2003). The authors 
eventually reported only an 8% contamination rate with less than half of those men being 
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diagnosed with prostate cancer. The authors concluded that PSA contamination in the 
trial should therefore, not lead to power problems as initially thought (Otto, Van Der 
Cruijsen et al., 2003). 
Additional pilot studies from the Rotterdam and Netherlands section of the 
ERSPC trial were performed to assess the randomization and testing procedures to, 
hopefully, show that continuing the ERSPC trial was warranted (Schroder, Denis & 
Roobol, 2003; Schroder, Roobol et al., 2005). The numbers of deaths for any cause were 
not significantly different at 19.2% and 20.9% respectively. Furthermore, 20% of the 
screened group and 32% of the control group died with prostate cancer, whereas only 
2.7% of the screening group and 17% of the control group died from prostate cancer. The 
authors noted that none of the pilot studies could provide any statistical analysis because 
of the lack of power, yet still believed continuing the trial seemed reasonable (Schroder, 
Roobol et al., 2005).     
Other studies have emerged that evaluated overdiagnosis and over treatment from 
the ERSPC trial data. Among those was one study in the Rotterdam section of the ERSPC 
that enrolled 42,376 men and reported 1,498 cases of prostate cancer during 2003 
(Draisma et al., 2003). They reported that lead times and overdetection could result in 
unnecessary treatment. Lead time is the time in which diagnosis of prostate cancer is 
increased by screening. Specifically it is defined as the amount of time between prostate 
cancer detection and either clinical diagnosis without screening or death of other causes. 
Overdetection occurs when cancers are found that would have never been detected in a 
man’s lifetime in the absence of screening. Both of these consequences have a large 
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impact on the net benefits of screening. Draisma and colleagues (2003) found that a 
man’s age was significant to predicting these rates noting that a mean age of 55 resulted 
in a lead time of 12.3 years and the overdetection rate was 27%. This means that a man 
age 55 would probably have been asymptomatic and not clinically diagnosed with 
prostate cancer until age 67.2 years and that 27% of those men diagnosed would have 
most likely received unnecessary treatment because of the early detection. At age 75, 
these rates changed to 6 years and 56% respectively. Draisma and colleagues (2003) 
further noted that their screening program increased the lifetime risk of prostate cancer 
diagnosis from 6.4% to 10.6% a relative increase of 65%.  These results suggest that 
regular screening for prostate cancer may advance a diagnosis by 10 years with about half 
screen detected men not having been diagnosed without screening. The authors 
concluded that screening rates of greater than one year should be applied to Dutch men of 
the Netherlands and that screening for prostate cancer is likely to be associated with early 
diagnosis with considerable overdetection. The study did not look at different races or 
ethnic groups within the Rotterdam registries considering only men of Dutch origin 
(Draisma et al., 2003). 
Similar studies examined the effects of over diagnosis due to screening. These 
studies included reviewing the magnitude of overdiagnosis and its impact on unnecessary 
treatment in men who may otherwise have insignificant indolent tumors (Etzioni, Penson, 
et al., 2002; Ciatto, Gervasi et al., 2004; Graif et al., 2007). Etzioni and colleagues (2002) 
developed a computer model to test relationships of the PSA test, diagnosis of prostate 
cancer, and death based on assumptions from the ERSPC trial. They found that after 
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hypothetically testing two million men age 60-84 years and using known parameter 
estimates for the expected lead times and incidence rates, the computer model predicted 
similar results observed by SEER registries during the decade 1988 through 1998; those 
being 29% in Caucasians and 44% in African Americans.  
Ciatto's group (2004) agreed that overdiagnosis depends on age and the 
magnitude of the lead time associated with detection through screening (Ciatto, Gervasi 
et al., 2004). Their study indicated that overdiagnosis is prevalent in the ERSPC trial 
(Ciatto, Gervasi et al., 2004).  
In a separate study examining the frequency of over and under diagnosis from two 
large cohort groups of men receiving prostate surgery, Graif and colleagues (2007) found 
that 27% of the 2,126 men reviewed were under diagnosed and only 5% were over 
diagnosed (Graif et al., 2007). These authors argued that although over diagnosis is 
existent, under diagnosis is also occurring and attention should be given to the cancers 
being missed without screening. Interestingly, a secondary finding from the study showed 
that decreasing the PSA threshold from 4.0 ng/ml to 2.5 ng/ml resulted in a reduction in 
the under diagnosis rate and an increase in the 5 year survival rate. The authors concluded 
that perhaps lowering the PSA threshold level from 4.0 ng/ml to 2.5 ng/ml should be 
considered when examining optimal screening protocols. 
  Two additional studies have emerged out of the Rotterdam section of the ERSPC 
which examined the progression of PSA over time (Schroder, Raaijmakers et al., 2005; 
Gosselaar et al., 2006). One study examined the time it took for PSA values to increase to 
3.0 ng/ml after a four year follow-up in men presenting with PSA values < 3.0 ng/ml at 
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the first round of screening (Schroder, Raaijmakers et al., 2005).  The study consisted of 
6,467 men randomized within the ERSPC and eligible for a second round screening at the 
4 year interval. The results show that men who presented at the first round with PSA 
values ranging from 3-3.9 ng/ml showed an increase in the proportion of cancers found in 
the second round. However, men who presented with PSA values ranging from 4-9.9 
ng/ml in the first screening remained unchanged at the second screening. Finally, men 
who presented with PSA values of > 10.0 ng/ml at first screening round showed a 
decrease in detecting cancers in the second round. An additional finding of the study 
confirmed other reports that PSA progression rates for men presenting with initial first 
round screenings of < 2.9 ng/ml was low suggesting that longer screening intervals may 
be appropriate for these men. The study concluded that since most of the cancers detected 
in the second round of screening occurred in men with PSA values of 3-3.9 ng/ml, a 
cutoff threshold of 3.0 ng/ml is a valid suggestion for second round screenings and longer 
screening intervals (Schroder, Raaijmakers et al., 2005). These data further support the 
change from 4.0 ng/ml to 3.0 ng/ml in the ERSPC trial; however, in the U.S. screening 
intervals remain at annual rates and 4.0ng/ml continues to be the threshold value.  
The second study also examined the 4 year progression of PSA test values at the 
second screening round with the hopes of reducing unnecessary biopsies by possibly 
increasing screening interval times and thus saving the health care system money 
(Gosselaar et al., 2006). The authors concluded that omitting the DRE and TRUS did not 
change the amount of interval cancers or detection of prostate cancers after 4 years and 
the decision to omit these tests from the ERSPC seemed justified (Gosselaar et al., 2006).  
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Therefore, it is logical to believe that if asymptomatic men who participate in 
population-based screenings have low initial PSA values that remain relatively 
unchanged over time, the likelihood of them progressing to values >4.0 ng/ml is minimal 
which is supportive of longer screening intervals and saving the health care industry 
millions of dollars in overdiagnosis and over treatment (Schroder, Raaijmakers et al., 
2005). Further, if these groups of men omitted the DRE/TRUS tests at second round 
screenings, even more savings could be realized by reducing the numbers of unnecessary 
and costly biopsies (Gosselaar et al., 2006).  
Another study of men from the Rotterdam section of the ERSPC examined 
prognostic factors associated with the screened group and control group (Van Der 
Cruijsen-Koeter et al., 2005).  Authors evaluated over 35, 000 men aged 55-74 years 
randomized during 1993-1999. The final selection included 17,635 men in the screening 
group and 17, 513 men in the control group. The goal was to determine screening 
characteristics between the two groups over a series of screening rounds. The prognostic 
factors evaluated were TNM staging and Gleason Score grading. Results showed both a 
favorable shift in stage and Gleason score in the screening group. For example, 84.2% of 
the cancers were detected in the screening group and 58.9% in the control group with 
most tumors being staged at T1and T2 (Van Der Cruijsen-Koeter et al., 2005). An 
important finding was differences in the numbers of men found to have distant metastasis 
in that within the screening group, only 7 men had advanced metastatic disease and 
within the control group, 27 men were found to have distant metastasis. Moreover, out of 
the total number of men, there was a 5.0 times greater likelihood of finding distant 
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metastasis in the control group which was statistically significant to the screening group 
at a p < 0.001 (Van Der Cruijsen-Koeter et al., 2005).  
Limitations to the study were noted with contamination rates of approximately 
5% from opportunistic PSA screening of the control group. The authors noted this rate to 
be comparable to a study by Otto and colleagues (2003) who also used the Rotterdam 
section of men where percentages of PSA contamination rates of 7.6% and 3.3% were 
found in the control group and screening group respectively (Van Der Cruijsen-Koeter et 
al., 2005).                 
A different study of the Rotterdam section examined PSA changes in men with 
and without prostate cancer after a four year period between two screening rounds. The 
authors acknowledged use of the PSA test as not being a proven cancer detection tool that 
also reduces cancer-specific mortality. Therefore, they focused on changes over time of 
the sub-forms of PSA such as the PSA velocity (PSAV), the PSA slope, and the PSA 
doubling time (PSADT) in men with positive, negative, and no biopsy indicated over a 
four year period after the initial first round screening. The PSA velocity was defined as 
how fast a PSA value rises from its initial value over one year. In the U.S. a PSA rise of 
0.75 ng/ml/year usually implies additional clinical work up be initiated. The PSA slope 
was defined by taking the differences between the base 2-logarithms from the initial PSA 
value and the second round PSA value and dividing by the time interval between the 
measurements. The PSA doubling time (PSADT) is the time it takes for an initial 
screening PSA result to double in value. The greater the velocity or doubling time of a 
PSA indicated a faster progression of disease to a more aggressive stage (Raaijmakers et 
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al., 2004). The results indicated that men with prostate cancer had a mean PSAV of 0.62 
ng/ml/year compared to men with no prostate cancer having a mean PSAV of 0.46 
ng/ml/year (p = 0.001). The PSADT was 5.1 years and 6.1 years in men with and without 
prostate cancer respectively (p = 0.002). The authors tried to improve specificity 
(reducing numbers of unnecessary biopsies) by fixing the sensitivity at 95% (which 
means that 95% of cancers would accurately be predicted). This review resulted in a 
PSAV specificity of 12.5% which indicates that 12.5% of the biopsies would be 
unnecessary while still accurately detecting 95% of the cancers. The PSADT resulted in 
saving 13% of unnecessary biopsies. The authors confirmed other reported observations 
of the lack of the specificity in the PSA test as the only indicator for biopsy. For example, 
it has already been observed that in only about 20-30% of men receiving biopsies and 
having PSA values > 4.0 ng/ml, that prostate cancer is detected. This leaves 70-80% of 
men having false positive test results leading to overdiagnosis and over treatment of 
possibly indolent cancers. The authors concluded that the sub-forms evaluated in their 
study could be helpful in improving screening guidelines. The authors noted limitations 
as only having two PSA test results over time and conceded that more tests over longer 
periods would be necessary to strengthen internal validity for use of the sub-forms of 
PSA (Raaijmakers, 2004). Additional limitations included using only the relative 
sensitivity of the sub-forms of PSA, in that using biopsy results for prostate cancer 
detection as the reference standard does not provide the absolute sensitivity and therefore, 
does not allow an understanding of the true numbers of cases that go undetected 
(Raaijmakers, 2004).  
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A similar study from the Switzerland arm of the ERSPC examined 7,124 men of 
whom 3,562 were randomized to the screened group and 3,562 men to the control group. 
Kwiatowski and colleagues (2004) found a prostate cancer detection rate of 2.5% in PSA 
tested men and only 7% of the men had distant metastasis while 93% had organ-confined 
disease. The authors concluded that the results suggested not recommending large 
screening programs and instead, physicians should have informed discussions with their 
patients at consultation concerning the risks and benefits of screening (Kwiatowski et al., 
2004).       
An additional study coming out of the Swedish section of the ERSPC examined 
the efficacy of PSA screening after a two year screening interval over an eight year 
period (resulting in 4 PSA measurements). Out of the 32,298 men enrolled as part of the 
Swedish arm, 10,000 men each were randomized to either the control group or screening 
group. Men with PSA values < 3.0 ng/ml received no further testing and were invited to 
return after two years, four years, and then six years for repeat evaluation. Men with PSA 
results > 3.0 ng/ml were offered further workup by a urologist for consideration of a 
DRE, TRUS, and sextant biopsy (Hugosson, Aus, Lilja, Lodding & Pihl, 2004; Schroder, 
Habbema, Roobol & Bangma, 2006). The authors noted that PSA was highly associated 
with prostate cancer risk in the first screening round with 14% of men with PSA levels 
between 3.0 and 4.0 ng/ml being diagnosed with cancer. However, the risk decreased 
significantly in the third and fourth rounds of screening (Hugosson et al., 2004).  The 
results noted that stage shifts corresponded with PSA levels to where advanced and 
metastatic diseases were relatively nonexistent in the later screening rounds when PSA 
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levels tended to be lower. The authors noted that these findings were consistent with 
Labrie’s study (2004) of the Quebec randomized trial. The study reported a 73% 
participation rate with results showing that during the eight year screening period only 43 
interval cancers were detected compared with 550 cancers found in the screened group 
and 197 cancers found in the control group. The authors concluded that the study showed 
that a two year screening interval was sufficient for detecting most cancers in the first 
round and that PSA screening does likely lead to stage and grade shifts with most tumors 
being detected at curable stages (Hugosson et al., 2004; Schroder, Habbema et al., 2006).      
The most recent study from the ERSPC published in the “New England Journal of 
Medicine” in March of 2009 identified 182, 000 men randomly assigned to either a 
treatment group receiving a PSA test every four years or a control group that did not 
receive any PSA testing (Schroder et al., 2009). The outcome of interest was prostate 
cancer specific mortality. It was determined that 82% of men from the screening group 
had at least one screening test offered. After a median 9 year follow up period, the 
incidence rate was 8.2% in the treatment group and 4.8% in the control group. The death 
rate ratio in the screened group compared with the control group was 0.80 (CI, 0.65-0.98; 
adjusted p value = 0.04) and the absolute risk difference was 0.71 death per 1000 men. 
This means that 1,410 men would have to be screened with 48 new additional cases of 
prostate cancer being treated in order to prevent one death from prostate cancer (Schroder 
et al., 2009). The authors concluded that screening PSA reduced the risk of dying from 
prostate cancer by 20% but was also associated with a high overdiagnosis risk (Schroder 
et al., 2009).      
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The ERSPC is not without limitations as initial findings from the Rotterdam 
section have illustrated. Biases of lead time, length, and selection may diminish the 
importance of such findings. For example, when comparing 1,014 men with screen 
detected prostate cancer within the screening group of the Rotterdam section with a 
control group from the same region, results indicate that after a 5-year follow-up period, 
only 2% had died from prostate cancer (Albers, 2007). The authors of those studies 
concluded that men of the screening group had a 98% survival rate and that these men 
were less likely to die before the 5 year follow-up period. However, this should not be 
surprising because men of screened groups are usually seen by their physician more often 
and that screen detected cancers usually are of early stage and localized, therefore, the 
higher survival rates experienced by these men may be attributable to lead-time bias.  
Even more disappointing is the conclusion that because initial results showed low 
numbers of deaths from prostate cancer, final conclusions from the ERSPC may not be 
drawn for more than the original 10 years thought to be sufficient and therefore continued 
follow-up periods may need to be extended out to 15 years ending in 2013 (Albers, 2007; 
http://www.cancer.gov/newscenter/qa/2009/plcoprostateresultsqa assessed February 
2011). Another possible disappointment of the ERSPC is the overdiagnosis and over 
treatment during the trial period. For example, there are a high percentage of patients who 
received surgery that may have been candidates for active surveillance instead. This is 
because at the time, it was not known that active surveillance was an important treatment 
option for these men. Because of this important finding, almost thirty three percent of 
men in the ERSPC would have been active surveillance candidates; however, 90% of 
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them chose aggressive treatment with increased side effects. Therefore, this change in 
treatment during the trial period may also bias the results.  
Finally, should long-term follow-up results show screening to be valuable at 
reducing cancer-specific mortality, it could be argued that active surveillance should have 
been offered more. In contrast, should final results show screening to be a poor predictor 
of reducing cancer-specific mortality, it could be argued that opportunistic screening rates 
were too high in the control group (Albers, 2007). What may prove to be important 
factors provided by the trial are changes in treatment management of prostate cancer, 
baseline PSA values, frequency of PSA testing, and threshold values of PSA for different 
age groups (Albers, 2007). Race was not adequately represented in the ERSPC trial or 
adequately understood in studies involving large population-based areas when evaluating 
disparate mortality rates. 
The most current result, as described earlier, is that nine year follow-up indicated 
a 20% reduction in cancer-specific mortality among the screened group compared with 
the non-screened group in men aged 55-69 years thus implying a survival benefit to PSA 
screening. The trial also resulted in a 40% increase in the number of prostate cancers 
diagnosed in the screened group during the same follow-up period 
(http://www.cancer.gov/newscenter/qa/2009/plcoprostateresultsqa assessed February 
2011).    
The Prostate Lung Colon and Ovarian Trial 
The PLCO cancer screening trial began recruitment in 1993 and closed in 2001 
with 154,942 total subjects enrolled including men and women from 10 cancer centers 
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across the U.S. The participating centers include the University of Colorado Health 
Sciences Center, the Lombardi Cancer Research Center of Georgetown University, the 
Pacific Health Research Institute, the Henry Ford Health System, the University of 
Minnesota School of Public Health/Virginia L. Piper Cancer Institute, the Washington 
University School of Medicine, the University of Pittsburgh/Pittsburgh Cancer 
Institute/Magee-Women’s Hospital, the University of Utah School of Medicine, the 
Marshfield (Wisconsin) Medical Research and Education Foundation, and the University 
of Alabama at Birmingham (Roemeling, 2006; Andriole, Levin et al., 2005). 
Subjects completed questionnaires on many baseline factors such as diet, tobacco 
and alcohol use, family history of cancer, use of certain selective drugs, and other risk 
factors. Recruitment was accomplished mainly through mailings (Pinsky, Ford et al., 
2008). All blood samples collected for PSA testing were stored in a central repository to 
allow for multiple study reviews (Andriole, Reding, Hayes, Prorok, & Gohagan, 2004). 
Men in the screened group were randomized, they received both a DRE and PSA 
test, they were of the ages 55-74 years old, and had no previously reported cases of 
cancer. These men received subsequent screening tests 12 months later each year for a 
total of six years of screening. Exclusion criteria included current treatment for cancer 
(except skin cancers), surgical removal of the entire prostate gland, participation in a 
different cancer-screening or primary prevention trial, and use of finasteride in the past 
six months. Finasteride (Proscar) is used to treat BPH and male balding and is one of two 
5-alpha-reductase inhibitors used to treat BPH, the second drug is known as dutasteride 
(Avodart). Both these drugs are equally effective for treating BPH and can reduce the 
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size of the gland by 20-30%. Finasteride is also known to reduce PSA values by as much 
as 50% and therefore could bias the PSA results for the trial (Carter, 2007; Andriole, 
Reding et al., 2004; Ford, Havstad, Demers & Johnson, 2005).  
Baseline socioeconomic demographics were gathered using a self-reporting 
questionnaire. Baseline PSA tests were performed using the Hybritech Immunoassay 
method (Beckham-Coulter, San Francisco, CA) with values > 4.0 ng/ml as the threshold 
value indicating possible cancer. Men with suspicious DRE or PSA were referred to their 
physician for additional work up.  
Because the National Cancer Institute and the Centers for Disease Control wanted 
to maintain ethnic diversity throughout the PLCO trial, they funded several activities to 
ensure that African Americans were adequately represented in the trial. Adequate 
representation would also assure distribution of appropriate information of the risks and 
benefits that would increase understanding of the possible interactions of treatment 
effects based on biological, social, and cultural factors associated with race (Pinsky, Ford 
et al., 2008; Stallings et al., 2000).  
The factors included in the decision making process for African American men to 
participate consists of cultural differences, perceptions of health care, and disparities in 
access to good quality care. Therefore one goal of the PLCO was to answer questions as 
to whether the current PSA threshold of 4.0 ng/ml should be different based on race and 
should African American men begin screening for prostate cancer at the same age as 
Caucasian men. These are questions that can only be answered if different ethnic groups 
are well represented. Unfortunately, as the trial recruitment ended, minority enrollment 
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made up only 14%, of which 6% were non-Hispanic blacks (Stallings et al., 2000). In 
order to address this low minority rate, the NCI and the CDC formed new projects during 
1997 aimed at understanding and overcoming barriers of participation in the trial and to 
increase the minority enrollment by 32%. For example, the African American Men 
Project (AA men at Henry Ford Health System in Michigan) was created and is a 
randomized trial designed to evaluate the efficacy of new ways to increase recruitment of 
African American men. In addition, a minority-based screening center was started at the 
University of Alabama, Birmingham to identify factors that influence the decisions of 
African American women who participate in the PLCO trial, and two behavioral research 
projects at the University of Pittsburgh were designed to evaluate the psychological 
factors that influence African American decisions to participate in cancer screening 
research (Stallings et al., 2000; Pinsky, Ford et al., 2008). The attempts made by the 
PLCO to have minority groups better represented were not as successful as originally 
planned but were similar to other multicenter cancer screening trials like the Prostate 
Cancer Prevention Trial, the STAR trial, the CARET trial, and the SELECT trial (Pinsky, 
Ford et al., 2008).   The final results of the PLCO are a few years away; however the 
initial screening round is complete and is made up of 38,355 men in control group and 
38,350 men in the screened group of the prostate arm of the trial. Clinical staging was 
assigned based on tumor extent using the TNM system and the AJCC method previously 
described. As discussed above, minority representation was less than had hoped as 
African American men represented only 4.5% of the screened group; whereas, 86.2% of 
men in the screened group were Caucasian. All age groups were well represented with 
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about half having college degrees. Compliance rates were similar across all age groups. 
Among men with abnormal DRE, PSA values less than 4.0ng/ml, and a biopsy, cancer 
detection rates were calculated as 3.2%, whereas men with positive DRE and PSA levels 
greater than 10.0 ng/ml, a 76% overall prostate cancer detection rate was calculated 
(Andriole, Levin et al., 2005). When considering the PSA test alone (without DRE) in 
men having PSA values > 4.0 ng/ml and who had a biopsy, a cancer detection rate of 
18% was found. The overall cancer detection rate on all 34,244 men having an initial 
PSA or DRE was only 1.6%. This rate varied with age from 1.0% for men 55-59 years to 
2.5% for men 70-74 years (Andriole, Levin et al., 2005).  
In summary, the PLCO trial has not yet reported 10 year data but only initial 
results from baseline first round screenings. After six rounds of annual screenings (7 
years), cancer detection rates increased by 22 % in men of the screening group with 50 
deaths and 44 deaths in the non-screening group. The difference in these numbers was 
not statistically significant and therefore, no survival benefit could be associated between 
PSA screening and mortality. These rates differ from the Rotterdam section of the 
ERSPC trial in that first round screenings from the ERPSC found a prostate cancer 
detection rate of 4.2%. The authors explained the difference as possibly being due to the 
higher biopsy rates in the ERSPC versus the PLCO (91% in the ERSPC and 31.5% in the 
PLCO). The ERSPC trial protocol called for specific follow-up in men with positive 
screening findings, whereas in the PLCO trial, men were referred to their primary health 
care provider for discussion of further work-up. Trial protocols may reflect differences in 
the U.S. and Europeans practice patterns within the medical community (see Table 5). 
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Table 5. Characteristics of Initial Findings from the PLCO Trial. 
 
Control group 
 
Screened group 
 
Proportion  
Caucasian            AA 
n = 38,355 n = 38,350 86.2%             4.6% 
Number of men having both a PSA & DRE (n = 34,244) [45%] 
Of which had positive 
results on  both tests 
Positive results on one 
test 
Negative results on both 
tests 
1.2% 12.9% 85.9% 
Cancer Detection Rate 
Among all men with +DRE and PSA < 4.0 3.2% 
Among all men with +DRE and PSA >10.0 76% 
Among all men having PSA alone and biopsy 
With initial PSA > 4.0 
18% 
Variation with age group 
55-59 yrs. 
70-74 yrs. 
 
1.0% 
2.5% 
Overall for all men having either DRE or PSA 1.6% 
 
In a separate study using data of the PLCO trial from the Henry Ford Health 
System, authors evaluated what effects false-positive results had on men returning for 
additional screenings. Out of the total 4,093 men from the health system, 2,290 qualified 
to participate. The demographic characteristics showed that 85.9% of the men were 
Caucasian and 14.1% were African American with all other ethnic groups excluded due 
to low numbers. The average age was 62.8 years and 71.6% had greater than a high 
school education. A univariate analysis for categorical covariates and screening behavior 
showed a strong association that men receiving a false-positive base line result from 
screening would most likely not return for his 12 month second round screening. 
Specifically, an odds ratio of 1.96 (95%CI, 1.36-2.83, P < 0.001) suggests that men were 
almost twice as likely not to return for subsequent screening when receiving a base line 
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false-positive result compared to men receiving a base line negative result (Ford, 
Havstad, Demers & Johnson, 2005). African American men were also less likely to return 
for a 12 month second round screening with an odds ratio of nearly 1.8 (95% CI, 1.2-2.6, 
p = 0.002). Finally, education level showed a significant negative association (OR 1.71; 
95%CI, 1.25-2.34, p < 0.001) and age was not statistically different with and odds ratio 
of 1.02 (95%CI, 0.99-1.05, p = 0.10). The authors noted one strength of the study as 
adequate representation of African American men (14%). A limitation of the study 
included that any information gained from subjects who agreed to participate in a long-
term screening trial may not be representative of the population because these individuals 
may be healthier. Furthermore, the authors noted that the results may not be generalized 
across other geographic regions. The final conclusions indicated a more shared decision 
making process between patient and provider discussing the meanings of false-positive 
results and their implications (Ford, Havstad, Demers et al., 2005).  
Another study to evaluate the probable time for low PSA levels (normal levels) to 
increase to higher levels (abnormal values) was examined using the PLCO data. A large 
proportion of screened men have PSA values less than 4.0 ng/ml which raises the 
question of when this group of men should return for subsequent screening intervals 
(Crawford et al., 2006). The study showed that the estimated probability for men with 
normal PSA values to convert to abnormal values varied with time. The results from this 
study suggest that a reduction in PSA tests, and therefore costs, could have been realized 
(Crawford et al., 2006). These results were similar to those found in the initial screening 
rounds from the ERSPC trial. Since a large proportion of men being screened had base 
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line PSA values of less than 2.0 ng/ml, reducing the number of PSA tests could result in a 
cost reduction as well (Crawford et al., 2006).  
In a separate study, researchers examined the “healthy volunteer effect” of the 
PLCO trial. Volunteers of screening trials tend to be healthier and more educated due to 
specific criteria of the study protocol (Pinsky, Miller et al., 2007). Certain inclusion and 
exclusion criteria can target healthier individuals who tend to be more educated, have 
higher incomes and lead healthier lifestyles. The study examined this health effect for 
cause-specific mortality rates. Unfortunately, the study excluded cancers as one of the 
incidence and mortality ratio computations and African American men only represented 
4.4% of the population within the study (Pinsky, Miller et al., 2007).  In addition, study 
findings showed that being African American, ever have smoked, low education, lack of 
physical activity, and not married were all associated with increased mortality (Pinsky, 
Miller et al., 2007).    
A more recent study emerged from within the PLCO that evaluated effects of 
baseline comorbidities on adherence to clinical trial protocols. In addition, factors such as 
age, race, gender, and psychological behavior that could affect whether subjects 
participating in clinical trials adhere to protocols were examined. African American men 
typically have low participation rates in cancer screening trials although they have higher 
incidence and mortality rates. The study sample was composed of 683 African American 
men older than 55 years from the Henry Ford Health System within context of the PLCO 
trial. The men were assigned either to a case management screened group (n = 344) or to 
a case management control group (n = 339). The case control managers received the 
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screening results and the baseline health histories of comorbidities. Health histories were 
obtained from the self-reported questionnaires (Ford, Havstad, Fields et al., 2008). The 
study hypothesis was that participants with comorbidities would show lower adherence 
rates to PLCO screening than participants without any comorbidity (Ford, Havstad, 
Fields et al., 2008). The results indicated no significant differences found between any of 
the health history conditions listed. The only comorbid condition showing a negative 
statistical significance (less likely to adhere to protocol) on adherence to the PSA test was 
smoking with an odds ratio of 0.6 (95% CI; 0.4-0.9, p < 0.05) for the PSA test. Family 
history of cancer showed a positive association to the DRE test (more likely to adhere) 
with an odds ratio of 1.5 (95% CI; 1.0-2.2, p < 0.05). The authors were also interested in 
whether the number of comorbid conditions would show an interaction to adherence, 
however the results indicated neither a positive or negative trend in adherence could be 
associated with the number of comorbidities (p > 0.30). The authors concluded that 
African American men with comorbidities were as likely to participate in clinical trials as 
Caucasians. The authors suggested limitations to include African American men from the 
Detroit metropolitan area and the baseline questionnaire did not include psychiatric 
comorbidities. Strengths of the study were that focus was on older African American men 
who tend to have higher incidence and mortality rates of prostate cancer. In addition, the 
study population was from a large metropolitan area that tended to be socio-
demographically representative of other larger urban areas so it is likely that these results 
may be generalized to older African American men from those regions (Ford, Havstad, 
Fields et al., 2008).      
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The most recent and first report coming out of the PLCO trial was published in 
the New England Journal of Medicine in March 2009. The aim was to note screening 
effects with PSA and DRE on prostate cancer-specific mortality (Andriole et al., 2009). 
The authors randomly assigned 76,693 men from 10 U.S. centers to receive either annual 
PSA screening or usual care, defined as sometimes including screening. The screening 
group received annual PSA tests for six years and a DRE for four years. The screening 
group compliance rates consisted of 85% for PSA testing and 86% for DRE testing with 
rates increasing from 40% in the first year to 52% by the sixth year for PSA testing 
(Andriole et al., 2009).  Results after 7 years of follow up indicated the incidence of 
prostate cancer to be 116 cases (2,820 cases) per 10,000 person-years in the screening 
group and 95 cases (2,322) per 10, 000 person-years in the control group.  These results 
show a rate ratio of 1.22 (CI, 1.16 to 1.29). The incidence of death per 10,000 person-
years was 2.0 (50 deaths) in the screening group and 1.77 (44 deaths) in the control group 
(rate ratio, 1.13, CI, 0.75 to 1.70). The authors concluded that after the 7 year follow up 
period, the mortality rate from prostate cancer was low and did not significantly differ 
between the two groups (Andriole et al., 2009).    
It is recognized that performing a study showing that screening can effectively 
reduce death rates and improve quality of life requires large resources. The PLCO study 
of the National Cancer Institute was based on the assumption that 74,000 men and a 10 
year follow-up period would be required to achieve sufficient power and to show that 
screening directly leads to reduced mortality due to slow growth progression rates of 
prostate cancer (Sandblom, 2004). With final results not available until further follow-up 
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reported, concerns for high risk contamination rates to the control groups because of 
previous screenings and the late start of the trial loom (Labrie et al., 2004).   
SEER-Medicare Screening Studies 
In addition to the population-based randomized trials from other countries and the 
PLCO listed above, there have been numerous smaller studies in the United States using 
some of the same variables as the larger studies, however, most included race as an 
independent variable as well. In looking at a comparison of PSA use among African 
American and Caucasian men from 1991-1998, Etzioni and colleagues (2002) reported 
that among Medicare claims data of elderly men PSA use had reached nearly 35% for 
Caucasians and 25% for African Americans during 1996. The authors concluded that 
older African American men were less likely to receive a PSA test than older Caucasian 
men and that regular screening in African Americans was lower than in Caucasians 
(Etzioni, Berry et al., 2002). Their study used SEER registry data from 13 geographic 
regions covering 14% of the U.S. population showing consistency between other survey 
data of screening behaviors between African Americans and Caucasians. Namely, that 
African Americans were less likely to use PSA screening; however, the actual testing 
rates estimated from the SEER registries indicate that the discrepancies may be lower 
than expected. Etzioni and colleagues (2002) determined that by 1998, approximately 
38% Caucasians and 31% African Americans received a PSA test at least annually. This 
translates into an odds ratio of 73%, a much greater ratio than reported from the New 
York Behavioral Risk Surveillance System (BRFSS) that estimated a ratio of 30% 
(Etzioni, Berry et al., 2002). Etzioni and colleagues (2002) concluded that this difference 
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may be due to the use of SEER registry which is an administrative claims database with 
results indicative of multiple areas combined unlike single area survey data. 
One substantial limitation when using SEER-Medicare linked datasets is the fact 
that the amount of heterogeneity across regions is extremely great. This was illustrated by 
Legler and colleagues (1998) earlier where they noted an association between prostate 
incidence and first-time PSA use in two SEER areas having different PSA testing 
patterns (Legler, Feuer, & Potosky, 1998).  Etzioni and colleagues (2002) also found 
large differences in testing patterns across SEER areas where Caucasians, surprisingly, 
had higher PSA testing rates in areas of greater African American populations such as 
Atlanta, Detroit, and Los Angeles. Caucasians had the lowest testing rates in Connecticut, 
Utah, and Iowa where their population was greater.  
Many variables are thought to be associated with the complex interrelations 
surrounding differences in prostate screening and mortality rates among races, especially 
in the U.S. and among African American and Caucasian men. Furthermore, use of a 
recent large administrative claims database coupled with the robust statistical method of 
propensity score analysis for mimicking randomization in this thesis will encourage 
exploration into the complexities of racial differences that will benefit educational 
programs, other research quests, and public policy. These ideas are supported in a study 
describing use of the SEER-Medicare data. The SEER-Medicare data provides for large 
population-based cohort studies that can be used longitudinally for tracking cancer, 
diagnosis, treatment, and outcomes (Warren, Klabunde, Schrag, Bach & Riley, 2002).  
However, one challenge of using observational data such as the SEER-Medicare files is 
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that participants are not randomly assigned and in order to make meaningful inferences 
researchers must control for differences in groups. Methods such as propensity scoring 
are recognized as analogous to randomization and therefore, the combination of the most 
recent SEER-Medicare dataset and a propensity analysis will be useful for describing 
disparate mortality rates and prostate screening in this study. 
Risk Factors and Prostate Cancer 
 
A summary of the studies associated with risk and prostate cancer are provided 
later in the chapter. An EPA report from 2004 placed risk factors associated with prostate 
cancer into two groups, endogenous and exogenous. Endogenous risk factors include 
family history of disease, hormones, African American race, and aging. Exogenous risk 
factors included diet (weight and obesity), environmental agents, occupation, and 
physical activities. Current knowledge of causes and prevention for prostate cancer 
remain unclear and virtually nonexistent (Bostwick et al., 2004). 
Among endogenous risk factors, family history is important. Men are two to three 
times more likely to develop prostate cancer if they have first degree relatives with 
prostate cancer (i.e. father, brother, son). However, the EPA report suggests that this 
association may be contaminated by selection bias as the clinical and pathological 
features of familial cancer can be similar to nonfamilial cancer (Bostwick et al., 2004; 
U.S. Preventive Services Task Force, 2002). Other studies have found that family history 
is consistently positively associated with prostate cancer risk and appears to have a 
stronger association than colon or breast cancer. For example, one epidemiological study 
found that African American men with known family history had a higher risk for 
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prostate cancer (odds ratio [OR] 3.2) compared with Caucasian men (OR 1.9), although 
the numbers were not significantly different (Whittemore, Wu et al., 1995). An additional 
study showed that 31.2 % of African American men reported a family history compared 
to only 22.2% of Caucasian men (Cotter, Gern, Ho, Chang & Burk, 2002).     
It is suggested that male hormones such as androgen and testosterone can affect 
cancer growth rates and tumor progression by actually changing clinically indolent 
tumors into more clinically apparent and aggressive tumors. Findings have shown that 
high levels of testosterone might increase a man’s risk over time although these studies 
also noted results that were inconsistent in confirming this relationship (Bostwick, 2004; 
Prostate Cancer Initiative-Centers for Disease Control and Prevention [CDC], 2007) (see 
Table 6). It has been hypothesized that testosterone may play an important role in 
developing prostate cancerous cells that could function as tumor catalysts. Testosterone 
promotes cell division that may result in an accumulation of spontaneous mutations over 
a lifetime and then suddenly appear in normal prostate tissue. Whatever its role, 
testosterone is most likely only a cofactor for prostatic carcinogenesis (Bostwick, 2004).  
Prostate cancer risk by race continues to be an important topic as African 
American men have the highest incidence of prostate cancer in the world. The risk for an 
African American man is higher than for Caucasians, Asians, Hispanics, Pacific 
Islanders, and Native Americans. From 1988 to 1992, race-specific incidence rates in the 
United States ranged from the lowest of 24.2 per 100,000 for Koreans to the highest of 
180.6 per 100,000 for African Americans (Bostwick, 2004). African Americans are more 
likely to present with advanced stage and their stage-specific mortality is worse than in  
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Table 6. Summary of Screening Studies, RCTs, and Case-Control Studies. 
  
Author 
(year) 
Study 
Category 
Study type 
or dataset 
Outcome measure Finding (s) Limitations 
Crawford 
(2008) 
Screening by 
PCPT 
Literature 
review 
Value of PSA As PSA rises 
Sensitivity decreases 
and  
Specificity increases 
None mentioned 
Harris & 
Lohr (2002)  
Screening by 
USPSTF 
RCT Efficacy of screening on 
mortality 
No difference in mortality 
between groups (8yr 
follow-up) 
Low participation 
Labrie et al. 
(2004) 
Screening RCT extension 
to above study 
Efficacy of screening on 
mortality 
62% reduction in  
mortality between groups 
(11yr follow-up) 
 
Age significant 
Low response rate 
(23.6%) 
Ethnic groups not 
evaluated 
Susceptibility 
bias high 
Lack of 
sociodemographic 
comparisons 
Death rates from 
other causes not 
evaluated 
Perron et al. 
(2002) 
Screening  Extent that increased 
incidence resulted in 
decreased mortality 
Change rates between 
incidence and mortality 
not inversely related  
Evaluation period 
only 1 yr. 
Quebec cancer 
registry uses in 
hospital discharge 
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Table 6: continued. 
 
Author 
(year) 
Risk Factor Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
ERSPC 
(Europe) 
Screening Large RCT 
(on going) 
Extent that 
early 
screening 
leads to 
reduced 
incidence 
and mortality  
Final results not available. 
Hope to show that early screening 
leads to 25% reduction in mortality 
Suspect selection 
bias, lead-time bias, 
and contamination 
bias. 
Over diagnosis and 
over treatment. 
Healthy men effect. 
Draisma et 
al. (2003) 
Overdetection 
and over 
treatment due 
to screening 
Rotterdam 
section of 
ERSPC 
Overdetectio
n from 
screening 
leads to over 
treatment and 
unnecessary 
treatment 
Men aged 55 had 27% overdetection 
rate and 12.3 yr. lead time 
Men aged 75 had a 56% overdetection 
rate. 
Dutch men should have greater than 1 
yr. screening interval   
Men limited to 
Dutch origin only 
No racial or ethnic 
groups included 
Etzioni, 
Penson et 
al. (2002); 
Ciatto et al. 
(2004); 
Graif et al. 
(2007) 
Overdetection 
and over 
treatment due 
to screening 
Computer 
Modeling;  
Cohort 
from 
ERSPC 
Magnitude of 
overdiagnosi
s and impact 
on 
unnecessary 
treatment 
2 million men modeled 29% 
overdetection rates in Caucasian and 
44% in African 
 American (Etzioni), Ciatto and 
colleagues agreed overdiagnosis is 
prevalent 
27% of men were found to have been 
underdiagnosed and only 5% 
overdiagnosed (Graif) 
Same as noted 
within ERSPC 
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Table 6: continued. 
 
Author 
(year) 
Risk Factor Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Van Der 
Cruijsen-
Koeter et al. 
(2005) 
Prognostic factors 
associated with 
screened/control 
group  
Rotterdam 
section of 
ERSPC 
TNM 
staging and 
Gleason 
score 
CDRa: 84% in screened group, 59% 
in control group. 
Distant mets: 7 men in screened 
group, 27 men in control group. 
Also 5x more likelihood  for distant 
mets in control vs. screened group 
Same noted 
within 
ERSPC and 
possible 
contamination 
rates 
Raaijmakers 
et al. (2004) 
PSA changes over 4 
yrs. in men with and 
without prostate 
cancer 
Rotterdam 
section of 
ERSPC 
PSA sub 
forms: 
PSAV 
PSADT 
Men with PCab: 
PSAV=0.62ng/mL/yr. 
PSADT = 5.1yrs. 
Men w/o PCa:  
PSAV=0.46ng/mL/yr. 
PSADT = 6.1yrs. 
Only had 2 
PSA tests 
over short 
follow up 
period 
Hugosson et 
al. (2004); 
Schroder et 
al. (2006) 
Screening Swedish 
section of the 
ERSPC 
PSA at 2yr 
intervals 
over 8yrs (4 
PSA tests) 
PSA highly associated with 
increased risk in 1st screening 
round. 
Stage shifts make advanced disease 
and mets nearly non-existent in late 
screening rounds 
Same noted 
within 
ERSPC 
Kwiatowski 
et al. (2004) 
CDR of prostate 
screening 
Switzerland 
section of the 
ERSPC 
CDR of 
PSA tested 
men 
Out of 7,124 PSA tested men 
CDR = 2.5% 
Men with mets = 7% 
Final conclusion: did not 
recommend large screening 
programs 
  
Same noted 
within 
ERSPC 
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Table 6: continued. 
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
PLCO 
(U.S.) 
Screening Large RCT  
(on going) 
Extent that early 
screening leads to 
reduced incidence 
and mortality 
Final results not available  
Ford, 
Havstad, 
Demers, et 
al. (2005) 
Screening PLCO data Effects of baseline 
false + results on 
men returning for 
second round 
screenings 
Men 2x more likely not to return 
for second round (OR 1.96) when 
receiving an initial false + 
compared with men receiving an 
initial negative result 
Education was significant (OR 1.71 
and)  
Age was not significant (OR 1.02) 
Information obtained 
from participants in 
long-term screening 
trials may not be 
representative of 
population due to 
healthy effect. 
Results may not be 
generalized across 
other geographical 
regions. 
Crawford et 
al. (2006) 
Screening PLCO data Time for normal 
PSA values to 
convert to 
abnormal levels 
1.5% of men with PSA <1.0ng/mL 
will convert to >4.0ng/mL in 5 yrs. 
33.5% of men with PSA 2.0-
3.0ng/mL will convert.  
79% of men with PSA 3.0-
4.0ng/mL will convert. 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
Table 6: continued.  
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Pinsky et al. 
(2007) 
Screening  PLCO data Examination 
of the healthy 
volunteer 
effect on 
overall 
mortality and 
cancer-
specific 
mortality 
PLCO members when compared to 
NHISc members tended to be: 
Better educated 
More physically active 
More likely to be married 
Less likely to smoke. 
In contrast, being AA, ever smoked, 
low education, lack of physical 
activity, and not married all were 
associated with increased mortality 
 
Study excluded cancers 
as a mortality ratio 
computation. 
AA men under-
represented at 4.4% 
Ford, 
Havstad, 
Fields, et al. 
(2008) 
Screening PLCO data Effects of 
comorbidities 
or number of 
comorbidities 
on adherence 
to RCT 
protocol 
No significant differences between 
comorbidities. 
Only smoking showed negative 
statistical significance on adherence 
to the PSA test (less likely to 
adhere to protocol, OR 0.6). 
No racial differences, AA’s with 
comorbidities as likely to 
participate as Caucasians 
Sample included elderly 
AA men from a single 
geographical location 
(Metro-Detroit). 
Questionnaire did not 
include psychiatric 
comorbidities 
Sandblom 
et al. (2004) 
Screening RCT pilot 
study 
Feasibility of 
a large 
population-
based 
screening 
program 
Three year screening interval 
sufficient for early stage prostate 
cancer. 
Cost effective 
 
Disparate mortality 
among race not studied. 
Small Population 
restricted to 1 
geographical city (n = 
9,026) 
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Table 6: continued. 
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Concato et 
al. (2001, 
2006) 
Screening  Nested Case-
control 
Association of 
mortality and 
PSA use 
No evidence of screening benefit in 
matched case-control in overall 
mortality. 
Evidence did exist for PSA screening 
and cancer-specific mortality for 
African Americans 
Race not matched 
initially. Race 
adjusted for in 
statistical analysis 
Weinmann 
et al. (2004) 
Screening Case-control Association of 
mortality on 
PSA and DRE 
use 
Inverse relation found between PSA 
and DRE with cancer-specific 
mortality. 
30% reduction in mortality 
Not able to 
separate effects of 
DRE on PSA. 
Initial rise in PSA 
use during study 
period may inflate 
odds ratio 
Weinmann 
et al. (2005) 
Screening Case-Control 
cohort from 4 
HMOs 
Association of 
mortality on 
PSA and DRE 
use 
Use of PSA and DRE was associated 
with reduced mortality in Caucasians 
but not African Americans 
Not able to 
separate effects of 
DRE on PSA. 
Low participation 
of African 
Americans.  
Possible 
misclassification 
bias. 
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Table 6: continued. 
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Etzioni, 
Berry et al. 
(2002) 
Screening SEER13 -
Medicare 
Registry 
1991-1998  
Comparing PSA 
use among AA 
and Caucasian 
AA less likely to use PSA. 
Variable testing patterns (i.e., 
Caucasians had higher PSA testing 
rates in areas of greater AA 
populations and less testing rates in 
areas of greater Caucasian 
populations) 
Administrative 
claims data yield 
combined results 
from multiple 
areas. 
Heterogeneity 
across geographical 
regions is great in 
SEER-Medicare 
registries 
a: CDR is cancer detection rate 
b: PCa is prostate cancer 
c: National Health Interview Survey
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Caucasians. In addition, African American men are more commonly diagnosed at earlier 
ages than Caucasian men (mean 63.7 years versus mean 68.1 years).  
From the NCI’s SEER Cancer Statistics Review of 2000-2004 dataset, recall that 
the median age at diagnosis for all races with prostate cancer is 68 years with 36.2% 
included in the range up to 64 years; 36.7% in the range between 65-74; 22.4% in the 
range of 75-84; and 4.7% for ages over 85 years (NCI, 2008). The report also listed the 
median age of death due to prostate cancer in the United States to be 80 years during 
2000-2004 with approximately 8% of deaths occurring for ages up to 64 years. The 
remaining 92% of deaths occurred after age 65 (NCI, 2008).  
Some studies suggest that diets high in fat vary among different races and could 
possibly contribute to a higher risk of prostate cancer. For example, Japanese men living 
in Japan have a lower incidence rate and lower fatty intake in their diets than Japanese 
men living in the U.S whose levels of fat intake closely resemble those of Western men. 
Immigrant studies have shown that when Japanese men move to the United States their 
incidence and mortality rates increased to levels similar to American men. Further, 
screening in the United States is greater among Caucasian men than African American 
men that intuitively may suggest that incidence rates for Caucasians would be higher, yet 
the opposite is true. Although it is clear that many factors contribute to the different race-
specific incidence rates, it is not clear as to what role these factors play on racial 
disparities. Factors such access to care, detection differences, differences in decision 
making, lacking communication processes between patient and physician, variable 
patterns of care, multiple treatment choices and options, genetics, and dietary differences 
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all contribute to the mixed results and limited knowledge gained to date (Bostwick, 
2004).  
Age has shown to increase a man’s risk of developing prostate cancer. For 
example in men 80 years and over, the incidence of prostate cancer was 80% as 
confirmed by autopsy (Bostwick, 2004). A study on the international trends of prostate 
cancer-specific mortality found, that age-specific death rates increased with age for most 
of the 24 countries studied. Results indicated that in the United States alone, age-specific 
death rates from 1979 to 1999 varied from less than 5 per 100,000 for men 50-54 years to 
nearly 250 per 100,000 for men 75-79 years (Oliver, May, & Gunnell, 2001). Whereas 
men younger than 40 years rarely have prostate cancer, prostate cancer is widely 
observed in men 65 and older suggesting that it could develop as a result of damaged 
genes seen in older men (Bostwick, 2004). 
Exogenous risk factors of prostate cancer include diet (weight and obesity), 
environmental agents, occupation, and physical activities. Different descriptive 
epidemiologic studies have shown that dietary factors may contribute to prostate cancer. 
However, not all studies of this type have reported the same association indicating again, 
that not all is clear when assessing risk and incidence of prostate cancer (Kolonel, 1996; 
Schuurman, Van den Brandt, Dorant, Brants & Goldbohm, 1999). For example, some 
studies have shown a positive correlation between incidence or mortality and fat intake in 
multiple countries including the United States. Many case-control studies have reported a 
positive association as well. However, few of those studies adjusted for energy intake and 
many reported differences in methodology (Heshmat et al., 1985; West, Slattery, 
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Robison, French & Mahoney, 1991; Whittemore, Kolonel et al., 1995; Rohan, Howe, 
Burch & Jain, 1995). Other studies differed in selection of controls and dietary 
assessment that resulted in selection bias issues and patient’s weight and caloric intake 
were often ignored.  
Some studies used quantitative parameters based on consumption of high fat 
foods such as meat and dairy products. One study found that the positive association 
disappeared when controlling for energy intake (Anderson et al., 1996). One clinical 
study examined the intake of antioxidants (e.g., herbal supplements and Lycopene found 
in tomatoes) to determine whether they had any protective properties against prostate 
cancer. Finally, other studies included dietary factors high in animal fat and low in fruits 
and diets high in Vitamin E and selenium again, examining their effects on prostate 
cancer (Bostwick et al., 2004; Prostate Cancer Initiative-CDC, 2007).  
Alcohol and smoking have been associated with increased risk of prostate cancer. 
Alcohol may increase a man’s metabolic clearance of testosterone, which could exhibit 
protective affects against cancer. However, most studies have found a significant link 
between alcohol and increased risk (Anderson et al., 1996; Slattery & West, 1993; Hayes, 
Brown, & Schoenberg, 1996; Dennis, 2000; Sesso, Paffenbarger & Lee, 2001). Hayes 
and colleagues (1996) found an elevated risk when men consumed between 2-6 drinks 
per week (OR 1.4; 95% CI 1.0-1.8). If men had greater than 6 drinks each week the risk 
increased by almost two times compared to men who never consumed alcohol (OR 1.9; 
95% CI 1.3-2.7). A different study showed an inverse risk associated with heavy 
consumption of alcohol, although no biological explanation was given (Breslow, 
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Wideroff, Graubard et al., 1999). A Harvard Health Study found a positive association 
for increased risk of prostate cancer with moderate consumption of alcohol when 
drinking liquor and not beer or wine (Sesso et al., 2001). In contrast, a study in Montreal 
found that drinking beer was associated with an increased risk and drinking at a younger 
age also increased risk (OR 3.8; 95% CI 1.6-9.3) for boys who began drinking before age 
15 (Sharpe & Siemiatycki, 2001).  
In regards to smoking, a plethora of data exist demonstrating inconsistent and 
contrasting evidence for the association of smoking and risk of prostate cancer. 
Numerous case-control studies examining the association between smokers and non-
smokers are reported but few have shown significant findings. Despite some studies 
demonstrating an increased risk in current and former smokers of greater than 40 
cigarettes per day, the lack of consistent findings and the lack of dose response 
relationships argues against any causal association (Hayes, Pottern et al., 1994). Because 
of the conflicting and inconclusive evidence on smoking and prostate cancer, an 
international consensus conference in 1996 concluded there was inadequate data to 
associate smoking with increased incidence. However, a more recent case-control study 
did find a dose response relationship in men who had smoked greater than 40 pack-years. 
The study also reported that cessation of smoking was positively associated with a 
reduced risk in prostate cancer (Plaskon, Penson, Vaughan, & Stanford, 2003). 
The effects of diabetes on prostate cancer risk have also been evaluated with a 
study in New York City finding that diabetics had a lower risk. However the lower risk 
was only associated with whites and Hispanics. Risk among African American men was 
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not affected if they were diabetic. It is believed that this may be due to black men 
generally having higher levels of testosterone and even though diabetes has a lowering 
effect on testosterone levels, it would not be sufficient to noticeably reduce risk 
(Rosenberg, Neugut, Ahsan & Shea, 2002). 
Another exogenous risk factor includes environmental agents. Exposure to low 
levels of estrogen and other natural plant substances have been associated with increased 
risk of prostate cancer. Agents such as agricultural chemicals, plastics, detergents, and 
some dyes, such as Red Dye No. 3, all contain small levels of estrogen. Some products 
made from soybeans, whole-grain cereals, seeds, nuts, and berries are converted by 
intestinal acids into estrogen (Adlecreutz et al., 1995). Exposure to cadmium and certain 
pesticides have shown an increase risk for developing prostate cancer as well. Cadmium 
is an environmental contaminant found in zinc mining and sewage disposal areas making 
it an occupational hazard. Most of the cadmium mined in the U.S. is used for metal 
plating. Smaller amounts of cadmium are used for pigments, batteries, and stabilizing 
plastics. When used for industrial purposes cadmium concentrations in food, soil, and air 
can be dangerously high. For example, in a population-based study in Utah, occupational 
exposures to cadmium showed a small increase risk for developing prostate cancer 
(Elghany, Schumacher, Slattery, West & Lee, 1990). In addition to being an occupational 
hazard, cadmium exposure may result from eating fish, drinking water, and smoking 
(Faroon, Williams, & O’Connor, 1994; Waalkes, Rehm, Parantoni, & Coogan, 1992) (see 
Table 7). 
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Table 7. Summary of Studies Evaluating Risk and Prostate Cancer. 
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Bostwick 
et al. 
(2004); 
USPSTFa 
(2002) 
Family 
history 
EPA report Family 
history and 
risk of 
developing 
prostate 
cancer 
Men are 2 to 3 times 
more likely to 
develop prostate 
cancer when 1st 
degree relative have 
it 
Report may contain selection 
bias as clinical and pathological 
features of familial and non-
familial can be similar 
Whittemor
e et al. 
(1995) 
Family 
history  
Unknown Family 
history and 
risk 
AA men with family 
history have almost 
2x higher risk than 
Caucasian (OR 1.9) 
Numbers not statistically 
different 
Cotter et 
al. (2002) 
Family 
history 
Unknown Family 
history and 
risk  
31.2% of AA men 
and 22.2% of 
Caucasian men 
reported having 
family history 
None listed 
Bostwick 
et al. 
(2004); 
CDCb 
(2007)  
Male 
hormones 
Report Testosterone 
and 
androgen 
and risk  
High levels of 
testosterone might 
increase a man’s 
risk over time. 
Hormones may 
affect cancer growth 
and progression 
Results inconsistent to confirm 
any relationship. 
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Table 7: continued. 
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Bostwick 
et al. 
(2004); 
NCIc 
(2008) 
Race/ 
Ethnicity 
Report Race and 
risk 
AA men 1.6 times 
more likely to present 
with advanced stage 
and with mets and 2.4 
times more likely to die 
than Caucasians 
None listed 
Oliver et 
al. (2001) 
Age Observational 
International 
study of 24 
countries 
Age and 
risk 
Increased age increases 
likelihood of 
developing prostate 
cancer. 
Death rates reported 
from1979-1999 5/100k 
in aged 50-54yrs 
250/100k in aged 75-
79yrs  
None listed 
Kolonel 
(1996); 
Schuurma
n et al. 
(1999)  
Diet 
(weight 
and 
obesity) 
Descriptive 
epidemiologic  
Fatty 
dietary 
intake 
Shown mixed results 
for positive association 
between mortality and 
fatty diet intake 
Not all studies have shown 
similar results indicating 
variable methodology and 
design. 
Selection bias, low response 
rates 
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Table 7: continued. 
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Anderson et 
al. (1996); 
Slattery & 
West 
(1993); 
Hayes et al. 
(1996); 
Dennis 
(2000); 
Sesso et al. 
(2001); 
Sharp & 
Siemiatycki 
(2001) 
Alcohol Observational 
Case-controls 
Alcohol 
consumption 
and 
increased 
risk 
Elevated risk for men 
consuming 2-6 drinks 
per week (OR 1.4). 
Men having >5-6 
drinks/week risk 
increased ~2x (OR 1.9). 
Increase risk found for 
liquor not wine or beer. 
Contrasted by an 
increase in risk when 
drinking beer and 
drinking at earlier age 
(OR 3.8 for boys 
beginning to drink 
before age 15) 
No definitive link could 
be found due to mixed 
results 
Hayes et al. 
(1994); 
Plaskon et 
al. (2003) 
Smoking Case-control Smoking and 
increased 
risk 
Few studies finding 
significance. 
One found increased 
risk and smokers of 40 
cigarettes per day. 
Another found reduced 
smoking was associated 
with a reduced risk 
Inconsistent and 
contrasting evidence 
indicating lack of support  
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Table 7: continued. 
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Rosenberg 
et al. 
(2002) 
Diabetes Observational  Diabetes 
and race on 
risk 
New York study found 
diabetes has a lowering 
risk effect on Caucasians 
and Hispanics but not for 
AA men 
None listed 
Adlecreut
z et al. 
(1995) 
Environme
ntal agents 
containing 
low levels 
of estrogen 
Unknown Chemicals, 
plastics, 
detergents, 
red dye 
no.3,  
Exposure to these agents 
have shown small 
association with increased 
risk 
None listed 
Elghany 
et al. 
(1990) 
Cadmium 
and some 
pesticides 
Unknown Cadmium  Cadmium is found zinc 
mining and sewage 
disposal areas. Also in 
pigments, batteries, and 
plastics. Exposure has 
shown increased risk  
None listed 
a: U.S. Preventive Services Task Force 
b: Centers for Disease Control - Prostate Cancer Initiative  
c: National Cancer Institute – SEER cancer statistics review
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Incidence and Prostate Cancer-Specific Mortality 
 
A summary at the end of this section details the studies on incidence and mortality 
reviewed in this chapter. In the early 1990s when screening with the PSA test began to 
increase, changes in prostate cancer incidence and mortality were observed both in the 
U.S. and internationally (Oliver, May & Gunnell, 2001; ACS, 2008). Incidence rates of 
prostate cancer in all races in the U.S. increased gradually from 1988 through 1992, then 
declined sharply until 1995 at which time they began to rise again slowly. The ACS 
attributes these trends to prostate cancer screening with use of the PSA test and a DRE. 
They suggested that the rising incident rate after 1995 was due to increased prostate 
screening based on emerging screening guidelines in men less than 65 years old.  
According to the National Cancer Institute’s SEER registries, incidence rates rose from 
112.7 and peaked at 190.1 per 100,000 men between the years 1989 and 1992 adjusting 
for annual age (Mettlin, Murphy, Rosenthal & Menck, 1998). Since the peak year of 
1992, rates declined each year thereafter to a level of 144 per 100,000 in 1994. The 
authors concluded that the pattern of incidence rates were a result of increased screening 
interventions. Data from SEER showed a dramatic increase in age-adjusted incidence 
near the same time. The data showed an increase by 20% each year from 1989 to 1992, 
after which rates decreased by almost 11% per year until 1994 where they stabilized.  
Mortality trends paralleled incidence rates in that during the late 1980s, the annual 
percent increase in the U.S. rose from 0.7% to 3.1% for Caucasian men and from 1.6% to 
3.2% for African American men. These rates began to decline in 1991 for Caucasians 
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dropping nearly 22% from 1991 to 1999 and decreasing 16% from 1993 to 1999 for 
African Americans (Harris & Lohr, 2002). 
In the United Kingdom, mortality trends were analyzed using the World Health 
Organizations (WHO) Mortality database for 1979–1997. Twenty four countries were 
evaluated using age-standardized death rates for men aged 50–79 years grouped into 5-
age categories (Oliver et al., 2001). Results from the United Kingdom study showed a 
greater than five-fold difference between the country with the lowest mortality rate 
(Japan with 15.1/100,000 men) and the country with the highest mortality rate (Sweden 
with 81.5/100,000 men). The U.S. was found to be a country with a high mortality rate 
during the 1990s. Although not included, the authors noted that mortality rates in the U.S. 
increased 1%-2% each year during the PSA era (1986-1992) and then declined sharply 
through the end of 1997.  
Of note, the United Kingdom study found that in countries where the PSA test 
was commonly performed, (U.S. and Austria) mortality rates decreased. Interestingly, the 
United Kingdom itself, a country with low PSA use, also experienced decreasing 
mortality rates. Additionally, results from the Tyrol region of Austria showed a 
decreasing mortality where PSA was free to all men of that region; however, no other 
region within Austria experienced a decline (Oliver et al., 2001).  
A similar study from the International Agency for Research on Cancer (IARC) 
using the SEER registries, examined age-standardized mortality rates from 15 countries 
over a 20 year period (Hsing, Tsao & Devesa, 2000). Results also found the U.S., among 
other countries, as a country having high mortality rates (Hsing et al., 2000). The study 
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also noted that African American men in the U.S. had the highest mortality rate of all at 
50-60 times higher than the lowest rates seen in Shanghai, China. Caucasians within the 
U.S. were found to have the second highest of all men (Hsing et al., 2000).       
In examining race and incidence and mortality, African American men in the U.S. 
are 1.6 times more likely to develop prostate cancer than Caucasians (258.3/163.4 rates 
per 100,000 age-adjusted to the 2000 U.S standard population). Additionally, African 
Americans are 2.4 times more likely to die from prostate cancer than Caucasians with 64 
deaths to every 26.2 deaths per 100,000 age-adjusted to the 2000 U.S. standard 
population (ACS-AA, 2007/2008). Reasons for these differences remain unclear. Factors 
such as late stage, higher disease grade, and less screening interventions may influence 
treatment strategies contributing to differences in mortality rates. To address these 
differences, a study to evaluate prostate incidence, mortality, and survival among African 
American men and Caucasian men was performed (Chu, Tarone & Freeman, 2003). The 
authors used data from the SEER registry of 1975-1999. Mortality rates were calculated 
from death certificates from the National Center for Health Statistics. All men in the 
study were divided into the following seven age groups. The study showed a decline in 
mortality beginning in 1990 for both races. However, the authors concluded these 
declines were mainly attributed to changes in medical practice patterns and not changes 
in prostate cancer risk factors (Chu et al., 2003). Moreover, the results showed that the 
declining mortality rates indicated a decline in deaths of men who had distant metastasis. 
Men with localized disease did not exhibit reductions until 1997. In addition, the 
declining mortality rates were greater among Caucasians compared with African 
107 
 
 
Americans. Disparate mortality rates between races remained high. For example, the 
mortality rate for Caucasians decreased to approximately 52 men per 100,000 whereas 
the rate settled at 100 African American men per 100,000 in 1999. The authors offered no 
explanation other than the fact that the number of Caucasian men receiving prostatectomy 
during the period was higher compared to African American men. These differences may 
reflect different treatment strategies either offered to or chosen by African American men 
(Chu et al., 2003).  
A study using SEER data from the three states of Connecticut, Iowa, and New 
Mexico examined prostate cancer mortality among African American men in relation to 
the PSA test. The authors noted that of the five states within the SEER registry at the time 
of their study, these three were the only ones with sufficient numbers of deaths of African 
American men needed to make reliable mortality rate estimates (Escobedo, Rivas & 
Holmes, 2004). The study included three time periods, 1979-1986 (before PSA use), 
1987-1990 (during PSA use), and 1991-1998 (after introduction of PSA test). The results 
showed an increase in mortality in Connecticut and Iowa and a decrease in mortality in 
New Mexico. In particular, Connecticut reported an increased annual percent change 
(APC) from the “before PSA” period to each of the other two periods by +4% and +20% 
respectively. Iowa reported an increased APC from the first period to the other two 
periods of +40% and +18% respectively. New Mexico reported a decrease in mortality in 
the last two periods compared with the first period of -41% and -55% respectively. The 
authors noted that during the study period changes in treatment procedures emerged and 
in fact, were different for New Mexico as compared to the other two states. For example, 
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the number of men receiving prostate surgery was five times greater in New Mexico than 
in Connecticut and Iowa, which could partially explain the decrease in mortality in that 
state. The authors were unable to assess the role that quality of care played in the three 
states while admitting that use of definitive treatments may have influenced observed 
mortality patterns. Further, PSA utilization was greater in Connecticut and Iowa than 
New Mexico whereas prostatectomy was used far more often in New Mexico. The 
authors felt that the limited adoption of the PSA test in New Mexico may have been due 
to barriers to access in a large land mass state with large numbers of men who were 
uninsured.  
Additional limitations included the fact that the SEER data of that time had not 
yet been linked to Medicare claims data; therefore, they could not assess socioeconomic 
factors and cancer burden regarding social classes. In addition, small sample sizes limited 
their ability to assess the impact of treatment strategies of curative intent over time. The 
study did not include data on comorbidities which may play a role in mortality statistics 
as well (Escobedo et al., 2004).   
A different study assessing racial differences in mortality showed similar results. 
The study consisted of a cohort of 4,686 men during 1980-1997 from the Henry Ford 
Health System cancer registry and examined differences in surgical use and the extent to 
which these differences were associated with disparate survival rates between African 
Americans and Caucasians (Tewari, Horninger et al., 2005). Three hypotheses were 
considered in the study, 1) that differences exist in stage and grade between African 
Americans and Caucasians, 2) African American men receive surgery less often than 
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Caucasians, and 3) that differences in survival between African Americans and 
Caucasians could be explained by differences in surgery rates and other confounders.  
Their results showed that overall, African American men were older, had higher 
Charlson comorbidity indices, had shorter follow-up periods, had lower incomes, and 
chose surgery less often than Caucasians (Tewari, Horninger et al., 2005). The 
multivariate analysis indicated a moderate association between poor survival and higher 
grade disease, older age, comorbidities, and lower income (p = 0.013). The authors noted 
that after adjusting for race, no difference in cancer-specific mortality existed (p = 0.29). 
In all cases, survival was better for Caucasians until adjusting occurred which tended to 
reduce or eliminate racial differences. The study reported that of all confounders, income 
(An SES component) explained 50% of the differences while treatment could account for 
approximately 34% of the differences in survival between African Americans and 
Caucasians (Tewari, Horninger et al., 2005). The authors concluded that more aggressive 
treatments such as prostatectomy and radiation therapy should be provided to African 
Americans in order to help reduce the disparity in mortality.  
Limitations of the study as noted by the authors included several potential biases. 
Of note, the treatment selection process in that treatments offered most often depend on 
which specialist the patient consults For example, urologists might suggest the patient 
have surgery whereas the radiation oncologist might offer radiation therapy or 
brachytherapy as the best treatment choice. The specialists may also choose younger 
healthier patients in order to influence better outcomes. Further, the authors noted that 
treatment technologies have improved and the fact that men are generally healthier and 
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thus live longer could influence differences in mortality as well. Strengths of the study 
were also reported and include sufficient numbers of African American men existed 
(41%) within the Henry Ford Health System, and therefore, a representative sample 
participated. In addition, the authors believed that using only the biopsy result for tumor 
grading in all treatment strategies helped protect against under-grading, a bias effect seen 
in other similar studies that used two different tumor grading systems. The two were 
biopsy scores for men receiving conservative management and radiation therapy and the 
surgical pathology score for the surgery patients. Obviously, a more accurate grade is 
achieved when the prostate gland is removed allowing for a more complete and thorough 
pathological exam. 
A study from 2004 was performed to try and explain racial differences in prostate 
cancer mortality among races. The authors examined SES factors, attitudes toward the 
health care industry, dietary factors, and outcomes after treatments (Freedland & Isaacs, 
2005). They reviewed much of the existing literature and found that when studies were 
adjusted for stage, grade, PSA and treatment received by the patient, African Americans 
and Caucasians had similar outcomes. It was concluded that the main contributing factor 
for racial disparities noted in these observation studies was most likely due to SES factors 
(Freedland, et al., 2005). For example, men’s perceptions about health and knowledge 
about prostate cancer screening were found to be highly dependent upon education and 
income levels. It is also known that African American men do not participate in 
screenings as often as Caucasians. Reasons for lower screening rates are plentiful and 
include minority status and lower socioeconomic status, limited access to care, often 
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distrust of the medical community, coping with disease, depression, and many others 
(Freedland, 2005; Marion & Schover, 2006). 
It is known that racial disparity exists in the care and the outcomes associated 
with prostate cancer. However the reasons for disparity still remain unclear. In two 
studies from 2000, authors evaluated whether African Americans were still more likely to 
die from prostate cancer after adjusting for confounders such as socioeconomic factors 
(SES). Socioeconomic factors were measured using ecologic variables at the census-tract 
level as well as covariates of stage, grade, age, comorbidities, and treatments to try and 
resolve the disparity (Robbins, Whittemore & Thom 2000; Merrill & Lyons, 2000; Du et 
al., 2006). Robbins and colleagues (2000) examined the extent of SES differences as 
measured at the census-tract level that accounted for racial differences in two end points 
of prostate cancer-specific mortality and overall mortality among men with prostate 
cancer. The study included men from the San Francisco Bay area within the SEER 
registry from 1973–1993. The study included only ecologic factors associated with SES 
because SEER data does not provide individual level data, only census-tract level 
(Robbins et al., 2000). Therefore, the study resulted in 1005 census tracts containing 
23,334 men. For each of the 1005 census tract levels, data were obtained from the 1990 
U.S. Census of Population and Housing Summary Tape File 3A (17). Robbins and 
colleagues (2000) obtained only two variables, percent of adult residents with a minimum 
of a high school education or higher and the percent of families below the poverty line. 
The authors believed that these two components were the most important in terms of 
health outcomes (Robbins et al., 2000). Cause of death was obtained from death 
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certificates. Out of the 23, 334 men in the study 19,996 were Caucasian and 3,338 were 
African American. The results showed that African American men were diagnosed at 
earlier ages, had lower SES status, and had a greater probability of presenting with higher 
stage and grade disease. The results also showed that after adjusting for age and stage, 
African American men were still 1.25 (95%CI; 1.14-1.37) times more likely than 
Caucasians to die from prostate cancer and when adjusting for SES factors, the death rate 
ratio decreased only slightly to 1.2 (95%CI; 1.07-1.35). The findings also indicated that 
African American men were only slightly less likely to obtain surgery than Caucasian 
men with absolute differences being only 7% (63.9%-56.9%) therefore the authors noted 
a negligible effect when adjusting for treatment received by both races (Robbins, 2000). 
They concluded that because the racial difference in death due to prostate cancer and SES 
factors was only minimal, that perhaps the risk is more closely associated with biological 
factors such as tumor virulence (Robbins, 2000).         
Merrill and Lyons (2000) evaluated the same end points examining whether 
African American men were more likely to die of prostate cancer than Caucasians once 
controlling for age, stage, grade, comorbid conditions, and treatment. A major objective 
covariate for monitoring progress of disease is age-adjusted mortality rates (Merrill & 
Lyons, 2000). However, Merrill believed that it may be more sufficient to examine 
mortality in partitions where cause of death has been monitored from when the disease 
was diagnosed. For example, they believed that mortality portioned by calendar years 
would allow for longer evaluation periods in which vital signs and cause of death could 
be associated to disease at diagnosis (Merrill & Lyons, 2000). Further, they evaluated 
113 
 
 
data from the SEER registry database linked to Medicare claims information because this 
registry links mortality rates to factors associated with disease at the time of diagnosis 
which is referred to as incidence-based morality (IBM). For example, Merrill and Lyons 
(2000) illustrated the IBM method by describing a case of tracking a man diagnosed with 
localized prostate cancer at age 65 in 1980 and who would not have been previously 
diagnosed with any other cancer. He suggested the man was treated with radiation 
therapy and then died in 1988. If this man was listed in the SEER registry, he would have 
been tracked from the time of his initial diagnosis until his death and then his death could 
be characterized by the factors associated with his disease at diagnosis. All men within 
Merrill’s study were identified and followed with this IBM method (Merrill & Lyons, 
2000). This approach was considered useful in that the IBM method takes mortality and 
looks back in time to identify variables associated with disease at diagnosis thus giving 
the advantage of greater insight into the observed mortality rates (Merrill & Lyons, 
2000). The SEER registry available at the time included data linked from 1973 through 
1995 from five states (Connecticut, Iowa, Mew Mexico, Utah, and Hawaii) and four 
metropolitan areas including Atlanta, San-Francisco-Oakland, and Seattle-Puget sound. 
The age categories included all ages, 50-59 years, 60-69 years, 70-79 years, and over 80 
years. Logistic regression analysis was used and odds ratios were calculated at the 95% 
confidence interval. Mortality rates were determined from deaths due to prostate cancer 
occurring 0 to 1 years within diagnosis, 0 to 2 years from diagnosis, up to 0-22 years 
since diagnosis.    
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The results showed that most prostate cancer IBM occurred during the 0 to 4 
years of diagnosis (Merrill & Lyons, 2000). As other studies have shown, Merrill and 
colleagues (2000) also found that most men in their study died with prostate cancer rather 
than from the disease itself (Merrill & Lyons, 2000). Their results were also comparable 
to other studies showing that African American men were approximately twice as likely 
to die from prostate cancer as Caucasian men were during 1988–1995. They also noted 
that African American men were about 1.6 times more likely to die from non-prostate 
cancer causes than Caucasians were. Each variable was added to the race-model one at a 
time from most significant to least. All factors between races had an effect on prostate 
cancer mortality with late stage disease having the greatest effect showing an increased 
likelihood of African Americans to die from prostate cancer with odds ratio of greater 
than 5.0 for each of the four year groups reported. However, only race-grade interactions 
for the years 1992-1993 and 1994-1995 were significant (Merrill & Lyons, 2000). A 
limitation noted in the study was that IBM rates may contain lead-time bias (bias found 
when a screening test advances the time of diagnosis without advancing the time of 
death). However, it was noted that when using death rates as reported on death 
certificates, lead-time bias is usually removed. Merrill and Lyons (2000) noted the IBM 
method to be a strength of the study because they used a 0-7 year period that closely 
mimicked death certificate trends (Merrill & Lyons, 2000). 
A 2006 study by Du et al. evaluated racial disparity and SES status among race 
and found similar results. The study used SEER-Medicare linked files from the eleven 
SEER areas and included 61, 228 men diagnosed with local/regional stage prostate 
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cancer. The SEER-11 registry included metropolitan areas of San Francisco/Oakland, 
Detroit, Atlanta and Seattle, Los Angeles County, the San Jose-Monterrey area, and the 
states of Connecticut, Iowa, New Mexico, Utah, and Hawaii representing greater than 
14% of the U.S. population (Du et al., 2006). Of the 61,228 men, 53,764 were Caucasian, 
6,321 were African Americans, with the remaining being of Hispanic descent.  
Outcome variables (dependent) were survival time in months (defined from date 
of diagnosis to date of death), all-cause mortality (defined as death from any cause and as 
identified in SEER), and prostate-specific mortality (defined as men dying of prostate 
carcinoma) (Du et al., 2006). Independent variables included SES factors (defined by 
SEER as education, poverty, and income), a comorbidity index assessed from Medicare 
claims by diagnosis or procedures performed one year prior to and one month after being 
diagnosed with prostate cancer. Other independent variables included treatments received 
by the men and as defined either from SEER data codes or Medicare claims data. These 
included surgery, radiation therapy, and hormones. Demographic data on age, race, AJCC 
staging, pathological grade, year of diagnosis, and geographic area were also obtained.  
Results indicated only slight differences in the proportions of men receiving any 
of the three treatment variables listed. For example, 23.9% of African Americans 
received hormone therapy compared with 27% of Caucasians and 28.7% Hispanics. The 
proportion of African American men receiving surgery or radiation therapy was 57.3% 
compared with 64.3% Caucasians and 59.6% Hispanics.  
Regarding the SES status, 73.4% of African American men fell within the lowest 
quartile compared with only 60.6% Hispanics and 17.9% Caucasians (Du et al., 2006). In 
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terms of race and prostate specific mortality, the final adjusted model showed differences 
but no significant interactions with African American men being 17% (Hazards 
Ratio[HR]: 1.17) more likely and Hispanics being 22% (HR: 0.78) less likely to die from 
prostate cancer than Caucasian men. The hazards ratios for African American men 
increased slightly when adjusting for education (HR: 1.2), income (HR: 1.18), or poverty 
(HR: 1.19) when compared with Caucasians. These results indicate that in men with the 
same Medicare coverage and with the same disease stage of localized cancer, African 
American men were more likely to present with higher grade disease. However, the 
differences in mortality between races as noted in the study were reduced if not 
eliminated when adjusting for SES status (Du et al., 2006).       
Other studies examining racial differences in survival and mortality after 
treatment for prostate cancer have been reported (Godley et al., 2003; Zeliadt, Potosky, 
Etzioni, Ramsey & Penson, 2004; Peters & Armstrong, 2005; Zeliadt et al., 2006; 
Richert-Boe et al., 2008). For example, Godley and colleagues (2003) examined men 
with prostate cancer from 1986 through 1996 from five SEER regions. These areas 
included Atlanta, Connecticut, Detroit, San Francisco, and Seattle mainly because these 
regions included sufficient numbers of African American men (Godley et al., 2003). Out 
of an initial 104, 537 men, the number remaining after removing those who did not meet 
study criteria was 43, 989. The study evaluated three endpoints, overall survival, non-
prostate cancer-specific survival, and prostate cancer-specific survival. Treatment 
outcomes were assessed using Kaplan-Meier survival curves and Cox regression models. 
The survival curves were used to analyze racial comparisons within treatment groups and 
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PSA testing eras (the pre-PSA era of 1986-1989, the early PSA era of 1989-1991, and the 
recent PSA era of 1992-1996). Other independent variables including SEER site, census 
tract education and income level, age at diagnosis, PSA testing era, tumor grade, race, 
treatment, and comorbidity scores were all assessed using Cox regression models. All 
statistical tests were two-sided and tested at an alpha of 0.05 (Godley et al., 2003).  
SEER staging definitions were based on clinical information and not on surgery; 
therefore for those men receiving prostatectomy, a possible misclassification bias existed 
because men initially classified as having localized disease could be upstaged to 
advanced disease once pathological findings were reported. This bias does not exist for 
men receiving radiation therapy and watchful waiting (Godley et al., 2003). To account 
for this potential bias, the authors classified all men having surgery as having localized 
disease because surgery is usually not indicated for advanced disease (Godley et al., 
2003). Race was classified from both SEER and Medicare claims and was either “black” 
when reported black from either source with a 96% agreement and as “white” when 
classified as white without black and non-Hispanic with a 93% ascertainment agreement 
(Godley et al., 2003).    
The study consisted of 38,242 (87%) Caucasian men and 5,747 (13%) African 
American men, all of whom differed significantly across most variables. For example, 
African American men were more likely to be 65-69 years old and less likely to be 
married. In addition, African American men were more likely to live in a census tract 
area where 25% of the residents had less than a high school education or in one where the 
household income was less than $23,000. Moreover, African American men were less 
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likely to have surgery and instead, were more likely to have chosen watchful waiting 
(Godley et al., 2003). The results further showed that survival was statistically 
significantly longer for Caucasians than for African Americans and when stratified by 
treatment, the disparity in survival was greatest for men receiving surgery and lowest for 
men receiving radiation therapy. For example, the study measured hazards ratio (HR) for 
each available treatment compared with death due to prostate cancer and found a HR of 
1.43 (95%CI: 1.29 to 1.58) among African American men receiving surgery relative to 
Caucasian, a HR of 1.12 (95%CI: 1.03 to 1.22) for African American men receiving 
radiation therapy, and a HR of 1.19 (95%CI; 1.12 to 1.26) for African American men 
receiving watchful waiting (Godley et al., 2003). The results also indicated that among 
surgery patients African American men died on average 1.8 years before Caucasian men 
and only 0.7 years and 1.0 year before those who received radiation therapy and watchful 
waiting respectively. Racial disparities still persisted after adjusting for all covariates as 
well.  
The authors concluded that among surgery patients, African American men 
between the ages of 65 and 84 have poorer survival rates with highest mortality rates than 
do Caucasian men compared to radiation therapy and less aggressive management. 
Possible explanations included reduced access and other social, environmental, and 
biological factors that may have played a role. Response to treatment due to genetic 
differences between races was also given as a possible reason for the observed disparity 
observed. Limitations of the study included not knowing tumor size and not having 
information on serum PSA levels. Further, SEER only provides census tract level data 
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and not individual level data for socioeconomic factors which could contribute to higher 
levels of misclassification and therefore not allowing for accurate estimates of income 
and education levels (Godley et al., 2003).  
Zeliadt and colleagues (2004) evaluated trends in men with localized prostate 
cancer using SEER registry data as well, noting that from a cohort of 90,128 men from 
1991 to 1999, African American men were 26% less likely to receive aggressive curative 
treatments than Caucasians. By 1999, use of hormone therapy (ADT) had begun to 
increase, however, African American men who chose conservative management 
(watchful waiting) were still less likely to be treated with ADT with 35.8% receiving 
hormones compared with 45.6% Caucasians receiving hormones (Zeliadt, Potosky et al., 
2004). The study found a significant racial disparity in the use of adjuvant hormone 
therapy (receiving hormones concurrently with radiation). The authors noted this as 
troublesome because recent studies have shown survival benefits when hormones are 
combined with radiation, especially when African American men typically present with 
advanced disease that would indicate hormone therapy.  
Peters and Armstrong (2005) reviewed the literature from 1992 through 2002 and 
in 2005, reported finding only 27 articles that matched their inclusion criteria. However, 
79% of those articles resulted in no significant racial differences in treatment outcomes. 
The remaining 21% found worse outcomes among African Americans in 5-year survival 
and rates of PSA failure (Peters & Armstrong, 2005). On the basis of their review, the 
authors noted that if African American men receive the same care and treatment as 
Caucasian men, no differences in outcomes were observed. There are many contributing 
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factors of why in spite of this, that African Americans present with higher grade disease 
and higher PSA levels. The authors concluded that perhaps efforts to increase or improve 
community PSA screening utilization to associate the racial differences noted may need 
to be addressed (Peters & Armstrong, 2005). 
In the study by Richert-Boe and colleagues (2008) an attempt to further explain 
racial differences in treatment outcomes was undertaken. They evaluated groups of men 
from the Kaiser Permanent Northwest (KPNW) which is a Health Maintenance 
Organization (HMO) located in Oregon and Washington State. One group consisted of all 
available men (both races) receiving treatment with curative intent (TCI), diagnosed with 
localized disease and matched on age, stage, and grade using logistic regression. In a 
different group, men were separated by race where African American men (n = 79) were 
individually matched to 158 Caucasian men on age, tumor grade, and year of diagnosis. 
The results showed that of group one, 3,040 Caucasian and 79 African American men 
met inclusion criteria with 82% of Caucasian men and 71% of African American men 
receiving TCI. Once all covariates were controlled for, African American men were less 
likely to receive TCI than Caucasian men (p = 0.01) (Richert-Boe et al., 2008).  
Of men of group two that were matched on all observed covariates, 56 African 
American men and 136 Caucasian men received TCI. Again, after adjusting for all 
covariates, African American men were less likely to be treated with TCI than Caucasian 
men (p = 0.02) and less likely to be offered TCI than Caucasian men (p = 0.004). The 
authors noted that these differences were not a result of lack of insurance as all men had 
similar coverage by being members of the same HMO; however, they did explain that 
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other factors such as limited transportation, job flexibility, access, and home support 
could have played a role (Richert-Boe et al., 2008). 
Summary of Literature Review 
This chapter provides an extensive review of multiple studies concerned with 
prostate cancer screening and disease-specific mortality among race, including two large 
randomized clinical trials currently underway in the U.S. and Europe. The enormous task 
of associating the value of PSA screening with reduced mortality as well as narrowing the 
racial gap between African Americans and Caucasians remains untold. There are known 
factors discussed in these reviews that make up racial disparities and those factors not yet 
discovered that are convoluted in ways that may never be explained. Therefore, research 
should not be limited to usual and customary reviews but, instead, should explore new 
innovative processes applied to real clinical practices in search of answers. In addition, 
there are common themes emerging throughout the literature that should be investigated 
in order to resolve complications such that progress can be made to eliminate health care 
inequalities. One such theme includes increased mortality rates among African American 
men with localized prostate cancer who tend to present with advanced grade and stage 
disease at diagnosis. Differences in treatment management and socioeconomic factors 
were also well documented. Most studies evaluated outcomes of cancer-specific mortality 
after adjusting for covariates of stage, grade, age, race, SES factors, comorbidities, and 
treatments. Because of the significance found in other studies, this study will include all 
the same variables into a robust method using the propensity scoring analysis to evaluate 
their effect on cancer-specific mortality (see Table 8).
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Table 8. Summary of Incidence and Mortality Studies. 
 
Author (year) Study Category Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Mettlin et al. 
(1998); 
ACS (2008) 
Mortality/Incidence 
trends 
NCI-SEER 
registries 
Mortality 
and 
incidence 
trends in 
U.S. 
U.S. incidence rose from 112 to 
190/100k from 1989-1992. 
Incidence dropped to 144/100k 
by 1994.  
Mortality trends paralleled 
incidence 
None listed 
Oliver et al. 
(2001) 
Mortality trends WHOa 
mortality 
database  
Mortality 
trends from 
24 countries 
in United 
Kingdom 
>5x difference in country with 
highest (Sweden 82/100k) and 
country with lowest (Japan 
15/100k) mortality rate.  
Noted correlation between PSA 
and decreased morality in 
countries performing the PSA 
(U.S. & Austria). 
Found decrease in mortality in 
U.K with low PSA use.  
None listed 
Hsing et al. 
(2000) 
Age-standardized 
Mortality  
IARCb and 
SEER 
registries 
15 countries 
over 20 yrs. 
AA men in U.S.  have highest 
mortality rates of all at 50-60 
times higher than the lowest 
rates in China. 
Caucasians in U.S have second 
highest   
None listed 
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Table 8: continued. 
 
Author 
(year) 
Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Collin et al. 
(2008) 
Age-
specific 
mortality 
trends in 
U.S. and 
U.K. 
Data from 
Cancer Research 
UK, London UK 
and Seer registry 
in U.S. 
Mortality 
trend 
comparison 
of both 
countries 
Mortality rates similar in 
both countries and peaking 
in 1990s. 
Trends diverged 
(separated) in 1994. 
U.S. APCc ↓@ 4% ea.yr. 
U.K. APC ↓@ 1% ea.yr. 
None listed 
Chu et al. 
(2003) 
Incidence, 
mortality, 
and 
survival in 
AA and 
Caucasian 
SEER registry 
from 1975-1999 
Race-based 
incidence, 
mortality, 
and 
survival 
Decline in mortality 
beginning 1990 for both 
races due to practice 
pattern changes not risk 
factors. Decline was 
greater in Caucasians. 
Racial disparate mortality 
rate high (i.e. by 1999 rate 
at 52/100k in Caucasian 
and 100/100k in AA 
None listed 
Escobedo et 
al. (2004) 
Mortality 
and PSA 
association
s among 
AA men  
SEER-registry 
from 3 states 
Connecticut 
Iowa, and New 
Mexico 
3 time 
periods of 
1979-1986 
1987-1990 
1991-1998 
Increased mortality in 
Connecticut, Iowa. 
Decrease in New Mexico. 
 
Treatment options 
changed during periods. 
PSA use greater in 
Connecticut and Iowa. 
Surgery given more often 
in New Mexico 
SEER not linked with 
Medicare (at that time). 
Small sample size. 
No comorbidity data. 
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Table 8: continued. 
 
Author (year) Risk 
Factor 
Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Tewari et al. 
(2005) 
Mortality: 
racial 
differences 
Henry Ford 
Health System’s 
cancer registry 
Surgery 
differences 
among 
races and 
the effects 
in survival 
of 4,686 
men from 
1980-1997. 
AA men were older, 
higher comorbid index, 
shorter follow-up periods, 
lower income, had surgery 
less often than Caucasians. 
Adjusting for race, no 
significant differences in 
mortality (P=0.290). 
Income (SES component) 
showed highest 
relationship explaining 
50% of differences.   
Treatment selection bias 
(urologist push surgery, 
radiation oncologist push 
radiation and 
brachytherapy) 
Physicians likely to 
choose healthier patients 
to improve outcomes. 
Freedland & 
Isaacs (2005) 
Mortality Literature review Racial 
differences  
When studies adjusted for 
age, grade, PSA, and 
treatment AA and 
Caucasians had similar 
outcomes. 
Main factor possibly SES 
based 
None listed 
Robbins et al. 
(2000) 
Mortality SEER registry 
1973-1993 San 
Francisco Bay 
area 
Extent that 
SES 
differences 
explained 
racial 
differences 
in 
mortality  
AA men diagnosed at 
earlier ages, had lower 
SES status, and greater 
stage and grade.  
Concluded that racial 
differences in mortality 
only minimally attributed 
to SES 
None listed 
 
 
 
 
125 
Table 8: continued. 
 
Author 
(year) 
Risk Factor Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Merrill & 
Lyons (2000) 
Mortality SEER-Medicare 
linked registry 
1973-1995. 
Used IBMd 
method to 
evaluate 
mortality 
Most IBM deaths occurred at 
the 0-4 yr. since diagnosis 
time frame. 
Found a >5 OR for AA men 
for the factor “late stage”  
IBM rates may 
contain lead-time 
bias. 
Du et al. 
(2006) 
All-cause 
mortality, 
survival, and 
prostate-
specific 
mortality 
versus 
treatment 
SEER 11 
registry linked to 
Medicare 
Racial 
disparate 
mortality 
In men with same Medicare 
coverage and same disease 
stage, AA men more likely to 
present with higher grade 
(OR 1.17) than Caucasians.  
No difference when adjusted 
for SES 
None listed 
Godley et al. 
(2003) 
Survival and 
mortality 
SEER 11 cities 
with well 
represented AA 
populations 
Survival/ 
mortality 
versus 
treatment 
and PSA 
testing 
between 
racial groups  
AA men more likely to be 
older and choose watchful 
waiting, have less education, 
less often married, less likely 
to have surgery. 
Mortality vs. treatment: AA 
HR1.43 for surgery, HR1.12 
for radiation, and HR1.19 for 
watchful waiting. 
Survival: AA men receiving 
surgery died 1.8 yrs. before 
Caucasians  
Potential 
misclassification 
bias. 
SEER only has 
census tract level 
SES data (not 
individual). 
Unknown tumor size 
Unknown PSA 
levels.  
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Table 8: continued. 
 
Author 
(year) 
Risk Factor Study type 
or datasets 
Outcome 
measure 
Finding (s) Limitations 
Zeliadt et al. 
(2004) 
Trend 
analysis 
SEER data from 
1991-1999 
Treatment 
trends 
among race  
AA men OR 0.74 for 
aggressive treatment, less 
likely to have ADTe 
compared with Caucasians 
None listed 
Peters & 
Armstrong 
(2005) 
Literature 
review 
Articles from 
1992-2002 
Treatment 
outcomes 
among race 
79% of articles reviewed 
showed no significant racial 
differences in treatment 
outcomes. 
The other 21% showed 
poorer survival and higher 
PSA failure rates among 
AA men 
None listed 
Richert-Boe 
et al. (2008) 
Group 
analysis 
HMO from 
Kaiser-
Permanente 
Northwest  
Racial 
differences 
in 
treatment 
outcomes 
AA men less likely to 
receive TCIf (P = 0.01) and 
less likely to be offered TCI 
(P = 0.004) 
Possible lack of access 
issues and lack of home 
support 
a: World Health Organizations 
b: International Agency for Research on Cancer 
c: annual percent change 
d: incidence-based mortality defined by SEER registry: monitoring a man from diagnosis through death enables longer 
evaluation periods capturing vital signs and cause of death that could be associated with disease at diagnosis. 
e: adjuvant hormone therapy  
f: treatment with curative intent
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CHAPTER 3: METHODOLOGY 
 
 
Introduction 
 
This chapter begins with a brief examination of the theory of the propensity 
scoring method with presentation of a few medical research applications. A description of 
common quality assessment tools to evaluate the effectiveness of balancing covariates 
used for the propensity scoring method is provided including graphical displays. Next, 
discussions of the data source including selection and exclusion criteria are provided.  
Then, a description of the analytic approach is provided including conceptual model 
guidance, research methodology, study variables, and hypothesis testing utilized for 
answering the primary aim of the study; to evaluate what effects screening PSA may have 
on racial disparate mortality rates among African American and Caucasian elderly men. 
In particular, examination of influential predictors of prostate cancer-specific mortality 
commonly seen from screening PSA is given. Finally, a description of the study 
limitations is provided.  
Theory of the Propensity Score 
The propensity score is a form of matching on groups in an attempt to balance or 
remove differences on a set of observed covariates in observational studies. Using 
observational data to estimate treatment effects may lead to large differences in subjects 
causing selection bias issues. When selection bias is due to unobserved variables,  
Controlling for the bias is difficult and even controversial. However, when bias is due
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to observed variables, traditional methods for controlling the bias are available. 
Multivariate matching of covariates is one method that may help to correct for 
differences in observed variables between two groups (Zhao, 2004).  
Multivariate matching is a method whereby sampling from a large population is 
done to create a control group (men who did not receive a screening PSA test) of which 
the distribution of covariates (independent variables) are similar to the distribution of 
covariates within a treatment group (men who did receive a screening PSA test). 
Multivariate matching is also a technique used for reducing bias from observed variables 
in the evaluation of observational studies having numerous possible independent 
variables (Rubin & Thomas, 1996). Matching with the estimated propensity score (p-
score) is a form of multivariate matching defined as the conditional probability that a 
patient would be assigned to a specific treatment group based on multiple relevant given 
observed covariates. The resultant p-score is a summary measure that controls for 
multiple confounders simultaneously by reducing them to a single composite balancing 
score. This p-score can then be used to match groups thereby reducing selection bias and 
thus simulating randomization (Rosenbaum & Rubin, 1983). One technique for finding 
these estimates is by using logistic regression as shown in equation 2, in that 
Eq.2                  
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is the estimated propensity score found from the logistic model.  
Researchers of non-randomized observational studies have no control over those 
receiving treatment, and covariates are most often not similar (Rosenbaum & Rubin, 
1983; Love, 2003; D’Agostino, 1998). Therefore, use of the p-score can adjust for these 
differences and simulate randomization. However, propensity score matching differs 
from randomization in that randomized experiments balance the probability distributions 
on both the observed and unobserved variables between groups, whereas, propensity 
scores can only balance on the observed variables. Further, the p-score is only an efficient 
estimator formed from a set of known covariates and makes no statement about the 
appropriateness of the set. The estimated p-score also does not promise to correct for 100 
percent of selection bias or refrain from creating new biases where none exists (Giordano 
et al., 2008).       
Rosenbaum and Rubin (1983) were instrumental in developing the propensity 
theory during the 1970s and throughout 1980s. Specifically, for the case where treatment 
equals one (1) and non-treatment equals zero (0), each subject from a sample has only 
two possible responses, r1 if the patient received the treatment and r0 if the patient did not 
receive the treatment.  Rosenbaum and Rubin further suggested that matching using 
propensity scoring and then stratifying patients by the p-scores into at least five quintiles 
could eliminate approximately 90% of all the bias (Rosenbaum & Rubin, 1983). Simply 
put, patients who have the same p-scores but choose different treatments or interventions 
remain comparable because the distributions of their covariates are balanced.   
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Propensity scoring has been used in retrospective observational studies where 
investigators have no control over who receives or does not receive treatment and where 
large differences in background characteristics exist between groups and should 
therefore, be controlled (D’Agostino, 1998; Rubin, 1997; Imbens, 2000; Luellen et al., 
2005). Because the propensity is a probability, the estimated p-score ranges from 0-1 and 
will vary depending upon sampling error. For instance, if patients are given an equal 
(50%) chance of being assigned to either the control group or treatment group (as in the 
case of randomization) their p-scores would be 0.50 (Luellen et al., 2005). However, in 
non-randomized observational studies a participant’s p-score is a function of their 
individual characteristics and, therefore would most likely vary from 0.50. For example, 
if a researcher assigns a 1 as treatment (screening PSA) and a 0 as non-treatment (not 
screening PSA) then a p-score greater than 0.50 would mean the patient had a higher 
tendency (propensity) to be assigned to the treatment group and a p-score below 0.5 
would mean the patient is less likely to be assigned to the treatment group.  
The methods for balancing two groups using propensity scoring analysis were 
defined by Luellen and colleagues (2005) and Rosenbaum and Rubin (1983) as well as 
many others. This research study will use matching and stratification. The reason is that 
this method has been described as being less sensitive than the other methods to 
nonlinearities in the relationship between p-scores and also because it is easiest and 
equally efficient as the other methods (Luellen et al., 2005; Rosenbaum & Rubin, 1983; 
D’Agostino, 1998). The definition of stratification was formally described by Rosenbaum 
and Rubin in a collection of papers which showed the theorems and provided proofs 
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developed in 1983 and essentially means that a model can be built to predict the 
probability that one group would receive a treatment and one group would not where the 
following notation,  
Propensity Score = est. Pr (Treated | background info (covariates)) 
shows that the propensity score is the estimated probability of being selected to the 
treatment group based on an individual’s background characteristics (observed 
covariates). Furthermore, it means that groups of subjects having similar p-scores are 
expected to have similar values of all background information (covariates) within 
aggregate groups (Love, 2003). Thus stratifying on the p-score produces unbiased 
estimates of the treatment effect. Since the p-score is a conditional probability of 
treatment assignment given a set of observed variables, the following expression 
e(X) = pr(T = 1|X) 
then defines that treatment assignment T and observed variables X are conditionally 
independent on the outcome response variable e(X). Therefore, by using a p-score to 
adjust the estimate of the treatment effect, we can essentially create a quasi-randomized 
experiment. In other words, if two subjects (one from each group) have the same p-score, 
then it can be imagined that the two subjects were randomly assigned to each group in the 
sense of being equally likely to be in the treatment group or control group (Rosenbaum & 
Rubin, 1983; D’Agostino, 1998; Luellen et al., 2005; Rubin & Thomas, 1996).   
Applications of the Propensity Score Method 
Studies demonstrating the practical use of the propensity scoring analysis exist in 
the medical field. These include areas comparing vascular access types and mortality, 
132 
 
 
education, coronary heart disease and aspirin use, and myocardial infarction as well as 
others. However, only a few have recently emerged from health services research 
including areas regarding cancer. In particular, propensity score analysis has been used in 
studies of screening for breast cancer, chemotherapy and lung cancer, lung biopsies, and 
long-term survival in men with advanced stage prostate cancer. 
In an intense breast cancer screening study, authors assessed the impact on stage 
of breast cancer at time of diagnosis comparing 58 women who participated in the study 
from Columbia Presbyterian Medical Center in New York. The 58 women were members 
of the Women at Risk (WAR) program, a program of research, education, and treatment 
for women of increased risk for developing breast cancer. The study compared the 58 
WAR members to 3,022 non-WAR members listed in the tumor registry and diagnosed 
from 1991-1997. Interestingly and likened to prostate cancer screening, a crude analysis 
showed that women in the WAR screening program were diagnosed at significantly 
earlier stages than non-WAR subjects with a resultant odds ratios of 2.2 and statistical 
significance with a p value equal to 0.001 (95%CI: 1.37-3.61) (Mitra, Schnabel, Neuget 
& Heitjan, 2001).  
Multiple logistic regression was used to estimate the p-scores for each woman on 
important relevant covariates. All women were placed into five strata based on the 
distribution of their respective p-scores. Generally, subjects with very low p-scores were 
placed in the first quintile meaning that these subjects were less likely to participate in the 
breast screening program. In contrast, women of the fifth quintile would have the highest 
p-scores depicting those most likely to participate (Mitra et al., 2001). The results 
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indicated that before p-score adjustment, 9 out of 16 baseline covariates significantly 
differed between the two groups thus making matching difficult. These covariates 
included numbers of pregnancies, numbers of births, age at first delivery, race, how the 
tumor was discovered, history of prior breast disease, breast cancer in mother, breast 
cancer in maternal aunt, and breast cancer in sister. There was also a significant 
difference noted with stage at diagnosis as previously reported in breast screening 
programs. Comparison between groups after p-score adjustment was accomplished by 
estimating a two-way analysis of variance (ANOVA) that included the p-score quintile 
and each of the 16 covariates. Results showed that after adjustment, all 16 covariates 
were balanced and showed no significant differences. In other words, the two groups 
were similar within each propensity score quintile. The authors also evaluated screening 
effect using multiple logistic regression with stage as the outcome variable and WAR 
membership as the predictor variable with p-scores included as a single variable. 
Including the p-score as a single variable allowed for a much simpler model than one 
using all 16 covariates.  The final model calculated an odds ratio of 1.52 (95%CI: 0.94-
2.46, p = 0.19) indicating that although WAR participants were more likely to be staged 
lower than non-WAR members, the association was not statistically significant (Mitra et 
al., 2001). The authors concluded that although initial unadjusted analysis suggested that 
being a member of a screening program was associated with a lower stage disease at 
diagnosis, statistical significance was lost once adjusting with estimated p-scores thus 
indicating the importance of considering other factors as reasons for influencing down 
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staging. The authors noted that using propensity scoring allowed for a more accurate 
assessment of the effectiveness of an intense screening program in this study.       
The effect that chemotherapy had on elderly patients with advanced stage IV lung 
cancer (non-small cell lung cancer, [NSCLC]) using instrumental variable analysis and 
the propensity scoring method was also conducted. The authors compared their analysis 
with the randomized clinical trial results of the Non-Small Cell Lung Cancer 
Collaborative Group (NSCLCCG) who found that patients treated with chemotherapy 
had a slight increase in median survival of 6 weeks and a 10% improvement in 1 year 
survival compared with patients receiving only supportive care (Earle et al., 2001). Using 
the SEER 11 registry dataset merged to Medicare files, which covered approximately 
14% of the U.S. population and a 94% matching rate, the authors were able to show 
similar results as presented by the RCT listed above. In particular and as seen in the lung 
RCT, patients more likely to receive chemotherapy were younger, males, non-black race, 
treated in a teaching hospital, and lived in certain geographic regions. Their results 
showed that the propensity scores were well balanced with an increased survival of 33 
days (42 days in the RCT) and an improvement in 1 year survival of 9% (10% in the 
RCT). The authors concluded that giving chemotherapy to elderly patients with stage IV 
lung disease in a non-clinical trial was effective noting slight beneficial results 
comparable to those seen in the RCT (Earle et al., 2001).  
Another study involving lung cancer examined the postsurgical prognosis in 
patients having non-small cell lung cancer (NSCLC) by comparing those with disease 
either found by biopsy or found at the time of surgery. Lung biopsy is an important tool 
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physicians use to help diagnose lung cancer, however, it can sometimes disrupt the 
vascular and lymphatic structures causing tumor cells to migrate to other areas 
(Nakajima, Sato & Takamoto, 2005). This may lead to tumor formation in nearby areas 
or along the biopsy tract and worsen prognosis in patients. Because of the known issues 
with biopsies the authors used propensity scores to evaluate by comparing prognosis in 
patients with cancer found at time of surgery to those with cancer found using biopsy. 
The propensity scores were entered as continuous variables into a Cox proportional 
hazards model along with other adjusted multiple confounder variables (Nakajima et al., 
2005). The results indicated that patients receiving a positive biopsy had a higher risk of 
cancer recurrence after surgery. Biopsy was shown to be a significant predictor for 
influencing the recurrence-free rate in patients with NSCLC. It was suggested that the 
biopsy procedure might worsen the prognosis of patients with resectable NSCLC 
(Nakajima et al., 2005). 
A more recent study compared long-term survival and different treatments in men 
with advanced stage prostate cancer using propensity scores. The study included 453 men 
from the Henry Ford Health System between 1980 and 1997 (Tewari et al., 2007). 
Treatment modalities were compared with two end points using the propensity scoring 
approach. The end points were overall survival and cancer-specific survival. Patient 
characteristics indicated that men treated with radiation therapy tended to be older and 
had more comorbidities than men treated with surgery or watchful waiting. African 
American men made up nearly 58% of the study population and were less likely to 
undergo surgery than Caucasians (20% versus 31%). The results showed that for any 
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given quintile of propensity score men receiving surgery were 68% less likely to die in 10 
years than men who chose watchful waiting and nearly 54% less likely to die than men 
receiving radiation therapy. Propensity scores showed only a slight improvement over the 
unadjusted rates. The authors noted that using the propensity method was a strength of 
the study as it allowed the comparison of three treatment modalities when all observed 
covariates were matched and well balanced (Tewari et al., 2007).  
Quality Measures of the Propensity Score Method 
Like any statistical analysis, it is important to evaluate the results of tests for 
quality and accuracy by some criteria before making inferences about relationships and 
associations. Tools to assess quality of matching can be useful for verifying how well 
confounders are balanced, especially when provided by graphical illustrations. For 
example to assess covariate balance, plots of propensity scores for observing overlap and 
plots of  percent absolute standardized differences will be provided.  
It is the believed that these examples of visual indicators for covariate assessment 
and balance will provide useful insight into screening PSA differences as related to each 
covariate distribution. In addition to graphic illustrations of covariate balance and 
outcome effects, standard numerical tests for independence for the ordered categorical 
variables and differences in means for continuous variables on sPSA along with two-
sided t-tests, odds ratios, and 95% confidence intervals will be presented. 
Data Source 
The SEER program is an epidemiologic surveillance system sponsored by the 
NCI and is comprised of cancer registries throughout various regions across the U.S. The 
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SEER data is considered highly valid and requires that all registries maintain the highest 
level of certification for data quality as provided by the North American Association of 
Central Cancer Registries (Warren, Klabunde, Schrag, Bach, & Riley, 2002). The 
program's benchmark for completeness of case ascertainment is 98%. The data source for 
this study is the most recent release of SEER-Medicare linked files from 1986 through 
2006. The SEER-Medicare database is a population based cancer registry covering 
approximately 26% of the U.S. population. The linked data is a collaborative effort of the 
NCI, SEER registries, and CMS with a greater than 97% matching accuracy rate of SEER 
individuals to their Medicare claims files (Warren et al., 2002; Wong et al., 2006). The 
particular SEER dataset used for this study is the SEER 17 registry made up of the 
following registries: Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San 
Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles, San Jose-Monterey, rural 
Georgia, the Alaska Native Tumor Registry, Greater California, Kentucky, Louisiana, 
and New Jersey. 
The specific files requested from SEER are the Patient Entitlement and Diagnosis 
Summary File (PEDSF) for men with prostate cancer and the Summarized Denominator 
Files (SUMDENOM) that includes Part A, Part B, and HMO information, for the period 
1986-2006. There is a PEDSF record available for each individual in the SEER database 
matched to their own Medicare enrollment record. The PEDSF files contain diagnosis 
information including a patient’s date of birth, date of death, sex, race, and state of 
residence. In addition, there are other variables derived from Census Bureau data on 
socioeconomic status at the census tract and zip code level. The SUMDENOM files are 
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generated by the NCI for non-cancer cases. The patients identified from this file represent 
a 5% random sample of Medicare beneficiaries that live in the SEER areas. These files 
contain information by calendar year for the months that a person became Medicare 
eligible from 1986-2006. Each person’s file contains their unique Health Insurance 
Claims number (HIC) with birth date, date of death, sex, race, state of residence, 
enrollment in both Part A and Part B with a separate file containing socioeconomic 
information at the zip code level and based on the 1990 and 2000 Census. The HIC 
number allows for tracking of patients between inpatient and outpatient files and from 
year to year (Cooper, Yuan, Jethva & Rimm, 2001).    
The Medicare files used for this study include the Medicare Provider Analysis and 
Review (MEDPAR) files for the years of availability (1986-2006). These files contain a 
single summarized record for each admission and will include up to 10 diagnosis and 5 
procedural codes from the International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) for the patient as well as all Part A bills for each calendar year. 
The second linked file requested from Medicare is the Outpatient Claims file for the years 
available of 1991-2006. This file contains the Part B claims for each calendar year from 
outpatient providers and ambulatory surgery centers. Information provided through these 
files include up to 10 diagnostic codes (ICD-9-CM) and 1 procedural code according to 
Current Procedural Terminology, 4th edition (CPT-4), the HIC number, dates of service, 
reimbursement amounts, facility provider numbers, revenue center codes and beneficiary 
demographics. The final file requested from Medicare for this study is the Carrier Claims 
file also called the physician/supplier or National Claims History record (NCH) and is 
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available from 1991-2006. This file contains 100 percent of physician/supplier (Part B) 
bills collected since 1991. These files also contain the HIC number for each patient. Each 
carrier claim record has a Health Care Procedure Classification Code (HCPCS) 
describing the billed service. All three of the files requested from Medicare include a 5% 
random sample of non-cancer cases.     
Sample 
The unit of analysis for this study includes the SEER regions listed above 
comprising nearly 26% of the U.S population. The population will include only two races 
defined as either African American or Caucasian. The ethnic groups of Asian Pacific 
Islander, Asian-American, and Hispanic/Latino populations are excluded because 
incidence and death rates were not calculated as a result of the lack of intercensal county 
population estimates from the U.S. Bureau of Census and because these groups of men 
have lower incidence and mortality rates than Caucasian men (Edwards et al., 2005; 
ACS, 2008). 
Patient eligibility included elderly men aged 66-85 years who were diagnosed 
with local/regional prostate cancers (T1 or T2) and enrolled in Medicare at least twelve 
months prior to diagnosis and for at least one month during study period. Although a 
patient becomes eligible and may enroll in Medicare at age 65, this study will include 
men beginning at age 66 to ensure at least one year of Medicare claims prior to diagnosis. 
This will allow more complete data on certain variables, especially comorbid conditions. 
Staging is based on the American Joint Commission on Cancer (AJCC) or SEER 
historic stage code when AJCC staging is missing. Tumor grade is defined as well 
140 
 
 
differentiated or moderately differentiated using Gleason score notation (Gleason, 1977). 
Poorly differentiated is excluded because this grade is usually associated with more 
advanced disease (Gleason, 1977). Search of Medicare files for the appropriate 
International Classification of Disease, ninth revision (ICD-9) and the Healthcare 
Common Procedural Coding System codes (HCPCS CPT-4) during 6 months prior to and 
6 months after a patient’s first PSA test as a Medicare enrollee will identify treatment 
strategy. The codes for treatment include surgery, external radiation therapy (including 
brachytherapy implants), neo-adjuvant or adjuvant hormone therapy (ADT), and watchful 
waiting (see Table 9). A patient receiving external beam after surgery will remain 
classified as surgical. For example, often men who receive prostatectomy require external 
beam radiation to protect against possible microscopic disease and to account for positive 
margins. An assumption is made that all men within the SEER registries of this study will 
have most likely had PSA tests by the time they reach the age of 66 years. PSA tests will, 
therefore, be identified from Medicare claims data and categorized according to the 
theoretical algorithm outlined below. Among men with prostate cancer, two groups 
(sPSA and dPSA) will be defined as men either having a screening PSA test or men who 
had PSA tests for any other reason other than for screening purposes (diagnostic reasons). 
For example, a man will be placed in the treatment group (sPSA) if he had PSA tests for 
screening purposes or he will be placed in the control group (dPSA) if he had PSA tests 
for diagnostic reasons and sPSA will be dichotomized as a “Yes” = 1 and dPSA as a "No 
= 0". The same algorithm and process will be applied to men without prostate cancer to 
form two similar groups. 
141 
 
 
Table 9. Patient Eligibility Criteria 
SEER site recode 54 (prostate)  
ICD-9 or ICD-10 185.9 or C619  
Medicare 
enrollment 
6 months prior to 
and after 1st PSA 
test, men age 66-
85 years. 
 
Men diagnosed 
with prostate 
cancer 
Localized/regional 
(SEER defined) 
 
Staging 
AJCC/SEER 
1 or 2  
Tumor grade T1: well 
differentiated 
(Gleason ≤ 4) 
T2: moderately 
differentiated 
(Gleason 5-7) 
1 
 
2 
 
Treatment and CPT 
code 
Surgery 
 
 
 
Radiation therapy 
 
 
 
 
 
 
 
 
Hormone therapy  
 
Watchful waiting 
Any form of prostatectomy including partial 
and radical, CPT 52601, 52612-52614, 
55801, 55810, 55812, 55815, 55821, 55831, 
55840-55845, 55866 and ICD-9 code 60.5 
External beam and brachytherapy implants, 
CPT 77401-77499, 77416, 77418, 77328, 
77778, 77750-77799 and ICD-9 procedural 
codes 92.21-92.29 and ICD-9 diagnosis 
codes V58, V66.1, V67.1 and C2638 or 
C2639, and C2640 or C2641 for 
brachytherapy stranded or non-stranded I-
125 and stranded or non-stranded Pd-103 
seeds. 
HCPCS J9202, J9217-J9219, J1950 and 
CPT 54520-54522, 54530 and 54535. 
No treatment CPT-code associated with 
diagnosis 
Screening test  PSA CPT 84152-84154, and 86316 and 
screening code G0103 
Race Caucasian 
African American 
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The algorithm to determine whether a man received screening PSA tests or 
diagnostic PSA tests is illustrated in Figure 4. According to the algorithm, a man will be 
categorized as having received a PSA test for "screening purposes" if he has no other 
prostate conditions or prostate treatment related CPT codes listed at the time of his first  
 
 
 
Figure 4. Algorithm to determine screening PSA vs. diagnostic PSA. 
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recorded PSA test as a Medicare enrollee and for a period 6 months prior to and 6 months 
after his first PSA test as a Medicare enrollee and/or he was asymptomatic and without  
any history or treatment for any prostate condition such as BPH or prostatitis (see Figure 
4 above). These results will be obtained from the CPT-4 codes listed in the Medicare 
MEDPAR files, the Carrier Claims files, and/or the Outpatient Claims files. The 
dichotomized outcome variable of interest is prostate cancer-specific mortality and 
overall mortality. 
Patient exclusion criteria will include those men with previous cancers, a second 
cancer diagnosed within the same month as prostate cancer, cancer in situ (non-cancerous 
tumors), less than 66 years old, diagnosis made upon death, neither Caucasian nor 
African American, no Medicare coverage, and being enrolled within an HMO 3 months 
prior to diagnosis. Further, men with T3 or T4 grade tumors, those with poorly 
differentiated tumors, and those with metastatic disease will be excluded because this 
group of men represents those of high grade disease.  Men who died of reasons other than 
prostate cancer (ICD-9 185.9 or ICD-10 C619) will be excluded as well. 
Analytic Research Approach 
An advantage of the propensity scoring method is that large numbers of covariates 
can be controlled by multivariate matching and creating a single composite p-score for 
each quintile thus simplifying the model (D’Agostino, 1998; Rosenbaum & Rubin, 1983; 
Rubin & Thomas, 1996). For example, adjusting (controlling) for large numbers of 
variables using traditional model-based regression can lead to large complex and 
complicated models making diagnostic checks on the goodness of fit difficult to assess. 
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Also, making interpretations and describing interactions of higher order terms may be 
difficult as well. The propensity method helps to reduce these difficulties (Mitra et al., 
2001).  
Rubin and Thomas (1996) showed that values resulting from regression 
adjustment on unmatched groups can lead to problems of linearity as well (Rubin & 
Thomas, 1996; Mitra et al., 2001). Therefore to address the question of to what extent 
PSA screening has on racial disparate mortality rates between African Americans and 
Caucasians this study will employ a propensity score method as part of its analysis.  
Conceptual Model 
 
This study is guided by a treatment and outcomes model outlined by Kane 
(1997a).  Kane (1997b) defined clinical outcomes as the culminated results of many 
multi-faceted factors. These may include baseline measurements, clinical health status, 
personal demographic/psychological characteristics, and treatment. In particular, he 
proposed outlining basic outcomes studies as a function of the factors by the following 
expression, 
Outcomes = f (baseline characteristics, personal and clinical 
characteristics, patient demographic/psychosocial characteristics, 
treatment [intervention], and p-score). 
 
This study uses a modified conceptual model in an attempt to isolate relationships 
between the outcome of mortality and various independent variables with hopes of 
uncovering the main effect of screening PSA on current racial health disparities (see 
Figure 5).
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Figure 5. Conceptual Treatment and Outcomes Model.
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Research Methodology 
 
This research study is a retrospective, observational exploration of secondary data 
using the SEER-17 registry dataset linked to Medicare claims registry.  The design will 
consist of a multi-phased process. Baseline characteristics along with summary and 
descriptive statistics will be determined before matching to note any significant group 
differences. The same patient characteristics will then be shown to evaluate the accuracy 
of the matching process. Table 10 is a simple illustration that quickly shows the 
difference in groups before and after matching and serves as a sample of how the data 
may look for this study. 
All independent variables were selected as previously identified in the review of 
the literature and defined based on the student's knowledge. In the next step, a propensity 
logistic regression model will be developed to estimate p-scores using the treatment 
(sPSA) as the dependent variable. Secondly, men will be matched based on having 
comparable p-scores and placed into one of five quintiles, where the first quintile 
indicates a lower propensity to screen (near 0) and the fifth quintile a greater propensity 
to screen (near one). The covariate distribution can then be examined using quality 
assessment tools previously described and by noting effects when using adjusted p-
values. The propensity logistic regression model will yield estimates of the probability 
distribution to receive the intervention (sPSA) and will range from 0-1. Through this step, 
p-scores are created by saving the predicted probabilities from the logistic model. This is 
an informative step to eliminate differences in the two groups and is not a formal 
hypothesis test. The covariates chosen will be included in a final main effects logistic 
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Table 9. Sample Baseline Characteristics by Group with Resultant p-scores before and 
after matching. 
 
Before matching on p-score 
 Variable sPSA 
(%) 
dPSA 
(%) 
P value 
Age 72 66 P < 0.05 
AA 
Caucasian 
34 
73 
57 
35 
P < 0.05 
P < 0.05 
Stage 
T1 
T2 
 
74 
66 
 
45 
38 
 
P < 0.05 
P < 0.05 
Grade 
1 
2 
 
62 
55 
 
28 
33 
 
P < 0.05 
P < 0.05 
After matching on p-score 
Variable sPSA 
(%) 
dPSA 
(%) 
P value 
Age 71 70 P = 0.33 
AA 
Caucasian 
44 
55 
47 
57 
P = 0.23 
P = 0.46 
Stage 
T1 
T2 
 
62 
54 
 
59 
55 
 
P = 0.37 
P = 0.78 
Grade 
1 
2 
 
53 
45 
 
49 
44 
 
P = 0.47 
P = 0.79 
 
regression model and listed in table format (see example Table 11).  From this output 
table, the odds ratios for each variable can be calculated as eb. And the z statistic is the 
ratio of the regression coefficient (ß) to the standard error SE(ß). Also 95% confidence 
intervals may be determined for each variable. Assessment of whether the p-score 
adjustments help to balance the covariates is illustrated by graphical display with adjusted 
p-values where in this case, p-values > 0.05 would indicate no significant differences 
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Table 10. Sample Main Effects Logistic Regression Model. 
 
Predictor 
Variable 
Regression 
Coefficient 
ß 
Standard 
error 
SE(ß) 
WALD 
(chi2) 
Sig. 
p-
value 
95% 
C.I. 
Intercept 
(constant) 
     
Variable 
(x1) 
     
Variable 
(x2) 
     
Variable 
(x3) 
     
    
between covariates and, therefore balance being achieved. In reviewing the propensity 
model results, interest is in the coefficients of the sPSA variable for non-statistically 
significance (p > 0.05) indicating balance.  If balance is achieved on all covariates within 
each strata, meaning there are no differences in the two groups, then it is safe to assume 
that most selection bias has been removed and a quasi-randomized study design achieved. 
Results of the first model with calculated p-score adjustments will be provided by 
subsequent logistic and Cox regression modeling.  
Assessment of covariate distributions within each quintile may show the inability 
to detect differences after p-score adjustment. For example, the initial regression model 
should indicate sufficient overlap of covariates by showing no extensive or consistent 
patterns of interactions between screening PSA and each quintile. This would allow for p-
score adjustments in all subsequent regression models to explicitly account for selection 
bias. Should assessment of overlap prove sufficient, subsequent logistic and Cox models 
can be used for the final group comparison.  The five quintiles will be displayed (see 
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Table 12) according to their p-scores with mathematic absolute percent differences in p-
scores for the outcome variables. Finally, logistic regression and Cox regression models 
of main treatment effects (sPSA) on mortality between races will be developed and 
formal hypothesis testing performed.   
Table 11. Summary of Propensity Scores, Count, and Means for Race. 
 
Strata Counts, n (%) Means Standardized 
Absolute 
Difference 
Propensity 
Score 
sPSA  dPSA Cancer Non-
cancer 
 
Quintile 1      
Quintile 2      
Quintile 3      
Quintile 4      
Quintile 5      
 
Study Variables 
 
The study variables are provided later in the section for the independent variables 
and the dependent variable. Age will be categorized into groups ranging from 66 to over 
85 years. Race is categorized as either Caucasian (1) or African American (2) according 
to SEER race recode in the PEDSF file. Tumor stage will be ordered as either T1 (1) or T2 
(2). Tumor Grade will be categorized as I or II. Socioeconomic factors will be determined 
from SEER data and because SEER-Medicare does not collect individual level 
socioeconomic status, this study will use Census Tract 2000 by percent mean for non-
high school graduate, high school graduate, some college (no degree), four years of 
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college (degree), and mean median household income as proxies for an individual’s 
socioeconomic status. 
Summary comorbidity measures will be assessed using a modified Charlson index 
known as the NCI combined indices described by Klabunde et al., 2000 and 2007. The 
NCI combined measure, unlike the Charlson indices which include using data from only 
one source (inpatient files), builds on the Charlson index by not only using inpatient 
claims but also physician claims data. It was shown that by using the two sources, better 
fit models resulted (Klabunde, Potosky, Legler & Warren, 2000; Klabunde, Legler, 
Warren, Baldwin & Schrag, 2007). The NCI combined approach derives weights 
calculated from conditions identified from either the inpatient or physician claims files 
and combines them into a single index. This method has demonstrated improved 
prediction of non-cancer mortality and treatment choice for breast and prostate patients 
(Klabunde et al., 2000; Klabunde et al., 2007). Their study used SEER-Medicare files 
that identified 53,503 eligible Medicare beneficiaries with prostate cancer. The authors 
found estimated hazard ratios or coefficients from survival estimation models, multiplied 
these weights by a dichotomized condition indicator (1 = having the condition and 0 = 
not having the condition) and then summed the weighted conditions to construct the 
single index. The weighted estimate values have been empirically derived and published 
values for the twelve most prevalent conditions will serve as the basis for the comorbid 
indices of this study. For clarification purposes, the comorbid conditions old myocardial 
infarct and myocardial infarct are described by ICD-9 diagnostic codes as men who have 
had a prior heart attack that has healed and exhibit no current symptoms or an acute heart 
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attack within the last 8 weeks, respectively. The outcome variable (dependent variable) 
used for this research study will be prostate cancer-specific mortality and overall 
mortality as recorded on death certificates within SEER files and as listed as cause of 
death where “Yes” = 1 or “No” = 0 (see Table 13).   
Table 12. Study Variables. 
 
Independent variables 
Name Type 
Age Groups at diagnosis (yrs.) 
 
66-69  referent variable 
70-74 
75-79 
80-84 
85+ 
Categorical 
 
14 
15 
16 
17 
18 Race 
Caucasian 
African American 
Categorical 
1 
2 
Stage 
Local/Regional  
In situ + Localized + Regional  
 
Binary  
1 
0 
Grade 
Grade I (Gleason ≤ 4) 
Grade II (Gleason 5-7) 
Categorical 
1  
2 
Screening PSA 
Yes 
No 
Binary 
1 
0 
Treatment 
Radiation 
Radioactive implant 
Any surgery 
Hormone therapy 
Categorical 
1 
2 
3 
4 
Socioeconomic Status (SES) 
Variables 
Marital Status 
Single/never married 
Married 
Separated 
Divorced 
Widowed  
Unknown 
Nominal 
1 
2 
3 
4 
5 
9 
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Table 13: continued. 
 
  
Census Tract Education 
 
≤ 12 years (non-high school grad) 
≥ 12 years (high school grad) 
Continuous 
 
% mean 
% mean 
College Education 
Some college (no degree) 
    At least 4 years of college 
Continuous 
% mean 
% mean 
Census Tract Median Household 
Income (USD) 
 
By zip code (% mean) 
Continuous 
 
 
% mean 
Comorbidity Indices (NCI- combined) 
 
Previous Myocardial Infarct 
Myocardial Infarct 
Congestive Heart Failure 
Peripheral vascular disease 
Cerebrovascular disease 
COPD 
Dementia 
Paralysis 
Diabetes 
Diabetes with sequelae 
Chronic Renal Failure 
Rheumatologic disease 
 
Continuous 
 
Coefficient  
0.054  
0.242 
0.874 
0.359 
0.266 
0.725 
0.777 
0.393 
0.239 
0.440 
0.678 
0.091 Dependent variable 
Overall Mortality  
Yes 
No 
Binary 
1 
0 
Prostate Cancer-Specific Mortality 
Yes 
No 
Binary 
1 
0 
 
Hypothesis Testing 
All statistical testing will be set to an α = 0.05 and two-sided. Summary and 
descriptive statistics using tests of proportions for all categorical independent variables 
and tests for differences in means for all continuous independent variables, including an 
ANOVA for the SES variables among the non-cancer group will be provided.   
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To test the hypothesis H1 that no statistically significant differences exist in 
prostate cancer-specific mortality rates among race for men with PSA screen detected 
cancer and men with clinically diagnosed cancer, cancer-specific mortality will be 
calculated and tests of proportions using logistic regression with odds ratios, confidence 
intervals, and p values compared. In addition, a sensitive analysis using conditional Cox 
regression models for censoring on time to event and to account for matched pairings will 
be evaluated to compare results with other models. In testing the hypothesis H2 that no 
statistically significant differences exist in overall mortality rates among race for men 
without prostate cancer receiving screening PSA tests and men receiving diagnostic PSA 
tests,  overall mortality will be calculated with tests of proportions using logistic 
regression and odds ratios, confidence intervals, and p values reported for comparison; 
conditional Cox regression models will be applied as a means of comparison with the 
results of other models as well. 
 To test hypothesis H3 that baseline (initial) PSA utilization rates among race in 
men with prostate cancer during the PSA era from 1986-2006 will show no statistically 
significant differences, F-Tests with one-tailed probability distributions will be reported. 
Likewise, to test hypothesis H4 that baseline (initial) PSA utilization rates do not differ 
among men without prostate cancer during the PSA era, F-Tests with one-tailed 
probability distributions will be calculated for the same time period. The PSA utilization 
rates for testing H4 will be derived from the SUMDENOM file of a 5% randomized 
group of men without prostate cancer.  
154 
 
 
Study limitations 
 
Medicare Data Limitations 
A limitation of the Medicare files is that not all services provided are captured in 
the claims files. For example, PSA screening provided by a community based screening 
program, services provided to a beneficiary by a Veteran's Administration facility, or 
services to a beneficiary who is employed and currently covered by a health plan (where 
Medicare would be the secondary payor). Other non-covered services are long-term care 
and lack of Hospital Maintenance Organization (HMO) enrollment (Warren et al., 2002). 
For example, HMOs are not required to send claims data on their enrollees to Medicare. 
This is a problem because HMO enrollees made up about 14% of the Medicare 
population as of 2001 with proportions varying greatly across SEER regions. For 
instance, some states have very little HMO enrollees while other states have high 
concentrations of HMO participants. Further, enrollees are free to move from one HMO 
to another and HMOs can sign up new participants anytime thus potentially increasing 
the number of missing data during a particular year. Because Medicare does not contain 
complete data on enrollees within HMOs, men that were enrolled into an HMO 3 months 
prior to diagnosis are excluded.   
It is also known that using claims data to estimate prostate screening is limited 
(Freeman et al., 2002; Potosky et al., 1995; Legler et al., 1998; Cooper et al., 2001). For 
instance, claims data may lead to incomplete or missing information, as they are 
sometimes created only for purposes of payment and therefore reasons for having PSA 
tests (screening vs. diagnostic) are not provided.  However, with the expansion of 
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Medicare's coverage and using the latest SEER-Medicare data coupled with use of the 
proposed algorithm in Figure 4, it is hopeful that distinguishing screening PSA tests from 
diagnostic PSA tests will be more accurate. 
SEER Data Limitations 
 
Generalization of the SEER data files to the U.S. population of elderly may be 
limited. The SEER registries were not randomly selected instead they were chosen based 
on quality of data submission and to adequately represent minority groups. Also, 
determining SES variables at the individual level is not possible within the SEER files 
therefore, only proxy measures using census tract data will be used. In order to 
investigate comparisons of SEER registrants to the national U.S. population, the NCI 
examined SES characteristics, HMO enrollment, and cancer mortality. 
In looking at SES factors of age groups and sex, NCI found persons within the 
SEER areas to be comparable to the elderly within the U.S. population (Warren et al., 
2002). However, with race they found differences. According to the 1990 census, the 
SEER areas tended to have lower proportions of Caucasians and higher proportions of 
other races. Also, individuals within SEER regions were more likely than persons within 
the U.S. population to live in urban areas (87% vs. 73% respectively) and more likely to 
live in affluent areas with only 9.5% of SEER individuals living in households with 
incomes below the poverty level compared with the U.S. average of 12.8% (Warren et 
al., 2002). Regarding the lack of HMO data, the same problem exists for the SEER files 
as in the Medicare files in that the proportion of SEER registrants enrolled in HMOs was 
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considerably greater than the U.S. populations with variations across states that could 
lead to greater numbers of missing data as well.  
Racial differences in mortality for men with prostate cancer have been previously 
noted with the NCI also noting that differences exist among SEER areas and the U.S. 
total. For all races, cancer mortality rates among men living in SEER areas compared to 
the U.S. total population were approximately 4% lower (218 versus 226.4 per 100,000 
men). When comparing race among men living within SEER areas and the U.S. total, 
African Americans had an approximate 2 times greater mortality rate than did Caucasians 
(417.7 versus 210.6). These values are consistent with chapter one's mention of the 
American Cancer Society's more recent numbers showing that African Americans were 
2.4 times more likely to die from prostate cancer than Caucasians (ACS, 2008; ACS-AA, 
2008; Warren et al., 2002).  
Because of misclassification bias or inaccurate cause of death listed on death 
certificates, SEER data calculates mortality based on incidence data. This incidence-
based mortality (IBM), examines mortality rates by variables determined at time of 
diagnosis, such as stage. Only the SEER files provide cause of death derived by the IBM 
method, therefore it will be used for determining prostate cancer-specific mortality within 
this study.  
Further, large administrative databases contain large amounts of selection bias 
threatening validity when using observational data for estimating outcomes. Attempting 
to control for this bias can be achieved by using multivariate matching such as propensity 
scoring analysis. However, it is suggested that it may be impossible to remove all 
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selection bias with any statistical analysis (Giordano et al., 2008). Potential explanations 
for selection bias that remains even after controlling is lack of information for 
unobserved and unmeasured covariates as well as lack of information on self-reported 
health surveys.    
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CHAPTER 4: RESULTS 
 
Introduction 
 
As presented in Chapter 3, this research study is a retrospective, observational 
exploration of secondary data using the SEER-17 registry dataset linked to the Medicare 
claims registry.  It provides an analysis of the association between prostate cancer 
screening with PSA testing and the effects of such tests on racial disparate mortality 
between African Americans and Caucasians. The study utilizes a fairly new method in 
the propensity analysis applied to both logistic regression and conditional Cox regression 
modeling. 
First, results for the prostate cancer cases are presented beginning with a 
traditional logistic and Cox regression model for the full unmatched data set without use 
of a propensity analysis. These models are compared to both the logistic and conditional 
Cox regression models that do have a propensity analysis later in the chapter. Subsequent 
results from the logistic and conditional Cox regression models with a propensity analysis 
applied are presented in a multi-phase approach with responses to research questions one 
and three and hypothesis H1 and H3 provided in Chapter 5 Discussion. The multi-phase 
approach begins with (a) sample selection, (b) demographics and data characteristics, (c) 
group selection, (d) propensity analysis, (e) propensity logistical and conditional Cox 
regression models (Luo, Gardiner, & Bradley, 2009), and (f) final comparisons of
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propensity matched regression models to traditional non-propensity regression models. 
The same systematic approach was repeated for the non-cancer group for examining 
research questions two and four and hypotheses H2 and H4. However, although the 
analysis for the non-cancer group will include the same detailed steps as noted above for 
the prostate cancer group, the reported results include less descriptive detail within items 
(a), (b), and (c) above and only select detailed results for (d), (e), and (f) above.   
The Prostate Cancer Analysis 
Sample Selection 
The selected sample originated from the linked SEER-Medicare registry 
consisting of one file from SEER (PEDSF) and 3 files from Medicare (MEDPAR, NCH, 
and Outpatient claims). The data make up almost 26% of the U.S. population with over 
224 million individual claims within 235 files searched. A total of 515,802 prostate cases 
registered through the study period before exclusions were identified. Table 14 shows the 
final exclusion criteria for all races that resulted in omitting 443,025 men and leaving a 
selected sample size of 72,777 men. There are statistically significant differences in the 
distribution of causes of exclusions between Caucasians and African American men; 
however, the largest variance occurred with having more African Americans being 
younger than 66 when diagnosed with prostate cancer. Further, African Americans were 
slightly more likely to be diagnosed with a greater degree of poorly differentiated tumors 
and approximately 20% less likely to have early stage disease compared with Caucasians. 
From this selected sample of all races, final exclusion criteria by race resulted in retaining  
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Table 13. Exclusion Criteria for Selected Sample. 
 
Exclusion Criteria Freq. % Cum. Cum. 
Freq. % 
Diagnosed before year 1987                                       16,356 3.17 16,356 3.17 
Race not Caucasian or AA                                          63,884 12.39 80,240 15.56 
First cancer is not prostate                                        25,124 4.87 105,364 20.43 
Age group at diagnosis <65y or unknown                    92,462 17.93 197,826 38.35 
Age at diagnosis <66                                                 17,158 3.33 214,984 41.68 
Poorly differentiated tumors                                     107,513 20.84 322,497 62.52 
Not local/regional disease                                                   64,130 12.43 386,627 74.96 
Another cancer diagnosed in same month                   1,532 0.30 388,159 75.26 
Died of reasons other than prostate cancer                 26,088 5.06 414,247 80.31 
Diagnosed from death certificate only                        2 0.00 414,249 80.31 
Unknown month of diagnosis                                  290 0.06 414,539 80.37 
HMO within 3 months before diagnosis                    22,248 4.31 436,787 84.68 
Not in both Part A & B within 3 months 
before diagnosis  
6,238 1.21 443,025 85.89 
Final Selected Sample                                               72,777 14.11% 515,802 100% 
 
65,738 (90.3%) Caucasians and 7,039 (9.3%) African Americans (χ2 3225.43, df 12, 
p<0.0001). A majority of exclusions for race included men with poorly differentiated 
tumors (93,471), diagnosed before reaching 65 years of age (76,721), and men diagnosed 
with greater disease extent than local/regional tumors (see Table 15). A smaller 
proportion were excluded for race because of death from something other than having 
prostate cancer (22,899), first cancer diagnosis not prostate cancer (22,713), and being a 
member in an HMO at least three months prior to diagnosis (19,819). Even fewer men 
were excluded for other various reasons such as not being a member in both part A and B 
of Medicare, other cancers diagnosed, and finally the month of diagnosis was unknown.  
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Table 14. Exclusion Criteria of Selected Sample by Race. 
 
 Percentage of 
exclusions 
Exclusion Criteria Cauc. AA   Cauc. AA   
  Total   Total 
Diagnosed before year 1987      14,093 1,367 15,460 3.55 2.42 3.43 
first cancer is not prostate 22,713 2,411 25,124 5.76 4.26 5.57 
age group at diagnosis <65y 
or unknown 76,721 15,741 92,462 19.45 27.82 20.50 
age at diagnosis <66 14,625 2,533 17,158 3.71 4.48 3.80 
poorly differentiated tumors 93,471 14,042 107,513 23.70 24.81 23.84 
not local/regional 57,550 6,580 64,130 14.59 11.63 14.22 
another cancer diagnosed in 
same month 1,369 163 1,532 0.35 0.29 0.34 
died of reasons other than 
prostate cancer 22,899 3,189 26,088 5.81 5.64 5.78 
Diagnosed from death 
certificate only 0 2 2 0.00 0.00 0.00 
Unknown month of diagnosis 256 34 290 0.06 0.06 0.06 
HMO within 3 months before 
diagnosis 19,819 2,429 22,248 5.02 4.29 4.93 
not in both Part A & B within 
3 months before diagnosis 5,179 1,059 6,238 1.31 1.87 1.38 
Selected Sample 65,738 7,039 72,777 16.67 12.44 16.14 
Total 394,433 56,589 451,022 100% 100% 100% 
 
 
Demographics and Data Characteristics 
 
Independent variables by race of the population sample show that significant 
statistical differences exist for the variable age among race (χ2 198.84, df 4, p< 0.0001); 
however, no differences were noted for the mean age at which a man was diagnosed 
(73years for Caucasians and 72 years for African Americans). Further, it is noted that 
based on percentage, more African American men were likely to be in the younger age 
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group (66-69 years) with the remaining age categories relatively equal. Significant 
differences were also noted for the variable historic stage (χ2 28.24, df 4, p < 0.0001) 
with most cases being staged as localized/regional for both races according to SEER 
definition (95.7% and 96.7%). For these reasons, the variable historic stage was 
combined and recoded as binary where a value of “1” was assigned as local/regional and 
a value of “0” assigned as all other categories. Only slight differences among race were 
noted for grade (χ2 4.757, df 1, p = 0.029) with a majority of men in both races having 
grade II defined as having Gleason scores ranging from 5-7 (93% of total); however, 
significant differences were seen for the categorical variable marital status (χ2 1575, df 5, 
p < 0.0001) where 73% of the total population were married. Within the marital status 
variable, African American men were more likely to be single/ never married and less 
likely to be married. Finally, for the remaining marital status categories, African 
American men were more likely to be separated, divorced, and/or widowed than 
Caucasian men in this selected sample (see Table 16).   
Socioeconomic status by race and zip code is depicted according to Census Tract 
2000 data. There are significant statistical census differences seen in the distribution 
throughout all the variables (p < 0.0001). Specifically, the mean percent of African 
Americans having less than a high school education is nearly twice that of Caucasians 
whereas almost the opposite is seen when comparing Caucasians to African Americans 
having four years of college. Income disparities among race also indicate the mean 
median income shows that, on average, Caucasians earned nearly 1.5 times more than  
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Table 15. Summary Count and Percentage for Variable by Race. 
 
Race Caucasian African 
  n (%) n (%) 
Age Group (yrs.)     
66-69 19,898 (30.3) 2,654 (37.7) 
70-74 23,112 (35.2) 2,393 (34) 
75-79 15,187 (23) 1,389 (19.7) 
80-84 5,864 (8.9) 447 (6.4) 
85+ 1,677 (2.6) 156 (2.2) 
Mean age at diagnosis 73 yrs. 72 yrs. 
Historic Stage     
0 (in situ) 6 (0.01) 1 (0.01) 
1 (localized) 2,780 (4.2) 217 (3.1) 
2 (regional) 38 (0.06) 10 (0.14) 
8 (localized/regional) 62,893 (95.7) 6,808 (96.7) 
9 (unstaged) 21 (0.03) 3 (0.04) 
Grade     
I  (Gleason <5) 4,378 (6.7) 421 (6) 
II (Gleason 6-7) 61,360 (93.3) 6,618 (94) 
Marital Status     
1 (single, never married) 3,657 (5.6) 940 (13.4) 
2 (married) 48,957 (74.5) 4,073 (57.9) 
3 (separated) 178 (0.27) 108 (1.5) 
4 (divorced) 2,357 (3.6) 607 (8.6) 
5 (widowed) 4,778 (7.3) 712 (10.1) 
9 (unknown) 5,811 (8.73) 599 (8.5) 
Total  65,738 (90.3) 7,039 (9.7) 
 
African Americans during the study period. Regarding whether a man completed high 
school or had some college, no differences were noted between races (see Table 17). 
Counts and percentages for the variables of treatment by race illustrate that for 
radiation treatments, African Americans were only slightly more likely to receive 
external beam radiation than Caucasians. Regarding radioactive implants, Caucasians 
were only somewhat more likely to have a prostate seed implant than African American 
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Table 16. Socioeconomic Status by Race (Percent by zip code Census Tract 2000). 
 
  Caucasian African American     
Percent 
by zip 
code 
(Census 
Tract 
2000) 
N  N non missing Mean 
Std. 
Dev. Min Max N  
N non 
missing Mean Std. Dev. Min Max 
N 
Total 
  
p-
value 
  65,738           7,039           72,777 of t-tests 
Non High 
School 
Graduate 
  
63,128 15.30 10 0 100 
  
6,763 27 12 1.81 75 
  
<.0001 
High 
School 
only 
63,128 26 10 0 80 6,763 28 7 5 50 
<.0001 
Some 
College 
Education  
63,128 28.66 7 0 100 6,763 26 6 7.78 53 
<.0001 
College 
Education 
(4 years) 
63,128 30.05 17 0 94 6,763 18 12 0 78 
<.0001 
Median 
Income 63,128 $53,826 $21,816 $7 $200,008 6,763 $36,961 $14,739 $7 $146,762 <.0001 
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men. The remaining treatment levels of radiation are more closely balanced based on 
percentages; however, significant differences do remain (χ2 194, df 9, p<0.0001).  
 The SEER registry changed the name of its variable for defining surgery of the 
prostate during this study period. The first name used, Site Specific Surgery, covered the 
period 1983-1997 and the second, Surgery of Primary Site, covered from 1998 onward. 
For the variable name Site Specific Surgery, prior to 1998 a majority of the sample 
population (82.5% Caucasians and 84% African Americans) either had no surgery or had 
surgery after 1998, and would therefore, be categorized by the new variable name 
Surgery of Primary Site. Only a small portion of men had needle biopsies (7.7% 
Caucasians and 8% African Americans), transurethral resection of prostate (TURP) 
combined with a surgical process that freezes the prostate called Cryoprostatectomy 
(2.2% Caucasians and 3.5% African Americans) or radical prostatectomy with or without 
lymph node dissection (4.8% Caucasians and 2.4% African Americans). The remaining 
surgical types performed prior to 1998 were negligibly small (χ2 138, df 17, P < 0.0001). 
The new surgery variable name Surgery of Primary Site began during 1998 and illustrates 
that 84% of Caucasians and 85.2% of African American men either had surgery recorded 
under the previous surgical period or had no cancer-directed surgery at all. A small 
number of men had a TURP with either an incidental benign cancer finding or with a 
positive cancer finding. And only a slightly larger portion of both races chose to have a 
radical prostatectomy surgery (χ2 91, df 16, p < 0.0001). Again, because the percentage 
of men having no surgery was high compared to that of men having any of the other 
surgical choices combined, the two variables, Site Specific Surgery and Surgery of 
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Primary Site were combined and recoded as binary where a value of 1 was assigned as a 
“yes”, a man had some type of prostate surgery during the study period and a value of 0 
assigned as a “no”, a man had no surgery of any type during the study period.   
In reviewing the variable radiation sequence with surgery, it is noted that of the 
total sample population, 97% of Caucasians and 96% of African Americans had no 
radiation and/or surgery. Only a small sample of men had external radiation after surgery 
which is a common treatment sequence when managing patients who have chosen 
prostatectomy followed by external beam radiation (χ2 36, df 6, p < 0.0001). Because the 
percentage of men from both races receiving no sequence of radiation with surgery was 
vastly different from the percentage who did and because the sample population for this 
study is sufficiently large, the variable radiation sequence with surgery was combined 
and recoded as binary with a value of “1” assigned as “yes”, a man had some sequence of 
radiation and surgery and a value of “0” assigned as “no”, a man had no combination of 
radiation with surgery.  
Regarding whether men received hormone therapy, a majority among both races 
elected not to have hormones at the time of their diagnosis (93% Caucasians and 88% 
African Americans). In addition, if race were independent of receiving hormone therapy 
at the diagnosis date, the data show that 99% of men could be expected not to receive 
hormone therapy (χ2 34, df 1, p < 0.0001). However, Caucasians were almost twice as 
likely as African Americans not to take hormone therapy within this population sample 
(OR 1.941, 95%CI 1.55-2.431).   
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In contrast, the decision not to have hormones decreased by almost one half 
during the 6 months following a diagnosis date (43.7% Caucasians and 44.6% African 
Americans). The test for independence between race and hormone therapy up to 6 months 
after being diagnosed shows that only 86% of men could be expected not to have 
hormones (χ2 36, df 1, p < 0.0001). Further, Caucasians remained only slightly more 
likely not to receive hormones than African Americans at the 6 month time (OR 1.32, 
95%CI 1.208-1.452) (see table 18).  
Group Selection 
 
The two groups, screening PSA and diagnostic PSA, were selected according to 
the algorithm in Figure 4 above.  A man was considered as having a true screening PSA 
(sPSA) if during the period 6 months prior to and 6 months after receiving his first PSA 
test as a Medicare enrollee the test was not associated with any other prostate condition, 
treatment, or symptom. Other conditions for being placed in the dPSA group include 
prostate surgery, histologic malignancy diagnosis, bladder neck obstruction, unspecified 
urinary tract infection, hematuria, increased frequency or abnormality in urination, 
radiation, or hormones. If any of these conditions or diagnoses were identified by claims 
codes CPT-4 or ICD-9, men were placed in the diagnostic group (dPSA); otherwise, they 
were placed in the screening group (sPSA). The number of men in the sPSA is slightly 
less than the number in the dPSA at 32,210 and 37,854 (final n = 70,064). When 
comparing race, there are statistically significant differences in the likelihood that 
Caucasian men received a sPSA test compared with African American men (χ2 291.5, df 
1, p<0.0001). Specifically, Caucasians were 1.6 times more likely to have a sPSA than  
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Table 17. Summary Count and Percentage for Treatment by Race. 
 
Treatment 
SEER Race Recode B 
Caucasian 
African 
American 
 n (%)  n (%) 
Radiation None 32,526 (49.5) 3,424 (48.6) 
Radiation Beam 17,420 (26.5) 2,164 (30.7) 
Radioactive Implants 9,026 (13.7) 624 (8.9) 
Combination Radiation beam/implants 4,409 (6.7) 562 (8.0) 
Recommended, unknown if administered 726 (1.1) 103 (1.5) 
Unknown 796 (1.2) 60 (0.9) 
Radiation sequence with 
surgery 
No radiation and/or cancer-directed surgery 63,798 (97) 6,753 (95.9) 
Radiation after surgery 1,734 (2.6) 259 (3.7) 
Site Specific Surgery Men part of next sequence SXPRIM1 (1998+) 54,219 (82.5) 5,914 (84) 
No surgical procedure 485 (0.7) 59 (0.8) 
Incisional, needle, or aspiration biopsy of primary site 5,048 (7.7) 562 (8.0) 
Unknown if surgery performed 163 (0.2) 9 (0.1) 
TURP, Cryoprostatectomy w/o lymph node dissection 1,463 (2.2) 173 (3.5) 
Radical Prostatectomy w/o lymph node dissection 779 (1.2) 101 (1.4) 
Radical Prostatectomy  with lymph node dissection 3,172 (4.8) 166 (2.4) 
Surgery of Primary Site 
(1998+) 
Men part of previous sequence SSSurg (1983-1997) 30,179 (45.9) 3,238 (46) 
No cancer-directed surgery 25,129 (38.2) 2,756 (39.2) 
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Table 18: continued. 
 
Treatment 
SEER Race Recode B 
Caucasian n(%) 
African 
American n(%) 
Surgery of Primary Site 
(1998+) continued 
TURP, NOS 288 (0.4) 52 (0.7) 
TURP, cancer incidental finding during surgery; benign 1,917 (2.9) 167 (2.4) 
TURP with cancer finding 651 (1.0) 127 (1.8) 
Cryoprostatectomy 195 (0.3) 31 (0.4) 
Radical Prostatectomy 6,671 (10.1) 604 (8.6) 
Unknown 478 (0.7) 35 (0.5) 
Hormones at time of 
diagnosis 
No 61,285 (93.2) 6,179 (87.8) 
Yes 470 (0.7) 92 (1.4) 
Hormones 1-6 months 
after 
No 28,068 (43.7) 3,142 (44.6) 
Yes 4,222 (6.4) 626 (8.9) 
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African Americans (OR 1.585, 95%CI 1.503-1.671). Among African Americans, a much 
lower percentage were screened compared to those having diagnostic PSA tests; only 
33% received sPSA tests while 59% received dPSA tests.  The variance illustrates that 
African American men were more likely to have their prostate cancers clinically 
diagnosed by waiting until they become symptomatic before seeing a physician instead of 
using early detection screening tests. These values coincide with the literature which 
shows that African American men historically only visit their physician when symptoms 
occur, resulting in use of the PSA test for screening purposes 10% less frequent than 
Caucasians (Behavioral Risk Surveillance System, Public Use Data File, 2004).  
Although this study does not include men who never had a PSA test recorded in 
any of their claims files, it is worth noting that 2,713 or almost 4% of the selected sample 
population met that definition. In addition, there is a significant difference in the 
likelihood that African Americans would even have a PSA test (χ2 467.5, df 1, p < 
0.0001) and they are only 36.6% as likely to have a PSA at all compared to Caucasians 
(OR 0.366, 95%CI 0.333-0.402) (see Table 19).  
Table 18. Summary Count and Percentage for Study Group by Race. 
 
SEER RACE Group 
  Screening PSA 
n (%) 
Diagnostic PSA 
n (%) 
No PSA 
n (%) 
Total 
n (%) 
Caucasian                     29,896 (45.5) 33,718 (51.3) 2,124 (3.2) 65,738 (100) 
AA                                                                                2,314 (33) 4,136 (59) 589 (8) 7,039 (100) 
Total count 32,210 (44.3) 37,854 (52) 2,713 (3.7) 72,777 (100) 
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Characteristics of the independent variables for the two study groups are shown in 
Table 20 and demonstrate differences among sPSA and dPSA groups. For the variable 
age, the greatest variance is shown among younger men within the age category from 66 
to 69 years old with almost twice as many having dPSA tests as having sPSA tests (χ2 
974, df 1, p < 0.0001). This may be explained by less men of this age range participating 
in community screenings or perhaps these younger men are not visiting a physician until 
they become symptomatic.  The remaining levels within age were somewhat more 
balanced.  
Table 19. Summary Count and Percentage for Study Groups by Independent Variable. 
 
 
Group by Independent Variables Screening PSA Diagnostic PSA 
n (%) n (%) 
SEER Race 
Recode B 
Caucasian 29,896 (47) 33,718 (53) 
African American 2,314 (36) 4,136 (63) 
Age Group at 
Diagnosis Year  
66-69 7,994 (37) 13,444 (63) 
70-74 12,182 (49) 12,433 (51) 
75-79 8,249 (51) 7,855 (49) 
80-84 3,004 (49) 3,143 (51) 
85+ 781 (44) 979 (56) 
Historic Stage  In situ 158 (6) 2,514 (94) 
Localized 5 (71) 2 (29) 
Regional 24 (51) 23 (49) 
Localized/Regional 32,012 (48) 35,303 (52) 
Unstaged 11 (48) 12 (52) 
Grade I  (Gleason score ≤ 4) 1,861 (41) 2,688 (59) 
II (Gleason score 5-7) 30,349 (46) 35,166 (54) 
Marital Status Single, never married 1,830 (41) 2,582 (59) 
Married 23,937 (47) 27,323 (53) 
Separated 97 (38) 157 (62) 
Divorced 1,098 (42) 1,533 (58) 
Widowed 2,369 (45) 2,862 (55) 
Unknown 2,879 (46) 3,397 (54) 
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Previous definitions used by SEER for the individual stages of localized and 
regional tumors included those confined to the organ of interest and which had not yet 
extended beyond the outer membrane directly into surrounding organs or into the 
lymphatic system. In addition, SEER included all in-situ staged prostate cancers as non-
invasive tumors and that had also not yet penetrated the gland’s peripheral membrane or 
extended outside the membrane. Further, prior to 1994 prostate cancer cases were not 
coded using a stage variable at all; however, during the year 1994-1995 SEER made a 
change to the older variable historic stage and began using a combined variable for all 
local and regionally staged prostate cancer cases. The combined variable is called 
local/regional and is reserved only for prostate cancers by SEER. This combined code for 
stage is used for this study and has been recoded as a binary dichotomized variable. In 
reviewing the variable stage of Table 20, it is evident that a majority of men in both 
groups (96%) were diagnosed with localized/regional or early stage disease (χ2 1796.6 df 
4, p < 0.0001).  
Also for the variable grade, 93.5% of the men of both races were a grade II 
defined as a Gleason score between 5-7 (χ2 50, df 1, p < 0.0001). Further, the screening 
group is slightly more likely than the diagnostic group to receive a diagnosis of grade II 
(OR 1.25, 95%CI 1.17- 1.32).  
When reviewing the categorical variable marital status for this elderly population, 
it is noted that for all marital categories, a greater proportion of men were in the dPSA 
group. The greatest variance is seen among men who were separated with 62% among 
the dPSA group and 38% among the sPSA group (χ2 73, df 5, p < 0.0001). The second 
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greatest variance occurred among men in both the single/never married and divorced 
category (59% dPSA: 41% sPSA and 58% dPSA: 42% sPSA respectively). Interestingly, 
men who were married demonstrated the least amount of variance among groups. This 
same trend is seen throughout the literature where married men trended toward obtaining 
more screening PSA tests than men without a significant other.   
Table 21 shows the distribution of socioeconomic variables by group including 
summary statistics and significance. Statistically significant differences exist within all 
categories. For example, the mean for men of the screening group was only slightly less 
than the mean of the diagnostic group for lower education whereas the mean for men 
attending higher education levels was greater for the sPSA group than the dPSA group.  
In addition, the median income for the screening group was just greater than the 
diagnostic group and statistically equivalent (see Table 21). 
Overall, differences among group characteristics for the various treatments men 
received do not vary greatly. In fact, they coincide very well with Table 18 which shows 
treatments by race. For example, the majority of men in both groups shared the first three 
treatment choices of no radiation, radiation beam, or radioactive implants (sPSA 89% and 
dPSA 89.4%) with only a small portion choosing a combination of external beam plus a 
radioactive implant (7% for both groups; χ2 287, df 9, p < 0.0001). Over 97% of screened 
men and 96% of non-screened men elected not to have any sequence of combined 
radiation beam with surgery as their treatment choice. Recall that the variable radiation 
and surgery were also dichotomized either as a “1” a man had some combined therapy or 
a “0” defined as a man chose not to have any combination of surgery and radiation.      
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Table 20. Socioeconomic Status by Group (Percent by zip code Census Tract 2000). 
 
 Group 
sPSA dPSA 
  
 Before p-score 
adjustment 
Percent by zip 
code (Census 
Tract 2000) 
N  N non missing Mean 
Std. 
Dev. Min Max N  
N non 
missing Mean 
Std. 
Dev. Min Max 
N 
Total 
Mean  
p-value 
  32,210           37,854           70,064 t-tests 
Non High School 
Graduate 
  
30,974 16 10 0 100 
  
36,333 17 11 0 94 
  
<.0001 
High School only 30,974 26 10 0 80 36,333 27 10 0 80 <.0001 
Some College 
Education  30,974 29 7 0 100 36,333 28 7 0 100 <.0001 
College 
Education (4 
years) 
30,974 30 17 0 94 36,333 28 17 0 94 
<.0001 
Median Income 29,620 $38,396 $16,097 $7 $129,661 35,010 $37,101 $15,800 $7 $129,661 <.0001 
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 When reviewing surgery as a treatment option, a high percentage of men who had 
surgery during one of the time periods prior to 1997 or after 1998 for the coded variables 
Site Specific Surgery (1983-1997) or Surgery of Primary Site (1998 +) and very small 
percentages for all surgery types combined. Therefore, the two variables were 
transformed and re-coded as binary as previously described. However, for purposes of 
detailing variance Table 22 shows where this variance occurred between groups. For 
example, men who chose radical prostatectomy with lymph node dissection (dPSA 6.2% 
and sPSA 2.8%) show an overall statistically significant difference between groups 
(χ21493, df 17, p < 0.0001). Table 22 further describes variance in the choice of no 
cancer-directed surgery of which almost half of the men in the screening group and a 
third of the men in the diagnostic group chose (42% and 36%). A majority of men among 
both groups who elected to have surgery chose radical prostatectomy with overall 
significant differences in both groups (χ2 286, df 16, p < 0.0001).  
 For hormone therapy, Table 22 shows a very high percentage of men from both 
groups electing not to receive hormones 6 months leading up to their first PSA test (99% 
and 94% respectively). However, this percentage drops significantly during the following 
6 months afterwards where only 20% of the screening group and 65% of the diagnostic 
group do not take hormones. In addition, group differences exist in the distribution of 
men taking hormones during the same month as their PSA and being diagnosed (χ2 491, 
df 1, p < 0.0001). Expectantly and perhaps due to symptoms, the percentage of men in the 
dPSA group receiving hormones during the 6 months following their initial PSA rose  
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Table 21. Study Group Characteristics by Treatment. 
 
Group Characteristics by Treatment 
Group 
sPSA dPSA 
n (%) n (%) 
Radiation None 15,122 (47) 19,339 (51) 
Radiation Beam 8,685 (27) 10,096 (26.7) 
Radioactive implants 5,006 (15) 4,412 (11.7) 
Combination Radiation beam/implants 2,312 (7) 2,596 (7) 
Recommended, unknown if administered 342 (1) 440 (1.2) 
Unknown 339 (1) 508 (1.3) 
Radiation sequence 
with surgery 
No Radiation and/or cancer-directed surgery 31,438 (97.6) 36,491 (96.4) 
Radiation after surgery 683 (2) 1,229 (3.3) 
Site Specific Surgery 
(1983-1997) 
men part of next sequence SXPRIM1 (1998+) 28,439 (88.3) 29,539 (78) 
No surgical procedure 172 (0.53) 361 (1) 
Incisional, needle or aspiration biopsy of 
primary site 
1,936 (6) 3,496 (9.2) 
Unknown 7 (0.02) 103 (0.30) 
TURP, Cryoprostatectomy w/o lymph node 
dissection 
328 (1) 1,143 (3) 
Radical Prostatectomy w/o lymph node 
dissection 
318 (1) 535 (1.4) 
Radical Prostatectomy with lymph node 
dissection 
906 (2.8) 2,346 (6.2) 
Surgery of primary 
site (1998+) 
men part of previous sequence SSSurg (1983-
1997) 
13,832 (43) 18,212 (48) 
No cancer-directed surgery 13,375 (41.5) 13,525 (35.7) 
TURP, NOS 140 (0.43) 187 (0.5) 
TURP, cancer incidental finding during 
surgery; benign 
909 (2.8) 1,103 (2.9) 
TURP with cancer finding 307 (1) 460 (1.2) 
Cryoprostatectomy 100 (0.3) 124 (0.33) 
Group Characteristics by Treatment 
Group 
sPSA n(%) dPSA n(%) 
Surgery of primary 
site (1998+) 
continued 
Radical Prostatectomy 3,226 (10) 3,799 (10) 
Unknown 209 (0.65) 303 (0.8) 
Hormone at time of 
diagnosis 
No 31,755 (98.6) 35,566 (94) 
Yes 0 (0) 554 (1.5) 
Hormone 1-6 months 
after diagnosis 
No 6,487 (20) 24,596 (65) 
Yes 0 (0) 4,828 (13) 
  
almost 9 times over those men receiving hormones during the same month as their PSA 
(13% vs. 1.5%). In addition, men in the screening group waited until taking hormones 
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until greater than 6 months after their PSA and diagnosis. Finally, group differences in 
the distribution of hormones from 1-6 months were significant (χ2 1229, df 1, p < 
0.0001).  Group and race summary statistics were examined for twelve previously 
defined comorbid conditions (Klabunde, Legler et al., 2007). The twelve comorbid 
conditions were assessed from hospital claims and physician claims beginning when a 
man became a Medicare enrollee and through a one year period until he turned 66 years 
old.  All comorbid indices were summated according to the formula, 
Σ12i=1 = (Χ1Y1 + X2Y2 + X3Y3…+…X12Y12) 
where X is the weighted coefficient and Y is the comorbid condition. The comorbid 
condition is defined as either being present (value 1) or not being present (value 0) 
(Klabunde, Legler et al., 2007). In looking at group comparison, note that statistical 
values were determined for the ratio of men among the dPSA group to men among the 
sPSA group (dPSA/sPSA). In other words, each odds ratio has been determined for the 
likelihood that men of the dPSA group would have the comorbid condition present. The 
same method is applied to race by comorbid condition where African American men are 
the numerated group. In all cases, odds ratios show that the dPSA group was more likely 
than the sPSA group to have any of the conditions. For example, when looking at 
whether a man had a previous heart attack (old myocardial infarct), men among the dPSA 
group were 1.4 times more likely than men of the sPSA group to report this condition 
(OR 1.41, 95%CI 1.25-1.59, p < .0001). With the exception of having a prior heart attack 
and rheumatologic processes, African American men within the dPSA group experienced 
the same trend (see Table 23).  This may be explained by the fact that men who receive 
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results positive for cancer from a diagnostic PSA test could include greater proportions of 
unhealthier African Americans (have more comorbid conditions) and/or those who may 
not participate in regular annual health screening programs (Robbins et.al, 2000; Pinsky 
et.al, 2008).  
  Of particular interest, Table 23 shows that for the variables dementia and chronic 
renal failure, the dPSA group and African American men were nearly three times more 
likely to have the condition than their Caucasian counterparts. With the exception of 
rheumatologic processes, all comorbid conditions were statistically significant for the 
dPSA group before adjusting for propensity scores (p-score). As for race, all comorbid 
conditions except having had a recent heart attack, chronic obstructive pulmonary disease 
(COPD), and a rheumatologic disease were statistically significant for African Americans 
having the condition present. 
Statistical Modeling 
Logistic and Cox Regression: Before Propensity Analysis 
Select outputs from the logistic regression model for the full population sample of 
72,777 men before a propensity analysis was performed are shown below. Complete 
output tables for both the logistic and Cox regression models are found in Appendix A 
(see Appendix A). These two models are compared to logistic and conditional Cox 
regression models that do include a propensity analysis for evaluating the effects of using 
p-score adjustments. There were 32,210 screened men, 37,854 non-screened men, and 
5,470 missing cases leaving a total of 67,307 men for this final analysis. 
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Table 22. Summary Statistics of Group and Race by Comorbid Condition. 
 
  Group Race 
  dPSA/sPSA AA/Caucasian 
Comorbidity OR 95%CI χ 2 df 
p-
value OR 95%CI χ 2 Df 
p-
value 
Previous Myocardial 
infarct 1.41 1.25-1.59 31.3 1 <.0001 0.666 0.53-0.842 11.7 1 0.001 
Myocardial infarct 1.18 1.03-1.36 5.7 1 0.017 1.092 0.873-1.37 0.59 1 0.442 
CHF 1.79 1.62-1.99 130 1 <.0001 1.75 1.53-1.99 69.4 1 <.0001 
Peripheral Vascular 
Disease 1.33 1.19-1.48 26.9 1 <.0001 1.7 1.47-1.97 51 1 <.0001 
Cerebrovascular Disease 1.33 1.23-1.45 49.7 1 <.0001 1.31 1.16-1.47 18.8 1 <.0001 
COPD 1.32 1.25-1.39 94 1 <.0001 1.07 0.978-1.17 2.16 1 0.142 
Dementia 2.78 1.85-4.19 26.2 1 <.0001 2.74 1.81-4.15 24.5 1 <.0001 
Paralysis 1.97 1.4-2.75 16.2 1 <.0001 3.08 2.15-4.4 41.9 1 <.0001 
Diabetes 1.18 1.11-1.25 32.3 1 <.0001 2.23 2.06-2.39 462 1 <.0001 
Diabetes with Sequelae 1.22 1.075-1.38 9.54 1 0.002 2.45 2.1-2.86 136 1 <.0001 
Chronic Renal Failure 2.65 2.13-3.28 83.8 1 <.0001 3.17 2.55-3.93 123 1 <.0001 
Rheumatologic process 1.15 0.98-1.35 2.98 1 0.084 0.766 0.57-1.029 3.2 1 0.076 
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Table 24 shows the number of men that were included in the analysis and those 
that were not. The outcome variable for this model is mortality where a value of “1” is 
coded as dead and a value of “0” coded as alive with censoring applied at the study cut-
off date of December 31, 2005 for all Cox modeling. Also, categorical variables were 
entered in all modeling with the first level being assigned as the reference indicator 
variable. For example, the categorical variable race is coded binary with Caucasian men 
assigned a value of “1” and African American men a value of “2” and with Caucasian 
being considered the first level and therefore entered as the reference variable. The 
overall model coefficients are shown to be significantly different at entry (p<.0001). 
Further, model summary coefficients do not explain much of the categorization (Cox & 
Snell R2 3.7% and Nagelkerke R2 13.3%). The classification table shows the model only 
correctly predicted 60 deaths and incorrectly predicted 15 (see Table 24).  
 Select outputs from the Cox regression model for the non-propensity analysis are 
provided later in this chapter. Of the total available 67,307 men, 64,695 were censored 
because they were still alive at the study cut-off date of December 31, 2005. The total 
number of deaths included 2,612 men with 5,470 cases removed. Also, overall model 
coefficients from Cox regression to be statistically significantly different for each of the 
entry steps (p<.0001) are provided. In addition, select outputs from both the logistic and 
Cox regression models for the sample population without use of a propensity analysis are 
illustrated later as well. The logistic regression model without p-score adjustment resulted 
in statistically significant differences for screening tests and being African American (p = 
.001, p = .015) with the non-screened men being 17% more likely to die than the  
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Table 23. Select Outputs from the Logistic Regression Model: Non-Propensity Analysis. 
 
 
 
screened group (OR 0.853) and African American men were 19% more likely to die than 
Caucasian men (OR 1.194) (see Table 25 and Table 26). However the Cox regression 
model with no p-score adjustment reports no statistical differences in screening  
Case Processing Summary
*unweighted cases n Percent
selected cases Included in Analyis 67,307 92.5
Missing Cases 5,470 7.5
Total 72,777 100
Unselected cases 0 0
Total 72,722 100
a. if weight is in effect, see classification table for the total number of cases
Omnibus Tests of Model Coefficients
Chi-squareDf Sig.
Step 1 Step 2551.208 37 0
Block 2551.208 37 0
Model 2551.208 37 0
Model Summary
Step -2 Log likelihood
Cox & Snell R 
Square Nagelkerke R Square
1 19543.639a 0.037 0.133
a. Estimation terminated at iteration number 7 because parameter estimates changed by less than .001.
Classification Tablea
Observed Predicted Percentage 
Mortality Correct
0 1
Step 1 Mortality 0 64,680 15 100
1 2,552 60 2.3
Overall Percentage 96.2
a. The cut value is .500
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Table 24. Select Outputs from the Cox Regression Model: Before Propensity Analysis. 
 
 
 
 
Table 25. Select Outputs from Logistic and Cox Regression Models: Before Propensity 
Analysis. 
 
Regression Outputs for Screening and African American Men: Before Propensity Analysis 
  B S.E. Wald df Sig. 
Exp 
(B) 
Logistic Model        
 Being screened -.159 .048 10.929 1 .001 .853 
Being African 
American 
.177 .073 5.869 1 .015 1.194 
Cox Regression 
Model 
      
Being Screened -.053 .047 1.289 1 .256 .948 
Being African 
American 
.134 .070 3.650 1 .056 1.144 
Case Processing Summary
n Percent
eventa 2,612 3.6
censored 64,695 88.9
Total 67,307 92.5
cases with missing values 5,470 7.5
cases with negative time 0 0
0 0
Total 5,470 7.5
Total 72,277 100
Omnibus Tests of Model coefficientsa
chi 2 df sig. chi 2 df sig. chi 2 df sig.
50706.85 1830.3 37 0 1387 37 0 1387 37 0
a. beginning blok number 1> method = enter
change from 
previous step
change from 
previous block
cases censored before the 
earliest event in a stratum
a. Dependent Variable: survival time recode (total # of 
months)
neg.2 Log 
Likelihood
overall (score)
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and slightly trends toward a greater mortality rate when being African American (p = 
.256 and p = .056 respectively).     
The Propensity Analysis 
The first step in performing a propensity analysis involved running a multivariate 
logistic regression model using the treatment or intervention, a screening PSA test in this 
case, as the dependent variable against all relevant covariate independent variables and 
comorbid conditions to calculate individual p-scores for all subjects. Recall that the p-
score simulates randomization by adjusting for observed selection bias through matching 
(Rosenbaum & Rubin, 1983; Rubin 2002; D’Agostino, 1998). The results of this model 
are saved as a new data set and used as an input file during the matching phase described 
below. 
Once the propensity scores were calculated one-to-one matched pairs were 
created from men in the screened group (sPSA = 1, “yes’) to men from the non-screened 
group (sPSA = 0, “no”). A matching macro designed to perform propensity score 
matching using SPSS syntax was applied for this step. Original basic core elements of the 
program were created by Raynald Levesque (http://pages.infinit.net/rlevesqu/). 
Levesque’s program was adapted for use with propensity matching by John Painter 
(www.unc.edu/~painter). Using the macro requires input from researchers, namely input 
of the new data file created in the first step of the propensity analysis described above 
where the estimated p-scores were already computed. The matching macro uses a similar 
technique known as Mahalanobis metric matching where matches are created within a 
defined propensity score caliper width of 0.2 standard deviations on the estimated p-score 
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of the treatment case (Rubin, 2002). This technique has been referred to as a greedy 
procedure because once a match is found and a pair created, that pair is removed from 
future match considerations. It has been reported that greedy matching algorithms have 
shortcomings of their own, in that studies with greater numbers of cases than controls 
both of which having high p-scores may result in high numbers of poor matches (Luo, 
Gardiner, & Bradley, 2009).   
The current study was not subject to these pitfalls as the beginning total sample 
population was sufficiently large enough to trim all poorly matched pairs leaving only 
resultant one-to-one pairs of equal numbers and nearly perfectly matched in p-scores. 
Further, an additional self-imposed study threshold tolerance of ±5 percent difference in 
propensity scores was set with pairs falling outside the criterion being trimmed from the 
sample. Therefore, by applying an accepted published restricted caliper of estimated p-
scores being within ±0.2 standard deviations among pairs along with a self-imposed 
maximum difference in estimated p-scores of ±5 percent, it is believed that the resultant 
matched pairs were adequate for this study.   
After matching is completed, the macro sorts the total sample population by all 
available treatment cases (sPSA) and starting with the first case, searches from the pool 
of all possible non-treatment cases (dPSA) for either an exact propensity score match or a 
match having the closest p-score. Once a match is found, the pair is removed from further 
searches to prevent possible repeat matches. This process continues until each treatment 
case has been assigned a match with a non-treatment case.  
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Finally, a new dataset of matched cases to non-cases is created and stored as a 
separate file. The matched pairs created from the macro are shown with the black line 
representing the sPSA group and the white line the dPSA group in Figure 6. Propensity 
scores are plotted on the y-axis in ascending order beginning with zero and finishing at a 
value close to one. Imbalance in covariate distributions appears as divergence in the two 
lines indicating a poor match. The number of matched pairs is shown across the x-axis. 
From the beginning pool of 72,777 men, the matching macro found 61,948 matches thus 
creating 30,974 pairs (see Figure 6). The next step was to observe the quality of the 
matching for noting incomplete or inexact matching. Incomplete matching occurs if not 
all case subjects were matched and inexact matching occurs when if a match is formed by 
two dissimilar subjects (Rubin, 2002). It is observed in Figure 6 that the two curves begin 
separating near 25,000 after which they tend towards an inverse relationship possibly 
indicating incomplete or inexact matching and/or presence of additional unknown biases 
caused from unobserved covariates, in both cases obviously poor matches. These poorly 
matched pairs caused by either incomplete or inexact matching and the possible presence 
of unknown covariates could lead to problematic inferences and therefore decisions must 
be cautiously made for removing them from the study population (Rubin, 2002) (see 
Figure 6). For these reasons and because the numbers of matched pairs remains large, it 
was decided to trim an additional 5,974 pairs  as they exhibit poor matching and their p-
scores fell outside study criteria of ± 5 percent difference and outside the predefined 
caliper width of ±0.2 standard deviations. Therefore, the final trimmed matched sample 
of 25,000 pairs chosen for the remaining statistical testing and comparisons of this study.      
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Figure 6. Illustration of Propensity Score Match and Overlap. 
A final step in using a propensity analysis is to consider stratification of the 
sample into quintiles, especially in studies where matched pairs may be incomplete or 
inexact or there are multiple controls matched to a single case. Forming quintiles based 
on the closeness of propensity score allows a ranking of the pairs by setting boundaries 
that could provide additional detailed information and thus possible improvements in 
balancing covariate distribution and end-point outcomes. Additional improvements may 
be observed because now pairs within each quintile are compared against each other 
across a smaller sample size where the p-scores are closer in value than those observed 
over the full sample (Rubin, 2002). Although the current study retained a sufficiently 
large number of nearly equally matched pairs (25,000 pairs) and arguably, forming 
quintiles may not be necessary, however, benefits of creating quintiles are the ability to 
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compare results from within each and compare to overall model results. A potential 
drawback is that as the sample data are divided into quintiles, the count per race may be 
reduced, especially for under-represented minority groups. As expected, the numbers of 
African American men of this study did decline within each quintile 1 through 5. For 
example quintile 1 contains 8,960:2,558 Caucasians to African Americans and for 
quintiles 2 through 5 the ratios are 6,992:1,092, 10,780:716, 7,810:90, and 10,992:10, 
respectively.  
Creating the quintiles was done arbitrarily with care taken when examining the 
data in Figure 6 above. Points of inflection in the graph were chosen as boundaries for 
each quintile and can be seen in Figure 7. The vertical parallel lines in Figure 7 illustrate 
where these break points occurred and serve to define quintile samples.  For example, the 
first quintile was chosen at a point occurring just after the first shoulder as the two curves 
begin to rise and then flatten out again. In particular, quintile 1 contains 5,759 matched 
pairs. The remaining 4 quintiles were defined the same way with quintiles 2 through 5 
containing 4,042 pairs, 5,748 pairs, 3,950 pairs, and 5,501 pairs respectively. The first 
quintile is composed of the lowest p-scores and represents men least likely to be 
screened, whereas the fifth quintile is composed of the highest p-score representing men 
most likely to be screened. 
After completing the propensity analysis, further examination of whether or not p-
score adjustments are helpful can be evaluated by comparing the absolute standardized 
differences in before and after p-score adjustment. Comparing before and after estimated 
probabilities and calculating absolute standardized differences are proven methods for  
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Figure 7. Final Trimmed Matched Pairs. 
demonstrating balance of groups and overlap of covariates.   
Comparing standardized differences may be an improved method for assessing 
bias among individual covariates across groups rather than individual tests of significance 
that only compare the means of those covariates (Rubin, 2002; Love, 2001). For example, 
results from the multivariate logistic regression model without p-scores are compared 
with results from the logistic model with p-scores for the 25,000 matched pairings. A 
compilation showing before and after estimated probabilities for having a screening PSA 
test versus not having a screening PSA test and before and after calculations of the 
absolute standardized differences is listed below. Calculating the absolute standardized 
differences for continuous covariates is simply the difference in means in the two groups 
Final Trimmed Group Showing Balance (overlap): 
MaxDiff: 5% 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1 5001 10001 15001 20001 25001 30001
trimmed matched pairs (n = 25,000) 
 
sPSA
dPSA
189 
 
 
divided by the standard deviation of the groups. And for the categorical variables, the 
absolute standardized difference is the difference in proportions of the two groups 
divided by the standard deviation of two proportions (Rubin, 2002). Further, it is 
common to express standardized differences in percentages with values within ±10% 
being the normally accepted threshold limit (Rubin, 2002; Love, 2001).  
Of the 39 predictor variables 36 were significantly different (p < 0.05) before 
matching which implies for those observed characteristics men were dissimilar resulting 
in unexplainable variance because of the presence of unknown biases (see Table 27). 
After matching, only 10 predictor variables remained significantly different and of those 
10 remaining different, three were from the categorical variable age (men 66-69 years, 
80-84 years, and 85 or older), one from the variable grade, two from the categorical 
variable marital status (single/never married and married), and three from the variable 
treatment (no radiation, radioactive implants, and surgery). The 10th variable remaining 
statistically different after p-score adjustment was median income from the 
socioeconomic variables.  
The variable hormone was statistically different before matching whereas 
afterwards, its resultant value was a constant as no men from the final matched data set 
had taken hormones (value = 0, “no”). In addition, the distributions for all the comorbid 
conditions became balanced after matching (see Table 27). Overall, it appears that using 
propensity matching has removed much of the bias between screened and non-screened 
men and for race. However, it is noted that for the categorical variable age, some 
unknown biases may still remain for three of the five categorical levels. Knowing that  
190 
 
 
Table 26. Variable Characterization of Significance and Percent Absolute Standardized 
Differences for Before and After Matching. 
 
Having a Screening PSA test Before Match After Match 
 p-value 
Abs. 
Std. Diff 
(%) p-value 
Abs. Std. 
Diff (%) 
Race <.0001 46.3 0.385 0.90 
Age     
66-69 yrs. <.0001 23.5 <.0001 0.22 
70-74 yrs. <.0001 10.5 0.770 0.84 
75-79 yrs. <.0001 11.4 0.174 2.2 
80-84 yrs. <.0001 3.5 0.001 3.3 
85+ yrs. <.0001 1.3 0.023 0.0 
Disease Extent     
Grade <.0001 22.6 0.044 7.5 
Stage <.0001 129.3 1.000 0.0 
Marital status     
Single/never married <.0001 18.74 0.002 5.5 
Married <.0001 5.63 0.038 4.42 
Separated 0.301 31.4 0.796 7.0 
Divorced 0.833 17.5 0.698 3.2 
Widowed <.0001 2.87 0.968 3.0 
Unknown <.0001 0.42 0.544 0.2 
Treatment Options     
None <.0001 8.4 <.0001 3.8 
Radiation beam <.0001 11.1 0.353 6.1 
Radioactive implant <.0001 0.7 <.0001 0.89 
Radiation/implant combination <.0001 1.2 0.297 0 
Radiation recom. unknown if taken 0.023 1.84 0.903 0.90 
Radiation/surgery combined <.0001 7.4 0.118 1.5 
Having any surgery <.0001 46.7 0.006 5.1 
Hormones <.0001 61.2 Constant  0 
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Table 27: continued. 
 
Having a Screening PSA test Before Match After Match 
Social Economic Variables     
Non-high school graduate <.0001 9.5 0.876 6.0 
High school graduate <.0001 10.0 0.923 6.0 
Some college <.0001 14.3 0.518 0.0 
4 yrs. College <.0001 11.76 0.568 5.8 
Median income <.0001 12.51 0.022 4.9 
Comorbid Conditions     
Previous myocardial infarct <.0001 4.38 0.253 1.0 
Myocardial infarct 0.017 1.85 0.934 0.08 
CHF <.0001 9.1 0.434 0.7 
Peripheral vascular disease <.0001 4.1 0.210 1.2 
Cerebrovascular disease <.0001 5.7 0.114 1.5 
COPD <.0001 8.4 0.063 1.1 
Dementia <.0001 4.0 0.378 0.80 
Paralysis <.0001 3.1 0.753 0.28 
Diabetes <.0001 4.9 0.149 1.5 
Diabetes with sequelae 0.002 2.4 0.939 0.07 
Chronic renal failure <.0001 7.13 0.893 0.12 
Rheumatologic process 0.084 1.33 0.243 1.1 
 
age is a predictor of mortality in and of itself, it was warranted to examine the variable 
separately for evaluating its effects on mortality among race and prostate cancer. 
Therefore, a comparison evaluation was performed by creating an age matched - 
propensity matched analysis and is detailed later. 
Figure 8 is a plot of the standardized differences presented in Table 27 where it is 
noted that 16 of the 39 covariates resulted in differences greater than ±10 percent before 
the propensity analysis while all 39 met threshold limits after the propensity analysis was 
applied (see Figure 8). The white dots form a line showing covariate imbalance before p- 
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Figure 6. Absolute Standardized Differences before and after Propensity Matching. 
 
score adjustment as noted in the amount of deviation away from the zero line, whereas 
the black dots form a line showing improved balance after adjusting with p-scores as they 
collectively align closer to the zero marker suggesting that most selection bias has been 
removed. Obviously standardized differences of zero reflect perfect balance in groups 
and overlap in covariate distribution.       
Logistic and Cox Regression: After Propensity Analysis 
At this point, the propensity analysis is complete and more traditional statistical 
methods may be applied and assessed. For example, logistic regression and conditional 
Cox regression models using propensity score adjustments were generated for the full 
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data set of 25,000 matched pairs (labeled FM) as well as for each quintile. Results from 
the full data set model (FM) along with results from the models for each quintile were 
compared to the full models developed without a propensity analysis applied. 
Conditional Cox regression models allow censoring for time to event to occur and 
can account for dependency of matched pairs by using a dummy variable created for each 
pair. For example, a dummy variable called “pairs” was created where each pair was 
numbered in sequence and ordered according to the numbering. Pairing variables were 
created for the full sample data set (FM) and for each of the quintile data sets.  
Selected summary statistics for the logistic regression and conditional Cox 
regression models are shown for the FM data and for all quintiles (Q1-Q5) respectively. 
Complete output results from each model appear in Appendices B through G. Panel A 
contains model summary statistics of the Cox & Snell R2 and Omnibus Model 
Coefficients from the logistic regression model.  The square of the correlation coefficient, 
R, is used in linear regression as a tool to describe the amount of variance accounted for 
by the model. The Cox & Snell R2 are similar to the correlation coefficient of linear 
regression models except that because the results are binary in logistic regression models, 
these coefficients may be viewed, cautiously, as being related to a proportion of how well 
the model categorized or classified mortality. The overall model fit for each quintile also 
shows significant differences as may be expected in models containing a majority of 
predictor variables contributing little or no significance to the overall model (see Table 
28). Panel B of Table 28 shows model coefficients from the conditional Cox regression 
model. In particular, the FM model and all five quintiles remained statistically different  
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Table 27. Model Summary and Omnibus Coefficients: A - Multivariate Logistic 
Regression, B - Conditional Cox Regression Models for Quintile. 
 
 
from the overall step through each change in entry.  Summary results from the logistic 
regression model for the FM data set and for each quintile show that 50,000 men had no 
missing data and 1,577 men were observed as dying with the model predicting only 4 
deaths, 3 of which were correctly predicted as being dead. In looking at quintile 1, there 
were 11,518 men (5,759 pairs) and zero missing cases among which 382 men were 
A: Logistic Regression Model Summary
Step -2 Log likelihood
Cox & Snell 
R Square Nagelkerke R Square
FM 13312.94a 0.014 0.058
Q1 3001.252a 0.034 0.133
Q2 2138.297a 0.019 0.076
Q3 3366.457a 0.015 0.058
Q4 2035.308a 0.009 0.039
Q5 2586.141a 0.007 0.031
A: Logistic Regression Omnibus Tests of Model Coefficients
 Chi-square df Sig.
FM Step, Block, Model 713.126 33 0
Q1 Step, Block, Model 399.392 36 0
Q2 Step, Block, Model 153.657 35 0
Q3 Step, Block, Model 178.886 34 0
Q4 Step, Block, Model 72.722 33 0
Q5 Step, Block, Model 73.311 32 0
B: Conditional Cox Regression Omnibus Tests of Model Coefficientsa
-2 Log LikelihoodOverall (score) Change From Previous Step Change From Previous Block
Chi-square df Sig. Chi-square df Sig. Chi-square Df Sig.
FM  1006.15    159.52 31 0 180.21 31 0 180.214 31 0
Q1   205.389 73.46 34 0 95.437 34 0 95.437 34 0
Q2       87.83 62.43 31 0.001 88.229 31 0 88.229 31 0
Q3   229.242 56.66 31 0.003 66.038 31 0 66.038 31 0
Q4   118.969 52.081 32 0.014 66.795 32 0 66.795 32 0
Q5   153.410 60.061 26 0 75.328 26 0 75.328 26 0
a. Beginning Block Number 1. Method = Enter
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observed as having died with the model’s predicted comparison of nine deaths. Of these 
nine, the model correctly predicted seven and incorrectly listed two men as dead with the 
remaining 380 men going undetected.  The model’s overall percentage of correct 
mortality prediction was 96.7 percent. This is most likely a ceiling effect in that it may be 
the same result laymen would predict merely by stating that every man would live. 
Ceiling effects are sometimes difficult to improve upon in future modeling. The 
remaining quintiles show similar results (see Table 29). 
Additional summary statistics from the logistic regression and conditional Cox 
regression models for the FM and each quintile show no significant differences in race 
and mortality; however, regarding being screened, slight statistically significant 
differences were noted among screening distributions and mortality; with non-screened 
men (β = -0.140) being approximately 0.87 times as likely to die (OR=0.87, p=.007). 
Results for the quintile data resulted in no statistically significant differences in mortality 
between screened and non-screened (sPSA vs. dPSA) men for all quintiles with the 
exception of number three which resulted in statistically significant differences at p=.004. 
It is noted that within quintile 3, screened men were almost 0.26 times as likely to die 
(OR 0.743) or similarly, non-screened men were almost 1.35 times more likely to die 
than screened men (OR 1/0.743) as indicated by a negative unstandardized beta 
coefficient (β) of -0.297. The beta coefficient represents the slope of a line showing 
direction of predictor distribution for significance with the odds ratio Exp (β) showing the 
impact of those differences. For example, a positive slope would have an odds ratio 
greater than one and a negative slope would have an odds ratio of less than one. 
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Table 28. Summary Classification for FM and Quintiles. 
 
Logistic Regression 
FM 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in analysis 50,000 100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 50,000 100 Observed 0 1 
    Mortality 0 48,419 1 100.0 
    1 1,577 3 .2 
      Overall Percentage     96.8 
 
Quintile 1 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in analysis 11,518 100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 11,518 100 Observed 0 1 
    Mortality 0 11,127 2 100 
    1 382 7 1.8 
      Overall Percentage     96.7 
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Table 29: continued. 
 
Quintile 2 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in analysis 8,084 100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 8,084 100 Observed 0 1 
    Mortality 0 7,825 0 100 
    1 259 0 0 
      Overall Percentage     96.8 
Quintile 3 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in analysis 11,496 100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 11,496 100 Observed 0 1 
    Mortality 0 11,085 0 100 
    1 411 0 0 
      Overall Percentage     96.4 
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Table 29: continued. 
 
Quintile 4 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in analysis 7,900 100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 7,900 100 Observed 0 1 
    Mortality 0 7,666 0 100 
    1 234 0 0 
      Overall Percentage     97 
Quintile 5 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in analysis 11,002 100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 11,002 100 Observed 0 1 
    Mortality 0 10,715 0 100 
    1 287 0 0 
      Overall Percentage     97.4 
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The remaining quintiles of 2, 4, and 5 show similar results with no statistically significant 
differences in screened versus non-screened men and mortality. Regarding race and the 
logistic regression model, there were no statistically significant differences among race 
and mortality for the FM and all quintiles when using p-score adjustment (see Table 30). 
Of particular interest, the fifth quintile resulted in a large regression coefficient (slope β), 
a large standard error for the coefficient (S.E.), and a large p-value that may be attributed 
to the vast difference in the proportion of Caucasian men to African American men in the 
sample (10,992:10, Caucasian men: African American men, respectively).  
Table 30 also shows similar results for the conditional Cox regression model with 
no statistically significant differences for the FM model and any of the five quintiles 
regarding men being screened and among race. However, quintile 5 resulted in a constant 
value for race and mortality with no other data reported, where again, it is believed that 
these extreme values and constancy for race of quintile five may be due to the low 
proportion of African American men in this sample (10,992:10). 
AGE Matched Models: After Propensity Analysis 
Because age is a known predictor of mortality and because initial model results 
within the sample population of this study may have retained unknown biases after the 
propensity analysis was applied, it was decided to examine age in a separate analysis 
using age matched and propensity matched pairings within quartiles. The fourth and 
fifth age category were combined because of too few men in the age group of over 85 
years in an attempt to keep the number of men per number of predictor variables 
sufficient enough to reduce the chances of introducing new unknown biases from an 
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Table 29. Summary Statistics for Logistic and Conditional Cox Regression on FM and Quintiles on PSA Screening and 
African American Men: After Propensity Analysis. 
 
Logistic Regression Output for Screening and African American Men 
  Β S.E. Wald df Sig. Exp(β) 
FM       
being screened -.140 .052 7.282 1 .007 .870 
being African American .058 .099 .342 1 .559 1.060 
Quintile 1       
 being screened -.196 .108 3.321 1 .068 .822 
being African American .148 .159 .861 1 .353 1.159 
Quintile 2        
being screened -.101 .128 .618 1 .432 .904 
Being African American .339 .520 .424 1 .515 1.403 
Quintile 3        
being screened -.297 .102 8.407 1 .004 .743 
being African American .551 .375 2.155 1 .142 1.735 
Quintile 4        
being screened .075 .142 .277 1 .599 1.077 
being African American -.608 1.194 .259 1 .611 .545 
Quintile 5        
being screened -.086 .143 .358 1 .549 .918 
Being African American -16.443 14180 .000 1 .999 .000 
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Table 30: continued. 
 
Conditional Cox Regression Adjusted for Matched Pairs on Screening and African American Men 
 Β S.E. Wald df Sig. Exp(β) 
FM       
Being screened -.001 .078 .000 1 .993 .999 
Being African American -.644 .369 3.040 1 .081 .525 
Quintile 1       
Being screened .019 .185 .010 1 .919 1.019 
Being African American 2.918 4.258 .470 1 .493 18.506 
Quintile 2       
Being screened -.292 .316 .856 1 .355 .747 
Being African American -1.215 39.584 .001 1 .976 .297 
Quintile 3       
Being screened -.182 .251 .523 1 .469 .834 
Being African American -.981 21.664 .002 1 .964 .375 
Quintile 4       
Being screened .646 .891 .526 1 .468 1.909 
Being African American -9.760 71.167 .019 1 .891 .000 
Quintile 5       
Being screened .508 .660 .593 1 .441 1.663 
Being African American    0a   
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under-represented sample size. All matched pairings created previously from 
predetermined p-scores were maintained with subsequent formation of quartiles for age 
created by using the categorical levels of age. For example, men previously matched by 
p-score were kept for the age analysis if they were also of the same age category. If a pair 
was matched by p-score but not of the same age category, they were trimmed from the 
sample leaving only p-score and age matched pairings. Therefore, matched pairs were 
formed where men aged 66-69 years formed the first age quartile (AQ1), men aged 70-74 
years formed AQ2, men aged 75-79 years formed AQ3, and all men over 80 years 
formed AQ4. In addition, men who were not paired by age in the first matched pairings 
were trimmed from the age quintiles. The resultant sample of age matched and propensity 
matched pairings for age categories contained 20,232 men (10,116 pairs). Table 31 is an 
output of frequency and percentages showing the results of the age quartiles.  
Table 31. Frequency Count for Age Matched Quartiles. 
 
Age Quartiles Frequency Percent Valid 
Percent 
Cumulative 
Percent 
AQ1(66-69) 9,392 46.4 46.4 46.4 
AQ2 (70-74) 7,058 34.9 34.9 81.3 
AQ3 (75-79) 3,118 15.4 15.4 96.7 
AQ4 (>80) 664 3.3 3.3 10 
Total 20,232 100 100 100 
 
The final trimmed and combined age quartiles were thus created as AQ1-AQ4 for 
men age 66-69 years, 70-74 years, 75-79 years, and over 80 years as shown in Figure 9. 
The figure illustrates the numbers of men within each age category decreasing for each 
age group with the majority being within the first and second age groups of 66-69 years  
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Figure 9. Final Bar Plot of Frequency Count for Age Matched Quartiles. 
 
and 70-74 years. The last two age categories contained fewer men but remained a large 
enough sample to maintain statistical modeling providing sufficient results. Model 
summary and omnibus model coefficients from both the logistic and  conditional Cox 
regression models appear in panel A and panel B below for each age quartile. Selected 
summary statistics from the logistic and conditional Cox regression model for the 
screened and non-screened group on mortality as well as for race on mortality for each 
age quartile are provided below with complete output tables presented in Appendices H 
through K.  
In particular, Table 32 panel A shows that overall model coefficients from the 
logistic regression model were statistically significantly different for all quartiles with the  
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Table 30. Model Summary and Omnibus Coefficients for Age Quartiles: A: Logistic 
Regression and B: Conditional Cox Regression. 
 
A: Model Summary from Logistic Regression 
Step -2 Log likelihood Cox & Snell R2 Nagelkerke R2       
AQ1 1698.70 0.007 0.041       
AQ2 1601.98 0.007 0.035       
AQ3 960.51 0.026 0.092       
AQ4 274.24 0.033 0.093       
A: Logistic Regression Omnibus Tests of Model Coefficients  
  Chi2 df Sig.      
AQ1 Step, Block, Model 65.739 29 0.00      
AQ2 Step, Block, Model 52.299 28 0.004      
AQ3 Step, Block, Model 82.214 28 0.00      
AQ4 Step, Block, Model 22.529 26 0.659      
B: Cox Regression Omnibus Tests of Model Coefficientsa 
Likelihood Overall (score) Change from Prev. Step Change from Prev. Block 
 Chi2 df Sig. Chi2 df Sig. Chi2 df Sig. 
AQ1 140.02 28.471 28 0.440 0 28 0.10 0 28 0.10 
AQ2 103.04 26.109 26 0.457 34.203 26 0.13 34.203 26 0.13 
AQ3 54.384 29.175 27 0.352 39.884 27 0.053 39.884 27 0.053 
AQ4 33.271 19.424 21 0.558 0 21 1.00 0 21 1.00 
a. Beginning Block Number 1 Model = Enter 
 
exception of the fourth for men over 80 years (p = .659) while Panel B of Table 32 shows 
no significant differences in coefficients for all age quartiles from the conditional Cox 
regression model.   
Additional summary statistics for the classification outputs from the logistic 
regression model are shown in Table 33 for each age quartile on mortality. The table 
shows a ceiling effect for each quartile’s correctly predicted overall mortality percentage 
of no less than 94.1% (AQ4). Summary statistics from both the logistic and conditional 
Cox regression model for each age quartile are presented later in the chapter. Results 
from the logistic regression model show no statistically significant differences in 
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Table 31. Logistic Regression Summary Classification for Age Quartiles. 
 
 
 
Logistic Regression 
AGE Quartile 1 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in 
analysis 
9,392 100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 9,392 100 Observed 0 1 
    Mortality 0 9,214 0 100 
    1  178 0 0 
      Overall Percentage     98.1 
AGE Quartile 2 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in 
analysis 
7,058 
 
100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 7,058 100 Observed 0 1 
    Mortality 0 6,88
1 
0 100 
    1 176 1 .6 
      Overall Percentage     97.5 
AGE Quartile 3 
Case Processing 
Summary 
Classification Table 
      Block 1 : Method = ENTER 
Included in analysis 3,11
8 
100 
  
Predicted 
Missing Cases 0 0 Mortality 
Percentage Correct Total 3,11
8 
100 Observed 0 1 
    Mortality 0 2,994 0 100 
    1 123 1 .8 
      Overall Percentage 
  
  96.1 
AGE Quartile 4 
Case Processing Summary Classification Table 
      Block 1 : Method = ENTER 
Included in analysis 664 100 
  
Predicted 
Missing Cases 0 0 Mortality Percentage 
Correct Total 664 100 Observed 0 1  
    Mortality 0 625 0 100 
    1 39 0 0 
      Overall Percentage     94.1 
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mortality among screened and non-screened men and among race and mortality for any 
of the four age quartiles. Regarding the conditional Cox regression model, Table 34 
shows no significant differences in mortality for screening and race in all four age 
quartiles. 
Table 32. Summary Statistics from Logistic and conditional Cox Regression for Age 
Quartiles on PSA Screening and African American Men: After Propensity Analysis. 
 
Logistic Regression Output for Screening and African American Men 
  B S.E. Wald Df Sig. Exp (B) 
Age Quartile 1       
 Being screened -.088 .153 .332 1 .565 .916 
Being African American .165 .249 .438 1 .508 1.179 
Age Quartile 2       
Being screened -.122 .155 .617 1 .432 .885 
Being African American .546 .285 3.673 1 .055 1.726 
Age Quartile 3       
Being screened -.231 .191 1.471 1 .225 .794 
Being African American -.361 .610 .351 1 .554 .697 
Age Quartile 4       
Being screened -.115 .350 .109 1 .741 .891 
Being African American -.138 1.077 .016 1 .898 .871 
Cox Regression Adjusted for Matched Pairs on Screening and African American Men 
 B S.E. Wald Df Sig. Exp (B) 
Age Quartile 1       
Being screened .000 .243 .000 1 1.000 1.000 
Being African American .000 54.375 .000 1 1.000 1.000 
Age Quartile 2 B S.E. Wald Df Sig. Exp (B) 
Being screened -.076 .350 .047 1 .829  
Being African American 4.731 3.763 1.581 1 .209 113.39 
Age Quartile 3       
Being screened -.719 .622 1.338 1 .247 .487 
Being African American -5.51 5.535 .991 1 .320 .004 
Age Quartile 4       
Being screened .000 1.200 .000 1 1.000 1.000 
Being African American .000 12.920 .000 1 1.000 1.000 
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The Non-Cancer Group Analysis 
The second part of this study included examining the same effects of screening 
PSA tests on men without prostate cancer. These men were pooled from the 
SUMDENOM files provided by the SEER-Medicare data linkage project. The NCI 
created this file from demographic and entitlement information for Medicare 
beneficiaries who do not have cancer. The file is created from a random 5 percent sample 
of Medicare beneficiaries residing in the same SEER areas and include years of 
eligibility, unique health insurance claim numbers (HIC), dates of birth, dates of death, 
sex, race, states of residency, enrollment in part A and/or Part B, and enrollment in 
HMOs.  
The file contained 263,548 patient records among which 163,501 were 
immediately excluded because of not being either Caucasian or African American. 
Another 9,032 men were excluded for other various reasons that included either not being 
in both Part A and Part B of Medicare, being in an HMO, or having been treated for 
prostate cancer. Unfortunately, it is common for some men to either be clinically 
misdiagnosed from false positive screening tests that result in treatment or to start 
treatment without first having the cancer pathologically confirmed both of which may be 
a leading cause of over utilization of treatment. Final exclusions were men who had other 
malignancies diagnosed, men with incomplete or insufficient diagnoses, and men who 
had no validated date of death recorded leaving a sample population of 91,015 men. 
Further analysis of the sample population determined numerous cases with missing 
values. In particular, men with missing values in all variables were trimmed reducing the 
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sample population to 15,557 men. From this sample, there were a few men with missing 
values from the socioeconomic variables so it was decided to impute these missing 
values. Therefore, the final trimmed data set with imputed missing values resulted in a 
sample population size of 15,557 men.   
The process for evaluating prostate screening effects for the non-cancer cases was 
the same as previously noted for the cancer cases in that, after sample selection, men 
were grouped according to the algorithm in Figure 4 above either as being screened 
(sPSA) or not screened (dPSA). After groups were formed, a traditional logistic 
regression with no propensity adjustment was performed as a base model in which to 
compare other models that did include a propensity analysis. The next step was to 
perform the propensity analysis on the final selected sample population of 15,557 men in 
the same manner as for the cancer cases namely, to calculate estimated p-scores, perform 
a match for creating pairs, and run both logistic and conditional Cox regression models 
for all subsequent model comparisons.   
Demographics and Summary Statistics 
Table 35 shows frequency statistics for group and race. Out of the total 15,557 
men, there were 11,341 (72.9%) men from both races who elected to be screened 
regularly and 4,216 (27.1%) men who received diagnostic PSA screenings. Regarding 
race, the table shows that the sample contained almost 92 percent Caucasians and only 
slightly greater than 8% African Americans. These percentages are similar to the 
percentages observed among men within the prostate cancer analysis where the larger 
sample size of 72,777 men approximated 90 percent and 10 percent respectively.     
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Table 33. Summary Count for Group and Race: Non-Cancer Group. 
 
Statistics for sPSA 
N Valid 15,557  
 Missing 0  
sPSA 
  Count Percent Valid Percent Cumulative Percent 
Valid dPSA 4,216 27.1 27.1 27.1 
 sPSA 11,341 72.9 72.9 100 
 Total 15,557 100 100  
Statistics for Race 
N Valid 15,557    
 Missing 0    
Race 
  Frequency Percent Valid Percent Cumulative Percent 
Valid Cauc. 14,276 91.8 91.8 91.8 
 AA 1,281 8.2 8.2 100 
 
Table 36 illustrates the percentage of men for screening and race by each 
comorbid condition. Interestingly, it is noted that screened men and non-screened men 
were evenly proportioned on each comorbid condition with similar results appearing for 
race. As seen in the table, a majority of men within this non-cancer sample do not have 
any of the comorbid conditions (see Table 36).  
An analysis of variance (ANOVA) between the screened and non-screened men 
for the socioeconomic variables (SES) (Census 2000) demonstrated statistically  
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Table 34. Summary Percent for Screened Men and Race by Comorbid Condition: Non-
Cancer Group. 
 
Comorbid Condition 
Screened Race 
No Yes Caus. AA 
% % % % 
Myocardial Infarction No 94.4 93.4 93.6 94.9 
Yes 5.6 6.6 6.4 5.1 
Old Myocardial Infarction No 91.4 90.7 90.7 92.5 
Yes 8.6 9.3 9.3 7.5 
CHF  No 86.6 87.9 87.9 84.2 
Yes 13.4 12.1 12.1 15.8 
Peripheral Vascular Ds. No 94.5 93.8 95.0 93.4 
Yes 5.5 6.2 6.0 6.6 
Cerebro Vascular Ds. No 87.4 87.2 87.4 85.9 
Yes 12.6 12.8 12.6 14.1 
COPD  No 79.6 80.7 80.4 80.3 
Yes 20.4 19.3 19.6 19.7 
Dementia No 98.0 98.4 98.4 96.7 
Yes 2.0 1.6 1.6 3.3 
Paralysis No 96.6 97.3 97.3 94.7 
Yes 3.4 2.7 2.7 5.3 
Diabetes  No 82.4 82.3 82.6 78.5 
Yes 17.6 17.7 17.4 21.5 
Diabetes Sequelae No 95.5 96.3 96.3 93.4 
Yes 4.5 3.7 3.7 6.6 
Chronic Renal Failure No 97.5 98.4 98.2 96.7 
Yes 2.5 1.6 1.8 3.3 
Rheumatologic Process No 99.0 98.7 98.7 99.1 
Yes 1.0 1.3 1.3 0.9 
 
significant differences in the distribution for men never completing high school (p=.017) 
and those having only some college education (p=.002). Regarding race, the ANOVA of 
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Table 37 illustrates that there were statistical significant differences for all SES variables 
with the exception of those who graduated from high school (p=0.103).  
Table 35. Analysis of Variance for Screening and Race on Socioeconomic Variables: 
Non-Cancer Group (Census Tract 2000). 
 
 
 
ANOVA 
 
sPSA Sum of Squares Df Mean Square F Sig. 
NonHighSchoolGrad Between Groups 562.6 1 562.6 5.65 .017 
HighSchool Between Groups 116.0 1 116.0 2.08 .149 
SomeCollege Between Groups 384.1 1 384.1 9.36 .002 
College4yrs Between Groups 194.2 1 194.2 1.35 .244 
Median Income Between Groups 354,524,101.3 1 354,524,101.3 1.25 .263 
 
Race Sum of Squares Df Mean Square F Sig. 
NonHighSchoolGrad Between Groups 25946.240 1 25946.240 265.18 .000 
HighSchool Between Groups 147.774 1 147.774 2.65 .103 
SomeCollege Between Groups 2829.700 1 2829.700 69.22 .000 
College4yrs Between Groups 14927.773 1 14927.773 105.03 .000 
Median Income Between Groups 35393920742.2 1 35393920742.2 126.023 .000 
 
212 
 
 
Statistical Modeling 
Logistic and Cox Regression: Before Propensity Analysis 
Table 38 lists select summary statistics from the multivariate logistic and Cox 
regression models for the non-cancer group without a propensity analysis applied. 
Complete output tables for both models are listed in Appendix L.  Table 38 shows 
statistically significant differences in mortality for both the logistic and Cox regression 
models for screening and race. For example, the logistic model reported a greater overall 
mortality rate for non-screened men being approximately 29% more likely to die than 
screened men (OR 0.775, β = -0.255, p<.0001) and that African American men had a 
higher overall mortality rate with an odds ratio of 1.42 (p<.0001).  Because this is a group 
of men without cancer, an explanation could be that men who chose screening were 
healthier and/or there is a survival benefit associated with early detection methods such 
as screening.    
Although the Cox regression model showed greater overall mortality for screened 
men, the difference trended only slightly greater with an odds ratio of nearly one and a 
direction also close to equal as indicated by a near zero slope in the beta coefficient (OR 
1.09, β = .085, p=.002). Regarding race, African American and Caucasian men also 
trended toward being equally likely to die with a similar odds ratio of 1.09 and p=.046 
(see Table 38).   
The Propensity Analysis 
The p-scores for the men without prostate cancer were calculated first followed by 
the creation of a matched pair data set.  Finally, the newly formed data set was evaluated 
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Table 36. Select Outputs from Logistic and Cox Regression Models: Non- Cancer Group 
Before Propensity Analysis. 
 
 
Logistic Regression Case Processing Summary
Unweighted Casesa N Percent
Selected Cases Included in Analysis 15,557 100
Missing Cases 0 0
Total 15,557 100
Unselected Cases 0 0
Total 15,557 100
a. If weight is in effect, see classification table for the total number of cases.
Cox Regression Case Processing Summary
N Percent
Cases available in analysis Eventa 6,754 43.40%
Censored 8,803 56.60%
Total 15,557 100.00%
Cases dropped Cases with missing values 0 0.00%
Cases with negative time 0 0.00%
Censored cases before the 0 0.00%
Total 0 0.00%
Total 15,557 100.00%
a. Dependent Variable: survival months
Categorical Variables Codings both Logistic and Cox Regression
Frequency Parameter coding
-1 -2 -3 -4
Age category 66-69 yrs. 750 0 0 0 0
70-74 yrs. 2074 1 0 0 0
75-79 yrs. 2873 0 1 0 0
80-84 yrs. 5920 0 0 1 0
85+ yrs. 3940 0 0 0 1
Race 1 Cauc. 14276 0
2 AA 1281 1
Regression Outputs for Screening and African American Men: Non Cancer Group: Before Propensity Analysis
B S.E. Wald Df Sig. Exp(B)
Logistic Model 
 Being screened -0.255 0.04 40.118 1 0 0.775
Being African American 0.352 0.066 28.187 1 0 1.422
Cox Regression Model
Being Screened 0.085 0.028 9.395 1 0.002 1.089
Being African American 0.09 0.045 3.964 1 0.046 1.094
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using logistic regression and conditional Cox regression. Before formal analysis, it was 
again helpful to examine how well the propensity scores overlapped or how well the two 
screening groups were balanced and matched. From the sample selection of 15,557 men 
of the non-cancer group, a final matched data set containing 8,426 men or 4,213 almost 
perfectly matched pairs was achieved. As seen in Figure 10, a plot of the propensity 
scores illustrates balance between groups. The dark thick line is the screened group 
(sPSA) and the light grey solid line overlays exactly on top and represents the non-
screened group (dPSA).    
 
Figure 7. Plot of p-scores for sPSA and dPSA Groups: Non-Cancer Group after 
Propensity Analysis. 
 
The same qualitative restrictions applied to the non-cancer group as did for the 
men with prostate cancer, namely, the absolute standardized differences of ±10 
percent for before and after matching and the self-imposed absolute differences in p-
scores of ±5 percent. Table 39 lists the absolute standardized differences. The table  
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Table 39. Variable Characterization of Significance and Percent Absolute Standardized 
Differences for Before and After Matching: Non-Cancer Group. 
 
Having a Screening PSA test Before Match After Match 
 
 p-value 
Abs. Std. 
Diff (%) p-value 
Abs. Std. 
Diff (%) 
Race <0.0001 45 0.447 0.02 
Age - - - - 
66-69 yrs. <0.0001 1.41 .02 4.0 
70-74 yrs. <0.0001 5.9 .237 4.4 
75-79 yrs. <0.0001 3.9 .06 4.8 
80-84 yrs. <0.0001 12.7 .015 10 
85+ yrs. <0.0001 22 .004 4.3 
Social Economic Variables - - - - 
non-high school graduate .370 0.70 .154 2.8 
high school graduate .388 2.6 .226 0.8 
some college .696 5.7 .652 5.5 
4 yrs. College .912 2.1 .244 0.26 
median income .007 2.1 .402 0.5 
Comorbid Conditions - - - - 
previous myocardial infarct .874 4.4 0.88 3.2 
myocardial infarct .094 3.0 .954 2.4 
CHF .000 5.0 .838 1.7 
peripheral vascular disease .000 3.2 .840 0.13 
cerebrovascular disease .000 0.50 .980 4.1 
COPD .000 4.0 .793 0.30 
Dementia .000 3.3 1.000 0.51 
Paralysis .670 4.3 .815 0.57 
Diabetes .000 0.24 .035 0.57 
diabetes with sequelae .000 4.0 .768 1.77 
chronic renal failure .004 6.3 .838 0.49 
rheumatologic process .141 2.6 .505 3.5 
 
shows only slight differences in before and after matching which could possibly indicate 
that this non-cancer group is healthier than what was observed in the cancer group.  
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Figure 11 is a plot of the absolute standardized differences for the before and 
after matching of pairs of the non-cancer group. As seen in the graph, the majority of 
covariates were unremarkable for the before match and remained nearly unchanged for 
the after match pairs. 
 
Figure 8. Absolute Standardized Differences for before and after Matching: Non-Cancer 
Group Analysis. 
 
The last three data points for the before match are shown as white boxes and 
represent the largest differences for the age category of men between the ages of 80-84 
years (12.7%), men over 85 years old (22%), and race (45%). These same three data 
points became more balanced after the match as shown with black boxes at 10%, 4.3%, 
and 0.02% respectively (see Figure 11).  
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Logistic and Cox Regression: After Propensity Analysis 
After completing the propensity analysis and reviewing balance and overlap of 
variables modeling was performed for the non-cancer group. Select outputs from the 
logistic and conditional Cox regression models for the non-cancer group with a 
propensity analysis are shown below. Complete output results from both models are 
listed in Appendix M. Note that of the available cases included (8,426) there were no 
missing cases with 3,728 men censored (44.2%) leaving 4,698 (55.8%) men available for 
the analysis. Overall model resulted in correctly predicting 68.2 percent of the deaths (see 
Table 40).  
The direction and significance for having a screening PSA test and being African 
American for the non-cancer group is shown below. Interestingly, when evaluating this 
group of men, the logistic regression model reported statistically significant differences in 
overall mortality for screened men and of African American race (p = 0.00 and p = 0.00) 
while the conditional Cox model resulted in no significant differences in mortality and 
screened men and being African American (p = 0.447 and p = 0.832). In particular, the 
negative beta coefficient (slope) from the logistic model indicated that non-screened men 
were more likely to die than screened men (OR 1.32) whereas the Cox model resulted in 
no differences. Regarding race, the logistic model indicated that African American men 
were more likely to die than Caucasian men (OR 1.45) with the Cox model showing no 
differences in mortality between races. These differences in statistical methods may 
indicate that a Cox regression approach, with its ability to censor on time-to-event terms 
as well as accounting for matched pairings through stratification, may be more robust and  
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Table 40. Select Outputs from Logistic and Cox Regression Models: Non-Cancer Group 
after Propensity Analysis. 
 
 
 
therefore, confirming it has a preferred statistical method for matched paired data sets as 
suggested by Luo, Gardiner & Bradley (2009) (see Table 41). Moreover, Cox regression 
modeling together with a propensity analysis and its ability to create equality through 
eliminating observed selection bias, may strengthen the external validity of retrospective 
observational studies. 
 Logistic Regression Case Processing Summary 
Unweighted Casesa   N Percent 
Selected Cases Included in Analysis 8,426 100 
  Missing Cases 0 0 
  Total 8,426 100 
Unselected Cases   0 0 
Total   8,426 100 
a. If weight is in effect, see classification table for the total number of cases. 
Conditional Cox Regression Case Processing Summary   
    N Percent 
Cases available in Eventa 4,010 47.60% 
  Censored 688 8.20% 
  Total 4,698 55.80% 
Cases dropped Cases with missing values 0 0.00% 
  Cases with negative time 0 0.00% 
  Censored cases before the earliest event in a stratum 3,728 44.20% 
  Total 3,728 44.20% 
Total   8,426 100.00% 
 a. Dependent Variable: survtimemonths   
Logistic Regression Omnibus Tests of Model      
    Chi-square df Sig. 
Step 1 Step 1698.668 23 0 
  Block 1698.668 23 0 
  Model 1698.668 23 0 
Model Summary 
Step -2 Log likelihood Cox & Snell R2 Nagelkerke R2  
1 9962.678a 0.183 0.244 
Classification 
a
          
  Observed   Predicted     
      Mortality   Percent 
Correct 
      0 1   
Step 1 mortality 0 3295 1121 74.6 
    1 1555 2455 61.2 
  Overall Percentage       68.2 
a. The cut value is .5 
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Table 37. Model Output from Logistic and Cox Regression for Being Screened and 
African American: Non-Cancer Group after Propensity Analysis. 
 
    
Regression Outputs for Screening and African American Men: Non-Cancer 
Propensity Analysis 
  B S.E. Wald Df Sig. Exp(B) 
Logistic Model        
Being screened -.281 .049 33.464 1 .000 .755 
Being African 
American 
.371 .080 21.524 1 .000 1.449 
       
Cox Regression 
Model 
      
Being Screened -.048 .064 .578 1 .447 .953 
Being African 
American 
1.068 5.038 .045 1 .832 2.911 
 
PSA Utilization Rates: Prostate Cancer Group 
The final analysis of this study included examining the number of PSA tests and 
utilization rates among race for the group of men with prostate cancer (H3) and then 
repeated for the group of men without prostate cancer (H4). The number of PSA tests and 
utilization rates among race for the men with prostate cancer and for the total sample 
population of 322,822 men who had PSA tests recorded are shown in panels A and B of 
Figure 12, whether for screening purposes or for opportunistic reasons. Figure 12 shows 
that throughout the study period, Caucasian men tended to have more PSA tests each year 
with a maximum of over 53,000 occurring in 1993 compared to only 4,867 PSA tests for 
African American men that same year (panel A). However in looking at PSA utilization 
rates for the period (panel B), there were no significant differences among race (F-Test,  
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Figure 9. PSA count (panel A) and Utilization Rate (panel B) by Race and Year: Prostate 
Cancer Group. 
 
one-tailed probability p=0.175). After 1993, it appears that for both Caucasian and 
African American men the number and rates tended to decline. In fact, the graph shows 
that after 1996, African American men tended to maintain a higher utilization rate than 
did Caucasian men. 
 
The Prostate Cancer Group – PSA use 
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When examining PSA utilization rates for the prostate cancer group, it was 
decided to also review the number of cases diagnosed as well as the diagnosis rate for 
the sample population. Figure 13 is a plot of the number of diagnoses by race and year 
(panel A) and the diagnosis rate by race and year (panel B). Panel A of Figure13 shows 
the number of diagnosis rising for Caucasian men until 1993 where it begins to decline 
slowly for seven years and then sharply rises again in 2000. This trend is followed by a 
slow decline throughout the remaining study period and ending in 2006. The number of 
diagnosis for African American men appears to have remained steady and then slowly 
rises around the year 2000 through 2006 (panel A). Panel B of Figure 13 shows similar 
trends for the diagnosis rate of both races throughout the study period and resulted in no 
statistically significant differences among the rates (F-Test, one-tailed probability 
p=0.689) (panel B). Interestingly, African American men experienced a higher diagnosis 
rate beginning in 1993 that coincided with a higher PSA utilization rate from 1995 
forward. These trends lasted throughout the study period for African American men (see 
Figure 13, panel B). 
PSA Utilization Rates: Non Cancer Group 
In reviewing the numbers of PSA tests performed for the non-cancer group by 
race and year, a dramatic increase occurred from 1990 until around 1994 for Caucasians 
with only minimal increases in numbers for African Americans. The time period from 
1997 through 2005 remained relatively unchanged for both races. The non-cancer group 
PSA utilization rates were similar for both Caucasian and African American men 
throughout the study period of 1992 through 2005. The data resulted in no statistically  
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Figure 10. Number of Diagnosis (panel A) and Diagnosis Rate (panel B) by Race and 
Year: Prostate Cancer Group. 
 
significant differences in the distributions of PSA utilization rates among race for the 
non-cancer group (F-Test, one-tailed probability p=0.466). In Figure 14, panel A shows  
 
The Prostate Cancer Group – Number Diagnosis and Diagnosis Rate  
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Figure 11. PSA Count (panel A) and PSA Utilization Rate (panel B) by Race and Year: 
Non-Cancer Group. 
 
the numbers of PSA tests by race and year with panel B showing the PSA utilization rates 
among race by year for the non-cancer group (see Figure 14).   
 
The Non-Cancer Group – PSA use 
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CHAPTER 5: DISCUSSION 
 
 
The results provided in Chapter 4 demonstrate similar findings reported by other 
researchers who have used a propensity analysis for health services research studies in 
that, adjusting for a man’s probability of receiving treatment based on a subset of 
observed covariates that almost exactly match those of another man should, theoretically, 
eliminate selection bias and remove differences between groups making them more equal 
thereby improving statistical inferences. Reduction in bias for equally matched groups 
would then render outcomes data more reliable and meaningful to large population-based 
retrospective observational analyses.  
The current study used a propensity analysis adjustment for reducing selection 
bias and for balancing covariate distributions among race for a group of men with 
prostate cancer and a separate analysis in a group of men without cancer. It is suggested 
that balance across observed covariates is achieved through sufficient overlapping of p-
scores and is noted by p-value changes from statistically significant to non-significant, by 
reduction in percent absolute standardized differences of less than 10%, and by plots of 
overlapping p-scores and/or the absolute standardized differences for both before and 
after application of the propensity analysis (Rubin 2002, D’Agostino 1998, Luellen 
2005). Results in Chapter 4 of before and after comparisons, plots of p-scores overlap, 
and plots of absolute standardized differences demonstrated balance and equality of base-
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line characteristics of comparison groups after applying a propensity score adjustment. 
These results demonstrate that this observational was sufficiently designed and are 
therefore believed to have strengthened the traditional regression modeling that occurred 
afterwards.  
This project demonstrated that disparate mortality among Caucasians and African 
Americans with prostate cancer did not exist for this study population when using a 
propensity analysis for eliminating differences among groups. Comparisons were made 
of models from multivariate logistic regression and Cox regression for the full sample 
group with and without a propensity analysis, comparisons were evaluated for the data set 
when stratified into five quintiles, and comparisons were examined with the data set 
stratified by age. A summary table of the comparisons is presented below. Panel A shows 
that the multivariate logistic models for both before and after propensity adjustments for 
screening effects on mortality resulted in statistically significant differences (p=.001 and 
p=.007). This could be supportive of a screening protective effect on mortality trending 
toward a survival benefit for early detection. However, it may also represent a weakness 
of logistic regression’s lack of censoring on time-to-event and its lack of accountability 
for matched paired data.  
Results from the Cox regression model (panel A) demonstrated something vastly 
different than the logistic model illustrating no statistically significant differences in 
screening effects on mortality from both the before and after propensity score adjustment 
(p=.256 and p=.993). These results indicate that censoring for survival data on closely 
matched pairs using a Cox regression model could influence outcomes that lead to the 
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assumption that no survival benefit exists when screening for the early detection of 
prostate cancer (see Table 42).  
Regarding whether differences exist among race and mortality, Table 42 panel A 
shows that before propensity score adjustments were applied, both the logistic and Cox 
regression models resulted in statistically significant differences for this sample 
population at p=.015 and p=.056 respectively, although the Cox model trended toward no 
difference among race and overall mortality at p=.056. In contrast, significance was lost 
once applying propensity score adjustments to both models for race and mortality 
(p=.559 and p=.081).  
In looking at the results for the data sets when stratified into quintiles and age 
quartiles, Table 42 panel B shows for both regression models that for all five quintiles 
and the four age quartiles, no statistically significant differences exist among screened 
men and race on overall mortality with the exception of quintile 3, where significant 
differences were noted for only being screened (p=.004). This may be explained because 
p-scores of the third quintile may represent men who are less decisive or who may 
procrastinate about health behavior decision making and not communicate well with their 
physicians. Therefore, they may be men who show significant differences as a result of 
hidden or unobserved biases that go unaccounted for. In addition, quintile five resulted in 
constants or very high values for race and mortality which is again, believed to be the 
result of an under represented sample of African Americans among quintile five as 
described earlier (see Table 42 panel B). 
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Table 38. Model Summary Outputs: Compilation of Before and After Propensity 
Adjustment: Prostate Cancer Group. 
 
Panel A            Full Data Set  
Before Propensity   After Propensity 
(p-value) (p-value) 
Logistic  Cox Logistic  Cox 
sPSA     0.001      0.256 0.007 0.993 
AA        0.015 0.056 0.559 0.081 
Panel B      Quintile Being screened 0.068 0.919 
Q1 Being African American 0.353 0.493 
     Q2 Being screened 0.432 0.355 
  Being African American 0.515 0.976 
Q3 Being screened 0.004* 0.469 
  Being African American 0.142 0.964 
Q4 Being screened 0.599 0.468 
  Being African American 0.611 0.891 
Q5 Being screened 0.549 0.441 
  Being African American 0.999 * 
Age Qtr.1 66-69yrs                     Being screened           0.565 1 
                                    Being African American 0.508 1 
Age Qtr. 2 70-74yrs                     Being screened 0.432 0.829 
                                       Being African American 0.055 0.209 
Age Qtr. 3 75-79yrs                     Being screened 0.225 0.247 
                                     Being African American 0.554 0.32 
Age Qtr. 4 over 80yrs                  Being screened 0.741 1 
                                     Being African American 0.898 1 
 
Despite these few shortcomings, it is believed that enough data support the first 
hypothesis (H1); therefore, the first hypothesis is accepted in favor of the null, that there 
were no statistically significant differences in mortality among race in men with prostate 
cancer for this sample population. Further support for accepting hypothesis one (H1) is 
seen in Table 43. The table compares cancer-specific mortality rates between Caucasians 
and African Americans as a population calculated for both before and after a propensity  
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Table 39. Study Population: Crude Unadjusted and Age-Adjusted Mortality by Race for 
Models Before and After Propensity Analysis: Prostate Cancer Group. 
 
Crude and Age-Adjusted Mortality for Race (per 100,000 men) 
African American: Caucasian 
No 
Propensity Propensity 
Crude Unadjusted Mortality 1.23 1.04 
66-69 yrs. 1.43 1.13 
70-74 yrs. 1.23 0.96 
75-79 yrs. 1.21 0.95 
80-84 yrs. 1.16 0.99 
85+ yrs. 1.32 1.03 
 
analysis was applied. It shows crude unadjusted mortality for the entire study population 
and also for age-adjusted mortality by the ratio of African Americans to Caucasians. For 
example, the study sample population resulted in African American men having a 1.23 
times greater mortality rate than Caucasian men before the propensity adjustment and 
nearly equal mortality rates (1.04) after applying p-scores. Differences in age-adjusted 
mortality rates improved as well after applying a propensity score adjustment (see Table 
43). 
In addition, Figure 15 illustrates further support for accepting hypothesis one in 
showing cancer-specific mortality rates by race and year before and after p-score 
adjustment. It appears that after applying a propensity adjustment, slight improvements 
were observed between before and after mortality rates (see Figure 15). Other researchers 
have reported similar results. In particular, Tewari compared long-term survival and 
different treatments in men with advanced stage prostate cancer using propensity scores. 
Their conclusion was that propensity scores showed slight improvements over the 
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Figure 15. Cancer-Specific Mortality Rate by Race and Year: Before (panel A) and After 
(panel B) Propensity Analysis. 
 
Cancer-Specific Mortality Rate: before and after Propensity Analysis 
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reported  unadjusted rates and noted that using the propensity method was a strength of 
the study as it allowed the comparison of three treatment modalities when all observed 
covariates were matched and well balanced (Tewari et al., 2007).  
Another study by Mitra et al. 2001 on breast cancer screenings found similar 
results using multiple logistic regression models to estimate the p-scores and placing 
women into five strata. The authors reported that before p-score adjustment, 9 out of 16 
baseline covariates significantly differed between the two groups where after applying 
the p-score adjustment, all 16 covariates were balanced showing no significant 
differences. The authors noted that statistical significance was lost once adjusting with p-
scores, therefore, allowing a more accurate assessment of the effectiveness for breast 
screening (Mitra, et al., 2001). 
 The results of Chapter 4 show mixed evidence regarding hypothesis 2 in that the 
logistic model demonstrated that statistically significant differences did exist between 
race and overall mortality among men within the non-cancer group while the Cox 
regression model resulted in no differences once the propensity analysis was applied. In 
reviewing Table 44, statistically significant differences remained unchanged between the 
before and after propensity analysis for being screened and African American from the 
logistic regression model (p<0.0001). However, the Cox regression model shows that 
significant differences were removed for screened men and being African American once 
p-scores were applied (see Table 44). Applying the propensity score adjustment appears 
to have improved the Cox regression model as no significant differences were noted in 
men who were screened and among race. African American men trended toward  
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Table 40. Model Results for Before and After Propensity Analysis: Non-Cancer Group. 
 
  
Before 
Propensity 
After 
Propensity 
  p-value p-value 
Logistic Model      
 being screened <.0001 <.0001 
being African American <.0001 <.0001 
Cox Regression Model     
being screened 0.002 0.447 
being African American 0.046 0.832 
 
significant differences before applying p-score adjustments (p=.046) yet lost significance 
once they were applied (p=.832). 
It may be intuitively tempting to reject hypothesis H2 in favor of the alternative 
that statistically significant differences do exit in overall mortality rates among screened 
men and race when evaluating the logistic regression model for both with and without a 
p-score adjustment. This could be because logistic regression does not consider survival 
censorship for time to event nor does the model account for matched paired data and 
therefore, the results may underestimate the influence of unobserved covariates and other 
hidden conditions present thus influencing the model results toward statistically 
significant differences.  
In contrast it is more compelling to accept hypothesis two (H2) that no statistically 
significant differences exist among screened men and race in overall mortality when 
using a Cox regression and a propensity analysis. This is explained from knowing that the 
idea behind a screening program is to detect cancers early and therefore reduce mortality 
as a result. Because this second analysis was from a population of men who never had 
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prostate cancer or any other cancer, reason insists for an understanding that screening 
cannot affect mortality unless cancer is present and mortality is used as the end point 
measurement. Further, these men were clinically followed over a long time period on 
comorbid conditions and were nearly perfectly matched on observed covariates which 
could increase the predictive power that overall mortality would be no different among 
race. Therefore, hypothesis two is also accepted in favor of the null, that there were no 
statistically significant differences in overall racial mortality among men of this sample 
population. 
In addressing hypothesis 3 and hypothesis 4 regarding PSA utilization for both the 
cancer and non-cancer groups, the results indicate no statistically significant differences 
in the distributions among race in men of the cancer group as well as among men without 
cancer (F-Test, one-tailed probability p=0.466 and p=0.175, respectively). Interestingly, 
African American men experienced a higher diagnosis rate beginning in 1993 that 
coincided with a higher PSA utilization rate from 1995 on through the end of the study 
period. Because of these findings, both hypothesis 3 and 4 are accepted in favor of the 
null, that no statistically significant differences in the distributions of PSA utilization 
rates existed between race for both the group of men with prostate cancer and among the 
group of men without cancer. 
Strengths of Study 
The current study utilized the most recent SEER population-based cancer registry 
data set compiled by the National Institute of Health sponsored by the National Cancer 
Institute merged with Medicare health care claims linked to patient demographic 
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information, initial PSA testing and diagnostic information, initial treatment, and long-
term follow-up status of national cancer incidence and mortality rates making the data 
suitable for health services research (Warren, Klabunde, Schrag, Bach, & Riley, 2002).   
The SEER Medicare linked database began collecting data in 1973 and now 
includes approximately 26% of the U.S. population. The SEER data are considered 
highly valid with quality and completeness studies performed yearly to ensure accuracy 
by holding the highest level of certification of quality as provided by the National 
American Association of Central Cancer Registries with a standard for completeness of 
data ascertained at 98% (Warren et al., 2002).  
Use of a large national population-based data set along with a propensity analysis 
as part of the methodology is considered a strength of the current study (Rosenbaum & 
Rubin, 1983; Love, 2003; Grimes & Schulz, 2002).  Further, use of a large national 
population-based data set provides sufficient amounts of patients for increased 
generalizability of results to the overall population. Use of such a large database allowed 
for extensive trimming of sample that still resulted in a sufficient final sample size and is 
considered a strength of this study.  
Limitations of Study 
As in most studies, limitations of the study include the lack of capturing claims 
from all services Medicare provides. For example, PSA screening provided by a 
community based screening program, services provided to a beneficiary by a Veteran's 
Administration facility, or services to a beneficiary who is employed and currently 
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covered by a health plan are not captured in the claims files and therefore, some men may 
have been excluded. 
It has also been reported that using claims data to estimate prostate screening is 
limited (Freeman et al., 2002; Potosky et al., 1995; Legler et al., 1998; Cooper et al., 
2001). For instance, claims data may lead to incomplete or missing information, as they 
are sometimes created only for purposes of payment and therefore reasons for having 
PSA tests (screening vs. diagnostic) nor PSA levels were not provided. In addition, this 
study did not include whether men had a DRE test along with their PSA blood test in 
which most screening programs would include both exams before recommending further 
clinical work up.   
Further, large administrative databases are known to contain large amounts of 
selection bias that may threaten validity when using observational data for estimating 
outcomes. Potential explanations for undetected selection bias remaining, even with 
controlling, is lack of information for unobserved and unmeasured covariates as well as 
lack of information on self-reported health surveys often found in retrospective 
observational studies.  
Other limitations may be the fact that this study only examined an elderly 
population of Medicare enrollees beginning at the age of 66 years old and did not 
consider younger men who are also susceptible to getting prostate cancer. Additionally, 
only cases of early stage disease of local/regional tumors were included. This restrictive 
age group and evaluation of only early stage disease could have limited the numbers of 
African American men in this study as it is known that African American men are 
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historically staged as late or advanced and can be found with prostate cancer at younger 
ages than Caucasian men. Finally, the study only examined men from two races. For 
these reasons results from this study can only be generalized to elderly men with similar 
early stage disease characteristics and among African Americans and Caucasians. 
Areas for Future Research 
The results of this study demonstrated that further work in health services is 
warranted and that it is feasible to apply a propensity analysis in observational 
retrospective research. Until results from randomized clinical trials are finalized, it may 
be beneficial to use retrospective observational studies of appropriate statistical methods 
and large population-based data sets as either surrogates for or complements to.   
There are multitudes of agencies and programs working to end disparities in 
cancer morbidity and mortality through advocacy, research, and educational programs 
(ACS, 2008; Centers for Disease Control and Prevention, 2008; The Patient Navigator 
[P.L. 109-18], 2005). One theme of the ACS’s 2015 challenge goals is to eliminate heath 
disparities within different segments of the U.S. population. The causes are complex with 
entangled variables likely from a combination of socioeconomic factors in work, income, 
education, and overall standard of living. In addition, economic and social barriers to 
prevention and early detection programs and the impact of racial and ethnic 
discrimination play a role.  The ACS works alongside lawmakers at the local, state, and 
federal levels in order to create, change, and influence public policy that have a 
significant impact on reducing the cancer disparity in the United States.  The ACS 
continues to fight for increased funding or to protect current funding to programs within 
236 
 
 
 
the Centers for Disease Control and Prevention (CDC) and health promotion. The effort 
extends into educational and screening programs targeted toward cancers that affect 
minorities, particularly African Americans.  The Patient Navigator bill signed into law 
by President George W. Bush in 2005 provides grant funding to skilled workers who can 
provide culturally designed education and intervention programs for improving access to 
care, outcomes, and quality of life issues to underserved communities (ACS-AA, 
2007/2008). The ACS has funded 76 studies allocating over 62 million dollars since 1999 
to the poor and underprivileged with 42 percent of funding devoted to African 
Americans. Studies include early detection and prevention programs, treatment 
improvements, and psychosocial coping and supportive measures (ACS-AA, 2009/2010). 
Prostate cancer screening with regard to when to begin, how often to repeat, and 
what the results tell physicians and patients continue to be topics for discussion at 
scientific seminars and medical meetings. Hopefully, this study will provoke new ideas 
and raise new questions that may someday lead to an actual finding of the effects that 
screening PSA tests have on mortality.     
Conclusion 
The results of this study are supportive of some research outcomes and 
contractive to others. Key findings of the study were that no significant differences exist 
in cancer-specific and overall mortality among race in men with prostate cancer and in 
men without prostate cancer. In addition and like the PLCO randomized clinical trial 
findings, no statistically significant survival benefit was noted for the PSA screening test. 
Further, no significant differences were found among both groups for PSA screening 
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utilizations throughout the study period.  These results could help shape future best-
practice guidelines and help guide public policy toward a more individualized race-based 
screening protocol providing physicians with new information about ways to 
communicate screening tests that may be best for their patients. 
It is usually accepted that hope lies within randomized clinical trials for showing 
whether PSA screening for early detection and prevention can lead to reduced mortality 
rates. However, it may now be safe to believe that well-designed retrospective 
observational studies may serve as surrogates when time and economic resources are 
limited. Should factors be identified from either design showing differences exist 
between African American and Caucasian men regarding screening and mortality then 
new race-based public policy prevention mechanisms should be expanded and further 
examined. 
Finally, it is believed that this study shows that Cox regression maybe an 
improved, more robust method for evaluating large population samples where censoring 
for survival is important and where matched pairs are utilized. Additionally, the results 
further suggest that applying a propensity analysis was helpful for this study. The two 
analyses together may play a role in future research. Further work in health services 
research using large population-based secondary data sets should be pursued 
incorporating Cox regression with survival time censoring, matched pairs, and a 
propensity analysis.
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Appendix A 
Logistic and Cox Regression: Non-Propensity Analysis 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
67307 92.5 
Missing Cases 5470 7.5 
Total 72777 100.0 
Unselected Cases 0 .0 
Total 72777 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 4127 .000 .000 .000 .000 .000 
2 49457 1.000 .000 .000 .000 .000 
3 233 .000 1.000 .000 .000 .000 
4 2466 .000 .000 1.000 .000 .000 
5 5012 .000 .000 .000 1.000 .000 
9 6012 .000 .000 .000 .000 1.000 
Radiation  0 34404 .000 .000 .000 .000  
1 18301 1.000 .000 .000 .000  
2 9047 .000 1.000 .000 .000  
4 4743 .000 .000 1.000 .000  
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9 812 .000 .000 .000 1.000  
Age at Diagnosis 
Year  
14 20559 .000 .000 .000 .000  
15 23646 1.000 .000 .000 .000  
16 15500 .000 1.000 .000 .000  
17 5920 .000 .000 1.000 .000  
18 1682 .000 .000 .000 1.000  
Grade  1 4338 .000     
2 62969 1.000     
SEER Race Recode   1 61110 .000     
 2 6197 1.000     
 
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 64695 0 100.0 
1 2612 0 .0 
Overall Percentage   96.1 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp (B) 
Step 0 Constant -3.210 .020 25862.871 1 .000 .040 
 
Variables not in the Equationa 
 Score Df Sig. 
 Variables sPSA 220.711 1 .000 
Race 9.440 1 .002 
Age 451.441 4 .000 
Age(1) 36.059 1 .000 
Age(2) 46.911 1 .000 
Age(3) 133.970 1 .000 
Age(4) 179.288 1 .000 
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Grade 47.339 1 .000 
HistStageCombinary 2130.418 1 .000 
MarStatus 103.361 5 .000 
MarStatus(1) 84.470 1 .000 
MarStatus(2) .106 1 .745 
MarStatus(3) .082 1 .774 
MarStatus(4) 19.777 1 .000 
MarStatus(5) 58.916 1 .000 
Radiation 221.652 4 .000 
Radiation(1) 5.190 1 .023 
Radiation(2) 171.911 1 .000 
Radiation(3) 24.183 1 .000 
Radiation(4) 1.015 1 .314 
RadSurgCombinary 127.107 1 .000 
SurgCombinary 722.977 1 .000 
Hormones 203.011 1 .000 
PctNonHSGrad 4.898 1 .027 
PctHSonly 4.746 1 .029 
PctSomeColl .000 1 .991 
Pct4yrColl 6.952 1 .008 
MedIncome 12.643 1 .000 
MyoInfarc .587 1 .443 
OldMyoInfarc 9.516 1 .002 
CHF 66.814 1 .000 
PeriphVascDisDx 41.460 1 .000 
CerebroVascDis 16.067 1 .000 
COPD 23.668 1 .000 
Dementia 158.872 1 .000 
Paralysis 7.745 1 .005 
Diabetes 21.596 1 .000 
DiabetesSequelae 10.350 1 .001 
ChronicRenalFail 16.698 1 .000 
Rheum 5.886 1 .015 
a. Residual Chi-Squares are not computed because of redundancies. 
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Block 1: Method = Enter 
  
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 2551.208 37 .000 
Block 2551.208 37 .000 
Model 2551.208 37 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 19543.639a .037 .133 
a. Estimation terminated at iteration number 7 
because parameter estimates changed by less than 
.001. 
 
Hosmer and Lemeshow Test 
Step Chi-square Df Sig. 
1 29.104 8 .000 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 64680 15 100.0 
1 2552 60 2.3 
Overall Percentage   96.2 
a. The cut value is .500 
 
Variables in the Equation 
Variables 
B S.E. Wald Df Sig. Exp (B) 
95% C.I. for EXP(B) 
Lower Upper 
 sPSA -.159 .048 10.929 1 .001 .853 .776 .937 
Race  .177 .073 5.869 1 .015 1.194 1.034 1.378 
Age   577.90 4 .000    
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Age(1) .398 .059 45.168 1 .000 1.489 1.326 1.672 
Age(2) .966 .061 247.93 1 .000 2.628 2.331 2.964 
Age(3) 1.353 .074 337.7 1 .000 3.870 3.350 4.471 
Age(4) 1.795 .099 328.06 1 .000 6.019 4.957 7.310 
Grade .001 .073 .000 1 .994 1.001 .867 1.154 
HistStage 
Combine 
-1.697 .063 723.87 1 .000 .183 .162 .207 
MarStatus   115.02 5 .000    
MarStatus(1) -.373 .081 21.166 1 .000 .689 .588 .807 
MarStatus(2) -.161 .346 .217 1 .641 .851 .432 1.676 
MarStatus(3) -.115 .132 .749 1 .387 .892 .688 1.156 
MarStatus(4) -.233 .103 5.156 1 .023 .792 .648 .969 
MarStatus(5) .294 .097 9.209 1 .002 1.342 1.110 1.624 
Radiation   56.364 4 .000    
Radiation(1) .105 .052 4.002 1 .045 1.110 1.002 1.230 
Radiation(2) -.502 .098 26.241 1 .000 .605 .500 .734 
Radiation(3) -.056 .102 .299 1 .585 .946 .775 1.155 
Radiation(4) -.902 .210 18.421 1 .000 .406 .269 .612 
RadSurgCombined .256 .096 7.170 1 .007 1.291 1.071 1.557 
SurgCombinary .924 .050 338.11 1 .000 2.520 2.283 2.780 
Hormones .815 .064 160.59 1 .000 2.259 1.991 2.562 
PctNonHSGrad -.008 .017 .233 1 .630 .992 .959 1.026 
PctHSonly -.003 .017 .035 1 .852 .997 .963 1.031 
PctSomeColl -.011 .017 .375 1 .541 .989 .956 1.024 
Pct4yrColl -.009 .017 .240 1 .624 .992 .958 1.026 
MedIncome .000 .000 .136 1 .713 1.000 1.000 1.000 
MyoInfarc -.813 .767 1.124 1 .289 .443 .099 1.995 
OldMyoInfarc 4.091 2.653 2.378 1 .123 59.816 .330 10841.5 
CHF .390 .120 10.463 1 .001 1.477 1.166 1.870 
PeriphVascDis .890 .321 7.694 1 .006 2.435 1.298 4.567 
CerebroVascDis -.102 .378 .073 1 .786 .903 .430 1.894 
COPD .084 .096 .752 1 .386 1.087 .900 1.313 
Dementia 2.133 .305 48.878 1 .000 8.442 4.642 15.353 
Paralysis 1.050 .817 1.653 1 .199 2.858 .577 14.169 
Diabetes .543 .316 2.943 1 .086 1.720 .926 3.198 
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DiabetesSequelae .315 .354 .792 1 .374 1.370 .685 2.742 
ChronicRenalFail .327 .292 1.255 1 .263 1.387 .782 2.459 
Rheum 1.346 2.033 .439 1 .508 3.843 .072 206.483 
Constant -1.958 1.733 1.276 1 .259 .141   
a. Variable(s) entered on step 1: sPSA, Race, Age, Grade, HistStageCombinary, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, Hormones, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, 
MedIncome, MyoInfarc, OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, Dementia, 
Paralysis, Diabetes, DiabetesSequelae, ChronicRenalFail, Rheum. 
 
 
 
Cox Regression: Non-Propensity Analysis  
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 2612 3.6% 
Censored 64695 88.9% 
Total 67307 92.5% 
Cases dropped Cases with missing 
values 
5470 7.5% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
0 .0% 
Total 5470 7.5% 
Total 72777 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
 
 
Categorical Variable Codingsb,c,d,e,f 
 Frequency (1) (2) (3) (4) (5) 
Agea 14 20559 0 0 0 0  
15 23646 1 0 0 0  
16 15500 0 1 0 0  
17 5920 0 0 1 0  
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18 1682 0 0 0 1  
Gradea 1 4338 0     
2 62969 1     
MarStatusa 1 4127 0 0 0 0 0 
2 49457 1 0 0 0 0 
3 233 0 1 0 0 0 
4 2466 0 0 1 0 0 
5 5012 0 0 0 1 0 
9 6012 0 0 0 0 1 
Racea  1 61110 0     
 2 6197 1     
Radiationa 0 34404 0 0 0 0  
1 18301 1 0 0 0  
2 9047 0 1 0 0  
4 4743 0 0 1 0  
9 812 0 0 0 1  
a. Indicator Parameter Coding 
b. Category variable: Age (Age at Diagnosis Year ) 
c. Category variable: Grade (Grade ) 
d. Category variable: MarStatus (Marital Status) 
e. Category variable: Race (SEER Race Recode B) 
f. Category variable: Radiation (Radiation ) 
 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
52093.490 
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Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) 
Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square Df Sig. 
Chi-
square Df Sig. 
Chi-
square df Sig. 
50706.859 1830.31 37 .000 1386.63 37 .000 1386.63 37 .000 
a. Beginning Block Number 1. Method = Enter 
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp (B) 
95.0% CI for Exp (B) 
Lower Upper 
sPSA -.053 .047 1.289 1 .256 .948 .865 1.039 
Race .134 .070 3.650 1 .056 1.144 .997 1.312 
Age   672.203 4 .000    
Age(1) .344 .057 36.587 1 .000 1.411 1.262 1.578 
Age(2) .899 .059 235.718 1 .000 2.456 2.190 2.755 
Age(3) 1.337 .070 366.609 1 .000 3.808 3.321 4.366 
Age(4) 1.898 .092 421.869 1 .000 6.674 5.568 7.999 
Grade .281 .068 17.101 1 .000 1.325 1.159 1.513 
HistStageCombinary -.415 .067 38.525 1 .000 .661 .579 .753 
MarStatus   99.915 5 .000    
MarStatus(1) -.367 .076 23.048 1 .000 .693 .597 .805 
MarStatus(2) .036 .325 .012 1 .913 1.036 .548 1.959 
MarStatus(3) -.052 .126 .169 1 .681 .950 .742 1.216 
MarStatus(4) -.226 .096 5.513 1 .019 .798 .661 .963 
MarStatus(5) .200 .091 4.772 1 .029 1.221 1.021 1.461 
Radiation   47.810 4 .000    
Radiation(1) -.185 .049 14.038 1 .000 .831 .754 .915 
Radiation(2) -.555 .096 33.560 1 .000 .574 .476 .693 
Radiation(3) -.386 .098 15.428 1 .000 .680 .561 .824 
Radiation(4) -.213 .204 1.093 1 .296 .808 .542 1.205 
RadSurgCombinary .531 .088 36.594 1 .000 1.700 1.431 2.019 
SurgCombinary -.283 .052 29.434 1 .000 .753 .680 .834 
Hormones .730 .059 152.076 1 .000 2.074 1.847 2.329 
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PctNonHSGrad .001 .020 .001 1 .979 1.001 .962 1.041 
PctHSonly .003 .020 .028 1 .867 1.003 .965 1.044 
PctSomeColl -.010 .020 .251 1 .616 .990 .952 1.030 
Pct4yrColl -.006 .020 .092 1 .762 .994 .956 1.034 
MedIncome .000 .000 2.662 1 .103 1.000 1.000 1.000 
MyoInfarc -1.244 .723 2.956 1 .086 .288 .070 1.190 
OldMyoInfarc 4.648 2.47 3.522 1 .061 104.368 .814 13383.93 
CHF .386 .110 12.443 1 .000 1.472 1.187 1.824 
PeriphVascDis .896 .293 9.338 1 .002 2.449 1.379 4.351 
CerebroVascDis -.080 .351 .052 1 .819 .923 .464 1.836 
COPD .035 .090 .150 1 .699 1.035 .868 1.235 
Dementia 1.849 .239 59.818 1 .000 6.352 3.976 10.149 
Paralysis .627 .732 .734 1 .392 1.872 .446 7.854 
Diabetes .671 .294 5.199 1 .023 1.955 1.099 3.480 
DiabetesSequelae .324 .328 .974 1 .324 1.383 .727 2.631 
ChronicRenalFail .481 .266 3.273 1 .070 1.617 .961 2.723 
Rheum 1.995 1.87 1.132 1 .287 7.350 .186 289.843 
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Appendix B 
Logistic Regression: FM with Propensity Analysis 
 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
50,000 100.0 
Missing Cases 0 .0 
Total 50,000 100.0 
Unselected Cases 0 .0 
Total 50,000 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 3177 .000 .000 .000 .000 .000 
2 36007 1.000 .000 .000 .000 .000 
3 170 .000 1.000 .000 .000 .000 
4 1877 .000 .000 1.000 .000 .000 
5 3839 .000 .000 .000 1.000 .000 
9 4930 .000 .000 .000 .000 1.000 
Age Group 14 15390 .000 .000 .000 .000  
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15 17268 1.000 .000 .000 .000  
16 11082 .000 1.000 .000 .000  
17 4856 .000 .000 1.000 .000  
18 1404 .000 .000 .000 1.000  
Grade 1 1 3298 .000     
2 46702 1.000     
SEER Race 
Recode B 
1 45603 .000     
2 4397 1.000     
 
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 48,420 0 100.0 
1 1,580 0 .0 
Overall Percentage   96.8 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald Df Sig. Exp (B) 
Step 0 Constant -3.422 .026 17922.383 1 .000 .033 
 
Variables not in the Equationa 
 Score df Sig. 
S
t
e
p
 
0
Variables sPSA 4.834 1 .028 
Race(1) .199 1 .655 
Age 317.368 4 .000 
Age(1) 22.218 1 .000 
Age(2) 61.884 1 .000 
Age(3) 83.037 1 .000 
Age(4) 90.969 1 .000 
Grade(1) 12.107 1 .001 
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HistStageCombinary 175.412 1 .000 
MarStatus 99.868 5 .000 
MarStatus(1) 68.013 1 .000 
MarStatus(2) .076 1 .783 
MarStatus(3) .002 1 .966 
MarStatus(4) 5.619 1 .018 
MarStatus(5) 81.400 1 .000 
Radiation 46.106 1 .000 
RadSurgCombinary 8.689 1 .003 
SurgCombinary 132.255 1 .000 
PctNonHSGrad 1.463 1 .226 
PctHSonly 1.104 1 .293 
PctSomeColl .825 1 .364 
Pct4yrColl 2.805 1 .094 
MedIncome .049 1 .824 
MyoInfarc .329 1 .566 
OldMyoInfarc .338 1 .561 
CHF 7.314 1 .007 
PeriphVascDisDx 3.894 1 .048 
CerebroVascDis 2.229 1 .135 
COPD 5.360 1 .021 
Dementia 52.031 1 .000 
Paralysis 1.624 1 .203 
Diabetes 3.232 1 .072 
DiabetesSequelae 1.844 1 .175 
ChronicRenalFail 2.445 1 .118 
Rheum 1.360 1 .244 
a. Residual Chi-Squares are not computed because of redundancies. 
 
 
 
Block 1: Method = Enter 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 713.126 33 .000 
Block 713.126 33 .000 
Model 713.126 33 .000 
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Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 13312.942a .014 .058 
a. Estimation terminated at iteration number 7 
because parameter estimates changed by less than 
.001. 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 48419 1 100.0 
1 1577 3 .2 
Overall Percentage   96.8 
a. The cut value is .500 
 
Variables in the Equation 
 
B S.E. Wald Df Sig. Exp (B) 
95% C.I. for exp (B) 
Lower Upper 
sPSA -.140 .052 7.282 1 .007 .870 .786 .962 
Race(1) .058 .099 .342 1 .559 1.060 .872 1.287 
Age   304.33 4 .000    
Age(1) .386 .077 24.854 1 .000 1.471 1.264 1.712 
Age(2) .948 .078 146.35 1 .000 2.580 2.213 3.009 
Age(3) 1.209 .092 174.23 1 .000 3.350 2.799 4.008 
Age(4) 1.565 .122 165.15 1 .000 4.782 3.767 6.071 
Grade(1) -.082 .093 .766 1 .381 .922 .767 1.107 
HistStageCombine -1.484 .153 94.354 1 .000 .227 .168 .306 
MarStatus   94.225 5 .000    
MarStatus(1) -.321 .102 9.810 1 .002 .726 .594 .887 
MarStatus(2) .035 .430 .007 1 .934 1.036 .446 2.407 
MarStatus(3) -.060 .165 .131 1 .717 .942 .682 1.301 
MarStatus(4) -.192 .130 2.184 1 .139 .825 .640 1.065 
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MarStatus(5) .381 .117 10.574 1 .001 1.463 1.163 1.840 
Radiation -.089 .021 18.632 1 .000 .915 .878 .952 
RadSurgCombine .237 .138 2.945 1 .086 1.268 .967 1.663 
SurgCombinary .734 .056 170.02 1 .000 2.084 1.867 2.328 
PctNonHSGrad -.023 .018 1.648 1 .199 .977 .943 1.012 
PctHSonly -.015 .018 .701 1 .402 .985 .950 1.021 
PctSomeColl -.025 .018 1.966 1 .161 .975 .941 1.010 
Pct4yrColl -.017 .018 .931 1 .335 .983 .948 1.018 
MedIncome .000 .000 .096 1 .756 1.000 1.000 1.000 
MyoInfarc -.099 .974 .010 1 .919 .906 .134 6.108 
OldMyoInfarc .375 3.767 .010 1 .921 1.455 .001 2342.6 
CHF .219 .181 1.469 1 .225 1.245 .874 1.774 
PeriphVascDisDx .433 .459 .888 1 .346 1.542 .627 3.792 
CerebroVascDis -.079 .500 .025 1 .874 .924 .347 2.461 
COPD .155 .123 1.591 1 .207 1.168 .918 1.487 
Dementia 2.122 .446 22.627 1 .000 8.345 3.481 20.002 
Paralysis 1.293 1.220 1.122 1 .290 3.642 .333 39.829 
Diabetes .400 .409 .957 1 .328 1.493 .669 3.329 
DiabetesSequelae .216 .476 .205 1 .651 1.240 .488 3.154 
ChronicRenalFail .460 .470 .958 1 .328 1.584 .631 3.977 
Rheum 1.327 2.636 .253 1 .615 3.769 .021 660.83 
Constant -.462 1.800 .066 1 .797 .630   
a. Variable(s) entered on step 1: sPSA, Race, Age, Grade, HistStageCombinary, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, 
MedIncome, MyoInfarc, OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, Dementia, 
Paralysis, Diabetes, DiabetesSequelae, ChronicRenalFail, Rheum. 
 
 
Cox Regression: FM with Propensity Analysis 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 1580 3.2% 
Censored 834 1.7% 
Total 2414 4.8% 
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Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
47586 95.2% 
Total 47586 95.2% 
Total 50000 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
 
 
Categorical Variable Codingsb,c,d,e 
 Frequency (1) (2) (3) (4) (5) 
Racea 1 45603 0     
2 4397 1     
Agea 14 15390 0 0 0 0  
15 17268 1 0 0 0  
16 11082 0 1 0 0  
17 4856 0 0 1 0  
18 1404 0 0 0 1  
Gradea 1 3298 0     
2 46702 1     
MarStatusa 1 3177 0 0 0 0 0 
2 36007 1 0 0 0 0 
3 170 0 1 0 0 0 
4 1877 0 0 1 0 0 
5 3839 0 0 0 1 0 
9 4930 0 0 0 0 1 
a. Indicator Parameter Coding 
b. Category variable: Race (SEER Race Recode B) 
c. Category variable: Age (Age at Diagnosis Year 1) 
d. Category variable: Grade (Grade 1) 
e. Category variable: MarStatus (Marital Status) 
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Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
1186.668 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) 
Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square Df Sig. 
Chi-
square Df Sig. 
Chi-
square df Sig. 
1006.454 159.521 31 .000 180.214 31 .000 180.214 31 .000 
a. Beginning Block Number 1. Method = Enter 
 
 
Variables in the Equationb 
 
B SE Wald df Sig. Exp (B) 
95.0% CI for Exp (B) 
Lower Upper 
sPSA -.001 .078 .000 1 .993 .999 .857 1.165 
Race -.644 .369 3.040 1 .081 .525 .255 1.083 
Age   57.235 4 .000    
Age(1) .944 .401 5.545 1 .019 2.570 1.172 5.640 
Age(2) 1.448 .419 11.926 1 .001 4.255 1.870 9.678 
Age(3) 1.707 .375 20.769 1 .000 5.512 2.645 11.486 
Age(4) 2.309 .398 33.655 1 .000 10.065 4.613 21.960 
Grade .366 .228 2.576 1 .108 1.441 .922 2.252 
HistStageCombine   . 0a .    
MarStatus   14.107 5 .015    
MarStatus(1) -.048 .273 .032 1 .859 .953 .558 1.627 
MarStatus(2) 1.032 .956 1.167 1 .280 2.808 .431 18.278 
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MarStatus(3) .192 .347 .308 1 .579 1.212 .614 2.393 
MarStatus(4) .107 .314 .117 1 .732 1.113 .602 2.059 
MarStatus(5) .597 .283 4.438 1 .035 1.816 1.042 3.165 
Radiation -.142 .044 10.485 1 .001 .868 .797 .946 
RadSurgCombinar .942 .302 9.766 1 .002 2.566 1.421 4.634 
SurgCombinary -1.20 .311 15.116 1 .000 .299 .163 .549 
Hormones   . 0a .    
PctNonHSGrad -.006 .094 .003 1 .953 .994 .827 1.196 
PctHSonly -.011 .095 .014 1 .905 .989 .821 1.191 
PctSomeColl -.003 .094 .001 1 .974 .997 .829 1.198 
Pct4yrColl .002 .094 .000 1 .983 1.002 .833 1.206 
MedIncome .000 .000 1.159 1 .282 1.000 1.000 1.000 
MyoInfarc -5.49 2.595 4.482 1 .034 .004 .000 .665 
OldMyoInfarc -8.46 8.673 .953 1 .329 .000 .000 5070.198 
PeriphVascDisDx -.084 1.106 .006 1 .940 .920 .105 8.037 
CerebroVascDis 1.276 1.414 .814 1 .367 3.583 .224 57.254 
COPD -.321 .337 .904 1 .342 .726 .375 1.405 
Dementia -.553 1.748 .100 1 .752 .575 .019 17.686 
Paralysis .181 4.648 .002 1 .969 1.199 .000 10841.24 
Diabetes 1.386 .938 2.181 1 .140 3.998 .635 25.150 
DiabetesSequelae .848 1.182 .514 1 .473 2.334 .230 23.670 
ChronicRenalFail -2.51 1.347 3.482 1 .062 .081 .006 1.135 
Rheum -5.89 5.477 1.157 1 .282 .003 .000 126.996 
a. Degree of freedom reduced because of constant or linearly dependent covariates 
b. Constant or Linearly Dependent Covariates S = Stratum effect. HistStageCombinary = .9635 + S ;  
Hormones = 0 + S ;  
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Appendix C 
Logistic and Conditional Cox Regression Output with Propensity Analysis 
Quintile 1 
 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
11518 100.0 
Missing Cases 0 .0 
Total 11518 100.0 
Unselected Cases 0 .0 
Total 11518 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 1220 .000 .000 .000 .000 .000 
2 7819 1.000 .000 .000 .000 .000 
3 70 .000 1.000 .000 .000 .000 
4 628 .000 .000 1.000 .000 .000 
5 756 .000 .000 .000 1.000 .000 
9 1025 .000 .000 .000 .000 1.000 
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Radiation 1 0 8099 .000 .000 .000 .000  
1 2190 1.000 .000 .000 .000  
2 420 .000 1.000 .000 .000  
4 513 .000 .000 1.000 .000  
9 296 .000 .000 .000 1.000  
Age at Diagnosis 
Year 1 
14 8684 .000 .000 .000 .000  
15 1337 1.000 .000 .000 .000  
16 729 .000 1.000 .000 .000  
17 473 .000 .000 1.000 .000  
18 295 .000 .000 .000 1.000  
Grade 1 1 1107 .000     
2 10411 1.000     
SEER Race Recode 
B 
 1 8966 .000     
 2 2552 1.000     
 
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 11129 0 100.0 
1 389 0 .0 
Overall Percentage   96.6 
a. Constant is included in the model. 
b. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald Df Sig. Exp (B) 
Step 0 Constant -3.354 .052 4227.513 1 .000 .035 
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Variables not in the Equationa 
 Score df Sig. 
Step 0  sPSA 4.919 1 .027 
Race .022 1 .883 
Age 299.591 4 .000 
Age(1) 3.050 1 .081 
Age(2) 73.170 1 .000 
Age(3) 42.311 1 .000 
Age(4) 146.239 1 .000 
Grade 8.452 1 .004 
HistStageCombinary 162.673 1 .000 
MarStatus 47.226 5 .000 
MarStatus(1) 35.682 1 .000 
MarStatus(2) .178 1 .673 
MarStatus(3) .002 1 .962 
MarStatus(4) 13.236 1 .000 
MarStatus(5) 22.842 1 .000 
Radiation 15.807 4 .003 
Radiation(1) 11.713 1 .001 
Radiation(2) 1.326 1 .250 
Radiation(3) 4.334 1 .037 
Radiation(4) .107 1 .744 
RadSurgCombinary 11.573 1 .001 
SurgCombinary 24.621 1 .000 
PctNonHSGrad .002 1 .968 
PctHSonly .027 1 .871 
PctSomeColl 1.820 1 .177 
Pct4yrColl .231 1 .631 
MedIncome .011 1 .916 
MyoInfarc .872 1 .351 
OldMyoInfarc 1.607 1 .205 
CHF 12.176 1 .000 
PeriphVascDis .980 1 .322 
CerebroVascDis 3.180 1 .075 
COPD 5.351 1 .021 
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Dementia 48.764 1 .000 
Paralysis 2.503 1 .114 
Diabetes 1.570 1 .210 
DiabetesSequelae .109 1 .741 
ChronicRenalFail 2.639 1 .104 
Rheum 3.126 1 .077 
a. Residual Chi-Squares are not computed because of redundancies. 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 399.392 36 .000 
Block 399.392 36 .000 
Model 399.392 36 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 3001.252a .034 .133 
a. Estimation terminated at iteration number 7 
because parameter estimates changed by less than 
.001. 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 11127 2 100.0 
1 382 7 1.8 
Overall Percentage   96.7 
a. The cut value is .500 
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Variables in the Equation 
 
B S.E. Wald df Sig. Exp (B) 
95% C.I. for exp (B) 
Lower Upper 
sPSA -.196 .108 3.321 1 .068 .822 .665 1.015 
Race .148 .159 .861 1 .353 1.159 .848 1.584 
Age (66-69)   152.36 4 .000    
Age(1)(70-74) .117 .181 .418 1 .518 1.124 .788 1.604 
Age(2)(75-79) .932 .180 26.755 1 .000 2.540 1.784 3.615 
Age(3)(80-84) 1.211 .207 34.298 1 .000 3.356 2.238 5.033 
Age(4)(85+) 2.201 .194 129.32 1 .000 9.034 6.182 13.201 
Grade -.063 .160 .155 1 .694 .939 .686 1.285 
HistStageCombine -1.655 .182 82.345 1 .000 .191 .134 .273 
MarStatus   42.549 5 .000    
MarStatus(1) -.563 .170 10.949 1 .001 .570 .408 .795 
MarStatus(2) .190 .626 .092 1 .762 1.209 .354 4.127 
MarStatus(3) -.164 .273 .362 1 .548 .849 .497 1.449 
MarStatus(4) -.233 .226 1.059 1 .304 .792 .509 1.234 
MarStatus(5) .493 .211 5.436 1 .020 1.637 1.082 2.477 
Radiation   19.740 4 .001    
Radiation(1) .524 .146 12.845 1 .000 1.688 1.268 2.248 
Radiation(2) .178 .341 .274 1 .601 1.195 .613 2.331 
Radiation(3) -.013 .355 .001 1 .970 .987 .492 1.979 
Radiation(4) -.804 .352 5.208 1 .022 .448 .224 .893 
RadSurgCombine .090 .237 .143 1 .706 1.094 .687 1.741 
SurgCombinary 1.112 .155 51.436 1 .000 3.039 2.243 4.118 
PctNonHSGrad -.014 .040 .121 1 .728 .986 .911 1.067 
PctHSonly -.002 .041 .002 1 .964 .998 .922 1.081 
PctSomeColl -.025 .041 .380 1 .538 .975 .900 1.056 
Pct4yrColl -.009 .041 .044 1 .834 .992 .916 1.074 
MedIncome .000 .000 .000 1 .990 1.000 1.000 1.000 
MyoInfarc -.480 1.59 .090 1 .764 .619 .027 14.224 
OldMyoInfarc 4.759 5.35 .789 1 .374 116.632 .003 4239913.2 
CHF .370 .230 2.593 1 .107 1.448 .923 2.271 
PeriphVascDis -.392 .801 .240 1 .624 .676 .141 3.245 
CerebroVascDis -.203 .815 .062 1 .803 .816 .165 4.030 
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COPD .231 .210 1.212 1 .271 1.260 .835 1.900 
Dementia 2.521 .486 26.958 1 .000 12.440 4.803 32.220 
Paralysis 2.334 1.30 3.186 1 .074 10.324 .795 134.006 
Diabetes .604 .739 .668 1 .414 1.830 .430 7.792 
DiabetesSequelae -1.027 .950 1.169 1 .280 .358 .056 2.305 
ChronicRenalFail .809 .498 2.639 1 .104 2.246 .846 5.963 
Rheum 3.552 4.69 .574 1 .449 34.896 .004 343248.32 
Constant -1.596 4.04 .156 1 .693 .203   
a. Variable(s) entered on step 1: sPSA, Race, Age, Grade, HistStageCombinary, MarStatus, 
Radiation, RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, 
Pct4yrColl, MedIncome, MyoInfarc, OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, 
COPD, Dementia, Paralysis, Diabetes, DiabetesSequelae, ChronicRenalFail, Rheum. 
 
 
Conditional Cox Regression Quintile 1 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 389 3.4% 
Censored 209 1.8% 
Total 598 5.2% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
10920 94.8% 
Total 10920 94.8% 
Total 11518 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
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Categorical Variable Codingsb,c,d,e,f 
 Frequency (1) (2) (3) (4) (5) 
Agea 14 8684 0 0 0 0  
15 1337 1 0 0 0  
16 729 0 1 0 0  
17 473 0 0 1 0  
18 295 0 0 0 1  
Gradea 1 1107 0     
2 10411 1     
MarStatusa 1 1220 0 0 0 0 0 
2 7819 1 0 0 0 0 
3 70 0 1 0 0 0 
4 628 0 0 1 0 0 
5 756 0 0 0 1 0 
9 1025 0 0 0 0 1 
Racea  1 8966 0     
 2 2552 1     
Radiationa 0 8099 0 0 0 0  
1 2190 1 0 0 0  
2 420 0 1 0 0  
4 513 0 0 1 0  
9 296 0 0 0 1  
a. Indicator Parameter Coding 
b. Category variable: Age (Age at Diagnosis Year 1) 
c. Category variable: Grade (Grade 1) 
d. Category variable: MarStatus (Marital Status) 
e. Category variable: Race (SEER Race Recode B) 
f. Category variable: Radiation (Radiation 1) 
 
 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
300.826 
284 
 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square Df Sig. Chi-square df Sig. Chi-square df Sig. 
205.389 73.469 34 .000 95.437 34 .000 95.437 34 .000 
a. Beginning Block Number 1. Method = Enter 
 
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp (B) 
95.0% CI for Exp (B) 
Lower Upper 
sPSA .019 .185 .010 1 .919 1.019 .710 1.463 
Race 2.918 4.258 .470 1 .493 18.506 .004 77918.81 
Age   16.470 4 .002    
Age(1) -4.051 5.699 .505 1 .477 .017 .000 1234.359 
Age(2) -3.213 5.897 .297 1 .586 .040 .000 4205.373 
Age(3) -1.334 4.824 .076 1 .782 .263 .000 3366.156 
Age(4) -.011 3.060 .000 1 .997 .989 .002 397.657 
Grade -.826 1.429 .334 1 .563 .438 .027 7.203 
HistStageCombine   . 0a .    
MarStatus   6.370 5 .272    
MarStatus(1) -1.785 2.083 .735 1 .391 .168 .003 9.949 
MarStatus(2) 13.848 120.3 .013 1 .908 1033086. .000 2.975E108 
MarStatus(3) -.478 .995 .230 1 .631 .620 .088 4.364 
MarStatus(4) .843 1.583 .283 1 .595 2.322 .104 51.689 
MarStatus(5) -.487 1.216 .161 1 .689 .614 .057 6.657 
Radiation   3.317 4 .506    
Radiation(1) .212 .442 .230 1 .631 1.236 .520 2.939 
Radiation(2) -1.960 2.318 .716 1 .398 .141 .001 13.223 
Radiation(3) -1.196 .907 1.737 1 .188 .302 .051 1.791 
Radiation(4) .632 1.049 .363 1 .547 1.882 .241 14.712 
RadSurgCombinary 1.070 .745 2.064 1 .151 2.916 .677 12.557 
SurgCombinary 1.259 3.783 .111 1 .739 3.522 .002 5850.057 
Hormones   . 0a .    
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PctNonHSGrad -.060 .233 .065 1 .798 .942 .596 1.488 
PctHSonly -.051 .238 .045 1 .831 .951 .596 1.515 
PctSomeColl -.180 .247 .528 1 .468 .835 .514 1.357 
Pct4yrColl -.103 .245 .178 1 .673 .902 .558 1.457 
MedIncome .000 .000 .100 1 .752 1.000 1.000 1.000 
MyoInfarc -9.569 4.094 5.462 1 .019 .000 .000 .213 
OldMyoInfarc 55.089 51.74 1.133 1 .287 8.407E23 .000 9.381E67 
CHF 3.442 5.198 .439 1 .508 31.263 .001 830301.47 
PeriphVascDis .233 3.832 .004 1 .952 1.262 .001 2308.350 
CerebroVascDis 8.999 8.123 1.228 1 .268 8097.961 .001 6.643E10 
COPD 2.301 3.144 .536 1 .464 9.982 .021 4731.409 
Dementia 7.801 10.68 .533 1 .465 2443.634 .000 3.040E12 
Paralysis 27.262 169.6 .026 1 .872 6.912E11 .000 1.656E156 
Diabetes 5.395 2.884 3.500 1 .061 220.360 .773 62793.265 
DiabetesSequelae -.960 3.458 .077 1 .781 .383 .000 335.926 
ChronicRenalFail 7.090 11.64 .371 1 .543 1199.333 .000 9.729E12 
Rheum   . 0a .    
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix D 
Logistic and Conditional Cox Regression Output with Propensity Analysis 
Quintile 2 
 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
8084 100.0 
Missing Cases 0 .0 
Total 8084 100.0 
Unselected Cases 0 .0 
Total 8084 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable HistStageCombinary is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
c. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 559 .000 .000 .000 .000 .000 
2 5614 1.000 .000 .000 .000 .000 
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3 29 .000 1.000 .000 .000 .000 
4 375 .000 .000 1.000 .000 .000 
5 656 .000 .000 .000 1.000 .000 
9 851 .000 .000 .000 .000 1.000 
Radiation 1 0 4463 .000 .000 .000 .000  
1 2233 1.000 .000 .000 .000  
2 638 .000 1.000 .000 .000  
4 619 .000 .000 1.000 .000  
9 131 .000 .000 .000 1.000  
Age at Diagnosis Year 
1 
14 3709 .000 .000 .000 .000  
15 2323 1.000 .000 .000 .000  
16 1213 .000 1.000 .000 .000  
17 591 .000 .000 1.000 .000  
18 248 .000 .000 .000 1.000  
Grade 1 1 747 .000     
2 7337 1.000     
SEER Race Recode B  1 7040 .000     
 2 1044 1.000     
 
 
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 7825 0 100.0 
1 259 0 .0 
Overall Percentage   96.8 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald Df Sig. Exp (B) 
Step 0 Constant -3.408 .063 2912.198 1 .000 .033 
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Variables not in the Equationa 
 Score Df Sig. 
Step 0 Variables sPSA .483 1 .487 
Race 1.475 1 .225 
Age 103.348 4 .000 
Age(1) .229 1 .633 
Age(2) 16.743 1 .000 
Age(3) 46.365 1 .000 
Age(4) 16.392 1 .000 
Grade 5.825 1 .016 
MarStatus 11.304 5 .046 
MarStatus(1) 8.987 1 .003 
MarStatus(2) .006 1 .940 
MarStatus(3) .093 1 .761 
MarStatus(4) 3.409 1 .065 
MarStatus(5) 4.880 1 .027 
Radiation 21.045 4 .000 
Radiation(1) 2.217 1 .136 
Radiation(2) 4.890 1 .027 
Radiation(3) 3.460 1 .063 
Radiation(4) 4.407 1 .036 
RadSurgCombine .004 1 .951 
SurgCombinary 68.383 1 .000 
PctNonHSGrad 2.160 1 .142 
PctHSonly .871 1 .351 
PctSomeColl .338 1 .561 
Pct4yrColl .438 1 .508 
MedIncome .012 1 .912 
MyoInfarc .339 1 .560 
OldMyoInfarc .021 1 .885 
CHF .080 1 .778 
PeriphVascDis .883 1 .347 
CerebroVascDis 2.288 1 .130 
COPD .924 1 .336 
Dementia .033 1 .856 
Paralysis .398 1 .528 
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Diabetes .000 1 .999 
DiabetesSequelae .222 1 .638 
ChronicRenalFail .531 1 .466 
Rheum .516 1 .472 
a. Residual Chi-Squares are not computed because of redundancies. 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 153.657 35 .000 
Block 153.657 35 .000 
Model 153.657 35 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 2138.297a .019 .076 
a. Estimation terminated at iteration number 20 
because maximum iterations have been reached. 
Final solution cannot be found. 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 7825 0 100.0 
1 259 0 .0 
Overall Percentage   96.8 
a. The cut value is .500 
 
 
 
 
290 
 
 
 
 
 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp (B) 
95% C.I. for EXP 
(B) 
Lower Upper 
sPSA -.101 .128 .618 1 .432 .904 .703 1.163 
Race .339 .520 .424 1 .515 1.403 .506 3.892 
Age   44.95 4 .000    
Age(1) -.349 .635 .303 1 .582 .705 .203 2.447 
Age(2) .281 .663 .180 1 .672 1.324 .361 4.857 
Age(3) .790 .574 1.895 1 .169 2.204 .715 6.790 
Age(4) 1.004 .444 5.099 1 .024 2.728 1.142 6.520 
Grade -.104 .234 .197 1 .657 .901 .570 1.426 
MarStatus   8.427 5 .134    
MarStatus(1) -.392 .307 1.632 1 .201 .676 .370 1.233 
MarStatus(2) .053 1.051 .003 1 .960 1.055 .135 8.266 
MarStatus(3) -.121 .387 .098 1 .754 .886 .415 1.893 
MarStatus(4) -.211 .321 .430 1 .512 .810 .431 1.520 
MarStatus(5) .232 .295 .616 1 .433 1.261 .707 2.248 
Radiation   .749 4 .945    
Radiation(1) .002 .169 .000 1 .989 1.002 .720 1.396 
Radiation(2) -.339 .405 .699 1 .403 .713 .322 1.577 
Radiation(3) -.030 .320 .009 1 .926 .971 .518 1.818 
Radiation(4) -18.528 3431.1 .000 1 .996 .000 .000 . 
RadSurgCombine -.290 .393 .544 1 .461 .748 .347 1.617 
SurgCombinary 1.135 .460 6.088 1 .014 3.110 1.263 7.661 
PctNonHSGrad -.172 .111 2.417 1 .120 .842 .677 1.046 
PctHSonly -.145 .111 1.696 1 .193 .865 .696 1.076 
PctSomeColl -.172 .112 2.374 1 .123 .842 .677 1.048 
Pct4yrColl -.155 .112 1.939 1 .164 .856 .688 1.065 
MedIncome .000 .000 .255 1 .613 1.000 1.000 1.000 
MyoInfarc 1.143 2.255 .257 1 .612 3.136 .038 260.517 
OldMyoInfarc -3.293 10.988 .090 1 .764 .037 .000 8.369E7 
CHF .618 .733 .709 1 .400 1.855 .441 7.808 
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PeriphVascDis .774 1.106 .490 1 .484 2.169 .248 18.959 
CerebroVascDis 1.507 1.345 1.256 1 .262 4.513 .324 62.965 
COPD .119 .409 .084 1 .772 1.126 .505 2.511 
Dementia -21.279 51728. .000 1 1.00 .000 .000 . 
Paralysis -44.863 28956. .000 1 .999 .000 .000 . 
Diabetes -.026 1.002 .001 1 .979 .974 .137 6.946 
DiabetesSequelae -.742 1.412 .276 1 .599 .476 .030 7.580 
ChronicRenalFail -24.968 14582 .000 1 .999 .000 .000 . 
Rheum 1.789 5.908 .092 1 .762 5.984 .000 639306 
Constant 12.259 11.097 1.220 1 .269 210850.6   
a. Variable(s) entered on step 1: sPSA, Race, Age, Grade, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, 
MedIncome, MyoInfarc, OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, 
Dementia, Paralysis, Diabetes, DiabetesSequelae, ChronicRenalFail, Rheum. 
 
 
Conditional Cox Regression for Quintile 2 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 259 3.2% 
Censored 125 1.5% 
Total 384 4.8% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
7700 95.2% 
Total 7700 95.2% 
Total 8084 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
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Categorical Variable Codingsb,c,d,e,f 
 Frequency (1) (2) (3) (4) (5) 
Agea 14 3709 0 0 0 0  
15 2323 1 0 0 0  
16 1213 0 1 0 0  
17 591 0 0 1 0  
18 248 0 0 0 1  
Gradea 1 747 1     
2 7337 0     
MarStatusa 1 559 0 0 0 0 0 
2 5614 1 0 0 0 0 
3 29 0 1 0 0 0 
4 375 0 0 1 0 0 
5 656 0 0 0 1 0 
9 851 0 0 0 0 1 
Racea  1 7040 0     
 2 1044 1     
Radiationa 0 4463 0 0 0 0  
1 2233 1 0 0 0  
2 638 0 1 0 0  
4 619 0 0 1 0  
9 131 0 0 0 1  
a. Indicator Parameter Coding 
b. Category variable: Age (Age at Diagnosis Year 1) 
c. Category variable: Grade (Grade 1) 
d. Category variable: MarStatus (Marital Status) 
e. Category variable: Race (SEER Race Recode B) 
f. Category variable: Radiation (Radiation 1) 
 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
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Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
176.059 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihoo
d 
Overall (score) 
Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square Df Sig. 
Chi-
square Df Sig. Chi-square df Sig. 
87.830 62.430 31 .001 88.229 31 .000 88.229 31 .000 
a. Beginning Block Number 1. Method = Enter 
 
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp (B) 
95.0% CI for Exp (B) 
Lower Upper 
sPSA -.292 .316 .856 1 .355 .747 .402 1.387 
Race -1.215 39.584 .001 1 .976 .297 .000 1.468E33 
Age   12.255 4 .016    
Age(1) -2.272 40.099 .003 1 .955 .103 .000 1.400E33 
Age(2) -1.202 40.183 .001 1 .976 .301 .000 4.809E33 
Age(3) 2.297 39.807 .003 1 .954 9.940 .000 7.612E34 
Age(4) 12.24 54.696 .050 1 .823 208864.64 .000 7.534E51 
Grade -4.511 2.527 3.186 1 .074 .011 .000 1.556 
HistStageCombine   . 0a .    
MarStatus   5.068 5 .408    
MarStatus(1) -5.148 3.667 1.971 1 .160 .006 .000 7.689 
MarStatus(2) 18.73 168.61 .012 1 .912 1.367E8 .000 4.601E151 
MarStatus(3) -.864 1.934 .200 1 .655 .421 .010 18.647 
MarStatus(4) -2.848 2.581 1.217 1 .270 .058 .000 9.128 
MarStatus(5) -1.838 2.174 .715 1 .398 .159 .002 11.270 
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Radiation   8.612 4 .072    
Radiation(1) -2.406 .839 8.235 1 .004 .090 .017 .466 
Radiation(2) -6.113 4.064 2.262 1 .133 .002 .000 6.378 
Radiation(3) -1.234 1.173 1.106 1 .293 .291 .029 2.903 
Radiation(4) -19.1 71.335 .072 1 .789 .000 .000 2.653E52 
RadSurgCombine 2.972 1.580 3.539 1 .060 19.523 .883 431.553 
SurgCombinary -4.439 39.456 .013 1 .910 .012 .000 4.546E31 
Hormones   . 0a .    
PctNonHSGrad .179 .390 .211 1 .646 1.196 .557 2.568 
PctHSonly .291 .384 .574 1 .449 1.338 .630 2.841 
PctSomeColl .060 .440 .018 1 .892 1.062 .448 2.513 
Pct4yrColl .000 .438 .000 1 1.000 1.000 .424 2.358 
MedIncome .000 .000 2.083 1 .149 1.000 1.000 1.000 
MyoInfarc 6.937 444.07 .000 1 .988 1029.705 .000 . 
OldMyoInfarc -15.04 665.60 .001 1 .982 .000 .000 . 
CHF -2.405 45.483 .003 1 .958 .090 .000 4.685E37 
PeriphVascDis -8.258 93.888 .008 1 .930 .000 .000 2.145E76 
CerebroVascDis 58.74 205.53 .082 1 .775 3.270E25 .000 2.900E200 
COPD 6.793 4.973 1.866 1 .172 891.397 .052 1.524E7 
Dementia   . 0a .    
Paralysis   . 0a .    
Diabetes -.192 4.230 .002 1 .964 .825 .000 3290.749 
DiabetesSequelae 4.883 3.741 1.703 1 .192 132.022 .086 201994.02 
ChronicRenalFail   . 0a .    
Rheum   . 0a .    
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix E 
Logistic and Conditional Cox Regression Output with Propensity Analysis 
Quintile 3 
 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
11496 100.0 
Missing Cases 0 .0 
Total 11496 100.0 
Unselected Cases 0 .0 
Total 11496 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable HistStageCombinary is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
c. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
d. The variable DEMENTIA (1) is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
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Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 612 .000 .000 .000 .000 .000 
2 8649 1.000 .000 .000 .000 .000 
3 29 .000 1.000 .000 .000 .000 
4 350 .000 .000 1.000 .000 .000 
5 846 .000 .000 .000 1.000 .000 
9 1010 .000 .000 .000 .000 1.000 
Radiation 1 0 6453 .000 .000 .000 .000  
1 2664 1.000 .000 .000 .000  
2 1566 .000 1.000 .000 .000  
4 695 .000 .000 1.000 .000  
9 118 .000 .000 .000 1.000  
Age at Diagnosis Year 
1 
14 2609 .000 .000 .000 .000  
15 4731 1.000 .000 .000 .000  
16 2469 .000 1.000 .000 .000  
17 1130 .000 .000 1.000 .000  
18 557 .000 .000 .000 1.000  
Grade 1 1 699 .000     
2 10797 1.000     
SEER Race Recode B  1 10784 .000     
 2 712 1.000     
 
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 11085 0 100.0 
1 411 0 .0 
Overall Percentage   96.4 
a. Constant is included in the model. 
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Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 11085 0 100.0 
1 411 0 .0 
Overall Percentage   96.4 
a. Constant is included in the model. 
b. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald Df Sig. Exp (B) 
Step 0 Constant -3.295 .050 4302.065 1 .000 .037 
 
 
Variables not in the Equationa 
 Score Df Sig. 
Variables sPSA 6.563 1 .010 
Race .862 1 .353 
Age 88.958 4 .000 
Age(1) 5.579 1 .018 
Age(2) 48.152 1 .000 
Age(3) 12.082 1 .001 
Age(4) .521 1 .470 
Grade 2.171 1 .141 
MarStatus 35.462 5 .000 
MarStatus(1) 19.778 1 .000 
MarStatus(2) 1.078 1 .299 
MarStatus(3) .020 1 .887 
MarStatus(4) 2.225 1 .136 
MarStatus(5) 30.046 1 .000 
Radiation 38.330 4 .000 
Radiation(1) 3.980 1 .046 
Radiation(2) 27.772 1 .000 
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Radiation(3) 4.308 1 .038 
Radiation(4) 2.573 1 .109 
RadSurgCombinary 1.845 1 .174 
SurgCombinary 40.731 1 .000 
PctNonHSGrad .343 1 .558 
PctHSonly .415 1 .519 
PctSomeColl 1.233 1 .267 
Pct4yrColl .090 1 .764 
MedIncome .416 1 .519 
MyoInfarc .796 1 .372 
OldMyoInfarc .226 1 .634 
CHF 1.926 1 .165 
PeriphVascDisDx .280 1 .597 
CerebroVascDis .708 1 .400 
COPD .854 1 .355 
Paralysis .111 1 .739 
Diabetes 1.754 1 .185 
DiabetesSequelae 2.324 1 .127 
ChronicRenalFail .037 1 .847 
Rheum .594 1 .441 
a. Residual Chi-Squares are not computed because of redundancies. 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 178.886 34 .000 
Block 178.886 34 .000 
Model 178.886 34 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 3366.457a .015 .058 
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Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 3366.457a .015 .058 
a. Estimation terminated at iteration number 20 
because maximum iterations have been reached. 
Final solution cannot be found. 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 11085 0 100.0 
1 411 0 .0 
Overall Percentage   96.4 
a. The cut value is .500 
 
 
Variables in the Equation 
 
B S.E. Wald Df Sig. Exp (B) 
95% C.I. for  Exp (B) 
Lower Upper 
sPSA -.297 .102 8.407 1 .004 .743 .608 .908 
Race .551 .375 2.155 1 .142 1.735 .831 3.619 
Age   39.48 4 .000    
Age(1) -.493 .437 1.276 1 .259 .611 .259 1.437 
Age(2) .163 .455 .128 1 .720 1.177 .483 2.870 
Age(3) .324 .400 .655 1 .418 1.383 .631 3.031 
Age(4) .388 .356 1.189 1 .275 1.474 .734 2.959 
Grade -.312 .214 2.121 1 .145 .732 .481 1.114 
MarStatus   29.91 5 .000    
MarStatus(1) -.428 .273 2.452 1 .117 .652 .381 1.114 
MarStatus(2) -17.99 7372.3 .000 1 .998 .000 .000 . 
MarStatus(3) .005 .365 .000 1 .990 1.005 .491 2.056 
MarStatus(4) -.073 .293 .061 1 .804 .930 .524 1.651 
MarStatus(5) .481 .265 3.276 1 .070 1.617 .961 2.721 
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Radiation   13.92 4 .008    
Radiation(1) .114 .128 .802 1 .371 1.121 .873 1.439 
Radiation(2) -.766 .302 6.452 1 .011 .465 .257 .839 
Radiation(3) -.300 .283 1.127 1 .288 .741 .425 1.289 
Radiation(4) -2.011 1.013 3.939 1 .047 .134 .018 .975 
RadSurgCombine .131 .268 .238 1 .625 1.140 .674 1.927 
SurgCombinary 1.089 .296 13.50 1 .000 2.972 1.662 5.313 
PctNonHSGrad -.023 .025 .813 1 .367 .978 .930 1.027 
PctHSonly -.015 .025 .336 1 .562 .985 .937 1.036 
PctSomeColl -.039 .026 2.237 1 .135 .961 .913 1.012 
Pct4yrColl -.026 .026 1.012 1 .314 .974 .926 1.025 
MedIncome .000 .000 .000 1 .999 1.000 1.000 1.000 
MyoInfarc -1.797 2.481 .525 1 .469 .166 .001 21.425 
OldMyoInfarc 4.317 9.259 .217 1 .641 74.926 .000 5.703E9 
CHF -.285 .895 .101 1 .751 .752 .130 4.349 
PeriphVascDis -.137 1.207 .013 1 .909 .872 .082 9.277 
CerebroVascDis -.055 1.246 .002 1 .965 .946 .082 10.878 
COPD .157 .358 .193 1 .660 1.170 .580 2.360 
Paralysis -42.24 58618. .000 1 .999 .000 .000 . 
Diabetes .922 .836 1.214 1 .270 2.513 .488 12.942 
DiabetesSequelae .944 .907 1.083 1 .298 2.571 .434 15.222 
ChronicRenalFail -23.03 59281. .000 1 1.000 .000 .000 . 
Rheum 4.447 5.217 .727 1 .394 85.366 .003 2353126 
Constant -.661 2.546 .067 1 .795 .516   
a. Variable(s) entered on step 1: sPSA, Race, Age, Grade, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, 
MedIncome, MyoInfarc, OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, 
Paralysis, Diabetes, DiabetesSequelae, ChronicRenalFail, Rheum. 
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Conditional Cox Regression for Quintile 3 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 411 3.6% 
Censored 208 1.8% 
Total 619 5.4% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
10877 94.6% 
Total 10877 94.6% 
Total 11496 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
 
 
 
Categorical Variable Codingsb,c,d,e,f 
 Frequency (1) (2) (3) (4) (5) 
Agea 14 2609 1 0 0 0  
15 4731 0 1 0 0  
16 2469 0 0 1 0  
17 1130 0 0 0 1  
18 557 0 0 0 0  
Grade
a 
1 699 0     
2 10797 1     
MarSt
atusa 
1 612 0 0 0 0 0 
2 8649 1 0 0 0 0 
3 29 0 1 0 0 0 
4 350 0 0 1 0 0 
5 846 0 0 0 1 0 
9 1010 0 0 0 0 1 
Racea  1 10784 0     
 2 712 1     
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Radiat
iona 
0 6453 0 0 0 0  
1 2664 1 0 0 0  
2 1566 0 1 0 0  
4 695 0 0 1 0  
9 118 0 0 0 1  
a. Indicator Parameter Coding 
b. Category variable: Age (Age at Diagnosis Year 1) 
c. Category variable: Grade (Grade 1) 
d. Category variable: MarStatus (Marital Status) 
e. Category variable: Race (SEER Race Recode B) 
f. Category variable: Radiation (Radiation 1) 
 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
295.281 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-
square df Sig. 
Chi-
square df Sig. 
Chi-
square df Sig. 
229.252 56.658 30 .002 66.029 30 .000 66.029 30 .000 
a. Beginning Block Number 1. Method = Enter 
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp (B) 
95.0% CI for Exp (B) 
Lower Upper 
sPSA -.199 .171 1.365 1 .243 .819 .586 1.145 
Race 1.098 1.255 .765 1 .382 2.997 .256 35.055 
Age   6.083 4 .193    
Age(1) -.943 1.582 .356 1 .551 .389 .018 8.645 
Age(2) -.454 1.651 .076 1 .783 .635 .025 16.152 
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Age(3) -.301 1.458 .043 1 .836 .740 .042 12.886 
Age(4) .574 1.178 .238 1 .626 1.776 .177 17.868 
Grade -.312 .609 .263 1 .608 .732 .222 2.412 
HistStageCombine   . 0a .    
MarStatus   4.565 4a .335    
MarStatus(1) .131 .768 .029 1 .865 1.140 .253 5.133 
MarStatus(3) .481 .907 .281 1 .596 1.618 .273 9.579 
MarStatus(4) .091 .747 .015 1 .903 1.095 .253 4.736 
MarStatus(5) .996 .701 2.021 1 .155 2.708 .686 10.696 
Radiation   7.547 4 .110    
Radiation(1) -.705 .330 4.570 1 .033 .494 .259 .943 
Radiation(2) -1.32 .840 2.482 1 .115 .266 .051 1.381 
Radiation(3) -1.28 .572 5.018 1 .025 .277 .090 .852 
Radiation(4) .269 1.592 .029 1 .866 1.309 .058 29.640 
RadSurgCombined 2.359 .734 10.331 1 .001 10.576 2.510 44.558 
SurgCombinary -.048 1.088 .002 1 .964 .953 .113 8.034 
Hormones   . 0a .    
PctNonHSGrad -.469 .225 4.329 1 .037 .626 .402 .973 
PctHSonly -.450 .223 4.080 1 .043 .637 .412 .987 
PctSomeColl -.504 .226 4.958 1 .026 .604 .388 .941 
Pct4yrColl -.497 .226 4.843 1 .028 .608 .391 .947 
MedIncome .000 .000 1.824 1 .177 1.000 1.000 1.000 
MyoInfarc -40.9 510.315 .006 1 .936 .000 .000 . 
OldMyoInfarc -21. 19.650 1.153 1 .283 .000 .000 3.642E7 
PeriphVascDisDx -2.42 3.043 .632 1 .427 .089 .000 34.640 
CerebroVascDis .146 3.701 .002 1 .968 1.158 .001 1637.211 
COPD -.435 1.046 .173 1 .677 .647 .083 5.022 
Dementia   . 0a .    
Paralysis   . 0a .    
Diabetes -.691 2.001 .119 1 .730 .501 .010 25.315 
DiabetesSequelae 2.520 2.735 .849 1 .357 12.424 .058 2642.014 
ChronicRenalFail   . 0a .    
Rheum -6.96 11.814 .348 1 .555 .001 .000 1.070E7 
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix F 
Logistic and Conditional Cox Regression Output with Propensity Analysis 
Quintile 4 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
7900 100.0 
Missing Cases 0 .0 
Total 7900 100.0 
Unselected Cases 0 .0 
Total 7900 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable HistStageCombinary is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
c. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
d. The variable DEMENTIA (1) is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
e. The variable CHRONIC RENAL FAILURE (2) is 
constant for the selected cases. Since a constant term 
was specified, the variable will be removed from the 
analysis. 
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Categorical Variables Codings 
 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital 
Status 
1 474 .000 .000 .000 .000 .000 
2 5316 1.000 .000 .000 .000 .000 
3 25 .000 1.000 .000 .000 .000 
4 260 .000 .000 1.000 .000 .000 
5 764 .000 .000 .000 1.000 .000 
9 1061 .000 .000 .000 .000 1.000 
Radiation  0 3960 .000 .000 .000 .000  
1 2467 1.000 .000 .000 .000  
2 827 .000 1.000 .000 .000  
4 595 .000 .000 1.000 .000  
9 51 .000 .000 .000 1.000  
Age at 
Diagnosis 
Year 1 
14 372 .000 .000 .000 .000  
15 3491 1.000 .000 .000 .000  
16 2452 .000 1.000 .000 .000  
17 1331 .000 .000 1.000 .000  
18 254 .000 .000 .000 1.000  
Grade 1 1 431 .000     
2 7469 1.000     
SEER 
Race 
Recode B 
 1 7819 .000     
 2 81 1.000     
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 7666 0 100.0 
1 234 0 .0 
Overall Percentage   97.0 
a. Constant is included in the model. 
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Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 7666 0 100.0 
1 234 0 .0 
Overall Percentage   97.0 
a. Constant is included in the model. 
b. The cut value is .500 
Variables in the Equation 
 B S.E. Wald df Sig. Exp (B) 
Step 0 Constant -3.489 .066 2764.500 1 .000 .031 
 
 
Variables not in the Equationa 
 Score df Sig. 
Step 0  sPSA .282 1 .595 
Race .850 1 .357 
Age 34.616 4 .000 
Age(1) 11.524 1 .001 
Age(2) .234 1 .629 
Age(3) 14.633 1 .000 
Age(4) 10.169 1 .001 
Grade .266 1 .606 
MarStatus 13.682 5 .018 
MarStatus(1) 1.791 1 .181 
MarStatus(2) 2.215 1 .137 
MarStatus(3) 1.010 1 .315 
MarStatus(4) .664 1 .415 
MarStatus(5) 10.404 1 .001 
Radiation 20.819 4 .000 
Radiation(1) 4.659 1 .031 
Radiation(2) 7.337 1 .007 
Radiation(3) 1.352 1 .245 
Radiation(4) 1.523 1 .217 
RadSurgCombinary .304 1 .582 
SurgCombinary 1.479 1 .224 
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PctNonHSGrad 4.118 1 .042 
PctHSonly 8.222 1 .004 
PctSomeColl 1.892 1 .169 
Pct4yrColl 5.891 1 .015 
MedIncome 3.544 1 .060 
MyoInfarc .124 1 .724 
OldMyoInfarc .006 1 .936 
CHF .551 1 .458 
PeriphVascDis 2.537 1 .111 
CerebroVascDis .030 1 .862 
COPD 1.650 1 .199 
Paralysis .031 1 .861 
Diabetes .082 1 .775 
DiabetesSequelae 12.352 1 .000 
Rheum .100 1 .752 
a. Residual Chi-Squares are not computed because of redundancies. 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 72.722 33 .000 
Block 72.722 33 .000 
Model 72.722 33 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 2035.308a .009 .039 
a. Estimation terminated at iteration number 20 
because maximum iterations have been reached. 
Final solution cannot be found. 
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Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 7666 0 100.0 
1 234 0 .0 
Overall Percentage   97.0 
a. The cut value is .500 
 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp (B) 
95% C.I. for Exp (B) 
Lower Upper 
sPSA .075 .142 .277 1 .599 1.077 .816 1.422 
Race -.608 1.194 .259 1 .611 .545 .052 5.652 
Age   18.35 4 .001    
Age(1) .968 1.033 .878 1 .349 2.631 .348 19.917 
Age(2) 1.272 1.068 1.41 1 .234 3.569 .440 28.954 
Age(3) 1.628 .958 2.88 1 .089 5.093 .779 33.285 
Age(4) 1.816 .827 4.81 1 .028 6.150 1.215 31.135 
Grade .174 .377 .214 1 .644 1.190 .569 2.490 
MarStatus   8.23 5 .144    
MarStatus(1) .067 .419 .025 1 .873 1.069 .470 2.430 
MarStatus(2) 1.109 .813 1.86 1 .173 3.030 .616 14.909 
MarStatus(3) -.210 .551 .145 1 .703 .811 .276 2.385 
MarStatus(4) -.119 .419 .081 1 .777 .888 .391 2.019 
MarStatus(5) .464 .364 1.62 1 .202 1.590 .780 3.242 
Radiation   3.387 4 .495    
Radiation(1) -.243 .170 2.05 1 .151 .784 .562 1.093 
Radiation(2) -.359 .479 .561 1 .454 .698 .273 1.786 
Radiation(3) -.266 .306 .753 1 .386 .767 .421 1.397 
Radiation(4) .532 .610 .762 1 .383 1.703 .515 5.625 
RadSurgCombine -.100 .606 .027 1 .869 .905 .276 2.970 
SurgCombinary .174 .573 .092 1 .762 1.190 .387 3.656 
PctNonHSGrad -.070 .116 .365 1 .546 .932 .743 1.170 
PctHSonly -.083 .116 .511 1 .475 .920 .733 1.156 
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PctSomeColl -.063 .117 .291 1 .589 .939 .747 1.180 
Pct4yrColl -.068 .117 .339 1 .560 .934 .744 1.174 
MedIncome .000 .000 .005 1 .945 1.000 1.000 1.000 
MyoInfarc 1.407 2.546 .306 1 .580 4.085 .028 600.147 
OldMyoInfarc -3.056 13.031 .055 1 .815 .047 .000 5.825E9 
CHF -19.92 10810.1 .000 1 .999 .000 .000 . 
PeriphVascDis 1.392 1.151 1.46 1 .226 4.025 .421 38.437 
CerebroVascDis -.565 1.949 .084 1 .772 .568 .012 25.932 
COPD .403 .523 .594 1 .441 1.496 .537 4.172 
Paralysis -45.11 102272 .000 1 1.00 .000 .000 . 
Diabetes -.831 1.243 .447 1 .504 .436 .038 4.980 
DiabetesSequelae 2.792 .958 8.49 1 .004 16.321 2.497 106.681 
Rheum -2.447 8.137 .090 1 .764 .087 .000 730957.2 
Constant 2.531 11.699 .047 1 .829 12.568   
a. Variable(s) entered on step 1: sPSA, Race, Age, Grade, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, 
MedIncome, MyoInfarc, OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, 
Paralysis, Diabetes, DiabetesSequelae, Rheum. 
 
Conditional Cox Regression for Quintile 4 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 234 3.0% 
Censored 131 1.7% 
Total 365 4.6% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
7535 95.4% 
Total 7535 95.4% 
Total 7900 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
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Categorical Variable Codingsb,c,d,e,f 
 Frequency (1) (2) (3) (4) (5) 
Agea 14 372 0 0 0 0  
15 3491 1 0 0 0  
16 2452 0 1 0 0  
17 1331 0 0 1 0  
18 254 0 0 0 1  
Gradea 1 431 0     
2 7469 1     
MarStatusa 1 474 0 0 0 0 0 
2 5316 1 0 0 0 0 
3 25 0 1 0 0 0 
4 260 0 0 1 0 0 
5 764 0 0 0 1 0 
9 1061 0 0 0 0 1 
Racea  1 7819 0     
 2 81 1     
Radiationa 0 3960 0 0 0 0  
1 2467 1 0 0 0  
2 827 0 1 0 0  
4 595 0 0 1 0  
9 51 0 0 0 1  
a. Indicator Parameter Coding 
b. Category variable: Age (Age at Diagnosis Year 1) 
c. Category variable: Grade (Grade 1) 
d. Category variable: MarStatus (Marital Status) 
e. Category variable: Race (SEER Race Recode B) 
f. Category variable: Radiation (Radiation 1) 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
185.763 
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Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likeliho
od 
Overall (score) 
Change From 
Previous Step 
Change From 
Previous Block 
Chi-
square df Sig. 
Chi-
square Df Sig. 
Chi-
square df Sig. 
118.969 52.081 32 .014 66.795 32 .000 66.795 32 .000 
a. Beginning Block Number 1. Method = Enter 
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
sPSA .646 .891 .526 1 .468 1.909 .333 10.943 
Race -9.76 71.167 .019 1 .891 .000 .000 2.180E56 
Age   .957 4 .916    
Age(1) 4.112 14.620 .079 1 .779 61.086 .000 1.701E14 
Age(2) 4.294 15.370 .078 1 .780 73.239 .000 8.870E14 
Age(3) 3.267 12.763 .066 1 .798 26.223 .000 1.918E12 
Age(4) 2.728 8.495 .103 1 .748 15.302 .000 2.604E8 
Grade 2.223 3.621 .377 1 .539 9.233 .008 11154.357 
HistStageCombine   . 0a .    
MarStatus   1.922 5 .860    
MarStatus(1) -1.40 5.294 .071 1 .790 .245 .000 7850.527 
MarStatus(2) -2.62 2.637 .989 1 .320 .073 .000 12.752 
MarStatus(3) -1.43 2.456 .341 1 .559 .238 .002 29.338 
MarStatus(4) -1.75 3.478 .253 1 .615 .174 .000 158.564 
MarStatus(5) -1.54 2.962 .272 1 .602 .213 .001 70.839 
Radiation   6.317 4 .177    
Radiation(1) -1.05 .760 1.928 1 .165 .348 .079 1.543 
Radiation(2) -.348 5.854 .004 1 .953 .706 .000 67824.379 
Radiation(3) -.308 1.354 .052 1 .820 .735 .052 10.435 
Radiation(4) 8.636 53.845 .026 1 .873 5629.86 .000 3.832E49 
RadSurgCombine 3.391 2.518 1.814 1 .178 29.693 .214 4126.941 
SurgCombinary -4.59 9.681 .226 1 .635 .010 .000 1751416.2 
Hormones   . 0a .    
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PctNonHSGrad .073 .289 .064 1 .800 1.076 .611 1.896 
PctHSonly .058 .287 .041 1 .839 1.060 .604 1.861 
PctSomeColl .136 .364 .139 1 .709 1.145 .562 2.336 
Pct4yrColl .146 .358 .167 1 .683 1.157 .574 2.333 
MedIncome .000 .000 .269 1 .604 1.000 1.000 1.000 
MyoInfarc -4.68 582.25 .000 1 .994 .009 .000 . 
OldMyoInfarc -63.73 120.02 .282 1 .595 .000 .000 3.043E74 
CHF -10.826 114.79 .009 1 .925 .000 .000 1.025E93 
PeriphVascDis 1.964 9.777 .040 1 .841 7.128 .000 1.496E9 
CerebroVascDis -9.506 19.188 .245 1 .620 .000 .000 1.601E12 
COPD -1.674 7.350 .052 1 .820 .187 .000 338148.89 
Dementia   . 0a .    
Paralysis   . 0a .    
Diabetes 1.456 5.046 .083 1 .773 4.291 .000 84735.501 
DiabetesSequelae 23.763 74.344 .102 1 .749 2.091E10 .000 3.997E73 
ChronicRenalFail   . 0a .    
Rheum -16.086 35.617 .204 1 .652 .000 .000 2.142E23 
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix G 
Logistic and Conditional Cox Regression Output with Propensity Analysis 
Quintile 5 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
11002 100.0 
Missing Cases 0 .0 
Total 11002 100.0 
Unselected Cases 0 .0 
Total 11002 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable HistStageCombinary is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
c. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
d. The variable DEMENTIA (1) is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
e. The variable PARALYSIS (1) is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
f. The variable CHRONIC RENAL FAILURE (2) is 
constant for the selected cases. Since a constant term 
was specified, the variable will be removed from the 
analysis. 
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Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 312 .000 .000 .000 .000 .000 
2 8609 1.000 .000 .000 .000 .000 
3 17 .000 1.000 .000 .000 .000 
4 264 .000 .000 1.000 .000 .000 
5 817 .000 .000 .000 1.000 .000 
9 983 .000 .000 .000 .000 1.000 
Radiation 1 0 4150 .000 .000 .000 .000  
1 4101 1.000 .000 .000 .000  
2 1655 .000 1.000 .000 .000  
4 1070 .000 .000 1.000 .000  
9 26 .000 .000 .000 1.000  
Age at Diagnosis Year 
1 
14 16 .000 .000 .000 .000  
15 5386 1.000 .000 .000 .000  
16 4219 .000 1.000 .000 .000  
17 1331 .000 .000 1.000 .000  
18 50 .000 .000 .000 1.000  
Grade 1 1 314 .000     
2 10688 1.000     
SEER Race Recode B  1 10994 .000     
 2 8 1.000     
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Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 10715 0 100.0 
1 287 0 .0 
Overall Percentage   97.4 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald Df Sig. Exp(B) 
Step 0 Constant -3.620 .060 3662.687 1 .000 .027 
 
Variables not in the Equationa 
 Score df Sig. 
Step 0  sPSA .433 1 .511 
Race .214 1 .643 
Age 18.443 4 .001 
Age(1) 16.067 1 .000 
Age(2) 6.018 1 .014 
Age(3) 6.860 1 .009 
Age(4) .073 1 .787 
Grade .619 1 .431 
MarStatus 21.862 5 .001 
MarStatus(1) 7.253 1 .007 
MarStatus(2) .456 1 .499 
MarStatus(3) .682 1 .409 
MarStatus(4) .968 1 .325 
MarStatus(5) 20.057 1 .000 
Radiation 35.031 4 .000 
Radiation(1) 4.411 1 .036 
Radiation(2) 13.763 1 .000 
Radiation(3) .983 1 .321 
Radiation(4) .698 1 .403 
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RadSurgCombinary .004 1 .950 
SurgCombinary .170 1 .680 
PctNonHSGrad 2.620 1 .106 
PctHSonly 4.789 1 .029 
PctSomeColl .246 1 .620 
Pct4yrColl 3.261 1 .071 
MedIncome .519 1 .471 
MyoInfarc .000 1 .990 
OldMyoInfarc .940 1 .332 
CHF .080 1 .777 
PeriphVascDis 2.497 1 .114 
CerebroVascDis .149 1 .700 
COPD .050 1 .823 
Diabetes .306 1 .580 
DiabetesSequelae 1.005 1 .316 
Rheum .627 1 .428 
a. Residual Chi-Squares are not computed because of redundancies. 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 73.311 32 .000 
Block 73.311 32 .000 
Model 73.311 32 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 2586.141a .007 .031 
a. Estimation terminated at iteration number 20 
because maximum iterations have been reached. 
Final solution cannot be found. 
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Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 10715 0 100.0 
1 287 0 .0 
Overall Percentage   97.4 
a. The cut value is .500 
 
Variables in the Equation 
 
B S.E. Wald Df Sig. Exp(B) 
95% C.I. for Exp(B) 
Lower Upper 
 sPSA -.086 .143 .358 1 .549 .918 .693 1.215 
Race -16.44 14180 .000 1 .999 .000 .000 . 
Age   11.403 4 .022    
Age(1) 16.116 10040 .000 1 .999 9982633 .000 . 
Age(2) 16.474 10040 .000 1 .999 1.427E7 .000 . 
Age(3) 16.664 10040 .000 1 .999 1.726E7 .000 . 
Age(4) 16.242 10040 .000 1 .999 1.132E7 .000 . 
Grade .184 .436 .178 1 .673 1.202 .512 2.823 
MarStatus   14.763 5 .011    
MarStatus(1) -.346 .405 .728 1 .393 .708 .320 1.566 
MarStatus(2) -17.67 9676 .000 1 .999 .000 .000 . 
MarStatus(3) .213 .500 .181 1 .670 1.237 .465 3.295 
MarStatus(4) -.473 .452 1.095 1 .295 .623 .257 1.512 
MarStatus(5) .314 .404 .605 1 .437 1.369 .621 3.019 
Radiation   20.496 4 .000    
Radiation(1) -.451 .142 10.094 1 .001 .637 .482 .841 
Radiation(2) -1.199 .305 15.483 1 .000 .302 .166 .548 
Radiation(3) -.421 .235 3.217 1 .073 .656 .414 1.040 
Radiation(4) -18.03 7820.6 .000 1 .998 .000 .000 . 
RadSurgCombine .418 .596 .492 1 .483 1.519 .472 4.888 
SurgCombinary .484 .802 .364 1 .546 1.622 .337 7.817 
PctNonHSGrad .055 .102 .289 1 .591 1.056 .865 1.289 
PctHSonly .056 .102 .304 1 .581 1.058 .866 1.292 
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PctSomeColl .044 .102 .182 1 .670 1.044 .855 1.276 
Pct4yrColl .049 .102 .228 1 .633 1.050 .860 1.282 
MedIncome .000 .000 .148 1 .701 1.000 1.000 1.000 
MyoInfarc .275 2.989 .008 1 .927 1.317 .004 461.590 
OldMyoInfarc -312.4 124736 .000 1 .998 .000 .000 . 
CHF -18.87 26481 .000 1 .999 .000 .000 . 
PeriphVascDis 2.557 1.334 3.674 1 .055 12.892 .944 176.079 
CerebroVascDis .842 2.317 .132 1 .716 2.320 .025 217.574 
COPD .802 .566 2.006 1 .157 2.230 .735 6.766 
Diabetes 1.338 1.064 1.582 1 .208 3.813 .474 30.686 
DiabetesSequelae -2.871 2.328 1.521 1 .217 .057 .001 5.427 
Rheum -6.958 11.153 .389 1 .533 .001 .000 2960889 
Constant -8.403 17375 .000 1 1.00 .000   
a. Variable(s) entered on step 1: sPSA, Race, Age, Grade, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, 
MedIncome, MyoInfarc, OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, 
Diabetes, DiabetesSequelae, Rheum. 
 
 
Conditional Cox Regression for Quintile 5 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 287 2.6% 
Censored 161 1.5% 
Total 448 4.1% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
10554 95.9% 
Total 10554 95.9% 
Total 11002 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
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Categorical Variable Codingsb,c,d,e,f 
 
 Frequency (1) (2) (3) (4) (5) 
Agea 14 16 0 0 0 0  
15 5386 1 0 0 0  
16 4219 0 1 0 0  
17 1331 0 0 1 0  
18 50 0 0 0 1  
Gradea 1 314 0     
2 10688 1     
MarStatus
a 
1 312 0 0 0 0 0 
2 8609 1 0 0 0 0 
3 17 0 1 0 0 0 
4 264 0 0 1 0 0 
5 817 0 0 0 1 0 
9 983 0 0 0 0 1 
Racea  1 10994 0     
 2 8 1     
Radiationa 0 4150 0 0 0 0  
1 4101 1 0 0 0  
2 1655 0 1 0 0  
4 1070 0 0 1 0  
9 26 0 0 0 1  
a. Indicator Parameter Coding 
b. Category variable: Age (Age at Diagnosis Year 1) 
c. Category variable: Grade (Grade 1) 
d. Category variable: MarStatus (Marital Status) 
e. Category variable: Race (SEER Race Recode B) 
f. Category variable: Radiation (Radiation 1) 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
228.739 
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Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likeliho
od 
Overall (score) 
Change From 
Previous Step 
Change From 
Previous Block 
Chi-
square Df Sig. 
Chi-
square df Sig. 
Chi-
square Df Sig. 
153.41 60.061 26 .000 75.328 26 .000 75.328 26 .000 
a. Beginning Block Number 1. Method = Enter 
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lower Upper 
sPSA .508 .660 .593 1 .441 1.663 .456 6.066 
Race   . 0a .    
Age   7.204 2a .027    
Age(1) -.417 .782 .284 1 .594 .659 .142 3.051 
Age(2) .575 1.001 .330 1 .565 1.778 .250 12.642 
Grade 3.07 1.729 3.154 1 .076 21.573 .727 639.751 
HistStageCombine   . 0a .    
MarStatus   1.129 5 .951    
MarStatus(1) .164 1.768 .009 1 .926 1.179 .037 37.697 
MarStatus(2) -13.3 270.8 .002 1 .961 .000 .000 5.476E224 
MarStatus(3) 11.19 98.69 .013 1 .910 72549.77 .000 7.346E88 
MarStatus(4) -.441 1.462 .091 1 .763 .643 .037 11.297 
MarStatus(5) -.377 1.322 .081 1 .775 .686 .051 9.157 
Radiation   13.059 3a .005    
Radiation(1) -1.474 .416 12.538 1 .000 .229 .101 .518 
Radiation(2) -1.147 1.833 .392 1 .531 .318 .009 11.532 
Radiation(3) -1.076 .597 3.246 1 .072 .341 .106 1.099 
RadSurgCombine .961 1.811 .281 1 .596 2.613 .075 91.017 
SurgCombinary -.801 3.467 .053 1 .817 .449 .001 401.450 
Hormones   . 0a .    
PctNonHSGrad .593 .284 4.348 1 .037 1.809 1.036 3.157 
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PctHSonly .599 .289 4.287 1 .038 1.819 1.032 3.206 
PctSomeColl .667 .295 5.093 1 .024 1.948 1.092 3.476 
Pct4yrColl .672 .294 5.205 1 .023 1.958 1.099 3.486 
MedIncome .000 .000 2.643 1 .104 1.000 1.000 1.000 
MyoInfarc -4.472 7.439 .361 1 .548 .011 .000 24557.688 
OldMyoInfarc   . 0a .    
CHF   . 0a .    
PeriphVascDis 3.047 4.529 .452 1 .501 21.042 .003 150729.64 
CerebroVascDis -8.363 9.210 .825 1 .364 .000 .000 16124.160 
COPD -1.683 2.572 .428 1 .513 .186 .001 28.718 
Dementia   . 0a .    
Paralysis   . 0a .    
Diabetes 4.433 3.177 1.947 1 .163 84.194 .166 42624.670 
DiabetesSequelae -24.81 434.3 .003 1 .954 .000 .000 . 
ChronicRenalFail   . 0a .    
Rheum -151.6 2976 .003 1 .959 .000 .000 . 
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix H 
Logistic and Conditional Cox Regression with Propensity Analysis 
AGE Quartile 1 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
9392 100.0 
Missing Cases 0 .0 
Total 9392 100.0 
Unselected Cases 0 .0 
Total 9392 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 739 .000 .000 .000 .000 .000 
2 7178 1.000 .000 .000 .000 .000 
3 41 .000 1.000 .000 .000 .000 
4 432 .000 .000 1.000 .000 .000 
5 343 .000 .000 .000 1.000 .000 
9 659 .000 .000 .000 .000 1.000 
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Radiation 1 0 5994 .000 .000 .000 .000  
1 1863 1.000 .000 .000 .000  
2 792 .000 1.000 .000 .000  
4 619 .000 .000 1.000 .000  
9 124 .000 .000 .000 1.000  
Grade 1 1 527 .000     
2 8865 1.000     
SEER Race Recode   1 8241 .000     
 2 1151 1.000     
 
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 9214 0 100.0 
1 178 0 .0 
Overall Percentage   98.1 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -3.947 .076 2720.053 1 .000 .019 
 
Variables not in the Equationa 
 Score Df Sig. 
Step 0 sPSA .206 1 .650 
Grade(1) .438 1 .508 
HistStageCombine 22.340 1 .000 
MarStatus 13.151 5 .022 
MarStatus(1) 6.265 1 .012 
MarStatus(2) 1.971 1 .160 
MarStatus(3) .005 1 .946 
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MarStatus(4) .041 1 .840 
MarStatus(5) 9.696 1 .002 
Race(1) .075 1 .784 
Radiation 1.158 1 .282 
RadSurgCombined 7.521 1 .006 
SurgCombinary 9.199 1 .002 
PctNonHSGrad .003 1 .953 
PctHSonly .699 1 .403 
PctSomeColl 6.224 1 .013 
Pct4yrColl 2.189 1 .139 
MedIncome 1.129 1 .288 
MyoInfarc .170 1 .680 
OldMyoInfarc .071 1 .790 
CHF .175 1 .676 
PeriphVascDis 2.823 1 .093 
CerebroVascDis 1.823 1 .177 
COPD .703 1 .402 
Dementia 3.537 1 .060 
Paralysis .271 1 .603 
Diabetes .010 1 .920 
DiabetesSequelae 2.567 1 .109 
ChronicRenalFail .854 1 .355 
Rheum 2.702 1 .100 
a. Residual Chi-Squares are not computed because of redundancies. 
 
Block 1: Method = Enter 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 76.269 31 .000 
Block 76.269 31 .000 
Model 76.269 31 .000 
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Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 1698.702a .007 .041 
a. Estimation terminated at iteration number 20 
because maximum iterations have been reached. 
Final solution cannot be found. 
 
Hosmer and Lemeshow Test 
Step Chi-square Df Sig. 
1 5.686 8 .682 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 9214 0 100.0 
1 178 0 .0 
Overall Percentage   98.1 
a. The cut value is .500 
 
 
 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I. for Exp(B) 
Lower Upper 
sPSA -.086 .153 .320 1 .572 .917 .680 1.237 
Race(1) .129 .249 .268 1 .605 1.138 .698 1.855 
Grade(1) -.071 .309 .053 1 .819 .932 .509 1.706 
HistStageCombine -1.451 .369 15.457 1 .000 .234 .114 .483 
MarStatus   14.971 5 .010    
MarStatus(1) -.323 .268 1.448 1 .229 .724 .428 1.225 
MarStatus(2) .651 .801 .660 1 .417 1.918 .399 9.226 
MarStatus(3) -.155 .437 .126 1 .722 .856 .363 2.017 
MarStatus(4) -.316 .485 .427 1 .514 .729 .282 1.884 
MarStatus(5) .587 .339 2.993 1 .084 1.799 .925 3.497 
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Radiation   11.715 4 .020    
Radiation(1) .699 .208 11.345 1 .001 2.013 1.340 3.023 
Radiation(2) .514 .315 2.666 1 .103 1.671 .902 3.096 
Radiation(3) .330 .354 .872 1 .350 1.392 .696 2.784 
Radiation(4) .044 .558 .006 1 .938 1.045 .350 3.117 
RadSurgCombine .226 .346 .424 1 .515 1.253 .636 2.470 
SurgCombinary .730 .191 14.592 1 .000 2.076 1.427 3.019 
PctNonHSGrad -.004 .011 .117 1 .733 .996 .975 1.018 
PctHSonly -.001 .010 .008 1 .930 .999 .980 1.019 
PctSomeColl -.030 .014 4.683 1 .030 .970 .944 .997 
MedIncome .000 .000 .118 1 .732 1.000 1.000 1.000 
MyoInfarc -.932 4.305 .047 1 .829 .394 .000 1817.095 
OldMyoInfarc -3.599 13.82 .068 1 .795 .027 .000 1.599E10 
CHF -.164 .840 .038 1 .845 .848 .163 4.405 
PeriphVascDisDx 2.483 1.347 3.396 1 .065 11.975 .854 167.886 
CerebroVascDis -4.037 2.777 2.112 1 .146 .018 .000 4.083 
COPD -.412 .483 .729 1 .393 .662 .257 1.706 
Dementia 3.059 1.503 4.140 1 .042 21.300 1.119 405.462 
Paralysis -40.21 2524 .000 1 .999 .000 .000 . 
Diabetes .806 1.256 .412 1 .521 2.239 .191 26.254 
DiabetesSequelae -39.58 7572 .000 1 .996 .000 .000 . 
ChronicRenalFail -24.76 8528 .000 1 .998 .000 .000 . 
Rheum 11.182 6.685 2.799 1 .094 71857 .147 3.519E10 
Constant -2.058 .950 4.693 1 .030 .128   
a. Variable(s) entered on step 1: sPSA, Race, Grade, HistStageCombinary, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, MedIncome, MyoInfarc, 
OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, Dementia, Paralysis, Diabetes, 
DiabetesSequelae, ChronicRenalFail, Rheum. 
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Conditional Cox Regression for AGE Quartile 1 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 178 1.9% 
Censored 101 1.1% 
Total 279 3.0% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
9113 97.0% 
Total 9113 97.0% 
Total 9392 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
 
 
Categorical Variable Codingsb,c,d,e 
 Frequency (1) (2) (3) (4) (5) 
Gradea 1 527 0     
2 8865 1     
MarStatusa 1 739 0 0 0 0 0 
2 7178 1 0 0 0 0 
3 41 0 1 0 0 0 
4 432 0 0 1 0 0 
5 343 0 0 0 1 0 
9 659 0 0 0 0 1 
Racea  1 8241 0     
 2 1151 1     
Radiationa 0 5994 0 0 0 0  
1 1863 1 0 0 0  
2 792 0 1 0 0  
4 619 0 0 1 0  
9 124 0 0 0 1  
a. Indicator Parameter Coding 
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b. Category variable: Grade (Grade 1) 
c. Category variable: MarStatus (Marital Status) 
d. Category variable: Race (SEER Race Recode B) 
e. Category variable: Radiation (Radiation 1) 
 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
140.016 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
104.759 28.023 26 .357 35.257 26 .106 35.257 26 .106 
a. Beginning Block Number 1. Method = Enter 
b.  
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lowe
r Upper 
sPSA -.127 .271 .221 1 .639 .880 .518 1.498 
Race .968 16.701 .003 1 .954 2.633 .000 4.327E14 
Grade .522 5.601 .009 1 .926 1.685 .000 98724.527 
HistStageCombine   . 0a .    
MarStatus   .883 5 .971    
MarStatus(1) -.466 7.998 .003 1 .954 .627 .000 4034013.4 
MarStatus(2) 5.520 95.537 .003 1 .954 249.604 .000 5.229E83 
MarStatus(3) -.845 3.136 .073 1 .788 .430 .001 200.889 
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MarStatus(4) -8.461 42.783 .039 1 .843 .000 .000 5.533E32 
MarStatus(5) -.123 4.328 .001 1 .977 .884 .000 4270.416 
Radiation   1.919 4 .751    
Radiation(1) .002 1.251 .000 1 .999 1.002 .086 11.629 
Radiation(2) -.846 9.066 .009 1 .926 .429 .000 2.234E7 
Radiation(3) -1.345 2.356 .326 1 .568 .260 .003 26.386 
Radiation(4) 32.06 112.81 .081 1 .776 8.417E13 .000 8.956E109 
RadSurgCombine 1.558 2.041 .583 1 .445 4.750 .087 259.594 
SurgCombinary -1.470 15.321 .009 1 .924 .230 .000 2.530E12 
Hormones   . 0a .    
PctNonHSGrad -.027 .311 .008 1 .930 .973 .529 1.789 
PctHSonly -.001 .421 .000 1 .998 .999 .438 2.280 
PctSomeColl -.085 .054 2.525 1 .112 .918 .827 1.020 
MedIncome .000 .000 .023 1 .880 1.000 1.00 1.000 
OldMyoInfarc 296.77 1593.9 .035 1 .852 7.737E128 .000 . 
CHF 10.128 72.182 .020 1 .888 25043.890 .000 6.926E65 
PeriphVascDisDx 20.389 119.40 .029 1 .864 7.157E8 .000 3.120E110 
CerebroVascDis 2.818 279.89 .000 1 .992 16.747 .000 2.932E239 
COPD -.288 11.961 .001 1 .981 .750 .000 1.138E10 
Dementia   . 0a .    
Paralysis   . 0a .    
Diabetes 1.734 7.609 .052 1 .820 5.665 .000 1.696E7 
DiabetesSequelae   . 0a .    
ChronicRenalFail -22.99 118.25 .038 1 .846 .000 .000 4.708E90 
Rheum 81.023 463.25 .031 1 .861 1.542E35 .000 . 
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix I 
Logistic and Conditional Cox Regression with Propensity Analysis 
AGE Quartile 2 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
7058 100.0 
Missing Cases 0 .0 
Total 7058 100.0 
Unselected Cases 0 .0 
Total 7058 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 407 .000 .000 .000 .000 .000 
2 5290 1.000 .000 .000 .000 .000 
3 22 .000 1.000 .000 .000 .000 
4 273 .000 .000 1.000 .000 .000 
5 457 .000 .000 .000 1.000 .000 
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9 609 .000 .000 .000 .000 1.000 
Radiation 1 0 3275 .000 .000 .000 .000  
1 2405 1.000 .000 .000 .000  
2 710 .000 1.000 .000 .000  
4 607 .000 .000 1.000 .000  
9 61 .000 .000 .000 1.000  
Grade 1 1 423 .000     
2 6635 1.000     
SEER Race Recode   1 6594 .000     
 2 464 1.000     
 
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 6881 0 100.0 
1 177 0 .0 
Overall Percentage   97.5 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -3.660 .076 2312.028 1 .000 .026 
 
Variables not in the Equationa 
 Score Df Sig. 
Step 0  sPSA .979 1 .322 
Grade(1) .589 1 .443 
HistStageCombinary 27.379 1 .000 
MarStatus 8.789 5 .118 
MarStatus(1) .055 1 .814 
MarStatus(2) .568 1 .451 
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MarStatus(3) 3.660 1 .056 
MarStatus(4) .204 1 .651 
MarStatus(5) 4.389 1 .036 
Race(1) 1.797 1 .180 
Radiation .090 1 .764 
RadSurgCombinary 1.432 1 .231 
PctNonHSGrad 3.714 1 .054 
PctHSonly 6.333 1 .012 
PctSomeColl .013 1 .911 
Pct4yrColl 6.839 1 .009 
MedIncome 4.316 1 .038 
MyoInfarc .003 1 .954 
OldMyoInfarc .791 1 .374 
CHF .543 1 .461 
PeriphVascDisDx .460 1 .497 
CerebroVascDis .001 1 .978 
COPD .039 1 .844 
Dementia 38.881 1 .000 
Paralysis 6.262 1 .012 
Diabetes .021 1 .884 
DiabetesSequelae .005 1 .945 
ChronicRenalFail 1.233 1 .267 
Rheum 1.609 1 .205 
. Residual Chi-Squares are not computed because of redundancies. 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 80.852 32 .000 
Block 80.852 32 .000 
Model 80.852 32 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 1573.433a .011 .055 
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Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 1573.433a .011 .055 
a. Estimation terminated at iteration number 20 
because maximum iterations have been reached. 
Final solution cannot be found. 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 6881 0 100.0 
1 176 1 .6 
Overall Percentage   97.5 
a. The cut value is .500 
 
 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I. for Exp(B) 
Lower Upper 
sPSA -.143 .155 .846 1 .358 .867 .639 1.175 
Race(1) .594 .290 4.199 1 .055 1.811 1.026 3.195 
Grade(1) -.179 .299 .361 1 .548 .836 .465 1.501 
HistStageCombine -1.280 .399 10.28 1 .001 .278 .127 .608 
MarStatus   11.69 5 .039    
MarStatus(1) .154 .373 .171 1 .679 1.167 .562 2.425 
MarStatus(2) -17.283 8452 .000 1 .998 .000 .000 . 
MarStatus(3) -1.027 .797 1.660 1 .198 .358 .075 1.708 
MarStatus(4) .023 .495 .002 1 .963 1.023 .388 2.700 
MarStatus(5) .820 .423 3.760 1 .052 2.271 .991 5.203 
Radiation   18.371 4 .001    
Radiation(1) .637 .185 11.855 1 .001 1.891 1.316 2.718 
Radiation(2) -.277 .389 .505 1 .477 .758 .353 1.627 
Radiation(3) .756 .279 7.327 1 .007 2.130 1.232 3.683 
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Radiation(4) -.604 1.03 .342 1 .559 .546 .072 4.144 
RadSurgCombine -.144 .394 .133 1 .715 .866 .400 1.875 
SurgCombinary .742 .180 17.060 1 .000 2.099 1.477 2.985 
PctNonHSGrad -.138 .132 1.088 1 .297 .871 .672 1.129 
PctHSonly -.142 .133 1.139 1 .286 .867 .668 1.126 
PctSomeColl -.136 .133 1.043 1 .307 .873 .673 1.133 
Pct4yrColl -.133 .133 1.013 1 .314 .875 .675 1.135 
MedIncome .000 .000 .157 1 .692 1.000 1.000 1.000 
MyoInfarc .739 3.07 .058 1 .810 2.094 .005 863.99 
OldMyoInfarc -14.450 19.1 .567 1 .451 .000 .000 1.126E10 
CHF -1.068 1.27 .699 1 .403 .344 .028 4.201 
PeriphVascDisDx -1.385 2.07 .448 1 .503 .250 .004 14.456 
CerebroVascDis -.447 1.90 .055 1 .815 .640 .015 26.776 
COPD .225 .400 .318 1 .573 1.253 .572 2.742 
Dementia 30.234 5172 .000 1 1.000 1.351E13 .000 . 
Paralysis 6.488 3.25 3.978 1 .046 657.409 1.119 38621 
Diabetes -.250 1.34 .035 1 .852 .779 .056 10.870 
DiabetesSequelae .196 1.73 .013 1 .910 1.217 .040 36.583 
ChronicRenalFail 1.714 1.58 1.173 1 .279 5.550 .250 123.34 
Rheum -191.92 5420 .000 1 .997 .000 .000 . 
Constant 10.608 13.2 .639 1 .424 40443.3   
a. Variable(s) entered on step 1: sPSA, Race, Grade, HistStageCombinary, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, 
MedIncome, MyoInfarc, OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, 
Dementia, Paralysis, Diabetes, DiabetesSequelae, ChronicRenalFail, Rheum. 
 
 
 
Conditional Cox Regression for AGE Quartile 2 
  
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 177 2.5% 
Censored 96 1.4% 
Total 273 3.9% 
Cases dropped Cases with missing 
values 
0 .0% 
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Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
6785 96.1% 
Total 6785 96.1% 
Total 7058 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
 
 
Categorical Variable Codingsb,c,d,e 
 
 Frequency (1) (2) (3) (4) (5) 
Gradea 1 423 0     
2 6635 1     
MarStatusa 1 407 0 0 0 0 0 
2 5290 1 0 0 0 0 
3 22 0 1 0 0 0 
4 273 0 0 1 0 0 
5 457 0 0 0 1 0 
9 609 0 0 0 0 1 
Racea  1 6594 0     
 2 464 1     
Radiationa 0 3275 0 0 0 0  
1 2405 1 0 0 0  
2 710 0 1 0 0  
4 607 0 0 1 0  
9 61 0 0 0 1  
a. Indicator Parameter Coding 
b. Category variable: Grade (Grade 1) 
c. Category variable: MarStatus (Marital Status) 
d. Category variable: Race (SEER Race Recode B) 
e. Category variable: Radiation (Radiation 1) 
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Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
137.243 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) 
Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square Df Sig. 
Chi-
square Df Sig. 
Chi-
square df Sig. 
103.040 26.109 26 .457 34.203 26 .130 34.203 26 .130 
a. Beginning Block Number 1. Method = Enter 
 
 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
sPSA -.115 .347 .109 1 .741 .891 .451 1.761 
Race 4.905 3.671 1.785 1 .182 134.963 .101 179945.410 
Grade -.378 1.195 .100 1 .752 .685 .066 7.130 
HistStageCombine   . 0a .    
MarStatus   2.478 4a .649    
MarStatus(1) -.636 1.569 .164 1 .685 .530 .024 11.463 
MarStatus(3) .751 2.095 .128 1 .720 2.119 .035 128.552 
MarStatus(4) -.707 1.225 .334 1 .564 .493 .045 5.435 
MarStatus(5) .429 1.230 .121 1 .728 1.535 .138 17.103 
Radiation   2.971 3a .396    
Radiation(1) .138 .547 .064 1 .801 1.148 .393 3.358 
Radiation(2) -2.512 1.821 1.902 1 .168 .081 .002 2.880 
Radiation(3) -.223 .778 .082 1 .774 .800 .174 3.673 
RadSurgCombine 2.992 1.768 2.865 1 .091 19.930 .623 637.309 
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SurgCombinary .370 2.586 .020 1 .886 1.448 .009 229.914 
Hormones   . 0a .    
PctNonHSGrad .434 .375 1.338 1 .247 1.544 .740 3.222 
PctHSonly .425 .383 1.231 1 .267 1.530 .722 3.243 
PctSomeColl .420 .385 1.194 1 .274 1.522 .716 3.235 
Pct4yrColl .384 .384 .999 1 .318 1.468 .691 3.117 
MedIncome .000 .000 1.276 1 .259 1.000 1.000 1.000 
MyoInfarc   . 0a .    
OldMyoInfarc -185.6 1378.9 .018 1 .893 .000 .000 . 
CHF 4.693 3.991 1.383 1 .240 109.175 .044 272523.863 
PeriphVascDisDx -46.56 457.78 .010 1 .919 .000 .000 . 
CerebroVascDis 1.503 7.215 .043 1 .835 4.496 .000 6231774.96 
COPD .389 2.241 .030 1 .862 1.476 .018 119.223 
Dementia   . 0a .    
Paralysis 28.686 418.06 .005 1 .945 2.871E1 .000 . 
Diabetes 2.900 3.756 .596 1 .440 18.180 .012 28646.852 
Rheum -65.38 1805.3 .001 1 .971 .000 .000 . 
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix J 
Logistic and Conditional Cox Regression with Propensity Analysis 
AGE Quartile 3 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
3118 100.0 
Missing Cases 0 .0 
Total 3118 100.0 
Unselected Cases 0 .0 
Total 3118 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 164 .000 .000 .000 .000 .000 
2 2186 1.000 .000 .000 .000 .000 
3 1 .000 1.000 .000 .000 .000 
4 84 .000 .000 1.000 .000 .000 
5 286 .000 .000 .000 1.000 .000 
9 397 .000 .000 .000 .000 1.000 
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Radiation 1 0 1456 .000 .000 .000 .000  
1 1133 1.000 .000 .000 .000  
2 279 .000 1.000 .000 .000  
4 224 .000 .000 1.000 .000  
9 26 .000 .000 .000 1.000  
Grade 1 1 181 .000     
2 2937 1.000     
SEER Race Recode   1 2963 .000     
 2 155 1.000     
 
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 2994 0 100.0 
1 124 0 .0 
Overall Percentage   96.0 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -3.184 .092 1207.164 1 .000 .041 
 
Variables not in the Equationa 
 Score df Sig. 
Step 0 sPSA .840 1 .359 
Grade(1) .221 1 .639 
HistStageCombinary 50.731 1 .000 
MarStatus 4.344 5 .501 
MarStatus(1) 1.928 1 .165 
MarStatus(2) .041 1 .839 
MarStatus(3) .139 1 .709 
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MarStatus(4) 3.191 1 .074 
MarStatus(5) .370 1 .543 
Race(1) 1.780 1 .182 
Radiation 9.068 1 .003 
RadSurgCombinary 2.901 1 .089 
SurgCombinary 38.416 1 .000 
PctNonHSGrad 10.473 1 .001 
PctHSonly 9.557 1 .002 
PctSomeColl .694 1 .405 
Pct4yrColl 10.993 1 .001 
MedIncome 3.817 1 .051 
OldMyoInfarc 1.806 1 .179 
CHF 1.255 1 .263 
PeriphVascDisDx 1.159 1 .282 
CerebroVascDis .652 1 .419 
COPD .081 1 .776 
Dementia .083 1 .773 
Paralysis 4.635 1 .031 
Diabetes .052 1 .820 
DiabetesSequelae .311 1 .577 
ChronicRenalFail .249 1 .618 
Rheum .545 1 .461 
a. Residual Chi-Squares are not computed because of redundancies. 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 88.025 32 .000 
Block 88.025 32 .000 
Model 88.025 32 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 960.505a .026 .092 
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Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 960.505a .026 .092 
a. Estimation terminated at iteration number 20 
because maximum iterations have been reached. 
Final solution cannot be found. 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 2994 0 100.0 
1 123 1 .8 
Overall Percentage   96.1 
a. The cut value is .500 
 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I. for Exp(B) 
Lower Upper 
sPSA -.251 .191 1.731 1 .188 .778 .535 1.131 
Race(1) -.355 .610 .339 1 .561 .701 .212 2.317 
Grade(1) .461 .438 1.110 1 .292 1.585 .673 3.737 
HistStageCombine -2.013 .516 15.233 1 .000 .134 .049 .367 
MarStatus   7.145 5 .210    
MarStatus(1) -.040 .478 .007 1 .933 .961 .376 2.454 
MarStatus(2) -18.905 40192.970 .000 1 1.000 .000 .000 . 
MarStatus(3) .555 .693 .640 1 .424 1.741 .448 6.775 
MarStatus(4) .622 .528 1.391 1 .238 1.863 .662 5.242 
MarStatus(5) .352 .527 .446 1 .504 1.422 .506 3.992 
Radiation   8.306 4 .081    
Radiation(1) -.352 .221 2.541 1 .111 .703 .456 1.084 
Radiation(2) -1.328 .533 6.196 1 .013 .265 .093 .754 
Radiation(3) -.547 .446 1.504 1 .220 .578 .241 1.387 
Radiation(4) -18.388 7519.152 .000 1 .998 .000 .000 . 
RadSurgCombine .586 .531 1.217 1 .270 1.796 .635 5.086 
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SurgCombinary .944 .217 18.846 1 .000 2.570 1.678 3.935 
PctNonHSGrad -.095 .159 .356 1 .551 .910 .666 1.242 
PctHSonly -.083 .160 .268 1 .605 .921 .673 1.259 
PctSomeColl -.077 .159 .234 1 .629 .926 .678 1.265 
Pct4yrColl -.075 .159 .224 1 .636 .928 .679 1.266 
MedIncome .000 .000 .023 1 .878 1.000 1.000 1.000 
MyoInfarc -70.812 29296.083 .000 1 .998 .000 .000 . 
OldMyoInfarc -321.281 101671.88
5 
.000 1 .997 .000 .000 . 
CHF -19.912 7638.910 .000 1 .998 .000 .000 . 
COPD .295 .478 .381 1 .537 1.343 .526 3.428 
PeriphVascDisDx 1.978 1.589 1.550 1 .213 7.230 .321 162.832 
CerebroVascDis 1.847 1.799 1.054 1 .305 6.338 .186 215.423 
Dementia -1.006 37528.289 .000 1 1.000 .366 .000 . 
Paralysis 7.230 3.615 4.000 1 .046 1380.649 1.155 1649722.3
5 
Diabetes .213 1.574 .018 1 .892 1.237 .057 27.076 
DiabetesSequelae -3.102 2.841 1.192 1 .275 .045 .000 11.770 
ChronicRenalFail -25.503 21802.214 .000 1 .999 .000 .000 . 
Rheum 6.498 6.768 .922 1 .337 663.980 .001 3.831E8 
Constant 6.430 15.907 .163 1 .686 620.312   
a. Variable(s) entered on step 1: sPSA, Race, Grade, HistStageCombinary, MarStatus, Radiation, 
RadSurgCombinary, SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, MedIncome, 
MyoInfarc, OldMyoInfarc, CHF, COPD, PeriphVascDisDx, CerebroVascDis, Dementia, Paralysis, 
Diabetes, DiabetesSequelae, ChronicRenalFail, Rheum. 
 
 
Conditional Cox Regression for Age Quartile 3 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 124 4.0% 
Censored 64 2.1% 
Total 188 6.0% 
Cases dropped Cases with missing 
values 
0 .0% 
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Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
2930 94.0% 
Total 2930 94.0% 
Total 3118 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
 
 
Categorical Variable Codingsb,c,d,e 
 Frequency (1) (2) (3) (4) (5) 
Gradea 1 181 0     
2 2937 1     
MarStatusa 1 164 0 0 0 0 0 
2 2186 1 0 0 0 0 
3 1 0 1 0 0 0 
4 84 0 0 1 0 0 
5 286 0 0 0 1 0 
9 397 0 0 0 0 1 
Racea  1 2963 0     
 2 155 1     
Radiationa 0 1456 0 0 0 0  
1 1133 1 0 0 0  
2 279 0 1 0 0  
4 224 0 0 1 0  
9 26 0 0 0 1  
a. Indicator Parameter Coding 
b. Category variable: Grade (Grade 1) 
c. Category variable: MarStatus (Marital Status) 
d. Category variable: Race (SEER Race Recode B) 
e. Category variable: Radiation (Radiation 1) 
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Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
94.268 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) 
Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square Df Sig. 
Chi-
square Df Sig. 
Chi-
square df Sig. 
54.384 29.175 27 .352 39.884 27 .053 39.884 27 .053 
a. Beginning Block Number 1. Method = Enter 
 
 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
sPSA -.719 .622 1.338 1 .247 .487 .144 1.648 
Race -5.510 5.535 .991 1 .320 .004 .000 208.210 
Grade 4.821 2.123 5.157 1 .023 124.097 1.935 7959.05 
HistStageCombine   . 0a .    
MarStatus   4.586 4a .332    
MarStatus(1) -.289 3.295 .008 1 .930 .749 .001 477.498 
MarStatus(3) 3.101 2.776 1.248 1 .264 22.212 .096 5120.85 
MarStatus(4) .783 2.924 .072 1 .789 2.189 .007 675.227 
MarStatus(5) -1.632 3.010 .294 1 .588 .196 .001 71.377 
Radiation   1.003 3a .800    
Radiation(1) -.296 .823 .129 1 .719 .744 .148 3.729 
Radiation(2) .792 3.095 .065 1 .798 2.207 .005 950.664 
Radiation(3) -.919 1.325 .481 1 .488 .399 .030 5.352 
RadSurgCombine 2.853 2.258 1.596 1 .206 17.345 .207 1450.46 
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SurgCombinary -5.766 4.870 1.402 1 .236 .003 .000 43.747 
Hormones   . 0a .    
PctNonHSGrad -1.523 .667 5.219 1 .022 .218 .059 .805 
PctHSonly -1.545 .694 4.956 1 .026 .213 .055 .831 
PctSomeColl -1.400 .638 4.818 1 .028 .247 .071 .861 
Pct4yrColl -1.354 .630 4.620 1 .032 .258 .075 .888 
MedIncome .000 .000 2.010 1 .156 1.000 1.000 1.000 
MyoInfarc -57.309 678.800 .007 1 .933 .000 .000 . 
OldMyoInfarc -243.409 3042.471 .006 1 .936 .000 .000 . 
CHF -18.248 188.057 .009 1 .923 .000 .000 1.412E152 
PeriphVascDisDx 3.467 5.907 .345 1 .557 32.050 .000 3415693. 
CerebroVascDis 24.444 340.227 .005 1 .943 4.129E1 .000 1.649E300 
COPD -4.417 3.924 1.267 1 .260 .012 .000 26.440 
Dementia   . 0a .    
Paralysis -3.860 759.718 .000 1 .996 .021 .000 . 
Diabetes .514 6.567 .006 1 .938 1.673 .000 650271.66 
DiabetesSequelae -12.457 373.365 .001 1 .973 .000 .000 . 
ChronicRenalFail   . 0a .    
Rheum -145.246 1805.370 .006 1 .936 .000 .000 . 
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix K 
Logistic and Conditional Cox Regression with Propensity Analysis 
AGE Quartile 4 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
664 100.0 
Missing Cases 0 .0 
Total 664 100.0 
Unselected Cases 0 .0 
Total 664 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
b. The variable HistStageCombinary is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
c. The variable Hormones is constant for the selected 
cases. Since a constant term was specified, the variable 
will be removed from the analysis. 
d. The variable DEMENTIA (1) is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
e. The variable PARALYSIS (1) is constant for the 
selected cases. Since a constant term was specified, the 
variable will be removed from the analysis. 
 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
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Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) (5) 
Marital Status 1 24 .000 .000 .000 .000 .000 
2 404 1.000 .000 .000 .000 .000 
3 1 .000 1.000 .000 .000 .000 
4 13 .000 .000 1.000 .000 .000 
5 107 .000 .000 .000 1.000 .000 
9 115 .000 .000 .000 .000 1.000 
Radiation 1 0 489 .000 .000 .000 .000  
1 116 1.000 .000 .000 .000  
2 27 .000 1.000 .000 .000  
4 20 .000 .000 1.000 .000  
9 12 .000 .000 .000 1.000  
Grade 1 1 41 .000     
2 623 1.000     
SEER Race Recode   1 631 .000     
 2 33 1.000     
 
Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 Mortality 0 625 0 100.0 
1 39 0 .0 
Overall Percentage   94.1 
a. Constant is included in the model. 
b. The cut value is .500 
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -2.774 .165 282.520 1 .000 .062 
 
Variables not in the Equationa 
 Score df Sig. 
Step 0  sPSA .027 1 .869 
Grade(1) 1.192 1 .275 
MarStatus 3.995 5 .550 
MarStatus(1) 1.223 1 .269 
MarStatus(2) .062 1 .803 
MarStatus(3) .079 1 .778 
MarStatus(4) 3.700 1 .054 
MarStatus(5) .011 1 .915 
Race(1) .508 1 .476 
Radiation .881 1 .348 
RadSurgCombinary .906 1 .341 
SurgCombinary 6.221 1 .013 
PctNonHSGrad 3.259 1 .071 
PctHSonly 1.820 1 .177 
PctSomeColl .143 1 .705 
Pct4yrColl 2.886 1 .089 
MedIncome 1.399 1 .237 
MyoInfarc .453 1 .501 
OldMyoInfarc .134 1 .715 
CHF .505 1 .477 
PeriphVascDisDx .958 1 .328 
CerebroVascDis .746 1 .388 
COPD 1.321 1 .250 
Diabetes .131 1 .718 
DiabetesSequelae .453 1 .501 
ChronicRenalFail .062 1 .803 
Rheum .188 1 .665 
a. Residual Chi-Squares are not computed because of redundancies. 
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Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 26.484 29 .600 
Block 26.484 29 .600 
Model 26.484 29 .600 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 270.287a .039 .108 
a. Estimation terminated at iteration number 20 
because maximum iterations have been reached. 
Final solution cannot be found. 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 Mortality 0 625 0 100.0 
1 39 0 .0 
Overall Percentage   94.1 
a. The cut value is .500 
 
 
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I. for 
Exp(B) 
Lower Upper 
sPSA -.060 .353 .029 1 .865 .942 .472 1.88 
Race(1) -.277 1.077 .066 1 .797 .758 .092 6.25 
Grade(1) -.347 .607 .326 1 .568 .707 .215 2.32 
MarStatus   3.345 5 .647    
MarStatus(1) -.356 .803 .197 1 .657 .700 .145 3.38 
MarStatus(2) -18.534 40192.970 .000 1 1.000 .000 .000 . 
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MarStatus(3) -.223 1.363 .027 1 .870 .800 .055 11.5 
MarStatus(4) -1.651 1.065 2.403 1 .121 .192 .024 1.54 
MarStatus(5) -.301 .876 .118 1 .731 .740 .133 4.11 
Radiation   2.938 4 .568    
Radiation(1) -1.015 .654 2.410 1 .121 .362 .101 1.30 
Radiation(2) -.613 1.077 .323 1 .570 .542 .066 4.47 
Radiation(3) .277 .886 .097 1 .755 1.319 .232 7.48 
Radiation(4) -18.840 11416.158 .000 1 .999 .000 .000 . 
RadSurgCombine 1.201 1.456 .680 1 .409 3.324 .191 57.7 
SurgCombinary .813 .414 3.844 1 .050 2.254 1.000 5.07 
PctNonHSGrad -.059 .291 .042 1 .839 .942 .533 1.66 
PctHSonly -.030 .295 .010 1 .919 .970 .544 1.73 
PctSomeColl -.025 .293 .008 1 .931 .975 .549 1.73 
Pct4yrColl -.028 .294 .009 1 .924 .972 .546 1.73 
MedIncome .000 .000 .030 1 .862 1.000 1.000 1.00 
MyoInfarc .786 5.308 .022 1 .882 2.196 .000 7240 
OldMyoInfarc 8.969 23.431 .147 1 .702 7856.32
4 
.000 6.91E23 
CHF -21.449 15560.851 .000 1 .999 .000 .000 . 
PeriphVascDisDx -52.916 26669.750 .000 1 .998 .000 .000 . 
CerebroVascDis 1.767 2.712 .425 1 .515 5.855 .029 1192 
COPD .567 .793 .511 1 .475 1.764 .372 8.35 
Diabetes -.048 3.149 .000 1 .988 .953 .002 456. 
DiabetesSequelae 3.356 3.023 1.232 1 .267 28.663 .077 10729 
ChronicRenalFail -27.313 59281.667 .000 1 1.000 .000 .000 . 
Rheum -
202.616 
249679.247 .000 1 .999 .000 .000 . 
Constant 1.313 29.214 .002 1 .964 3.717   
a. Variable(s) entered on step 1: sPSA, Race, Grade, MarStatus, Radiation, RadSurgCombinary, 
SurgCombinary, PctNonHSGrad, PctHSonly, PctSomeColl, Pct4yrColl, MedIncome, MyoInfarc, 
OldMyoInfarc, CHF, PeriphVascDisDx, CerebroVascDis, COPD, Diabetes, DiabetesSequelae, 
ChronicRenalFail, Rheum. 
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Conditional Cox Regression for Age Quartile 4 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 39 5.9% 
Censored 22 3.3% 
Total 61 9.2% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
603 90.8% 
Total 603 90.8% 
Total 664 100.0% 
a. Dependent Variable: Survival time recode (total # of months) 
 
 
Categorical Variable Codingsb,c,d,e 
 Frequency (1) (2) (3) (4) (5) 
Gradea 1 41 0     
2 623 1     
MarStatusa 1 24 0 0 0 0 0 
2 404 1 0 0 0 0 
3 1 0 1 0 0 0 
4 13 0 0 1 0 0 
5 107 0 0 0 1 0 
9 115 0 0 0 0 1 
Racea  1 631 0     
 2 33 1     
Radiationa 0 489 0 0 0 0  
1 116 1 0 0 0  
2 27 0 1 0 0  
4 20 0 0 1 0  
9 12 0 0 0 1  
a. Indicator Parameter Coding 
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b. Category variable: Grade (Grade 1) 
c. Category variable: MarStatus (Marital Status) 
d. Category variable: Race (SEER Race Recode B) 
e. Category variable: Radiation (Radiation 1) 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
33.271 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) 
Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square df Sig. 
Chi-
square Df Sig. 
Chi-
square df Sig. 
33.271 19.424 21 .558 .000 21 1.000 .000 21 1.000 
a. Beginning Block Number 1. Method = Enter 
 
 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lower Upper 
sPSA .000 1.200 .000 1 1.000 1.000 .095 10.511 
Race .000 12.92 .000 1 1.000 1.000 .000 9.951E10 
Grade .000 4.051 .000 1 1.000 1.000 .000 2805.46 
HistStageCombined   . 0a .    
MarStatus   .000 4a 1.000    
MarStatus(1) .000 6.804 .000 1 1.000 1.000 .000 618847.5 
MarStatus(3) .000 6.795 .000 1 1.000 1.000 .000 608551. 
MarStatus(4) .000 7.729 .000 1 1.000 1.000 .000 3795993 
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MarStatus(5) .000 8.064 .000 1 1.000 1.000 .000 7318555 
Radiation   .000 3a 1.000    
Radiation(1) .000 2.135 .000 1 1.000 1.000 .015 65.607 
Radiation(2) .000 6.085 .000 1 1.000 1.000 .000 151081 
Radiation(3) .000 3.353 .000 1 1.000 1.000 .001 715.290 
RadSurgCombinary .000 5.186 .000 1 1.000 1.000 .000 25971 
SurgCombinary .000 10.31 .000 1 1.000 1.000 .000 5.984E8 
Hormones   . 0a .    
PctNonHSGrad .000 2.245 .000 1 1.000 1.000 .012 81.466 
PctHSonly .000 2.081 .000 1 1.000 1.000 .017 59.048 
PctSomeColl .000 2.230 .000 1 1.000 1.000 .013 79.137 
Pct4yrColl .000 2.182 .000 1 1.000 1.000 .014 72.032 
MedIncome .000 .000 .000 1 1.000 1.000 1.000 1.000 
MyoInfarc   . 0a .    
OldMyoInfarc   . 0a .    
CHF .000 19.91 .000 1 1.000 1.000 .000 9.016E16 
PeriphVascDisDx .000 15.00 .000 1 1.000 1.000 .000 5.940E12 
CerebroVascDis .000 37.30 .000 1 1.000 1.000 .000 5.654E31 
COPD .000 8.316 .000 1 1.000 1.000 .000 1.198E7 
Dementia   . 0a .    
Paralysis   . 0a .    
DiabetesSequelae   . 0a .    
ChronicRenalFail   . 0a .    
Rheum   . 0a .    
a. Degree of freedom reduced because of constant or linearly dependent covariates 
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Appendix L 
Logistic Regression: Non Cancer Group–No Propensity Analysis 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
15557 100.0 
Missing Cases 0 .0 
Total 15557 100.0 
Unselected Cases 0 .0 
Total 15557 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) 
age category       14 750 .000 .000 .000 .000 
      15 2074 1.000 .000 .000 .000 
      16 2873 .000 1.000 .000 .000 
      17 5920 .000 .000 1.000 .000 
      18 3940 .000 .000 .000 1.000 
Race 1 14276 .000    
2 1281 1.000    
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Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
 Mortality 0 8803 0 100.0 
1 6754 0 .0 
Overall Percentage   56.6 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -.265 .016 268.299 1 .000 .767 
 
Variables not in the Equationa 
 Score df Sig. 
Step 0 Variables sPSA 113.425 1 .000 
Race(1) 16.420 1 .000 
Age(66-69yrs) 2320.165 4 .000 
Age(70-74yrs) 551.340 1 .000 
Age(75-79yrs) 220.610 1 .000 
Age(80-84yrs) .759 1 .384 
Age(85+) 1761.868 1 .000 
NoHighSchool 18.742 1 .000 
HighSchool 6.411 1 .011 
SomeCollege 5.792 1 .016 
College4yrs 15.151 1 .000 
MedInc 6.987 1 .008 
Myocardial 1.287 1 .257 
OldMyocardial .129 1 .720 
CHF 114.608 1 .000 
CerbroVascDs 43.775 1 .000 
COPD 91.624 1 .000 
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Dementia 52.186 1 .000 
Paralysis 15.022 1 .000 
Diabetes 10.873 1 .001 
DiabetesSequelae 46.897 1 .000 
ChronicRenalFail 26.550 1 .000 
Rheumatology .709 1 .400 
a. Residual Chi-Squares are not computed because of redundancies. 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 2943.796 22 .000 
Block 2943.796 22 .000 
Model 2943.796 22 .000 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 18352.127a .172 .231 
a. Estimation terminated at iteration number 5 
because parameter estimates changed by less than 
.001. 
 
Classification Tablea 
 
Observed 
Predicted 
 mortality Percentage 
Correct  0 1 
Step 1 mortality 0 7071 1732 80.3 
1 3184 3570 52.9 
Overall Percentage   68.4 
a. The cut value is .500 
 
357 
 
 
 
 
Variables in the Equation 
 
B S.E. Wald Df Sig. Exp(B) 
95% C.I. for 
Exp(B) 
Lower Upper 
sPSA -.257 .040 40.611 1 .000 .774 .715 .837 
Race(1) .354 .066 28.436 1 .000 1.424 1.251 1.622 
AGE(66-69yrs)   2033.36
6 
4 .000    
AGE(70-74yrs) .868 .137 40.121 1 .000 2.381 1.820 3.114 
AGE(75-79yrs) 1.542 .132 137.017 1 .000 4.674 3.610 6.050 
AGE(80-84yrs) 2.091 .128 266.050 1 .000 8.096 6.297 10.409 
AGE(85+) 3.331 .131 648.136 1 .000 27.958 21.635 36.130 
NoHighSchool .014 .015 .947 1 .330 1.015 .985 1.044 
HighSchool .014 .015 .823 1 .364 1.014 .984 1.044 
SomeCollege .007 .015 .218 1 .641 1.007 .978 1.037 
College4yrs .003 .015 .030 1 .863 1.003 .974 1.032 
MedInc .000 .000 7.693 1 .006 1.000 1.000 1.000 
Myocardial -.512 .310 2.733 1 .098 .599 .327 1.100 
OldMyocardial .110 1.162 .009 1 .924 1.117 .115 10.886 
CHF .459 .064 51.969 1 .000 1.583 1.397 1.794 
PeriphlVascDs .512 .210 5.948 1 .015 1.669 1.106 2.520 
CerbroVascDs .813 .201 16.335 1 .000 2.254 1.520 3.342 
COPD .563 .063 79.963 1 .000 1.757 1.553 1.988 
Dementia .895 .182 24.112 1 .000 2.448 1.712 3.499 
Diabetes 1.320 .199 43.838 1 .000 3.743 2.533 5.533 
DiabetesSeque 1.454 .216 45.530 1 .000 4.282 2.807 6.533 
ChronRenFail .571 .200 8.195 1 .004 1.771 1.197 2.618 
Rheumatology 2.490 1.739 2.052 1 .152 12.067 .400 364.38 
Constant -3.579 1.478 5.866 1 .015 .028   
a. Variable(s) entered on step 1: sPSA, Race, AGE (66-69yrs), NoHighSchool, 
HighSchool, SomeCollege, College4yrs, MedInc, Myocardial, OldMyocardial, CHF, 
PeripheralVascDs, CerbroVascDs, COPD, Dementia, Diabetes, DiabetesSequelae, 
ChronicRenalFailure, Rheumatology. 
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Cox Regression: Non-Cancer-Non Propensity Analysis 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 6754 43.4% 
Censored 8803 56.6% 
Total 15557 100.0% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
0 .0% 
Total 0 .0% 
Total 15557 100.0% 
a. Dependent Variable: survival months 
 
Categorical Variable Codingsb,c 
 Frequency (1) (2) (3) (4) 
Racea 1 14276 0    
2 1281 1    
Agea       14 750 0 0 0 0 
      15 2074 1 0 0 0 
      16 2873 0 1 0 0 
      17 5920 0 0 1 0 
      18 3940 0 0 0 1 
a. Indicator Parameter Coding 
b. Category variable: Race (race) 
c. Category variable: AGE Cat (age category) 
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Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
111926.818 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) 
Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square df Sig. 
Chi-
square df Sig. 
Chi-
square df Sig. 
104553.34
1 
9511.48
2 
23 .000 7373.47
8 
23 .000 7373.47
8 
23 .000 
a. Beginning Block Number 1. Method = Enter 
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lower Upper 
sPSA .085 .028 9.395 1 .002 1.089 1.031 1.149 
Race .090 .045 3.964 1 .046 1.094 1.001 1.195 
Age(66-69yrs)   7410.66 4 .000    
Age(70-74yrs) 1.665 .146 130.042 1 .000 5.286 3.970 7.037 
Age(75-79yrs) 1.376 .152 81.974 1 .000 3.960 2.939 5.334 
Age(80-84yrs) -.937 .145 41.859 1 .000 .392 .295 .521 
Age(85+) -3.407 .136 628.743 1 .000 .033 .025 .043 
NoHighSchool -.045 .009 23.395 1 .000 .956 .939 .974 
HighSchool -.044 .009 21.356 1 .000 .957 .940 .975 
SomeCollege -.054 .009 32.186 1 .000 .948 .930 .966 
College4yrs -.041 .009 19.459 1 .000 .959 .942 .977 
MedInc .000 .000 30.651 1 .000 1.000 1.000 1.000 
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Myocardial .299 .216 1.931 1 .165 1.349 .884 2.058 
OldMyocardial 1.823 .797 5.226 1 .022 6.189 1.297 29.535 
CHF .134 .040 11.031 1 .001 1.143 1.056 1.237 
PeriphVascDs .099 .135 .541 1 .462 1.104 .848 1.438 
CerbroVascDs .396 .143 7.631 1 .006 1.486 1.122 1.969 
COPD .347 .041 71.518 1 .000 1.415 1.306 1.534 
Dementia .108 .100 1.158 1 .282 1.114 .915 1.354 
Paralysis .141 .186 .575 1 .448 1.151 .800 1.657 
Diabetes 1.208 .135 80.218 1 .000 3.346 2.569 4.357 
Diabetes Sequela .896 .131 46.620 1 .000 2.450 1.894 3.168 
ChronicRenfail .339 .119 8.187 1 .004 1.404 1.113 1.771 
Rheumatology 3.684 1.172 9.878 1 .002 39.804 4.001 395.963 
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Appendix M 
Logistic and Conditional Cox Regression: Non Cancer Group with Propensity Analysis 
Logistic Regression Output 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
8426 100.0 
Missing Cases 0 .0 
Total 8426 100.0 
Unselected Cases 0 .0 
Total 8426 100.0 
a. If weight is in effect, see classification table for the 
total number of cases. 
 
Dependent Variable 
Encoding 
Original 
Value 
Internal 
Value 
0 0 
1 1 
 
Categorical Variables Codings 
 
Frequency 
Parameter coding 
(1) (2) (3) (4) 
age 
category 
66-69yrs 355 .000 .000 .000 .000 
70-74yrs 945 1.000 .000 .000 .000 
75-79yrs 1393 .000 1.000 .000 .000 
80-84yrs 3079 .000 .000 1.000 .000 
85+ 2654 .000 .000 .000 1.000 
Race 1 Cauc. 7514 .000    
2 AA 912 1.000    
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Block 0: Beginning Block 
 
Classification Tablea,b 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 0 mortality 0 4416 0 100.0 
1 4010 0 .0 
Overall Percentage   52.4 
a. Constant is included in the model. 
b. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -.096 .022 19.548 1 .000 .908 
 
 
Variables not in the Equationa 
 Score Df Sig. 
Step 0 Variables sPSA 25.380 1 .000 
Race(1) 8.276 1 .004 
AGE (66-69yrs) 1296.899 4 .000 
AGE (70-74yrs) 293.270 1 .000 
AGE (75-79yrs) 160.792 1 .000 
AGE (80-84yrs) 18.255 1 .000 
AGE (85+) 1034.592 1 .000 
NoHighSchool 13.662 1 .000 
HighSchool 7.533 1 .006 
SomeCollege 9.588 1 .002 
College4yrs 10.969 1 .001 
MedInc 6.629 1 .010 
Myocardial 3.483 1 .062 
OldMyocardial .444 1 .505 
CHF 90.151 1 .000 
PeripheralVascDs 11.004 1 .001 
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CerbroVascDs 22.323 1 .000 
COPD 57.370 1 .000 
Dementia 29.845 1 .000 
Paralysis 12.239 1 .000 
Diabetes 6.454 1 .011 
DiabetesSequelae 23.218 1 .000 
ChronicRenalFail 11.906 1 .001 
Rheumatology .245 1 .621 
a. Residual Chi-Squares are not computed because of redundancies. 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficients 
 Chi-square Df Sig. 
Step 1 Step 1698.668 23 .000 
Block 1698.668 23 .000 
Model 1698.668 23 .000 
 
 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke R 
Square 
1 9962.678a .183 .244 
a. Estimation terminated at iteration number 5 
because parameter estimates changed by less than 
.001. 
 
Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 mortality 0 3295 1121 74.6 
1 1555 2455 61.2 
Overall Percentage   68.2 
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Classification Tablea 
 
Observed 
Predicted 
 Mortality Percentage 
Correct  0 1 
Step 1 mortality 0 3295 1121 74.6 
1 1555 2455 61.2 
Overall Percentage   68.2 
a. The cut value is .500 
 
Variables in the Equation 
 
B S.E. Wald Df Sig. Exp(B) 
95% C.I. for 
Exp(B) 
Lower Upper 
Step 
1a 
sPSA -.281 .049 33.464 1 .000 .755 .686 .830 
Race(1) .371 .080 21.524 1 .000 1.449 1.239 1.695 
Age(66-69yrs)   1183.5 4 .000    
Age (70-74yrs) .755 .186 16.464 1 .000 2.127 1.477 3.062 
Age (75-79yrs) 1.403 .178 62.311 1 .000 4.067 2.871 5.761 
Age (80-84yrs) 1.968 .172 130.61 1 .000 7.159 5.108 10.034 
Age (85+) 3.248 .175 345.71 1 .000 25.733 18.273 36.239 
NoHighSchool .006 .015 .173 1 .677 1.006 .977 1.037 
HighSchool .010 .015 .451 1 .502 1.010 .980 1.041 
SomeCollege -.002 .015 .012 1 .912 .998 .969 1.029 
College4yrs -.002 .015 .014 1 .904 .998 .969 1.028 
MedInc .000 .000 1.504 1 .220 1.000 1.000 1.000 
Myocardial -1.074 .439 5.984 1 .014 .342 .145 .808 
OldMyocardial -.642 1.596 .162 1 .688 .526 .023 12.026 
CHF .597 .086 48.457 1 .000 1.816 1.535 2.149 
PeriphlVascDs .369 .300 1.512 1 .219 1.446 .803 2.603 
CerbroVascDs .762 .298 6.532 1 .011 2.143 1.194 3.844 
COPD .586 .085 47.739 1 .000 1.796 1.521 2.121 
Dementia .830 .231 12.894 1 .000 2.293 1.458 3.606 
Paralysis .253 .379 .446 1 .504 1.288 .613 2.709 
Diabetes 1.527 .272 31.506 1 .000 4.605 2.702 7.848 
DiabetesSequel 1.338 .286 21.892 1 .000 3.810 2.175 6.671 
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ChronicRenFail .453 .241 3.532 1 .060 1.573 .981 2.524 
Rheumatology 3.214 2.372 1.836 1 .175 24.877 .238 2600.4 
Constant -2.805 1.512 3.442 1 .064 .061   
a. Variable(s) entered on step 1: sPSA, Race, Age (66-69yrs), NoHighSchool, HighSchool, 
SomeCollege, College4yrs, MedInc, Myocardial, OldMyocardial, CHF, PeripheralVascDs, 
CerbroVascDs, COPD, Dementia, Paralysis, Diabetes, DiabetesSequelae, ChronicRenalFailure, 
Rheumatology. 
 
 
Conditional Cox Regression Output 
 
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Eventa 4010 47.6% 
Censored 688 8.2% 
Total 4698 55.8% 
Cases dropped Cases with missing 
values 
0 .0% 
Cases with negative 
time 
0 .0% 
Censored cases before 
the earliest event in a 
stratum 
3728 44.2% 
Total 3728 44.2% 
Total 8426 100.0% 
a. Dependent Variable: survtimemonths 
 
 
Categorical Variable Codingsb,c 
 Frequency (1) (2) (3) (4) 
Racea 1Cauc 7514 0    
2 AA 912 1    
Age Cat 66-69 355 0 0 0 0 
70-74 945 1 0 0 0 
75-79 1393 0 1 0 0 
80-84 3079 0 0 1 0 
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85+ 2654 0 0 0 1 
a. Indicator Parameter Coding 
b. Category variable: Race (Race) 
c. Category variable: AGE Cat (age category) 
 
 
Block 0: Beginning Block 
 
Omnibus Tests of 
Model 
Coefficients 
-2 Log Likelihood 
2524.442 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model Coefficientsa 
-2 Log 
Likelihood 
Overall (score) 
Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square Df Sig. 
Chi-
square df Sig. 
Chi-
square df Sig. 
1403.481 708.829 23 .000 1120.96 23 .000 1120.9
61 
23 .000 
a. Beginning Block Number 1. Method = Enter 
 
Variables in the Equation 
 
B SE Wald Df Sig. Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
sPSA -.048 .064 .578 1 .447 .953 .841 1.079 
Race 1.068 5.038 .045 1 .832 2.911 .000 56566.767 
Age(66-69yrs)   11.617 4 .020    
Age(70-74yrs) -5.826 4.927 1.398 1 .237 .003 .000 46.075 
Age(75-79yrs) -11.47 6.095 3.541 1 .060 .000 .000 1.610 
Age(80-84yrs) -17.43 7.199 5.867 1 .015 .000 .000 .036 
Age(85+) -24.02 8.392 8.193 1 .004 .000 .000 .001 
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NoHighSchool .045 .031 2.036 1 .154 1.046 .983 1.112 
HighSchool .050 .041 1.465 1 .226 1.051 .970 1.139 
SomeCollege .036 .081 .203 1 .652 1.037 .885 1.215 
College4yrs .041 .035 1.357 1 .244 1.041 .973 1.115 
MedInc .000 .000 .702 1 .402 1.000 1.000 1.000 
Myocardial .471 8.082 .003 1 .954 1.601 .000 1.213E7 
OldMyocardial 2.386 15.80 .023 1 .880 10.865 .000 3.058E14 
CHF .224 1.094 .042 1 .838 1.251 .147 10.675 
PeriphVascDs -1.104 5.475 .041 1 .840 .332 .000 15167.984 
CerbroVascDs -.097 3.886 .001 1 .980 .908 .000 1843.893 
COPD .302 1.149 .069 1 .793 1.352 .142 12.856 
Dementia -.001 2.059 .000 1 1.000 .999 .018 56.565 
Paralysis 1.631 6.986 .055 1 .815 5.110 .000 4519734.8 
Diabetes 2.173 1.032 4.434 1 .035 8.788 1.162 66.437 
DiabetesSequelae 1.057 3.587 .087 1 .768 2.879 .003 3256.562 
ChronicRenalFail 1.212 5.944 .042 1 .838 3.360 .000 385305.99 
Rheumatology 18.659 27.98 .445 1 .505 1.269E8 .000 8.349E31 
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